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Overview 
Studying the metabolite output, the “exometabolome,” of bacterial communities provides insight into 
the metabolic interactions occurring within that ecosystem. As such, a metabolomic approach can be 
used to gain further understanding of the human gut microbiota. As the microbes that reside in the 
human gastrointestinal (GI) system, the ecosystem has extensive impacts on the human body. In vitro 
systems for culturing gut microbes circumvents the ethical and technical challenges of in vivo studies, 
while, at the same time,  lends itself to metabolomic investigations. The nutrient solutions in which 
microbial communities representative of the human gut microbiota are cultured contain a wealth of 
metabolomic data. In this thesis, metabolomic characterization is used to validate an in vitro gut-
mimicking bioreactor system. This provided support for the ability to establish standardized protocols 
on preparing, culturing and reporting on in vitro gut microbiota. Furthermore, the metabolomic 
approach to studying gut microbes was used in applications relevant to clinical and industrial 
research. The findings from this thesis demonstrate the application of a metabolomic approach to 
studying the human gut microbiota in a single-stage continuous stirred tank reactor (CSTR) system. 
More importantly, the research here exemplifies the ways in which metabolomic insight can be 
translated into deciphering the complex interactions of the human gut microbiota. 
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Chapter 1 Introduction 
 
The field of metabolomics focuses on the complete set of metabolites produced by an organism, 
referred to as the metabolome1. As the summative product of an organism’s biochemical processes, 
the metabolome produces a “snapshot” of that organism’s metabolic state in that particular 
environment and at that particular time. A metabolomic approach could be taken to investigate the 
state of bacterial communities by observing the metabolite changes occurring in the nutrient solutions 
in which those microbes are grown. The metabolomic data of a bacterial community reveals 
information on both the metabolite production and nutrient consumption by the culture as a whole. As 
such, this type of characterization is directly applicable to understanding complex microbial consortia 
such as the human gut microbiota. As a consortium of bacteria residing in the large intestines of the 
human gastrointestinal (GI) tract, the metabolic interaction between the microbial community and the 
human host has direct implications on the physiology of both sides of the commensal relationship. On 
the one hand, there are a multitude of measurements that comment on the health and physiology of 
the human body, but assessment of the gut bacteria is not as straight forward. One means of studying 
the gut microbiota is by culturing the bacteria in vitro in a single-stage continuous stirred tank reactor 
(CSTR) system, and allowing the bacteria to grow as a community culture. There are many 
advantages in using such a system to study the gut microbiota, one of which is that it lends itself to 
metabolomic studies. In characterizing the metabolites in the spent media of the in vitro mixed 
culture, the human gut microbiota can be directly studied and subjected to experimentation. 
The driving hypothesis of this thesis is that nuclear magnetic resonance (NMR)-based 
metabolomic data found in nutrient solution is an effective approach to studying the human gut 
microbiota in vitro. This overarching theme can be broken down into two subsequent sub-hypotheses. 
The first is that metabolomic data within spent media obtained from culturing a gut microbial 
 1 
 community can be used to evaluate the microbial changes imparted by in vitro growth, thereby 
validating the single-stage CSTR system used to mimic the human large intestines. This hypothesis 
will be tested by three main objectives. The first was to develop a standard method of reporting on 
fecal metabolomes. The second was to develop a protocol for preparing samples from the gut-
mimicking bioreactor for NMR metabolomic analysis. The last objective was to determine the 
importance of the proportional bacterial makeup of fecal inoculum relative to the resulting in vitro 
community culture. The second hypothesis tested was that the metabolite profiles of gut bacteria 
communities grown in a single-stage CSTR system will sufficiently describe and compare the 
metabolic interactions taking place in the community culture, and define metabolic functions unique 
to each culture. Two main objectives were set to test this hypothesis. The first was to characterize 
feces-derived and defined communities that were representative of the human gut microbiota based 
on their metabolite signatures. The second was objective was to evaluate the communities’ metabolic 
responses to different types of perturbations to the cultures’ CSTR environment.  
Establishing metabolite profiles for solutions that contained large numbers of metabolites is a 
difficult task with several challenges that can be overcome with training and practice. Therefore, the 
first goal was to demonstrate that NMR can be used to create metabolite profiles of a semi-well-
defined solution such as serum-free cell culture media. In the first experimental chapter (Chapter 4), a 
targeted profiling approach is illustrated, followed by an experiment that demonstrates the 
applicability of the technique in investigating cell culture media. The experiment presented in this 
chapter examined the ability to create and use metabolite profiles of a chemically-defined media that 
underwent non-biological processing steps. More specifically, metabolite profiles were used to assess 
the chemical changes resulting from UV irradiation. As a nutrient solution, unspent defined cell 
culture media was an appropriate matrix to develop the analytical skills involved in building 
 2 
 metabolite profiles from complex 1H NMR spectra. The examination shows an initial demonstration 
of targeted profiling techniques to build accurate and precise metabolite profiles. 
Since fecal water has been the matrix of preference in metabolomic research on the human 
gut microbiota, Chapter 5 dressed the methodological concerns in reporting on fecal metabolomes. 
Even though fecal water is widely studied in the gut microbiota field2–4 and is used as the inoculant 
for gut-mimicking CSTR systems5,6, there is a lack of standardization of the biofluid in terms of 
preparation for NMR-based metabolomic analysis. Therefore, samples of fecal water of various 
concentrations were examined by metabolomic analysis. This systematic evaluation of fecal water 
samples provided evidence to suggest a means of standardizing reports on fecal metabolome. 
Next, the methodological approaches for studying human gut microbiota based on 
metabolomic descriptions of community cultures grown in vitro in an anaerobic CSTR was 
established (Chapter 6). Two experiments were conducted to characterize different aspects of 
propagating mixed cultures in a CSTR that mimicked the conditions of the human colon. First, 
attention was directed towards developing and validating an appropriate protocol for preparing 
samples collected from the gut-mimicking bioreactor. To this end, bioreactor samples were prepared 
for NMR-based metabolomic analysis using different methods. Comparing these different preparation 
protocols determined the effects of syringe filtration and ultracentrifugation on the metabolite profile 
of a given sample. The last experiment in this chapter studied CSTR-grown cultures that started from 
inoculants with various proportions of bacterial biomass. Given the limited standardization of the 
fecal inoculants used for in vitro community cultures, the impact of the inoculant on the in vitro 
culture was the focus of the investigation.  
The final experimental chapter (Chapter 7) applied the metabolomic analyses developed in 
previous chapters to characterize the human gut microbiota. The first experiment presented compared 
 3 
 various bacterial communities, where these communities were either feces-derived, obtained from 
different individuals, or obtained through the culture of a defined community that was modelled on a 
fecal community. The objective of this study was to describe different gut bacterial communities 
based on their metabolic characteristics in a single-stage CSTR system. Having established a baseline 
metabolomic view of the gut microbiota, the second experiment in this chapter extended our analysis 
to characterizing the gut microbiota under various conditions. The objective of this investigation was 
to capture perturbations to the cultures’ metabolome when the gut microbial community was 
subjected to different treatments. This study was a demonstration of how metabolomic investigation 
could be applied in a manner that would be relevant to clinical and industrial understanding of the 
human gut microbiota.  
 Experimental work pertaining to the preparation of fecal water, fecal inoculants and defined 
community inoculants; development and operation of the gut mimicking CSTR system; and 
collection and preparation of samples were all conducted in the Allen-Vercoe lab of the University of 
Guelph. The focus of this thesis was on the metabolomic implications of the experimental work and 
to conduct metabolic analyses on the collaborative projects. 
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 Chapter 2 Literature Review 
2.1 The Metabolomic Approach 
Metabolomic research, originally rooted in plant7 and toxicology8 research, was developed as a 
complementary tool to functional genomics in order to incorporate molecular interactions within our 
understanding of biological systems9,10. Since then, metabolomics has become an approach in its own 
right and has been applied in disease diagnosis11, nutrition assessment12 and microbial studies13. 
Metabolomic research is diverse in its application because it focuses on the complete set of low 
molecular weight metabolites produced by a given organism, referred to as the metabolome1. 
Compared to other “-omes” such as the genome, transcriptome and proteome, the metabolome is most 
descriptive of the organism’s phenotype. The metabolome can contain a wide variety of molecules 
with different physical properties; from low molecular weight fatty acids and volatile organic acids to 
higher molecular weight amino acids, carbohydrates and lipids. Consequently, multiple analytical 
platforms are required to capture an entire metabolome. Furthermore, a comprehensive metabolome 
captures the metabolic state of the organisms at a given time, meaning that the metabolome studied is 
strongly influenced by temporal and spatial parameters of the experiment14. Therefore, a powerful 
metabolomic approach must begin with careful experimental design, followed by the use of analytical 
methods that are high-throughput and robust, and completed using appropriate statistical analyses of 
the collected dataset. 
Given that no single analytical strategy can capture the metabolome as a whole, the choice in 
the platform selected involves trade-offs between advantages and disadvantages associated with each 
technique. There are two main analytical methods used to obtain metabolite data: mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) spectroscopy. 
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 2.1.1 Mass Spectrometry 
Mass spectrometry (MS) is an analytical tool that identifies compounds by separating ions generated 
from organic or inorganic materials based on their mass-to-charge ratio10,15. MS is usually coupled 
with a separation step such as gas chromatography (GC-MS) or liquid chromatography (LC-MS), 
though there are several other techniques that can be employed in conjunction with MS, such as 
Fourier transform ion cyclotron resonance (FTICR-MS)16. One of the main strengths of using MS is 
the sensitivity of the technique, where the lower limit of detection of compounds can be on the order 
of picamolar or nanomolar concentrations. MS has also been demonstrated to be robust, yielding 
reproducible identification and quantification of metabolites17. On the other hand, MS-based 
techniques require labour-intensive preparation steps that destroy the sample in the process of 
extracting, separating and detecting the metabolites18. Intrinsic to the separation process is a bias 
towards which metabolites are observed, therefore requiring additional derivatization steps to broaden 
the scope of compounds targeted19. For example, GC-MS targets volatile metabolites that are also 
thermostable up to 280 °C, but samples can be derivatized to convert compounds from non-volatile 
and thermolabile to volatile and themostable before being analyzed by GC-MS20,21. 
2.1.2 Nuclear Magnetic Resonance Spectroscopy 
NMR spectroscopy is another analytical tool by which to identify and quantify compounds. It 
functions by applying strong magnetic fields to induce atoms to spin at a precession rate proportional 
to the strength of the magnet applied. Within the externally applied magnetic field, about half of the 
nuclei will be in the lower energy “up” spin state and half in the higher energy “down” spin state. The 
gap between the two energy states corresponds to a specific frequency of electromagnetic radiation. A 
high-power radio frequency is applied to the sample to excite all the nuclei of a given type (i.e. 1H). 
The sum of all the nuclei precessing at a specific resonant frequency form a net magnetization of the 
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 sample. As the spins drop back from the high energy spin state to low energy spin state, the process of 
relaxation releases energy that can be observed by the NMR receiver as a signal, referred to as the 
free induction decay (FID) at that resonant frequency. Since an FID signal is a function of time, 
Fourier transform converts an FID signal to a function of frequency, which separates the signals into 
multiple peaks at their corresponding frequencies. The absorbed RF energy, which is exactly the 
energy gap between the two spin states, promotes nuclei in the low-energy spin-state to a high-energy 
spin-state. The energy emitted during the subsequent relaxation process from high-energy back to 
low-energy spin states is what is detected as that atom’s signal. The spectrometer can use the 
characteristic frequency of a given nucleus, such as a proton (1H) or carbon (13C), and obtain 
information on all 1H or 13C atoms in a sample4.  
One of the advantages of using NMR spectroscopy is that structural information of 
compounds found in the sample are also relayed through the resonant frequency. An atom’s structural 
environment impacts its resonance frequency because small magnetic fields from surrounding atoms 
within a molecule influences the external magnetic field in the immediate surroundings of that 
nucleus. These variations to the external magnetic field, localized to individual nuclei, is described as 
the chemical shift, and is influenced by molecular symmetry and the types of electronegative atoms 
nearby, which have consistent and predictable effects on its surroundings. Therefore, the chemical 
shift of an atom, measured in parts per million (ppm) conveys structural information about its 
associated molecule and is reflected based on the location of the signal along the spectrum4. 
Additionally, nuclei in close proximity (within three bonds) affect the external magnetic field 
experienced by neighbouring nuclei, an effect called spin-spin splitting. Therefore, neighbouring 
nuclei mutually alter each other’s resonance frequencies and alter the magnetic field experienced. 
Spin-spin splitting is represented in the spectrum by “splitting” the resonance peak corresponding to 
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 the nucleus of interest into multiple peaks, set apart by J Hz, where J is the coupling constant. The 
pattern of peak splitting depends on the number of neighbouring nuclei and the intensity of the split 
peaks is determined by Pascal’s triangle4.  
NMR has also been demonstrated to be a robust analytical tool that yields reproducible 
results suitable for metabolomic analysis of biofluids22,23. Furthermore, the sample preparation 
process for NMR spectroscopy is non-destructive and simple as the preparation procedure only 
involves adding an internal standard compound in deuterated solvent to the sample to control for drift 
in the magnetic field and for downstream quantification. Another benefit of using NMR spectroscopy 
for obtaining metabolomic data is the non-selective nature of the technology. Since NMR utilizes the 
quantum properties of molecules, the resonant frequency of all atoms are affected by the external 
magnetic field. The NMR spectrometer can target the characteristic frequency of a particular type of 
nucleus to obtain the resonance frequency information of all metabolites that contain the targeted 
atom within the sample. Most applications of NMR utilize 1H or 13C atoms to relay the metabolite 
make-up of a sample. This is because the sensitivity of NMR spectroscopy is directly related to the 
abundance of the targeted atom as well as the strength of that atom’s nuclear magnet. For example, 
the reduced sensitivity of NMR to 13C signals in comparison to 1H is compounded by the fact that 13C 
exists at much lower natural abundance (about 1.1%) and has a weaker nuclear magnet than 1H. Since 
the sensitivity of the platform is dependent on the abundance of nuclei, NMR spectroscopy has 
relatively weak sensitivity. While there are hardware solutions to improve signal intensity and 
sensitivity, the lower limit of detection using NMR spectroscopy is still on the order of micromolar 
concentrations24.  
Just as there are many different throughput and separation techniques used to enhance various 
attributes of MS, there are many different NMR experiments that adjust the spectral acquisition 
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 process to augment particular characteristics of NMR as a platform for obtaining metabolomic data. 
For example, there are experiments that aid with water suppression25,26, improve signal de-
convolution27,28, or  high-throughput interpretation of NMR spectra29,30.  
1D-1H-nuclear Overhauser effect spectroscopy (1D-NOESY) pulse sequence has become the 
NMR experiment of choice when it comes to performing NMR-based metabolomic studies23. Inherent 
to its popularity, one of the main benefits of using 1D-NOESY is that, as an established procedure, 
the results obtained from the pulse sequence can be consistently compared with other studies using 
the same experiment. Moreover, the widespread use of ID-NOESY in metabolomic research has led 
to development of downstream processing tools, such as Chenomx NMR Suite (Chenomx Inc., AB), 
that facilitate the interpretation of the acquired spectra31. One factor that likely contributed to the 
ubiquitous use of ID-NOESY for metabolomic analyses is the compatibility of most modern NMR 
spectrometers with the hardware requirements of the experiment. In terms of the spectroscopic 
advantages of the ID-NOESY, it is an experiment that requires minimal optimization while still 
conferring adequate suppression of solvent signals32. 1D-NOESY exploits the difference in T1 
relaxation time of the solute and solvent in order to discriminate the two components of the matrix. 
Another aspect of 1D-NOESY that contributes to the successful suppression of the solvent signal is 
by using a series of pulse sequences to select against resonances from parts of the sample that did not 
experience the pulses at full efficacy or experienced non-homogenous fields. The third mechanism of 
1D-NOESY that facilitates selection against unwanted signals is through the use of phase cycling. 
Phase cycling is a complex mechanism as its effects are embedded within many aspects of the 
experiment. Generally, signals of interest are “cycled through” various phases, so it is reversed 
relative to the phase of the NMR receiver. This way, external noise source contaminating a signal are 
subtracted while the signal of interest is added when alternately reversing the direction of the desired 
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 signal and the NMR receiver. Given the quality of solvent suppression and the ease of integrating the 
resultant spectra into downstream analyses, this experiment can be appropriately applied to 
metabolomic studies.  
2.1.3 Principal Component Analysis 
The rich information contained within complex metabolomic data can be extracted using appropriate 
statistical tools. Multivariate analyses have been applied to interpret quantitative and qualitative 
annotations of metabolites, such as compound concentration and compound identity33,34. Principal 
component analysis (PCA) is one such analysis that provides an overall view of the data structure, 
revealing trends and groupings within the data. This pattern recognition technique allows 
visualization of datasets that have many correlated variables associated with each observation. Within 
metabolomics, the metabolites are the variables associated with each observation, and an observation 
is a metabolomic spectra (NMR or otherwise). PCA is able to create a model based on the samples 
and their respective metabolite profiles by transforming the correlated variables into a reduced set of 
new, independent variables, called principal components (PCs)35. Mathematically, the original data is 
represented as the covariance measured between every variable to form a covariance matrix. Once the 
variable relationships are captured in terms of their covariance, the eigenvectors of the covariance 
matrix represent score coordinates and the eigenvalues of the covariance matrix represent the loading 
values. The interpretation of these new PC variables in the context of metabolomics is that the score 
coordinate values illustrate how the spectra are related to one another, and the loading values depict 
how the metabolites contributed to the PCs. Graphically, when spectra are located along a given PC, 
it demonstrates that they are related along that axis, while the coordinate value of a metabolite in the 
same PC space illustrates how that metabolite relates to those spectra. Loading plots illustrate how the 
metabolites relate to those spectra36. The ability to visually detect patterns of similarity and 
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 differences within metabolite profiles is the main strength of PCA and has been the driving force for 
its popularity in metabolomic analysis.  
2.2 1H NMR-Based Metabolomics 
As mentioned earlier, the NMR spectrometer can use the characteristic frequency of different nuclei 
to relay information on the structure and concentration of metabolites in a sample. Since the 
sensitivity of the NMR is directly related to the abundance of that atom, monitoring the 1H provides 
the greatest relative sensitivity as it is found at almost 100% natural abundance. For this reason, one 
dimensional proton NMR (1D-1H NMR) is often employed for obtaining metabolomic data in various 
fields, including cell culture research37 and study of human biofluids38. 1D-1H NMR spectra can 
provide quantitative identification of the spectral peaks through “targeted profiling,” a method 
whereby spectral peaks are individually matched with metabolite signatures obtained from a library of 
pure compound spectra31. This method of analyzing the spectra allows one to interpret the spectral 
signals, even when the peaks overlap, a characteristic often encountered in 1D-1H NMR spectra of 
complex solutions. Previous assessment of targeted profiling determined that the accuracy and 
precision of quantification is influenced by the combination of the degree of convolution affecting the 
metabolite’s signals and the magnitude of the compound’s concentration; compounds that are highly 
convoluted and found at low concentrations will have greater measurement error39. Since 
measurement error in targeted profiling approaches are compound-dependent, peak-specific strategies 
have been developed to improve measurement accuracy39–41. These strategies involve group-wide 
review of profiled spectra to establish confidence in each metabolite’s observation; generation of a 
master profiling list for consistent metabolite identification; or performing a validation experiment to 
define quantification accuracy within that sample type. 
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 2.2.1 Metabolomic study of Cell Culture Processes 
Within the framework of a single-cell organisms, the metabolome is composed of the 
endometabolome and the exometabolome, which refers the organism’s intracellular metabolites and 
extracellular metabolites respectively13. Since the metabolome is regarded as the most accurate 
description of the organism’s phenotype, it can be applied as an analytical tool in cell culture 
processes. For example, metabolomics has been used in culturing various cell lines, providing 
complementary data to genomic and proteomic measurements. In the field of industrial 
biotechnology, areas of focus for cell line metabolomics include phenotype classification, monitoring 
bioprocesses and ensuring consistent product quality. For example, metabolomic data have been used 
as a high-throughput screening tool for strain classification. E. coli strains containing mutations in the 
tryptophan metabolism pathway were identified based on the unique metabolite profiles associated 
with altered tryptophan pathways42. Discriminating mutant strains using metabolite profiles is directly 
relevant to industrial biotechnology since screening for and identifying cell line variants that strongly 
impact downstream products is highly desirable. Cell line metabolomics is also relevant to industrial 
processes as it can contribute to monitoring cell physiology during production. One example is in 
production of fuel ethanol using Saccharomyces cerevisiae. The environments imposed on the yeast 
cells during fermentation can illicit stress responses that could ultimately impact the end product43. In 
such a case, the metabolic changes undergone by the cells in response to the harsh environments of 
fuel ethanol production were identified and contributed to determining the ideal growth conditions 
and media supplementation required for particular strains of yeast44. Using metabolomic data for 
bioprocess monitoring also allows one to assess the production process. For example, NMR-based 
metabolomics was used to assess the scalability of producing a therapeutic protein in Chinese hamster 
ovary (CHO) cells45. Aranibar et al found that biochemical signatures associated with differences in 
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 production levels in a 5000-L and 7-L bioreactors were related to energy metabolism, like adenosine 
nucleoside phosphates and UDP-glucose, 1,6-glucose bisphosphate and UDP-galactose. Another area 
of consideration in production of bio-therapeutics is assessing the nutrient feed provided to the cell 
cultures. Referred to as “fermentanomics,” assessing metabolite components in media46,47 could 
reveal information on product quality and cell culture productivity. Nutrient consumption and 
metabolite accumulation in the media can strongly influence cell culture performance47,48. Therefore, 
rational medium designs paired with NMR-based monitoring have been executed to direct nutrient 
consumption in order to control product quality46. One such example of this was the marked increase 
in the production of monoclonal antibodies in CHO cells by supplementing the media with additional 
methionine, tryptophan and tyrosine due depletion of those amino acids in conditions of excess 
glutamine and glucose. 47. The wide-ranging applications to which metabolomic data contributes to 
cell culture processes attests to the depth and versatility of the tool. Beyond analysing pure cell 
cultures, which provides metabolomic views of an entire organism, the metabolomic approach also 
has potential in deciphering whole biological systems, such as the human body. 
2.3 The Human Gut Microbiota 
The microbiota of the human gut is an intricate community that interacts symbiotically with the 
human host to influence health and physiology. It is estimated that the number of microorganisms 
residing within the human gastrointestinal (GI) system (Figure 2-1) is approximately 1014 cells, ten 
times that of the number of human cells in the body49. Such a complex ecosystem of microorganisms, 
mostly bacteria50, interact closely with its environment via genetic and metabolic signals. Over the 
past decade, there has been an increased interest in characterizing the human gut microbiota through 
analyses of such signals. On one hand, the establishment of the Human Metagenomic Project (HMP) 
Consortium and the Metagenomics of Human Intestinal Tract (MetaHIT) reflect some of the 
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 collective efforts researchers have put forth to use genetic characterizations to identify the microbiota 
and the roles they play within the microbial ecosystem and with the human host51,52. On the other 
hand, metabolomic studies have been used to explore and understand relationships involving the gut 
microbiota which are not encoded within the genome53. Complementary to metagenomic studies, 
researching the metabolic interactions amongst the gut microbiota and with the host cells have 
contributed tremendously to establishing relationships between bacterial communities and with the 
human body, in healthy and disordered states54. 
  
 14 
  
Figure 2-1. Anatomy of the human GI tract. Segments of large intestines labeled in black; segments 
of small intestines labelled in grey. 
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 2.4 Metabolomic Study of the Human Gut Microbiota  
When applied to bacterial communities, metabolomic approaches give insight into the metabolic 
activities engaged by the entire population. Within the context of the human gut microbiota, the 
mixed culture metabolome not only reflects the metabolic activities of the enteric bacteria, but it also 
represents the bacterial compounds to which the human body is exposed. Metabolomic studies of the 
human gut microbiota have been heavily focused on analyzing the compounds found in feces. 
Understanding gut bacteria through feces is an attractive approach as the procedure is non-invasive, 
yet still provides a wealth of information on the human-gut microbe relationship. Specifically, the 
study of the aqueous phase of feces, referred to as fecal water, has provided valuable information 
regarding host-bacterial changes under different conditions. The fecal metabolome was demonstrated 
to be an effective tool in assessing dietary effects, such as polyphenol-rich diets55, daily apple 
intake56,  and red meat consumption57. In clinical research, investigating the fecal metabolome has 
resulted in biomarkers for Crohn’s disease58 and colorectal cancer59, and has been an effective 
diagnostic tool for ulcerative coslitis3 and irritable bowel syndrome60. The ability to obtain these 
findings via a non-invasive procedure is one of the main benefits of using feces to study the gut 
microbiota. Unfortunately, fecal samples have been shown to vary greatly between individuals and 
within an individual over time due to differences in gut physiology and variable diets, which in turn 
can affect properties of fecal samples, such as pH, moisture level and metabolite concentrations61.  
Therefore, one of the main drawbacks of examining stool samples is the heterogeneity of the matrix 
and the lack of standardization in preparing and analyzing the samples. There has been some effort in 
establishing optimised preparation procedures of fecal samples for the purposes of analyzing just the 
exometabolome62, or both the intra- and exometabolomes55. However metabolomic data obtained 
from different preparation protocols and different batches of feces still cannot be performed without a 
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 means of standardizing the sample’s content. Interpretation of fecal metabolomes is further 
complicated by the fact that it is a reflection of host-microbe co-metabolism, where the fecal 
metabolome represents the cumulative effects on the host and the gut microbiota. Reproducibility of 
the metabolomic data is another obstacle in fecal metabolome research. The exact composition of the 
gut microbiota has been shown to vary with host age, nutrition, behaviour and health2,54,63, so 
controlling for such experimental factors or recreating the exact conditions of previous studies can be 
quite difficult. Therefore, a system that allows for control over the experimental parameters subjected 
to the gut microbiota would circumvent the challenges of using fecal samples to study the gut 
microbiota. 
2.5 Studying the Gut Microbiota using Model Organisms 
The use of model organisms such as mice and rats allow for greater control over the subjects’ diet and 
environment. The use of model organisms also widens the scope of experimental conditions that 
could be researched when it comes to understanding gut-host interactions, as some treatment 
conditions, such as antibiotic exposure, would have ethical limitations for human studies64. For 
example, the administration of imipenem/cilastatin sodium, a broad spectrum β-lactam antibiotic to 
Wistar rats housed in a specific-pathogen-free environment was performed to assess its effects on the 
gut microbial-mammalian co-metabolism63. Examination of the metabolome of both urine and feces 
demonstrated that profound changes to the host and microbe metabolism occurred rapidly (within the 
first day of treatment), while recovery from antibiotic treatment was gradual. The main metabolites 
that underwent large fold changes with treatment included aromatic benzene compounds, 
carbohydrates, short chain fatty acids (SCFA) and compounds of the tryptophan metabolism pathway. 
The metabolic perturbations observed were attributed to impacts on the gut microbiota rather than to 
host metabolic pathways since the antibiotic used had poor systemic absorption. At the same time, 
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 host-microbial co-metabolism was still observed as there were changes to metabolites that are found 
in both mammalian and microbial physiology. Given that the gut microbiota are different across 
different species of model organisms and from humans2, the applicability of studies performed in vivo 
can be enhanced through “humanizing” the model organisms’ gut microbiota. Germ-free or 
gnotobiotic mice, which are devoid of or have defined gut microbiota, can be inoculated with 
microbial consortia derived from human donors. Using this model, Martin et al. introduced human 
baby microbiota (HBM) to germ-free mice and examined the effects introducing Lactobacillus 
paracasei as a probiotic and a two dietary regiments (glucose-lactose mix and a galacto-
oligosaccharaide-rich prebiotic mix); all the while comparing them to conventional and 
conventionalized mice54,65. Generally, they found that HBM mice had different levels of bacteria 
compared to the HBM mice that were supplemented with a probiotic, which also had different levels 
of bacteria than conventional and conventionalized mice. On the other hand HBM mice given a 
probiotic had similar levels of gut microbes as HBM mice supplemented with both a prebiotic diet 
and probiotic treatment, though the HBM mice subjected to the prebiotic diet had greater levels of 
bifidobacteria over time. In examining the fecal metabolic profiles, specific metabolic features could 
be attributed to the HBM community, the probiotic treatment and the two dietary regiments (basal 
glucose-lactose mix and prebiotic feed). Many of these identifying metabolic signatures involved 
changes to SCFA levels, such as acetate, butyrate and propionate, amino acid changes and also 
compounds associated with energy metabolism, such as succinate, glucose and lactose. Furthermore, 
there was a time-scale component to the changes observed, where the metabolite profiles of 
conventional and conventionalized mice were stable over time, while the HBM mice under different 
diets diverged from each other over time. These experiments conducted by Martin et al. exercised the 
power of NMR-based fecal metabolomics to examine the human gut microbiota under modulated 
environmental conditions. As exemplified in the studies described, studying the fecal metabolome in 
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 an in vivo model allows one to assess the host-microbial co-metabolism and retain a moderate level of 
control over the experimental parameters, such as diet, environmental exposure and pharmaceutical 
treatment. 
2.6 Studying the Gut Microbiota In Vitro 
2.6.1 Batch Fermenters 
The gut microbiota can also be studied through in vitro models. Where there are many model designs, 
the basis of these in vitro models involve the growth of fecal microbiota in a fermentation reactor 
operating anaerobically under physiological conditions. As the complexity of the bioreactor designs 
increase, so does the resemblance of the model to biological conditions. Batch reactors consist of 
culturing fecal inoculum in a single vessel supplied with nutrients, though without replenishment. 
Since batch reactors grow the bacteria in a closed system, the growth medium strongly influence the 
growth of the community culture. In one experiment6, the microbial communities reached similar 
maximum cell densities at the same time (18 h) in three kinds of brain heart infusion (BHI) media that 
varied in carbohydrate concentration. The different kinds of media had varying ability to maintain the 
initial fecal microbiota as measured by denaturing gradient gel electrophoresis (DGGE). For example, 
the low-carbohydrate BHI medium had the greatest ability to maintain the inoculum culture as 
indicated by similar DGGE profiles, while the high-carbohydrate BHI medium resulted in a DGGE 
profile with considerably fewer bands. In general, the Bacteroidetes phylum was more dominant in in 
vitro cultures, whereas the Firmicutes phylum were less dominant in in vitro cultures. Batch reactors 
are relatively cost effective, and easy to operate66. For these reasons, batch reactors are suitable for 
experiments geared towards high-throughput screening for specific metabolic functions6, such as 
bioconversion of plant lignans by gut microbes67. Batch fermenters accommodate growth of fecal 
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 microbes only on short-term basis (24-48 h) because extended growth of the complex community can 
lead to unwanted selection of certain bacterial strains as nutrients are quickly consumed and the 
environment in the batch system changes over time. For this reason, continuous reactors that allow a 
more constant environment by replenishing nutrients and controlling pH are favored to mimic natural 
physiological conditions.  
2.6.2 Single-Stage Continuous Culture Systems 
Single-stage continuous stirred tank reactor (CSTR) models or single-stage semi-continuous culture 
systems (SCCS) allow for sustained nutrient feeding to the fecal microbes, and permit longer culture 
durations on the scale of several weeks. CSTR and SCCS models have been validated to maintain 
metabolic activity close to that of the initial fecal inoculum, as measured by hydrolytic and reductive 
enzyme activities, production of volatile fatty acids, hydrogen, methane and carbon dioxide68. Shifts 
in fecal bacteria being cultured in single stage CSTRs and SCCSs include the enrichment of bacteria 
in the phylum Bacteroidetes and diminishment of bacteria in the phylum Firmicutes, similar to 
changes observed in communities grown in batch reactors. These shifts were independently observed 
in several validation studies, though the extent of the population shifts differed across studies. For 
example, Allison et al69 observed slight decreases in overall count of anaerobes, with slight increases 
in Bacteroidetes and decreases in Firmicutes genera like Clostridia, and Eubacteria, though increases 
in other Firmicutes like Lactobacilli and Streptococci were also observed over a 14-day period. 
Campbell et al68 saw a decrease in the total number of microbes in their SCCS-cultured fecal 
communities. The fecal inocula contained seven different genera, with 81% being Bacteroides and 
Eubacterium. 31% of anaerobic colonies could not be subcultured. In comparison, the 21-day in vitro 
culture only had four different genera characterized, with 89% being Bacteroides, Eubacterium, and 
Clostridium spp and only 13% of isolated anaerobes could not be subcultured. In the CSTR system 
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 used by McDonald et al5, fecal microbial communities became enriched in phylum Bacteroidetes and 
diminished in phylum Firmicutes, such as Clostridium (cluster XIVa), and Bacilli after 4-5 weeks in 
the in vitro model.  
 Single stage CSTR systems and SCCS reactors also lend themselves to studying the effects of 
prebiotics and probiotics on gut microbial communities. Prebiotics are nondigestible food ingredients 
that selectively stimulate the growth or activity of bacteria in the GI tract, with the purpose of 
beneficially impacting the host70. Probiotics refers to live microbial supplements used to improve the 
intestinal microbial balance, with the aim of beneficially impacting the host71. Duncan et al72 used a 
range of carbohydrates to study substrate impact on microbial composition using 16S rRNA probes. 
The investigators then continued on to use these substrates to screen for highly competitive strains 
that had potential to be used as new probiotic strains. The total number of anaerobes remained the 
same with changing substrates, except when fed with pectin, which causes a global decrease in the 
number of anaerobes. Furthermore, specific bacterial populations were strongly impacted by certain 
substrates. Dhalia inulin increased Eubacterium cylindroides by 100-fold and Ruminocoocus bromii 
and Ruminococcus flavefaciens by 10-fold. The change in bacterial composition was also reflected in 
the production of SCFA. The proportional make-up of acetate-propionate-butyrate metabolites 
showed that acetate production was greatest with pectin (75%-16%-8%) and that growth on 
amylopectin produced the highest proportion of propionate and butyrate (44%-42%-14%). The 
impact of different substrates on the ability of probiotic candidates to compete with resident gut 
microbiota varied, with inulin and amylopectin facilitating the survival of Rosuria strains. Another 
application of single-stage CSTR has involved the study of fructo-oligosaccharides (FOS) as a 
prebiotic to prevent the degradation of isoflavone genistein by the gut microbiome and preserve its 
anti-carcinogenic properties73. Steer et al. found that FOS increased the total count of anaerobic 
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 bacteria, where Bifidobacterium spp. and Lactobacillus spp. were enriched and Bacteroides spp. and 
Clostridum spp. were decreased. Additionally, isoflavone genistein degradation was detected to a 
lesser extent with FOS-supplemented media than the unmodified recipe. These two examples 
illustrate the applicability of using single-stage continuous reactor systems to investigate the 
metabolic functions of the gut microbiota beyond the screening capabilities of batch reactors. 
2.6.3 Multi-Stage Continuous Culture Systems 
Characterizing the entire large intestine as a continuous culture system is still a simplification of the 
organ’s operation. In truth, only the ascending colon receives steady nutrients from the small 
intestines and performs peristaltic mixing of the colon contents. The transverse and descending colon 
experience restricted nutrient supply and no mixing. As such, the different sections of the colon – 
ascending, transverse and descending – can be represented in vitro by using multi-stage continuous 
culture (MCC) systems. There have been many types of reactor designs that aim to recreate the 
spatial, temporal, and biochemical aspects of the large intestine. Bearne et al. designed a two-stage 
reactor system, where the two vessels differed in pH74, while Macfarlane and Gibson developed a 
three-stage continuous culture system. In the three-stage system, the ascending, transverse and 
descending colon are mimicked by connecting three vessels differing in pH, operating volumes and 
dilution rates75. Compartmentalizing the different segments of the large intestines revealed that the 
bacteriological content of the three reactor resembled that of the large intestines in terms of total 
anaerobic counts, but differed from in vivo examples in terms of species make up. Population 
densities of Bifidobacteria and Bacteroides were similar to the human large intestines. But the levels 
of Clostridium perfringens were greater in the first and second reactors than the ascending and 
transverse colon, while Escherichia coli was greater in the third reactor than in the descending colon. 
These species variation from one reactor to the next also meant that the vessels were also different 
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 metabolically. Carbohydrate fermentation occurred mostly in the first “ascending colon” reactor, 
while an increase in branch chain fatty acids (BCFA) and phenolic compound due to the fermentation 
of amino acids that was observed in the second “transverse colon” reactor and third “descending 
colon” reactor.  
A more comprehensive representation of the human gastrointestinal (GI) system is the 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME) system developed by Molly et al76. 
In the SHIME system, five consecutive reactors varying in working volume and residence time are 
used simulate the entire gastrointestinal tract. The first two reactors mimic the small intestine, where 
the duodenum and jejunum are represented in the first reactor and the ileum is represented in the 
second reactor. These reactors received successive inoculations of nutrition suspension representative 
of human western diets. The last three reactors represented the three sections of the large intestine 
with each vessel receiving a single fecal inoculation. Enumeration of the bacteria revealed that the 
microbial compositions in the SHIME system were comparable to in vivo communities. Metabolic 
assessments were made through measurement of volatile fatty acids (VFA), headspace gases (CO2, 
CH4, and H2) and ammonium. Based on these parameters, there were significant differences between 
the SHIME culture and in vivo values from literature. Acetic acid, and propionic acid were generally 
found at higher molar ratios and butyric acid was consistently detected at lower molar ratios in the 
SHIME simulator compared to in vivo literature values. The headspace gas composition and ammonia 
levels were consistent across the various media types used, but differed from reference values. This 
divergence could be attributed to the use of O2-free N2 to maintain an anaerobic atmosphere. 
Constantly sparging the headspace with N2 has been shown to impact bacterial metabolism77. 
Recently, there have been modifications made to existing single stage and MCC systems to create 
anaerobic conditions using only the gasses produced by the fecal bacteria78,79. 
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 2.6.4 Mimicking Physiological Characteristics 
The continuous culture systems described thus far allow metabolites and microbes to accumulate in 
the reactors until steady-state is reached all the while having both compounds and microorganisms 
removed together. The drawback of this system is that in vivo, metabolite concentrations are 
maintained relatively low as they are absorbed by the host. The accumulation of metabolites in in 
vitro systems can inhibit growth of certain microbes. One design that has attempted to address these 
concerns, has incorporated peristaltic mixing, water absorption and metabolite absorption80,81. In this 
design, a dialysis membrane enclosed in a tubular system has been used to remove bacterial 
metabolites and water. This, combined with flexible silicone membranes undulated by water pressure 
to simulate peristaltic mixing of luminal contents, further allows the reactor to be inoculated at high-
densities despite the viscosity of the solutions. In this system, microbial stabilization was reached in 
24 hours and the in vitro community was sustained stably for over three weeks. Validation and 
characterization of in vitro microbial diversity in this system80,82 has led to applications such as 
investigating the effects of various carbohydrates, such as inulin83 and lactulose84, on microbial 
composition and metabolic activity and attributing carbohydrate fermentation functions to specific 
microbial populations by using isotope-labelled substrates and isotope-labelled RNA probing85,86. 
2.6.5 Challenges of In Vitro Models 
Despite the advances in developing bioreactor designs to mimic the human GI tract, there are still 
challenges and limitations to using in vitro models. With respects to physiological factors, in vitro 
studies of gut microbiota lack host-microbe interactions. As such, the impact of the microbial 
activities on the host organism and the host’s feedback reaction to the microbes cannot be measured. 
Furthermore, direct comparisons of community cultures from different fermentation experiments, 
even those using similar models, cannot be made. Part of the variability is attributed to inter-
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 individual differences in the bacterial make up within the gut. Since the gut microbial ecosystem is 
individually unique, in vitro communities are inherently different as they are derived from feces 
collected from different sources. Therefore, inter-individual variability must be taken into account in 
experimental designs, ensuring that treatment or disease effects are greater than biological variability. 
In terms of engineering challenges, variable retention times in the bioreactors is another confounding 
factor that impairs cross-experimental comparisons. Child et al87 found that retention time strongly 
influences substrate availability, and bacterial colonization, which in turn shapes the entire in vitro 
community. Some bioreactor model validation studies take this factor into account and characterize 
its effects75,81.  Another aspect of consideration is defining when steady-state has been established. 
The amount of time required to reach steady-state is highly variable, even within a single bioreactor 
design. For example, single-stage continuous culture systems have been observed to reach steady-
state as early as 5 days to as late as 4-5 weeks after inoculation5,68,69. Since the achievement of steady-
state is not independent of retention time, it is expected that the time required to reach a stable 
microbial environment is variable across in vitro models. Rather, attention should be focused on 
establishing a definition of steady state, whether it be based on microbial composition, metabolic 
production, or functional activity, and confirm its achievement within a given model. Lastly, in vitro 
models could easily lend themselves to metabolomic studies. However, the large majority of the in 
vitro-based investigations have placed its emphasis on microbial composition and microbial activity. 
Considerations of metabolic functions were usually probed only to the extent of VFAs of SCFAs or 
gaseous products such as H2, CO2, CH4 and NH4. Holistic examination of the metabolome of in vitro-
propagated communities could be the next avenue of characterization in the movement to understand 
the human gut microbiota.  
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 Chapter 3 Materials and Methods 
3.1 NMR Sample Preparation 
Samples analyzed with NMR spectroscopy were prepared to contain 10% internal standard solution, 
which was composed of 5 mM 4,4-dimentyl-4-sialpentane-1-sulfonic acid (DSS) and 0.2% w/v 
sodium azide in 99.9% D2O (Chenomx Incs., Edmonton, Canada). This internal standard solution 
served as a chemical shape indicator (CSI) for software analysis of the spectra, while at the same time 
inhibiting bacterial contamination of the samples. The sample-DSS solutions were vortexed and 
transferred to 5-mm NMR tubes (NE-UL5-7, New Era Enterprises Inc., Vineland, NJ) for scanning. 
Samples were prepared on the day of scanning, and kept on ice until ~10 min before being scanned to 
allow the sample to return to room temperature. 
3.2 NMR Spectra Acquisition and Processing 
The 1D-1H NMR spectra were acquired at the University of Waterloo Nuclear Magnetic Resonance 
Facility using a using the first increment of a NOESY pulse sequence (1D-NOESY) on a 600 MHz 
Bruker Avance NMR spectrometer. The NMR spectrometer was operated using XWIN-NMR 3.5 
software and a Triple Resonance Probe (TXI 600). The 1D-NOESY pulse sequence compatible with 
the Chenomx software used to analyze the NMR spectra involved a 1 s presaturation that consisted of 
a 10 ms relaxation delay with a 990 ms presaturation period for water suppression at an induced field 
strength/gammaB1 of ~80 Hz41. This was followed by two 90° high power pulses and a 100 ms 
mixing time and another 90° high power pulse before a 4 s acquisition period. The total recycle delay 
in the experiment was 5 s. A total of 4 steady state scans and 32 scans were performed to obtain NMR 
spectra for a given sample (Figure 3-1).  
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Figure 3-1. Schematic of 1D-NOESY pulse sequence. Figure credited to Chenomx application note 
on Investigating the criteria for accurate quantitative results with Chenomx NMR Suite88. 
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 Chenomx software was used to construct metabolite profiles from the 1D-1H NMR spectrum 
(Figure 3-2). The corrected experimental spectra were assigned compounds by targeted profiling, 
superimposing compound signals in the built-in library to spectral peaks. The area of the spectrum 
signal relative to the reference compound was used for metabolite quantification. Profiled 
concentrations were divided by 0.9 to adjust for dilution with the internal standard solution during 
sample preparation for NMR spectroscopy. Sample spectra in each experiment were profiled 
according to scan order.  
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Figure 3-2. NMR spectrum of typical gut-mimicking single-stage CSTR sample after phase, baseline 
and shim correction steps. 
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3.3 Metabolite Profiles 
The Chenomx software was also used to construct metabolite profiles from the 1D-1H NMR 
spectrum. The corrected experimental spectra were assigned compounds by targeted profiling, 
superimposing compound signals in the built-in library to spectral peaks allowed for assignment of 
compound identity, and the area of the spectrum signal relative to the reference compound was used 
for metabolite quantification. Sample spectra in each experiment were profiled according to scan 
order. Once the metabolite profiles were assembled, each compound was assessed post hoc for 
confidence in the compounds’ identification and quantification. Confidence in a compound was 
determined by the number of clusters in the compound’s NMR signal, level of convolution with other 
compound signatures, and the signal-to-noise ratio of the compound. Only high-confidence 
compounds were included in subsequent analyses.  
3.4 Statistical Analysis 
All statistical analysis was performed using R, the statistical programming language89. The following 
packages were used: RSQLite, RODBC, ggplot2, gridExtra, reshape2, plyr, and RColorBrewer and 
all base packages accompanying R. 
3.5 Bioreactor Operation and Inoculation 
Bioreactor operation and experimentation was performed by members of the Emma Allen-Vercoe lab 
at the University of Guelph. Preparation and operation of the single stage, continuous stirred-tank 
reactor has been previously described90,91. The Infors Multifors bioreactor system (Infors, 
Switzerland) was used throughout this body of work. 500-mL Multifors bioreactors (3 Multifors 
systems, Infors AG, Switzerland), with working volumes of 400 mL were operated as continuous 
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 stirred tank reactors. Conditions were set to mimic the distal human gut (37ºC, pH 6.9-7.0, gentle 
agitation, oxygen-free, and fed with a constant supply of mucin and insoluble starch substrates at a 
flow rate of ~400 mL/day). Maintenance of pH was automated with addition of 5% v/v HCl and 5% 
w/v NaOH. Vessels were maintained anaerobic by bubbling O2-free N2. The growth medium used in 
the bioreactor system was developed by the Emma Allen-Vercoe lab at the University of Guelph, and 
has been previously described90,91, and is outlined in Table 3-1. Prior to inoculation, a sample of 
growth medium was collected from the bioreactor vessel to assess for bacterial contamination. The 
media sample was plated on fastidious anaerobe agar (Acumedia; Lansing, Michigan) supplemented 
with 5% defibrinated sheep’s blood (Hemostat Laboratories; Dixon, California) and incubated in 
aerobic or anaerobic conditions, at 37 °C. The CSTR system used to culture the mixed bacterial 
communities was inoculated with either 25% (v/v) of 10% (w/v) fresh fecal slurry, or 12.5% (v/v) of 
defined culture suspension relative to the bioreactor working volume. Once inoculated, the culture 
was gently agitated. Medium feed was started 24 h post-inoculation.  
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 Table 3-1. Composition of growth medium. 
Reagent1 Concentration (g/L) 
Peptone waterb 2 
Yeast extractc 2 
NaHCO3b 2 
CaCl2a 0.01 
Pectin (from citrus)a 2 
Xylan (from beechwood)a 2 
Arabinogalactana 2 
Starch (from wheat, unmodified)a 5 
Caseind 3 
Inulin (from Dahlia tubers)d 1 
NaCla 0.1 
K2H2PO4a 0.04 
KH2PO4b 0.04 
MgSO4e 0.01 
Bile saltsa 0.5 
Hemine 0.005 
Menadionea 0.001 
L-cysteine HClb 0.5 
Porcine gastric mucin (type II)a 4 
  
1Chemical suppliers are indicated in superscripts: (a) Sigma-Aldrich (Oakville, Ontario); (b) Thermo Fisher 
Scientific (Ottawa, Ontario); (c) BD (Franklin Lakes, New Jersey); (d) Alfa Aesar (Ward Hill, Massachusetts); 
(e) BDH (Radnor, Pennsylvania). Chemical suppliers Adapted from McDonald et al, 20145. 
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 3.6 Collection and Preparation of Fecal Inocula 
Collection of fecal samples and the preparation of fecal inocula was performed by members of the 
Allen-Vercoe group as per the approval of the Research Ethics Board of the University of Guelph 
(REB#09AP011). The procedure was previously described and is summarized here90,91. Fresh fecal 
samples were obtained from four healthy individuals (Table 3-2), none of whom had a recent history 
of antibiotic treatment prior to time of donation. Donors provided fresh fecal samples in a sealed 
sterile plastic container which was placed in an anaerobic chamber (atmosphere 90% N2, 5% CO2 and 
5% H2) within 5-10 min of defecation. Each fecal samples were processed into a 10% (w/v) fecal 
slurry by mixing 5 g of feces in 50 mL of growth medium for 1 minute with a stomacher (Tekmar 
Stomacher Lab Blender, Seward; Worthing, West Sussex, UK). Once homogenized, the fecal slurry 
was centrifuged (10 min, 175 x g) to remove large particulates, such as residual undigested food92. 
The remaining supernatant was used as fecal inoculum for the gut-mimicking bioreactors used in the 
studies. 
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 Table 3-2. Fecal sample donors. 
Donor Sex Age 
(yr) 
Time elapsed between most recent 
antibiotic treatment and sample collection 
 
A Male 44 6 years  
B Female 26 9 months  
C Male 25 11 months  
D Female 42 8 years  
E Female 7.72 6 months  
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 3.7 Preparation of Defined Communities 
The defined community cultures were prepared and described by Schroeter, 201491. These defined 
bacterial communities were referred to as Microbial Ecosystem Therapeutic (MET) cultures as they 
were originally developed as a community culture probiotic for therapeutic purposes. In short, pure 
bacterial isolates, identified by 16S rRNA gene sequencing, were obtained from fresh feces collected 
from two different donors: Donor D, a 41-year old female and Donor A, a healthy 44-year old male. 
33 species were selected from the axenic fecal cultures isolated form Donor D to prepare a defined 
community, MET-1. Similarly, MET-2 was prepared from 33 species selected from Donor A. The 
breakdown of bacterial isolates found within MET-1 and MET-2 can be found in Table A1 and Table 
A2, respectively. Additionally, another 32 species from Donor D were selected to prepare the defined 
community, MET-2A. From the axenic fecal cultures isolated from Donor A, 32 species were 
selected to prepare the defined community, MET-3A. Once each of the bacterial strains were grown 
in pure culture using appropriate growth medium and conditions, an inoculum was created by 
combining biomass scraped from each culture plate and suspended in degassed 0.9% saline (37 °C). 
The final suspension volume for MET-1 was 30 mL while the final suspension volume for MET-2, 
MET-2A and MET-3A was 75 mL. The defined communities MET-2B and MET-3B were designed 
to be variants of MET-2A and MET-3A, respectively. MET-2B and MET-3B were prepared the same 
way as MET-2A and MET-3A, but differed from their respective parent cultures in that almost every 
isolate was added to the inocula in different proportions. The bacterial isolates for each of the four 
cultures and details of their biomass are detailed in Table A3. The same procedure for preparing 
defined community inoculants was repeated for the replicate experiment. Due to poor growth of four 
of the isolates in the pure cultures, the inocula for each of the defined communities had a different 
amount of bacteria for those poor-growth isolates as compared to the original experiment. These 
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 differences are highlighted in Table A3. None of the defined community inocula included all four of 
the poor-growth isolates, so each defined community inocula only had 2-3 isolates that were different 
between the two replicate experiments. Given that the variant communities, MET-2B and MET-3B, 
had altered biomass in nearly every isolate, the deviations between the replicate experiments’ inocula 
was considered to be negligible as any variations contributed by such differences would be 
indistinguishable from noise. A summary of the defined communities and the parent communities 
from which they were derived is shown in Table 3-3. 
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 Table 3-3. Defined Communities and Their Parent Communities 
Culture Number of 
Bacterial species 
Derived from 
Fecal Culture 
Derived from 
Defined Culture 
MET-1 33 Donor D - 
MET-2 33 Donor A - 
MET-2A 32 Donor D - 
MET-2B 32 - MET-2A 
MET-3A 32 Donor A  
MET-3B 32 - MET-3A 
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 Chapter 4 Metabolite Profiles of Media 
4.1 Chapter Objective 
While the process constructing metabolite profiles is relatively straightforward, doing so in an 
accurate and precise manner requires technical refinement. In this chapter, the techniques involved in 
obtaining the metabolite profiles of nutrient solutions is demonstrated, first through a step-by-step 
illustration, then in an experiment that exemplifies the application of the technique for the purpose of 
metabolomic analysis. The experiment presented in this chapter examined the metabolites of a semi-
well defined media for culturing Chinese hamster ovary (CHO) cells and investigated the effects of 
UV irradiation of that media on the metabolite profile of the media and on the media’s ability to 
support the culture of CHO cells. The analysis of semi-defined, unspent cell culture media is an 
appropriate platform to introduce the NMR-based metabolomic techniques developed thus far to 
analysis of nutrient solutions. 
. 
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 4.2 Constructing Metabolite Profiles 
4.2.1 Section Objective 
The purpose of this section is to illustrate NMR spectra of solutions containing a large number of 
metabolites and demonstrate how metabolite profiles are constructed from these convoluted spectra 
using Chenomx NMR suite software. 
4.2.2 Processing NMR Spectra 
The raw NMR spectra were processed manually as described in Chapter 3. Figure 4-1A depicts the 
raw NMR spectrum (0.9-1.5 ppm) of a defined media for CHO cells, where the signal peaks are out 
of phase, and neither baseline correction nor shim correction have been applied. Once the spectrum 
has been phase corrected (Figure 4-1B), baseline corrections can be made by setting the baseline 
manually. Figure 4-1C exemplifies the same NMR spectrum but with phase and baseline corrections 
applied. Figure 4-1D and Figure 4-1E show how shim correction is applied throughout the spectrum 
using the internal shape indicator, DSS. The blue DSS template is overlaid with and adjusted to fit the 
spectral DSS signal at 0.0 ppm. Mismatches between the spectral DSS signal and the software DSS 
template is considered to be a spectral artifact produced by imperfections in the NMR 
instrumentation. Therefore, all the NMR spectrum signals are altered to match DSS (Figure 4-1E). 
Figure 4-1F shows the NMR spectrum (0.9-1.5 ppm) after all the NMR processing steps. Each of 
these steps aid in producing the ideal NMR spectrum, without altering signal peak area which will 
facilitate signal identification and compound quantification in subsequent steps of building a 
metabolite profile. 
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Figure 4-1. Effects of each spectral processing step on the NMR spectrum. The NMR spectrum 
within the range of 0.9-1.5 ppm of defined media for CHO cells is used as an example. (A) Raw 
NMR spectrum, no processing steps applied. (B) Applying phase corrections. (C) NMR spectrum 
after phase correction and baseline correction. (D) and (E) Applying shim correction to DSS signal at 
0.0 ppm. (F) NMR spectrum after phase, baseline and shim corrections applied. 
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 4.2.3 Building Metabolite Profiles 
The assignment of compound identity to peak signals and quantifying those metabolite concentrations 
are performed using a targeted profiling technique. This method of interpreting the NMR spectra 
involves using the templates in the Chenomx NMR suite software library of compounds. By matching 
the compound templates to spectral signals, the identity of the compound is confirmed and the 
compound concentration is set (Figure 4-2). Assigning compound identities consistently for a given 
signal and setting compound concentration with high precision, even in areas of the spectrum with a 
high degree of signal convolution, are skills that are only developed with practice.  
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Figure 4-2. Identifying and quantifying compounds in NMR spectrum of defined CHO media (0.9-
1.5 ppm). Black line represents the NMR spectrum. Blue dotted line represents the software’s 
compound template, not yet fitted to the spectrum. Compound template fitted to the spectrum to 
confirm metabolite assignment and concentration to the corresponding signal is shown in transparent 
blue. Red line represents the sum line, showing the area of the spectrum that has already been fit with 
a compound, where overlaying templates have an additive effect. Green line represents the 
subtraction line, which is the difference between the NMR spectrum (black) and the profiled 
compounds (red). (A) Non-profiled spectrum. (B) Isoleucine. (C) Valine. (D) Leucine. Only clusters 
between 0.9 and 1.5 for each compound are shown. Signal clusters outside this range would also be 
used to determine compound identity and concentration. 
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 4.3 Treating Cell Culture Media with UV Irradiation against Adventitious 
Agents: Minimal Impact on CHO Performance 
4.3.1 Journal Article Authorship 
Sandi Yen1,#,  Stanislav Sokolenko1,#, Bhavik Manocha1, Ankit Patras2 , Farnaz Daynouri-Pancino2, 
Eric JM Blondeel1, Michael Sasges2, Marc G Aucoin1,* 
1Waterloo Institute for Nanotechnology, Department of Chemical Engineering, University of 
Waterloo, 
Waterloo, Ontario, Canada, N2L3G1 
 2Aquafine Corporation, Valencia CA, USA, 91355-4198 
#: contributed equally to this work 
*corresponding author: Marc G. Aucoin, Department of Chemical Engineering, University of 
Waterloo, Waterloo, ON, CANADA  N2L 3G1, Tel: 1-519-888-4567 x36084, Fax: 1-519-888-4347, 
e-mail address: maucoin@uwaterloo.ca 
4.3.2 Justification of Original Work 
The following journal article was published in Biotechnology Progress on July 29, 2014. The 
experiment was a collaborative project between the Aucoin group at the University of Waterloo and 
the Sasges team at Trojan Technologies (London, ON, Canada)/Aquafine Corporation (Valencia, CA, 
USA). UV irradiation of solutions and related protocols were conducted by Trojan UV, while 
metabolite analyses and cell culture experiments were performed by the Aucoin group of University 
of Waterloo. The objective of this experiment was to investigate the effect of UV irradiation on the 
chemical composition of cell culture media and to determine the level of irradiation that can be 
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 tolerated before negative effects are observed in simple batch growth cell culture. Within the Aucoin 
group the contributions towards this project must be credited to several team members under the 
supervision of Marc Aucoin. The cell culture responsibilities were shared between Sandi Yen and 
Bhavik Manocha. Antibody analyses were performed by Jann Catherine Ang and metabolite profiles 
of cell culture media were constructed by Sandi Yen. Data analysis and interpretation was performed 
by Stanislav Sokolenko. The overall manuscript was written primarily by Sandi Yen and Stanislav 
Sokolenko, with editing provided by Eric Blondeel. This work is included in this thesis because 
establishing metabolite profiles of unspent defined media was the initial step to being able to build 
metabolite profiles of complex solutions to be encountered throughout the body of the thesis. Unspent 
defined media established foundational skills in NMR-based metabolite analysis because it is a 
solution that contains many metabolites, thus producing complex NMR spectra. At the same time, the 
known composition of the media provided information on the accuracy and sensitivity of the 
metabolite profiles. In this respect, the experiment presented here fits appropriately as the preliminary 
work within this body of research. With minor editorial changes to fulfill formatting requirements, 
this chapter is substantially as it has been submitted and published in Biotechnology Progress. 
4.3.3 Abstract 
Sterility of cell culture media is an important concern in biotherapeutic processing. In large scale 
biotherapeutic production, a unit contamination of cell culture media can have costly effects. 
Ultraviolet (UV) irradiation is a sterilization method effective against bacteria and viruses while being 
non-thermal and non-adulterating in its mechanism of action. This makes UV irradiation attractive for 
use in sterilization of cell culture media.  The objective of this study was to evaluate the effect of UV 
irradiation of cell culture media in terms of chemical composition and the ability to grow cell cultures 
in the treated media. The results showed that UV irradiation of commercial cell culture media at 
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 relevant disinfection doses impacted the chemical composition of the media with respect to several 
carboxylic acids, and to a minimal extent, amino acids. The cumulative effect of these changes, 
however, did not negatively influence the ability to culture Chinese Hamster Ovary cells, as evaluated 
by cell viability, growth rate and protein titre measurements in simple batch growth compared to the 
cells cultured in control media exposed to visible light.  
4.3.4 Introduction 
Sterility is an ongoing challenge for commercial bioprocesses, particularly in the production of 
biotherapeutics, where sterility assurance levels are mandated across entire manufacturing processes. 
Major pharmaceutical companies have suffered significant losses due to both bacterial and viral 
contaminations at various stages of production93–95. Such incidents call attention to the need to 
address the risk profile associated with biopharmaceutical products. As an ingredient in the 
production process, culture media is a potential source of contamination that can propagate 
downstream and ultimately affect patient safety. Complementary media sterilization methods can 
confer additional safeguards for biopharmaceutical production and act as a viral barrier to mitigate 
contamination risks. 
Sterility assurance levels of 6, or a probability of 10-6 that a single viable microorganism 
survives the sterilization process and is present in the final product, is the level of sterility that has 
become the standard requirement for pharmaceutical products and sterilization processes96. This level 
of sterility is traditionally accomplished via terminal sterilization processes by high heat and 
pressure97,98, which can be inappropriate for solutions having heat-labile components. High-
temperature/short-time (HTST) pasteurization is also widely used as an upstream viral barrier. While 
this technology has been shown to be effective in inactivating viruses in media99,100, HTST has been 
shown to be incompatible with certain serum containing media100. Applying HTST can also cause 
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 phosphate- and calcium-based precipitates to form, ultimately impacting the operation of the HTST 
system101,102.   
As an alternative to heat treatments, aseptic procedures require all production equipment and 
components to be either ‘single-use’ disposable or steam-sterilized before use. Cell media are often 
subjected to sterile filtration with 0.22 µm filters following aseptic steps to further preclude media 
contamination97.  
Ultraviolet (UV) radiation is known to be an effective sterilant against various biological 
contaminants, including bacteria and viruses103–106. For example, active cytomegalovirus (CMV), can 
be reduced by one log with a UV fluence of 5 mJ/cm2 107, while minute virus of mice (MVM) requires 
only 2 mJ/cm2 108,109. More resistant viruses, such as adenovirus require up to 306 mJ/cm2 to achieve a 
log inactivation of approximately 6 15,16.  
UV disinfection is favourable for its non-thermal and non-adulterating characteristics, and 
has been adopted by several industries, including the biopharmaceutical industry, for packaging and 
surface sterilization applications112–115. UV irradiation is able to approach the sterilization criteria of 
6-log reduction with MS2 bacteriophage, which is used as a model challenge organism and used to 
asses reduction equivalent fluence of a UV system116–118. This makes UV irradiation a sterilization 
process fitting for diverse biopharmaceutical applications, such as in the sterilization of polyethylene 
bottles as well as the disinfection of air, water and surfaces104.  
The application of UV irradiation to cell culture media as a sterilization method has been 
limited thus far and conducted primarily in industry. Previous work on UV irradiation of media has 
suggested that treatment can result in changes to substrate concentrations or the production of various 
by-products119, possibly leading to cell growth failure120 or changes in critical quality attributes 
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 (CQA) of the final product. The objective of this work was to investigate the effect of UV irradiation 
on the chemical composition of cell culture media and to determine the level of irradiation that can be 
tolerated before negative effects are observed in simple batch growth cell culture. 
4.3.5 Materials and Methods 
4.3.5.1 Experimental design 
Two culture media were evaluated in this study: a protein-free, serum-free, chemically defined 
medium optimized for the growth of Chinese hamster ovary (CHO) cells and expression of 
recombinant proteins in suspension culture, as well as Media 199 (M199), formulation 11150, a fully 
defined protein-free, serum-free media used to culture chick embryo fibroblasts. Four UV irradiation 
doses were considered in this work, 110 mJ/cm2, 180 mJ/cm2, 250 mJ/cm2, and 400 mJ/cm2. Due to 
the wide range of UV fluence at which bacteria and viruses are inactivated, these high level dosages 
were selected to be effective against both bacteria, which are more UV-sensitive, and viruses, which 
tend to be more UV-resistant110. Fluence was estimated based on the log-reduction of MS2 
bacteriophage in the media given that 110 mJ/cm2 yields a 5-log reduction of this organism. 
To best characterize the overall chemical changes in media, we used a nuclear magnetic 
resonance (NMR)-based metabolomics approach to characterize a large variety of media metabolites 
that could potentially be affected by the UV treatment. To achieve a high level of confidence in the 
observed effect of UV treatment on metabolite concentrations, each treatment was repeated 3-6 times 
per sample set, with multiple sample sets generated over a 4 month period. This allowed the 
separation of observation and process variability from the quantification of treatment effect.  
The impact of UV irradiation on cell growth was determined by culturing cells in treated 
media. Two controls were used for the analysis: unmodified media that had not been treated in any 
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 way, which is referred to as samples receiving 0 mJ/cm2, and non-irradiated samples that had been 
stirred and exposed to air for the same duration as the UV-irradiated samples. 
4.3.5.2 Media irradiation 
Irradiation of media was executed by Trojan Technologies (London, Ontario, Canada). A collimated 
beam apparatus equipped with a low-pressure mercury lamp emitting at 254 nm was used for uniform 
and quantified UV irradiation of media121. The calibration, fluence determination and quality 
assurance protocols associated with UV irradiating solutions were carried out according to 
standardized practices in the water disinfection industry122. The media was irradiate at low volumes, 
~5 mL, in 10-mL beakers with stirring to ensure uniform UV delivery throughout the liquid solution.  
The actual UV fluence delivered to the media was calculated based on the measured UV dose emitted 
by the collimated beam and the optical properties of the media being treated. 
4.3.5.3 Verification of UV fluence 
In order to establish the actual UV fluence values delivered to the culture media, a viral clearance test 
was conducted using a challenge organism inoculated into the culture media. The challenge organism, 
MS2, is a single-stranded RNA virus, with an icosahedral shell approximately 27 nm in diameter, 
used extensively in validation of UV disinfection systems for drinking water123. 
MS2 bacteriophage was suspended in phosphate-buffered saline and irradiated in a collimated 
beam to various UV fluence values. The buffer used in this characterization had high transparency at 
254 nm, typically 90% at 1 cm, so that the UV intensity gradient in the fluid was small, and therefore 
the uncertainty in the UV fluence was small. The 254 nm irradiance at the sample surface was 
measured using a radiometer with NIST-traceable calibration. The UV fluence gradient caused by 
optical absorbance of the fluid, along with the effects of beam divergence, non-uniformity, and 
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 surface reflection were all accounted for as recommended in the standard method. The samples were 
stirred during irradiation to ensure that all organisms were exposed to the same integrated UV fluence 
over the course of the irradiation. After irradiation, each sample was diluted serially and aliquoted 
into culture tubes containing 1 mL Escherichia coli broth culture and 20 mL of molten tryptone yeast 
extract glucose agar containing triphenyl tetrazolium chloride. The mixtures were mixed by inversion 
and plated into sterile Petri dishes. The agar was allowed to solidify and the plates were incubated at 
35_C60.5_C for 18–24 h before performing a plaque assay. The plates were then evaluated to 
determine the number of plaque forming units. By comparing with the control (non-irradiated) 
sample, the relationship between UV dose and the log-reduction of this population of MS2 was 
established. 
With the UV-sensitivity of the organism determined, the UV dose applied to the culture 
media was determined by using MS2 as the dose indicator. This is sometimes denoted as “Reduction 
Equivalent Dose (Fluence),” since it is inferred from the log reduction of a well-characterized 
challenge organism. MS2 from the characterized population was inoculated into samples of the 
culture media, and the optical properties of the inoculated media were measured. The optical 
properties of the media were used to calculate the irradiation times necessary to achieve a desired UV 
dose in the collimated beam apparatus. The samples were then irradiated for the prescribed time, and 
then serially diluted and cultured as described above. The log reduction in numbers of active MS2 
were used to calculate the UV dose received by the media in each irradiation by using the sensitivity 
of the MS2 as established by the buffer tests. The resulting Reduction Equivalent Dose vs. target dose 
has been plotted and may be seen in Figure 4-3. This relationship was used to determine the UV 
fluence values used in subsequent irradiations of mammalian cell culture media. 
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Figure 4-3. Received UV fluence in commercial media measured by bioassay (MS2 bacteriophage) 
vs. target value. The “Reduction Equivalent Dose (R.E.D.)” applied to the culture media was 
determined by well-characterized MS2 phage as the dose indicator (Target dose). 
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 4.3.5.4 Cell culture 
CHOBRI cells, obtained from the National Research Council Canada, were suspension-adapted cells 
grown in proprietary, serum-free growth media blend, BioGro-CHO, supplied by BioGro 
Technologies Inc. (Manitoba, Canada). The cells were adapted to grow in a commercial serum-free, 
chemically-defined CHO media, supplemented with GlutaMAXTM (Invitrogen Corp., Burlington, 
Canada) and HT Supplement (Invitrogen Corp., Burlington, Canada). The parental culture was 
routinely maintained in shaker flasks kept in a humid incubator (37º C, 5% CO2) and agitated at 100 
rpm. Both the parental and experimental cultures were cultured in 125 mL, graduated non-pyrogenic 
polycarbonate Erlenmeyer flasks (Corning Inc., NY, USA). Once the mother flask reached a viable 
cell density of 2-3x106 cells/mL, the experimental cultures were inoculated at a seeding density of 
0.2x106 viable cells/mL. 
For culture tests, the irradiated and control samples of CHO media were supplemented with 
GlutaMAXTM and HT Supplement after media irradiation and prior to inoculation. GlutaMAXTM and 
HT Supplement were not subjected to UV irradiation in these experiments. Multiple irradiated 
samples were pooled to achieve 15-20 mL volumes required for culture growth and supplemented as 
above. 
4.3.5.5 Cell count 
Each experimental culture was counted at 24-hour intervals for five days using both the classic 
haemocytometer counting method, and with a Coulter Counter Z2 (Beckman-Coulter, Miami, USA) 
for cell size distribution analysis. Samples counted in the haemocytometer were prepared in a 1:2 
dilution with Trypan blue (10% w/v in PBS) before loading the diluted sample into the counting 
chamber. In circumstances where the cell count was greater than 3-4 x 106 viable cells/mL, the 
sample was diluted by a factor of 10 using CHO media as the diluent, while maintaining a 50:50 ratio 
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 of dye to sample and diluent. Cell size distributions were obtained from a Coulter Counter Z2 by 
loading samples diluted 100-fold in Isoton® II solution. Cell viability was also calculated daily based 
on haemocytometer counts. 
4.3.5.6 NMR spectroscopy and metabolite profiling 
NMR samples were prepared by the combination of 630 μL of media and 70 μL of internal standard 
composed of 99.9% D2O with 5 mM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) serving as a 
chemical shape indicator (CSI) and 0.2% w/v sodium azide to inhibit bacterial growth (Chenomx Inc., 
Edmonton, Canada). The solution was vortexed and pipetted into 5 mm NMR tubes (NE-UL5-7, New 
Era Enterprises Inc., Vineland, NJ, USA) for scanning. NMR spectra were obtained with a 600 MHz 
Bruker Avance spectrometer, equipped with a Triple Resonance Probe (TXI 600). The spectra were 
acquired using the first increment of the NOESY pulse sequence with a 1-second presaturation pulse, 
followed by a 4-second acquisition time. All spectra processing was carried out with Chenomx NMR 
Suite 7.5 (Chenomx Inc., Edmonton, Canada). Baseline, phase, shim, and chemical shape corrections 
were all performed manually using tools available with the software. Briefly, baseline correction was 
carried out by the selection of cubic spline points to subtract from the observed spectra, while shim 
correction corresponded to reference deconvolution to remove line asymmetry124. Subsequently, 
compounds were quantified by targeted profiling. The observed spectra were superimposed with 
Chenomx’s built-in library of chemical resonances, with metabolite concentration quantified using 
DSS as a reference compound (for more information on targeted profiling, see Weljie et al.31). 
4.3.5.7 Antibody titer 
After 5 days of culturing, the supernatant for the CHO cultures were collected. Each acquired sample 
was concentrated down to 1 mL volume using a Centriprep Centrifugal filter unit with an Ultracel-10 
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 membrane (EMD Millipore, MA, USA). The concentrated samples were passed through a Protein A 
HP Spin Trap column (GE Healthcare) and purified IgG antibodies were collected. Antibody titer 
(total extracellular protein) was determined using a PierceTM BCA protein assay kit (Pierce 
Biotechnology, Rockford, USA). 
4.3.6 Results 
4.3.6.1 NMR metabolite analysis 
Twenty-eight compounds were identified and quantified in the media by NMR, of which twelve 
compounds were found to have statistically significant trends with respect to UV irradiation: 
pyruvate, acetate, arginine, lysine, threonine, tryptophan, tyrosine, choline, methionine, formate, 
ethanolamine and pyridoxine (in decreasing order of concentration change). When the concentration 
profiles of these compounds were compared to changes from exposure to visible light and air (without 
UV) in the control samples, it was found that five compounds had similar changes from visible light 
and air exposure: arginine, threonine, choline, methionine, and ethanolamine. These changes may be 
related to exposure to oxygen or to the effects of room light, but are not related to UV exposure, since 
there was negligible UV exposure in these controls. Concentrations of pyruvate, acetate, and formate 
were also observed to change with exposure to visible light and air, albeit much less than under UV 
treatment. Therefore, the observed concentration changes of only seven compounds could be directly 
linked to UV exposure - pyruvate, acetate, lysine, tryptophan, tyrosine, formate, and pyridoxine. The 
concentration profiles of these compounds were all approximately linear as a function of UV fluence 
(Figure 4-4). The specific concentration changes can be seen in Table 4-1, calculated per 100 mJ/cm2 
of UV fluence. Amino acids changed the least in relative concentration, ranging from decreases of 3% 
to 7%. A much greater effect was observed for the carboxylic acids, with acetate concentration, for 
example, increasing twofold. 
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Figure 4-4. Compound concentration as a function of UV fluence. The box-plots contain aggregated 
data from multiple experiments in which exposures were performed 3-6 times at each level. 
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 Table 4-1. Changes in compound concentration per 100 mJ/cm2 of UV dose.2 
Compound Concentration Change (μM) Concentration Change (%) 
Pyruvate -218.7 +/- 6.6 -13.0 +/- 0.4 
Acetate 152.1 +/- 3.4 164.0 +/- 3.6 
Lysine -91.5 +/- 21.4 -3.7 +/- 0.9 
Tryptophan -70.6 +/- 5.6 -6.9 +/- 0.5 
Tyrosine -39.6 +/- 7.2 -3.3 +/- 0.6 
Formate 13.2 +/- 0.5 86.5 +/- 3.5 
Pyridoxine -2.0 +/- 0.2 -15.6 +/- 1.6 
 
  
2Linear regression was performed on the change in compound concentration as a function of UV dose with the 
presented number corresponding to the predicted concentration change per 100 mJ/cm2 (with the +/- 
representing standard deviation). 
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 4.3.6.2 Cell culture 
Cell culture performance was primarily assessed by viability, growth rate, and final cell 
concentration. Controls (exposed to visible light) were cultured alongside cultures grown in UV-
treated media to account for changes in cell behaviour. Overall, UV-treatment of the media did not 
have a significant effect on cell growth. Therefore, any variability observed in cell growth and protein 
production can be attributed to random effects imparted by the experimental environment, such as 
visible light. Cell viabilities of both treated and control samples were routinely above 95%, with no 
significant difference between the two groups as tested by paired Student’s t-test at the 95% 
confidence level. Additionally, no differences were observed in cell size distributions (data not 
shown). Growth rates can be seen in Figure 4-4A and the final cell concentrations in Figure 4-5B. 
Overall, the differences between treated and control cultures were not statistically significant.  
In the course of this study, quail muscle fibrosarcoma (QM5) cells were also cultured in 
M199 media treated with a dose of 110 mJ/cm2. No differences were observed between QM5 cells 
grown in UV-treated and those grown in control media. In both cases, the cells were able to reach 
confluence within 4 days, with no apparent changes in morphology. Higher UV doses were not 
assessed for this media. 
4.3.6.3 Protein titre 
Similar to the growth data, recombinant IgG protein titers from the CHO cells were found to be very 
similar for UV-treated and control media. Comparing the yield on a purely volumetric basis suggested 
that UV-treated media may result in somewhat better protein production (Figure 4-5C). However, 
when integrated viable cell density was used to calculate specific protein production levels on a per-
cell basis125, there were no significant differences in protein yield (Figure 4-5D).  
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Figure 4-5. (A) Comparison of cell culture performance on control (white) and treated (grey) media. 
In all cases, controls (exposed to visible light) were cultured alongside cultures grown in UV-treated 
media to account for changes in cell behaviour over a 4-month period. No statistically significant 
differences were observed between treated and control media for any of the culture parameters, as 
assessed with a two-sample t-test at a 95% confidence level. a) Mean exponential phase growth rates 
(with standard errors) for cell cultures grown in UV-treated and control media. Values were 
calculated from the log-regression slope of concentration data from days 1-3. (B) Mean final cell 
concentrations (with standard errors) for cell cultures grown in UV-treated and control media. For the 
250 mJ/cm2 dose, the cultures grown on treated media resulted in nearly identical final 
concentrations, leading to overlapping error bars. (C) Mean protein yield (with standard errors) for 
cell cultures grown in UV-treated and control media. (D) Mean specific protein yield (with standard 
errors) for cell cultures grown in UV-treated and control media. Values were calculated by dividing 
the volumetric protein yield by the integrated viable cell density. For the 250 mJ/cm2 dose, the 
cultures grown on treated media resulted in nearly identical specific protein yield, leading to 
overlapping error bars.  
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 4.3.7 Discussion 
Although UV irradiation has been previously reported to negatively impact cell growth120, the 
limiting UV dose values were not indicated. No negative effect was observed in this work for either 
CHO cells grown in UV-irradiated CHO medium or QM5 cells grown in UV-irradiated M199, 
suggesting that the impact of UV-irradiation cannot be generalized, or the effect is only encountered 
when pushing the culture beyond a simple single batch process. The metabolic changes observed due 
to UV irradiation of media did not impact the overall pH measurement of the media solutions used. It 
should be noted that we have observed pH shifts in other irradiated media (data not shown), though 
none in this work. This is in part due to the sodium bicarbonate buffer in the media and the relatively 
small absolute changes of impacted compounds, such as acetate.  
Observed changes in substrate concentrations were also limited. Amino acid concentration 
changes that did occur were on the order of 1-7% per 100 mJ/cm2. Most cell culture media contain 
these compounds in excess so the extent of degradation of amino acids from UV irradiation, even at 
high UV doses, is unlikely to impact culture performance. The small changes in substrate 
concentration also meant that any specific degradation products were generally masked by overall 
compound variability, which we have previously found to be approximately 5%-10% for most 
compounds, measured as a coefficient of variation39 . Pyridoxine was the only vitamin that could be 
observed with NMR, and therefore no general conclusions can be made about overall vitamin 
stability. However, the cell growth data indicates that the level of vitamin degradation was too low to 
impact cell growth compared to our control.  
The largest changes in compound concentration in these media were observed for carboxylic 
acids. Pyruvate concentrations were found to decrease by approximately 13% per 100 mJ/cm2, with 
acetate and formate increasing by 160% and 90% per 100 mJ/cm2, respectively. This corresponded to 
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 absolute changes of 218 μM, 152 μM, and 13 μM for pyruvate, acetate, and formate respectively. The 
three compound concentrations showed parallel trends in both control (visible-light-exposed) and 
treated media. Considering the high degree of precision in its quantification (2% coefficient of 
variance including set-to-set variability), pyruvate concentration can be seen as an attractive marker 
for assessing the overall effect of UV treatment in cell culture media using NMR spectroscopy. As 
previously mentioned, no additional impact on cell growth was observed compared to the control in 
spite of such changes to these metabolites.  
This decrease in pyruvate is not altogether surprising. Pyruvate has been previously identified 
to be a prominent antioxidant in biological systems and has been found to yield acetate when reacting 
with peroxynitrite, a powerful oxidant126, or hydrogen peroxide127. It may serve a similar role in the 
quenching of oxidative products formed during UV treatment. Based on absolute concentration 
changes, it would appear that acetate is the major product of such reactions, although formate may 
also be involved.  
The UV doses applied in this study would achieve disinfection for most adventitious agents 
relevant to CHO cell culture, such as mouse minute virus and reovirus95,103,110. Since filtration is seen 
as an effective method to remove larger virus and bacteria, UV disinfection is primarily seen as a 
complementary method to inactivate adventitious agents not captured by filtration.  
4.3.8 Conclusion 
The UV doses applied in this study did not functionally impair the culture media tested, as measured 
by cell growth and antibody production of CHO cells. Cell morphology was not impacted and the cell 
size distribution was comparable between cultures grown in UV-treated media and control media that 
had only been exposed to visible light. These findings were consistent at various fluence levels, even 
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 at very high exposure levels of 400 mJ/cm2. QM5 cells were also unaffected by media irradiation, 
though media was only exposed to UV doses up to 110 mJ/cm2. Changes to major media components 
were largely limited to carboxylic acids, with only minimal changes in amino acid concentrations. 
The findings in this study serve as a demonstration of some of the changes that can occur to cell 
culture media after applying UV sterilization. While these results cannot be generalized to all cell 
lines and culture media, this study provides insight into the effects of UV-sterilization in cell culture 
applications.  Further validation with investigations focusing on longer culture duration, higher cell 
densities, repeated passaging in UV-treated media, and ultimately the effect on protein product 
critical quality attributes is currently being undertaken. 
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 Chapter 5 Standardization of Fecal Water Samples and Analysis 
5.1 Chapter Objective 
The focus of this chapter is on setting a level of standardization on reporting on the fecal metabolome. 
Fecal water is the aqueous phase of fecal samples that is prepared by adding water (buffer) to feces, 
mixing and recovering the liquid phase after removing the solids and centrifugation. Even though 
fecal water is the accepted means of studying gut microbiota2–4, there is still a need to developing a 
standard means of preparing and reporting on the biofluid for metabolomic purposes. Granted, there 
have been investigations into various approaches for studying fecal water using other metabolomic 
tools20,21. To develop an appropriate standard for reporting on fecal metabolome, metabolite profiles 
of fecal water obtained from varying water to feces ratio were examined to determine the minimal 
concentration of feces required for metabolite analysis of fecal water, and propose normalization 
techniques for reporting on fecal metabolomes. 
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 5.1.1 Materials and Methods 
5.1.1.1 Preparation of Fecal Water Samples 
Fecal water samples were prepared as follows. Stool samples were collected from Donor E, a 
neurotypical, physiologically healthy female (Table 3-3) with no dietary restrictions or any use of 
antibiotics within 6 months of sample collection. After collection, samples were stored at -80 °C. 
Frozen stool samples were thawed and the desired amount was weighed into a bag, along with 
autoclaved PBS. The stool-PBS mixture was homogenized in a stomacher for 1 minute, and the slurry 
was subsequently ultracentrifuged for 2 hours at 50 000 rpm, 4°C. The supernatant was extracted by 
needle and syringe. The supernatant in the syringe was shaken vigorously and then passed through 
0.22 µm syringe filter. The samples were prepared in increasing concentrations of feces, between the 
ranges of 8-35% (w/v) (Table 5-1), and aliquoted into duplicate samples. Fecal water samples were 
stored at 4°C until transport (on ice) to the Aucoin lab the next day. The samples were stored at -80 
°C upon receipt of the samples until NMR analysis 12 days later. On the day of NMR scanning, fecal 
water samples were thawed at room temperature and prepared for NMR spectroscopy as outlined in 
the Chapter 3. 
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 Table 5-1. Fecal concentration of fecal water samples. Duplicate samples were 
provided for each fecal concentration. 
Mass of raw 
stool samples (g) 
Volume of 
PBS (mL) 
Fecal concentration 
(g/mL) 
Fecal concentration 
(w/v %) 
2.6 30 0.09 9% 
5.6 30 0.19 19% 
15.2 60 0.25 25% 
8.2 30 0.27 27% 
9.1 30 0.30 30% 
20.6 60 0.34 34% 
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 5.1.1.2 Statistical Analysis 
Trends in metabolite concentration due to changes in fecal concentration were evaluated for linearity 
by using linear regression. Correlations were evaluated with Pearson product-moment correlation 
coefficient, r. Normalizing compound concentrations to be independent of fecal concentration was 
calculated by dividing metabolite concentration by fecal concentration. Normalizing compound 
concentrations to acetate, an internal metabolite was calculated by dividing the metabolite 
concentrations by the concentration of acetate from the same metabolite profile.  
5.1.2 Results 
5.1.2.1 Fecal Water Analysis and Sample Preparation 
In total, 39 compounds were identified and quantified in each of the metabolite profiles of the fecal 
water samples. An overview of the profiles indicated that there was a linear relationship (p < 0.05 at 
the 95% confidence level) between the fecal concentration and the metabolite concentrations. 
Furthermore, there was a strong positive correlation (correlation coefficient > 0.74) between the fecal 
concentration at which the samples were prepared and the observed compound concentrations (Figure 
5-1). The only compound that did not follow this trend was ethanol. Ethanol did not have a significant 
linear relationship between compound concentration and fecal concentration. The changes in 
compound concentrations were apparent even by comparing the NMR spectra directly (Figure A1). 
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Figure 5-1. Metabolite profile overview. Compounds exhibiting significant linear relationship and a 
strong correlation between metabolite concentration and fecal concentration are identified by 
illustrating the trends in a solid black line. Otherwise, a dashed line is used. Mean concentration from 
duplicate samples shown. 
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 5.1.2.2 Normalization of Metabolite Concentrations 
The linear relationship between metabolite concentration and fecal concentration means that 
metabolite concentrations can be normalized as metabolite concentrations per unit of feces. Dividing 
the metabolite concentration by fecal concentration expresses the metabolites in terms of mmol/g of 
feces. Given that all the samples examined here were identical in composition and different only in 
their dilution, the normalized metabolite concentration should be very similar across different fecal 
concentrations. Indeed, the spread of the normalized values is quite narrow for each compound 
(Figure 5-2A). 
Alternatively, metabolite concentrations can be normalized to an internal compound such as 
acetate. Since acetate was a compound that was consistently found at high levels (~4 times larger than 
the next most abundant compounds), it is an attractive marker to gage the contents of the fecal 
samples. Normalizing the metabolite concentrations to acetate was performed by dividing each 
metabolite concentration by the mean acetate value for each fecal concentration. Reporting 
compounds as a percent of acetate presented the metabolite concentrations independent of fecal 
concentration. The success of acetate-normalization was demonstrated in the narrow range observed 
in the acetate-normalized values for every compound. (Figure 5-2B). 
In comparing the efficacy of each type of normalization, it was noticeable that the spread of 
normalized values, as measured by range, in acetate-normalized values is generally smaller than that 
of the normalization by fecal concentration. The reason that range is used for the comparison instead 
of standard deviation was because standard deviation is a measurement that is magnitude dependent. 
Inherent to the normalization method, acetate-normalized values must be between 0 and 1, while the 
fecal concentration-normalized values must be within 1-3 orders of magnitude of the original mM 
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 concentration. The scale differences between the two types of normalization limit the meaningfulness 
of comparing the standard deviation values directly.  
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Figure 5-2. Normalized compound concentrations. Bars represent range of normalized values. (A) 
Normalized by fecal concentration. Calculated by dividing observed compound concentration (mM) 
by fecal concentration (g/mL). (B) Normalized by mean acetate concentration. Calculated by dividing 
observed compound concentration (mM) by mean acetate concentration for each fecal concentration. 
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 5.1.2.3 Impact of NMR Spectra on Metabolite Profiles 
As mentioned before, 39 compounds were included in the metabolite profiles of the fecal water 
samples. Even though all 39 compounds were assigned and quantified with relatively high 
confidence, certain compounds became increasingly difficult to profile as fecal concentration 
decreased. The decreased resolution, related to the signal-to-noise ratio of the spectra, can yield larger 
variance in compound quantification, or even impair proper assignment of compound identification. 
Examples of compounds that had signals that were sensitive to low fecal concentrations included 
proline, choline, pyroglutamate, p-cresol, arabinose, and glucose (Figure 5-3, Figure A2). For 
example, proline and glucose both had clusters within the 3.2-3.55 ppm range of the spectrum that 
were crucial for both identification and quantification of these two compounds, as they are relatively 
free of convolution with other metabolite signals in this region. As seen in Figure 5-3, proline and 
glucose clusters were far less prominent relative to the spectrum’s noise levels in the low fecal 
concentration sample compared to the high fecal concentration sample. So, in the spectra representing 
higher concentrations of feces, compounds such as proline and glucose could be assigned and 
quantified with relatively high accuracy and confidence. However, if the low fecal concentration 
samples were profiled independently, i.e. in the absence of also profiling high fecal concentration 
samples, these compounds could be lost due to the lack of evidence for profiling those subtle signals. 
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Figure 5-3. Profiling confidence impacted for certain compounds. (A) Spectrum overlay of 
metabolite profiles of samples for different fecal concentration (3.2-3.55 ppm). (B) Comparison of 
spectra for lowest fecal concentration (9%) with highest fecal concentration (34%); specifically 
looking at signals for proline and glucose – two compounds which had profiling confidence sensitive 
to fecal concentration. Metabolite signals highlighted in red represent concentrations profiled to fit 
the low fecal concentration spectrum. Light grey line represents the subtraction line between the 9% 
fecal water spectrum and all profiled metabolites. Note: only the proline and glucose NMR signal 
clusters found within 3.2-3.5 ppm are presented here. 
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 5.1.3 Discussion 
5.1.3.1 Trends in Metabolite Profiles 
The metabolite profiles followed a linear trend as fecal concentrations decreased, as expected. 
Ethanol was the only compound that did not have a strong, linear relationship between compound 
concentration and fecal concentration. Currently the reason for such a randomized pattern of ethanol 
concentration observed is unclear. While vapour pressure could be a contributing factor, other volatile 
compounds, such as methanol, which has a higher vapour pressure than ethanol128, did not exhibit 
random patterns. 
5.1.3.2 Normalization of Metabolite Concentrations 
The metabolite concentrations were normalized to the amount of feces present in the samples by 
dividing the metabolite concentrations by the concentration of feces used to prepare the samples. The 
normalized compound concentrations were calculated to be very similar across samples of various 
fecal concentrations, re-enforcing the linear relationship between the two parameters. While 
normalizing the metabolite compounds by fecal concentration enables one to compare samples 
prepared from the same stool sample, it does not address the variability in water content from one 
stool sample to the next. Not accounting for the water content of the original stool sample leaves 
dilution as a factor that is not fully controlled in preparation of fecal water samples, and could 
ultimately skew the metabolite measurements. One means of overcoming this challenge is to estimate 
the water content of feces by weighing the stool sample before and after freeze drying129. Therefore, a 
true means of normalizing metabolite measurements to fecal matter content would account for 
dilutions made during the fecal water preparation process as well as dilution due to the water content 
of the original stool sample. 
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 Alternatively, reporting the metabolite concentrations independent of feces content 
circumvents measurement of water content and fecal water dilutions. Normalizing the metabolite 
profile to the most prominent compound, acetate, presented the metabolites independent of fecal 
concentrations, while still able to make comparisons across several fecal donations. Acetate is an 
attractive normalization marker as it is one of the main microbial fermentation products and has been 
consistently reported as one of the most abundant compound found in fecal metabolomes3,61,130. Even 
in in vitro conditions designed to favour production of other SCFAs, acetate is still present in a 
relatively significant amount131. In performing this normalization, the acetate-normalized compound 
concentrations had small standard deviations, which corresponded to the linear regression model for 
compound concentration vs fecal concentration. In fact, compared to normalization by fecal 
concentration, acetate-normalization yielded a narrower spread of normalized values obtained from 
samples varying in amount of feces content. It should be noted that since acetate-normalization 
expresses compounds as a ratio, evaluations on acetate levels and comparisons of metabolite levels 
based on magnitudes are masked. Therefore, it would be ideal to report on both the compound 
concentrations, as well as their ratio values. 
5.1.3.3 Impact of Spectral Limitations 
The “profile-ability” of the NMR spectra of fecal water samples should also be taken into 
consideration when choosing the appropriate fecal concentration. As the fecal concentration 
decreases, the signal-to-noise ratio of low-concentration compounds worsens and the accuracy and 
confidence at which the compound can be quantified and identified deteriorates. Proline, choline, 
pyroglutamate, p-cresol, arabinose and glucose were highlighted as compounds with which the 
profiling confidence was sensitive to low fecal concentrations. Even though they were not necessarily 
the compounds found at the lowest concentration in the profiles, they had lower thresholds for 
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 limitations of quantification and identification due to their chemical shift, surrounding peak signals, 
and signal-to-noise ratios of peaks. Essentially, at low fecal concentrations, the metabolite 
concentrations of certain compounds were no longer within the limit of quantification, and in the case 
of arabinose, within the limit of detection. These profiling concerns pertain mostly to the fecal water 
samples of 9% and 19% fecal concentration. In comparing the samples containing fecal water within 
the range of 25%-34% fecal concentration, the higher fecal concentration samples did not differ 
greatly from the mid-range fecal concentration, in terms of ability to distinguish compound signals 
from noise signals. 
5.1.3.4 Minimum Level of Feces Required in Fecal Water Samples 
As mentioned earlier, the composition of fecal samples can be highly variable; for example, a gram of 
one stool donation could have more water content than one gram of another stool donation. Instead of 
evaluating a fecal water sample based on its concentration of feces, the sample could be identified 
based on an internal compound. Acetate is a compound that has been consistently observed at high 
concentrations in fecal water samples, and could be used not only to normalize the compound 
concentrations, but also to gage the contents of the fecal water sample. The samples of decreasing 
fecal concentration demonstrated that fecal concentrations at 25% and higher had metabolite profiles 
that sufficiently cleared the limit of quantification and limit of detection for all the compounds. This 
minimal fecal concentration could also be expressed as 7.3 mM of acetate, or 0.43 g/L of acetate. The 
linear relationship between fecal concentration and acetate concentration as well as the ubiquity of 
acetate in fecal water sample enables this compound to act as a proxy in evaluating the contents of 
fecal water samples. 
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 Chapter 6 Metabolomic Characterization of Gut-Mimicking CSTR 
6.1 Chapter Objective 
The purpose of this chapter is to use a metabolomic approach to evaluate the in vitro tools used to 
study the human gut microbiota. Two experiments were performed with the aim of establishing 
further methodological understanding of both fecal water samples and community cultures grown in 
vitro in an anaerobic continuous stirred tank reactor (CSTR). The first experiment focused on 
developing a protocol for preparing samples of gut microbiota grown in vitro for NMR-based 
metabolomic analysis purposes. In determining the effects of different stages of sample preparation, 
such as syringe filtration, centrifugation, etc., a protocol for NMR-based metabolomic analysis was 
developed. The second experiment presented in this chapter addresses the limited degree 
standardization of the fecal inocula used for in vitro community cultures. Here, the impact of the 
inoculum on the resulting in vitro culture was investigated by culturing several defined communities 
derived from inocula that contained the same bacterial species, but varied in the proportions at which 
the bacteria they were present in the inoculum. 
  
  
 74 
 6.2 Gut-mimicking CSTR Effluent Sample Preparation and Analysis 
6.2.1 Experiment Objective 
Samples collected from the gut-mimicking bioreactors require an initial processing step to remove 
cell material and large media particulates before being suitable for metabolite analysis. The purpose 
of the following experiment was to determine the effects of various preparation protocols on the 
metabolite profiles. Two techniques – ultracentrifugation or syringe filtration – were examined to 
establish an appropriate sample preparation protocol.  
6.2.2 Materials and Methods 
6.2.2.1 Experiment Design 
Along with testing five different ultracentrifugation speeds, two filtration procedures were also tested 
to see if they could be used as an alternative method for cell and particulate separation. The 
experiment was conducted to evaluate the effects of various stages in the sample processing 
procedure. In a first step, some samples were subjected to a “soft spin” (4000 rpm 4, °C, 3 min) to 
remove the bulk of large insoluble material (pre-processing stage) before being subjected to higher 
centrifugal forces. In a second step (processing stage), samples were subjected to either 
ultracentrifugation (4 °C, 2 h) or syringe filtration (35 mm). Following these two stages, all samples 
were subjected to a post-processing stage consisting of filtration, through a 0.22 μm syringe filter. 
The different conditions examined are outlined in Table 6-1. 
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 Table 6-1. Sample treatment conditions. 
Pre-Process Process Number of Replicates 
Soft spin Ultracentrifuge  Experiment 1 Experiment 2 
 rpm g   
Yes 10 000 7 360 3 3 
Yes 20 000 29 430 3 3 
Yes 30 000 66 230 3 3 
Yes 40 000 117 730 3 3 
Yes 50 000 183 960 3 3 
No 10 000 7 360 3 0 
No 50 000 183 960 3 0 
Soft spin Syringe filtration    
Yes Serial filtration 
(1.0μm, 0.80μm, 
0.45μm) 
 3 0 
Yes Single-step 
filtration 
 3 8 
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 6.2.2.2 Sample Collection and Handling 
An effluent reservoir was collected and stored at 4 °C on the 28th day post-inoculation from a CSTR 
system propagating feces-derived cultures obtained from Donor A. This reservoir was mixed with a 
stir bar and sampled in 30-mL volumes for subsequent processing. The effluent reservoir ensured that 
variability seen in the metabolite results originated from processing differences, and not due to 
sample-to-sample variability. Ultracentrifugation was performed on Beckman L8-55M, with a 
Beckman Ti70 rotor and 30-mL Beckman polyallomer Optiseal tubes. Once processed, samples were 
scanned by NMR.  
6.2.2.3 Statistical Analysis 
The precision of the metabolite profiles was assessed by analyzing the relative standard deviation 
(RSD) of the control, non-ultracentrifuged samples in Experiment 2 (Appendix B1.). The two types of 
filtration procedure, serial and single-step filtration, were compared to each other using Student’s t 
test at the 95% confidence level. A linear regression was used to model this data from all the 
processing methods (serial filtration, single-step filtration and ultracentrifugation), and the 
significance of this model was tested by ANOVA. Finally, the metabolite profiles from both 
experiments were modelled to determine which factors affected the trends observed. This was done 
using a multiple linear regression (MLR) model using the equation shown in Appendix B2. Since the 
majority of the compounds demonstrated linear trends, the non-linear terms in this model were not 
evaluated. Furthermore, the experiment-process interaction term was not tested since none of the 
samples in Experiment 2 were subjected to the soft spin pre-processing step. The three-factor 
interaction term was also not evaluated since the small number of replicates would be unlikely to 
yield enough information to assess such an interaction. The significance of each term in this complex 
model was evaluated at p < 0.0009, which is the alpha value of 0.05 after it has been subjected to the 
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 Bonferroni correction (Appendix B3.) to reduce sensitivity to type I error. In this way, a more 
simplified model was determined. The simplified model produced by each iteration of model 
simplification was compared to the previous model by ANOVA to assess whether the two models 
were statistically different. The simplified model comments on the effects of ultracentrifuge speed, 
experiment, and the pre-processing step on the metabolite profiles. The effects of ultracentrifuge 
speed was evaluated using the percent change in concentration per 10 000 rpm for each metabolite. 
This was obtained by using the slope and predicted concentrations from the simplest MLR model 
(Appendix B4. ). The absolute percent decrease in concentration per 10 000 rpm was also analyzed as 
a function of molecular weight of the corresponding compound. The importance of bias effects was 
determined as the absolute percentage of the bias coefficient divided by the intercept of the simplified 
MLR model.  
6.2.3 Results 
6.2.3.1 Profiling Variability 
The samples subjected to single-step syringe filtration in Table 6-1 were used to assess the precision 
of the metabolite. Since the eight replicate samples were aliquots of the one sample that had been 
subjected to the preparation protocol, the only source of variability would be the steps involved in 
constructing the metabolite profiles. The precision of each compound was evaluated based on its 
relative standard deviation, where the acceptable level of precision was set at 15%, or if near the limit 
of quantification, 20%. The only compounds that had a RSD value greater than 15% were p-cresol 
(20.6%) and thymine (16.7%) (Figure A4). Indeed, both p-cresol and thymine were near their limits 
of quantification in the samples assessed for precision.  
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 6.2.3.2 Processing Methods 
Ultracentrifugation speeds, serial filtration (1 μm, 0.8 μm, 0.45 μm and 0.22 μm) and single-step 
filtration (0.22 μm only) were tested. One of the samples subjected to single-step filtration in 
Experiment 2 had an unusually high concentration of formate (>0.3 mM), whereas all concentrations 
of formate in other filtered samples, single-step or serial, did not exceed 0.13 mM. Since this point 
was an outlier, it was excluded from all analyses. Between the serial filtration and single-step 
filtration processing methods, no compounds were found to be statistically different. Since the two 
filtration process methods did not create significantly different metabolite profiles, they were grouped 
as one set of “control” samples (0 rpm) for the ultracentrifuge-based processing methods.  
6.2.3.3 Sources of Effects Impacting Metabolite Concentration 
The metabolite profiles were modelled to describe the observed trends in compound concentrations. 
This model was formed by eliminating non-significant terms from a complex, general model until the 
simplest model that described the relationships remained. As seen in Figure A3, no compounds in the 
two interaction effects and the pre-processing effect were significant, revealing that these factors did 
not contribute to the concentration trends observed, and thus should be removed from the model. The 
simplest model illustrated that the trends observed were the effects of ultracentrifuge speed and 
experiment only. This indicated that the effect of the ultracentrifuge speed, which was significant for 
almost every compound, was independent of other factors, such as experiment and preprocessing 
steps. Similarly, the effect of experiment, where it was significant, was also independent of all other 
explanatory factors.   
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 6.2.3.4 Effect of Ultracentrifuge Speed 
The simplest MLR model that described the metabolite data showed that almost all compounds in the 
metabolite profiles demonstrated significant linear relationships with ultracentrifuge speed. These 
compounds demonstrated a negative linear relationship between compound concentration and 
ultracentrifuge speed, except for p-cresol, which had a positive linear relationship in both experiments 
(Figure 6-1). The compounds that did not exhibit significant linear changes with increasing 
centrifugal force are shown in Table A4. While the linear relationships exhibited by most of the 
compounds were statistically significant, the percent decrease in metabolite concentration per 10 000 
rpm was on average 1.8% + 0.87% in Experiment 1 and 1.8% + 0.90% in Experiment 2. These linear 
decreases in concentration with ultracentrifuge speed appeared to be directly related to the molecular 
weight of the corresponding compound in Experiment 1. However, this effect was not reproduced in 
Experiment 2, where no significant relationship was observed between the absolute percent decrease 
and molecular weight (Figure 6-2).  The only compound to increase in concentration with centrifugal 
force was p-cresol, which exhibited a 49.5% increase per 10 000 rpm in Experiment 1 and 41.3% 
increase per 10 000 rpm in Experiment 2. 
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Figure 6-1. Compounds that demonstrate significant linear relationship with centrifugal force. 
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Figure 6-2. Effect of molecular weight on percent concentration decrease. (A) Experiment 1, y = 
21.86x + 59.65, p-value = 0.015; (B) Experiment 2, y = -3.84x + 110.76, p-value=0.641. 
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 6.2.3.5 Comparison of Replicate Experiments 
52 compounds were identified and quantified in the metabolite profiles in both experiment replicates. 
The same compounds were found in the metabolite profiles of both experiment sets. An overview of 
the two experiments indicated that the two sample sets were very similar to each other, as overlaying 
the metabolite profiles from the two experiment’s samples revealed that the compound concentrations 
followed similar trends (Figure 6-1). In conducting the experiment twice, the degree to which the 
ultracentrifuge effects were reproduced from one experiment to the next was assessed. 38 compounds 
exhibited the same trend in both experiments, in both the concentrations observed and the change in 
concentrations observed (Table A5). In some compounds however, the concentrations observed were 
biased by the experiment but the rate of concentration change remained the same between Experiment 
1 and Experiment 2 (Figure 6-3). There was no consistency across these 14 compounds which had 
greater concentrations in the second experiment. Furthermore, five of these compounds, benzoate, 
beta-alanine, betaine, pyroglutamate and uracil, did not have significant changes in concentration with 
ultracentrifuge speed in either experiment. Even though the experiment bias observed in these 
compounds were significant, the importance of this effect was revealed when the magnitude of the 
experiment difference was examined relative to the concentrations observed (Table 6-2). Most 
compounds with significant bias only exhibited concentration differences between 2-10% of the 
observed concentration. Uracil, beta-alanine and pyruvate changed by 11 + 2 %, 15 + 2 % and 19 + 1 
%, respectively, and of these three, only pyruvate demonstrated a significant decrease with 
ultracentrifugation.  
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Figure 6-3. Compounds that had significant experiment bias based on MLR model. Slopes 
significantly different than zero shown as solid lines, otherwise, depicted as dashed lines. 
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 Table 6-2. Absolute percent change due to experiment bias based on: 𝑦𝑦 = 𝛽𝛽𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑥𝑥𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 + 𝛽𝛽𝑠𝑠𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒𝑠𝑠𝑒𝑒𝑒𝑒𝑥𝑥𝑠𝑠𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒𝑠𝑠𝑒𝑒𝑒𝑒  +  𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖. 
Compound Intercept Experiment 
Bias 
Bias Standard 
Error 
Absolute 
Percent Change 
Standard Error of 
Percent Change 
Aspartate 0.30 0.012 0.003 3.9 1.1 
Benzoate 0.09 -0.005 0.001 5.5 1.4 
beta-Alanine 0.07 0.011 0.002 15.4 2.6 
Betaine 0.009 0.0003 8.88E-05 4.0 1.0 
Glycine 0.79 0.0347 0.005 4.3 0.7 
Lactate 0.06 -0.006 0.001 9.0 2.0 
Leucine 1.1 0.046 0.012 4.2 1.1 
Ornithine 0.27 -0.02 0.003 7.5 1.1 
Phenylacetate 0.64 0.025 0.005 3.9 0.9 
Phenylalanine 0.40 0.014 0.004 3.5 0.9 
Propionate 37.6 1.1 0.27 2.8 0.7 
Pyroglutamate 0.24 -0.02 0.006 8.9 2.3 
Pyruvate 0.18 -0.03 0.002 18.7 1.2 
Uracil 0.10 -0.01 0.002 11.0 2.4 
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 6.2.4 Discussion 
6.2.4.1 Profiling Variability 
The metabolite profiles obtained in these experiments can be relied upon to provide precise values. 
The eight samples subjected to single-step filtration in Experiment 2 were used to evaluate the 
variability of each compound concentration. All of the compounds demonstrated good precision in 
their quantification, with RSD values less than 15%. The only two compounds that exhibited greater 
spread than that were p-cresol and thymine, which were near their limits of quantification. These 
guidelines for acceptable thresholds of precision are outlined in bioanalytics methods validation 
protocols from the American Food and Drug Administration (FDA)132. 
6.2.4.2 Pre-Processing Treatments 
One of the elements tested involved the presence or absence of a “soft spin” step prior to any 
ultracentrifugation. The purpose of the “soft spin” was to remove cells and cell debris without 
exposing the supernatant to intracellular metabolites. This step was excluded for two 
ultracentrifugation conditions in order to isolate the effects of the “soft spin.” When the metabolite 
concentrations from duplicate experiments were evaluated as a function of all the experiment factors 
(ultracentrifuge speed, pre-processing treatment and experiment replicate) and their possible 
interactions, pre-processing treatment did not influence the concentration observed for any of the 
compounds. Therefore, the pre-processing step of performing a soft spin prior to ultracentrifugation 
did not affect the metabolite concentrations. 
6.2.4.3 Effect of Ultracentrifuge Speed 
Negative linear relationships between compound concentration and centrifugal force applied to the 
samples were consistently observed throughout the metabolite profiles, prevalent to 37 of the 52 
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 compounds observed. While the relationship between compound concentration and centrifugal force 
is clear, the absolute rate of concentration change does not seem to be a function of the molecular 
weight of the compounds. Furthermore, the concentration changes observed were minimal, averaging 
~2% decrease in concentration per 10 000 rpm. The only compound found to increase linearly with 
centrifugal force was p-cresol, averaging at 45.4% per 10 000 rpm. Given the high rate of increase 
with centrifugal force applied, compounded with the contextual relevance this compound has to 
enteric microbial metabolism, it is evident that importance should be placed on being transparent 
regarding sample preparation procedures. Anaerobic catabolism of aromatic amino acids, 
phenylalanine, tyrosine and tryptophan, occur at the aliphatic side chains to produce phenols like p-
cresol. p-Cresol has been shown to be produced by Clostridium difficile and C. scatologenes from 
tyrosine via decarboxylation of 4-hydroxyphenylacetate133,134. Furthermore, p-cresol was formed from 
cell-free extracts of C. difficile, where decarboxylation of 4-hydroxyphenylacetate was facilitated by 
combining the protein fraction of the cell-free extracts with the filtrate fraction, serine, or an α-keto 
acid like pyruvate134. The proposed mechanism for converting p-cresol from 4-hydroxyphenylacetate 
was a two-protein system where a decarboxylase was kept in the active, reduced form by an α-keto 
acid dehydrogenase. While 4-hydroxyphenylacetate was not observed in the samples, it has been 
observed in the metabolite profiles of other feces-derived cultures within this body of work. 
Therefore, it is possible that the level of 4-hydroxyphenylacetate in this sample set was below the 
level of detection. Upon examining the absolute rate of concentration change with ultracentrifuge 
speed, the combined rate of tyrosine and phenylalanine was still ~2 times lower than that of p-cresol, 
suggesting that if tyrosine and phenylalanine does play a role, they cannot be the only source. 
Tryptophan was not observed in the metabolite profiles. 
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 6.2.4.4 Comparison of Replicate Experiments 
Samples obtained from the same pool of bioreactor effluent were used in both replicate experiments 
to eliminate sample-to-sample variation. Indeed the compounds that were identified in the metabolite 
profile from one replicate experiment to the next were identical. The concentration changes observed 
in the duplicate experiments were explained independently by ultracentrifuge speed and experiment. 
This is important because an interaction effect between these two factors, indicated by different rates 
of change in concentration depending on the experiment, would infer that compounds were 
inconsistent in their response to ultracentrifugation from one experiment to another, even under 
controlled conditions. The linear regression modelled above demonstrated that there was no 
significant interaction occurring between any of the experimental factors, so the metabolites’ response 
to the sample preparation protocols was consistent, and thus, predictable. Experiment bias, indicated 
by a parallel shift in the linear regression from one experiment to another, would mean that there were 
overall concentration differences between experiment sample sets. Of the 14 compounds that had 
significant experiment bias, most of these compounds differed by only 2-10% of the observed 
corresponding compound concentration. Uracil, and beta-alanine had greater discrepancies between 
experiments, revealing that these two compounds may be sensitive to factors not controlled within 
this experiment. Pyruvate levels were also not reproduced from one experiment to the next, as it also 
demonstrated significant experiment bias. However, the impact of ultracentrifuge speed on pyruvate 
levels was reproduced, with levels decreasing by 2% per 10 000 rpm in both replicate experiments. In 
general, the compound concentrations between the two sample sets were identical and the compounds 
response to ultracentrifugation could be predicted. 
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 6.3 Effects of Varying Inoculum Biomass Proportions 
6.3.1 Experiment Objectives 
The objective of this experiment was to determine the impact of the biomass makeup of inoculants on 
the resulting in vitro community. To evaluate this, defined communities were cultured from inocula 
that contained the same bacterial species, but the proportional makeup of the bacteria in the seeding 
culture varied across inocula. The hypothesis driving this experiment was that in vitro communities 
develop similar metabolite profiles when the seeding culture is composed of the same bacterial 
strains, regardless of the proportions at which the bacteria are present in the inoculum. 
6.3.2 Materials and Methods 
6.3.2.1 Experiment Outline 
Two different defined communities, Microbial Ecosystem Therapeutic-2A (MET-2A) and MET-3A 
were studied in a CSTR system that consisted of twin vessels, operating in parallel. In a given CSTR 
run, one vessel was inoculated with a defined community and the other was inoculated with the same 
defined community, but with different biomass proportions of the same bacteria strains. The varied 
communities were termed MET-2B or MET-3B, depending on the respective parent community. 
Culturing each defined community and its reciprocal community was repeated 5 months after the 
initial experiment (Figure 6-4). Therefore, Run 1 and 3 are duplicate experiments of each other, and 
Run 2 and 4 are duplicate experiments.  
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Figure 6-4. Experiment overview. Variants of two different defined communities derived from fecal 
communities obtained from different donors were examined: MET-2 and MET-3. The A and B 
variants of the MET-2 and MET-3 communities have the same bacterial strains, but have varied 
proportional makeup of those bacteria. Run 1 (R1) and Run 3 (R3) were duplicate experiments and 
Run 2 (R2) and Run 4 (R4) are duplicate experiments. 
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 6.3.2.2 Sampling and Storage 
Samples were collected directly from the bioreactor vessel throughout the duration of the bioreactor 
runs to monitor the cultures’ growth. Long, sterile sampling needles that punctured a silicone septum 
were used to directly access the bacterial culture in the bioreactor vessel. 4-mL samples were 
aliquoted into 2 2-mL tubes and stored at -80 °C. Samples from day 6, 14, and 20 from each 
bioreactor run were selected for metabolite analysis. Samples were thawed, then centrifuged at 14 500 
rpm for 5 min to pellet the cell fraction. The supernatant was subsequently filtered through 0.45 μm 
and 0.22 μm syringe filters (Corning; Corning, New York) and stored for up to 4 days at 4 ºC until 
NMR scanning.  
6.3.2.3 Statistical Analysis 
The metabolite profiles of each community culture were annotated by identifying the compounds’ 
chemical taxonomic classes. The metabolite profiles could then by analyzed according to these 
taxonomic classes, examining the prevalence of each compound class within a profile, and how these 
class proportions change when weighted to compound concentrations. The chemical taxonomic class 
of each compound was identified based on classifications listed in the Human Metabolome 
Database135 (www.hmdb.com). The magnitude of the metabolite profile represented by a given 
compound class, referred to as the class weight, was calculated as the sum of concentrations of 
metabolites of that class within a metabolite profile. The class weight as a proportion, referred to as 
class percentage, was presented by dividing the class weight by the total sum of metabolite 
concentrations in the profile. The mean class weight within a given culture was also calculated. Two 
samples were selected at random to be scanned in triplicate and be used to assess profiling variability. 
The precision of the compound concentrations were assessed based on the relative standard deviation 
(RSD) in each triplicate set. RSD was calculated as shown in Appendix B1. The mean of each set of 
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 triplicates was used as the concentration for each respective sample (that were analyzed in triplicate). 
Student’s t tests were also applied to assess the run-to-run differences between the two pairs of 
duplicate experiments performed for each defined culture, MET-2A, MET-2B, MET-3A and MET-
3B. It should be noted that the three time-course data points from each run were considered as one 
group when comparing the duplicate runs. While a time-matched comparison across duplicate runs 
would be more ideal, comparing the runs across all three time points was sufficient as the two runs 
were expected to behave the same. Even so, a more stringent level of significance would give more 
allowances for some dynamicity in the progression of the runs. Moreover, performing the Student’s t 
test repeatedly (for every compound and every defined culture) leaves the test to be prone to type I 
error. For these two reasons, a Bonferroni correction was applied to the alpha value, which defined 
the significance level as p ≤ 0.0075 (Appendix B3.). PCA was used to analyze the metabolite profiles. 
This multivariate analysis was performed using the function “prcomp” within the R base package 
“stats”. Linear regression was used to assess the trends of compound concentrations over time (day 4-
20) via the “aov” function in the R base package “stats”. This function is a form of ANOVA that 
assesses the variation of concentrations about a linear regression model and compared it to the 
variation of the concentrations about the grand mean. Significance was determined at the 90% 
confidence level (p < 0.1). This confidence level was chosen because in this case, several weak linear 
trends had significance values between 0.05 and 0.1. 
6.3.3 Results 
6.3.3.1 Profiling Variability 
For the majority of compounds, the relative standard deviation was less than or equal to 15%. (Figure 
A5). Compounds that had a spread greater than 15% from the mean are shown in Table 6-3. 
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 However, even with the spreads observed, the two samples done in triplicate could still be 
distinguished from each other as demonstrated by PCA (Figure 6-5).  
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 Table 6-3. Compounds with RSD in replicate samples > 15% 
Sample 1 Sample 2 
Compound RSD (%) Compound RSD (%) 
Betaine 16.5 Benzoate 19.3 
Fructose 24.3 Fructose 21.4 
Fumarate 21.3 Glucose 21.4 
Hydroxyacetone 16.8 Glycine 28.0 
Proline 28.4   
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Figure 6-5. PCA score plot of triplicate samples. 
  
 95 
 6.3.3.2 Replicate Runs 
Run 1 and Run 3 were duplicate experiments that propagated MET-2A and MET-2B. Run 2 and Run 
4 were duplicate experiments that propagated MET-3A and MET-3B. While the duplicate Runs may 
have been identical in the seeding population, there were slight differences in the metabolite profiles 
of each pair of replicates (Figure A6). These differences became apparent in a PCA score plot of all 
the samples (Figure 6-6). In this overall model, Run 2 and 4 produced similar metabolite profiles of 
one another, but Run 1 and 3 clustered distinctly from one another. The variation along principal 
component (PC) 1, along the x-axis, accounted for 60.3% of the total variation and accounted for the 
differences between the defined culture types, MET-2A and MET-3A. The variation along the y-axis, 
PC2, occurred predominantly due to differences between Run 1 and Run 3 and differences between 
Run 2 and 4.  Since differences between the duplicate runs occurred along PC2, which accounted for 
only 8.3% of the total variation, the differences between the duplicate runs were much smaller than 
the differences between the types of defined communities (MET-2A vs MET-3A).  
Since all four cultures were propagated in duplicate runs, the reproducibility of each culture 
could be assessed by using Student’s t-test to compare each compound between the two runs. The 
compounds that differed significantly between the duplicate runs are shown in Table 6-4. All of these 
compounds, except for fumarate, had within-run mean concentrations greater than 15% of the 
between-run mean concentration. 
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Figure 6-6. PCA score plot of metabolite profiles of all bioreactor samples. Metabolite concentrations 
have been mean centered and unit variance scaled in order for equal-weighted comparison between 
compounds. 
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 Table 6-4. Compounds that differed significantly between duplicate runs. 
Compound Culture T Statistic P value Absolute Percent 
Difference3 
Fumarate MET-2A -5.1 0.008 8.8 
Propionate MET-2A 5.3 0.007 28.2 
Aspartate MET-2B -10.7 0.002 28.5 
Glycine MET-3A 5.2 0.007 32.3 
Glycine MET-3B 5.5 0.005 43.9 
Isoleucine MET-3B 13.2 0.0003 16.5 
 
  
3Percent difference = |mean concentration within a run – mean concentration from duplicate runs|/mean 
concentration from duplicate runs. 
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 6.3.3.3 Metabolite Profiles 
Metabolite profiles were constructed for 24 samples. Each profile contained 41 compounds where the 
assignment of the signal’s compound identity and concentration were considered to be high 
confidence. The total concentration of the metabolite profiles was greater in MET-3A-based cultures 
(MET-3A and MET-3B) than to MET-2A-based cultures (MET-2A and MET-2B), and similar 
between a defined culture and its reciprocal (Figure 6-7). The structure of the metabolite profiles was 
fairly consistent across all four different seeding populations. Based on the number of compounds 
profiled, amino acid and amino acid derivatives (39%) comprised most of compounds identified, 
followed by  fatty acids and conjugates, carboxylic acids and derivatives  and monosaccharides which 
each accounted for ~10%. When the taxonomic classes in the metabolite profiles were weighted to 
the compounds’ concentration, the proportions of classes were drastically altered. Carboxylic acids 
and derivatives dominated in the profiles, followed by fatty acids and conjugates, alcohols and 
polyols and amino acids and derivatives (Table 6-5). The distribution of these weighted compound 
classes was fairly similar across all four cultures, with slight differences between the MET-2A-type 
cultures and the MET-3A-type cultures. The most noticeable differences were a dramatic increase in 
carboxylic acids and a decrease in fatty acids in MET-3A-type cultures compared to MET-2A-type 
cultures.  
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Figure 6-7. The breakdown of compound classes in metabolite profiles of each defined culture. 
Proportions of compound classes were weighted to compound concentration. The class weights 
shown are the mean class weights of profiles within a given culture. 
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 Table 6-5. Proportion of Compound Classes, weighted to concentrations. 
Compound Class MET-2A MET-2B MET-3A MET-3B 
Carboxylic acids and derivatives 59.4 62.5 71.4 73.0 
Fatty acids and conjugates 16.5 13.6 9.2 9.9 
Alcohols and polyols 15.3 14.8 12.4 10.3 
Amino acids and derivatives 3.9 4.4 2.3 2.4 
Sugar alcohols 3.1 2.9 2.6 2.5 
Monosaccharides 1.1 1.1 0.6 0.5 
Hydroxy acids and derivatives 0.2 0.2 0.2 0.2 
Phenylacetic acid derivatives 0.1 0.2 0.1 0.1 
Carbonyl compounds 0.1 0.01 0.1 0.1 
Diazines 0.09 0.01 0.1 0.1 
Alkylamines 0.07 0.08 0.2 0.2 
Benzoic acid and derivatives 0 0 0.01 0.01 
Pyrrolidines 0 0 0.7 0.7 
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 6.3.3.4 Defined Cultures vs Their Reciprocals 
Most of the compounds tend to a common point over time between a given culture and it’s 
reciprocal. Compounds that reach this common point at Day 20 in a weak linear fashion in at least 
one run are shown in Figure 6-8A and Figure 6-10A. The compounds shown in Figure 6-8B and 
Figure 6-10B reach a common point at Day 20, but in a non-linear pattern. It is notable that the 
achievement of a common point is not always observed across duplicate runs (Figure 6-9 and Figure 
6-11). The compounds that do not reach a common point by Day 20 in any of the runs are listed in 
Table 6-6. 
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Figure 6-8. Compounds that reach the same level by Day 20 across a MET-2A culture and its 
reciprocal (MET-2B). (A) Compounds that display time trends that demonstrated a linear model in 
both runs. (B) Compounds that have time trends that are not linear. 
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Figure 6-9. Common point reached in only one run for MET-2A and MET-2B. 
 
 104 
  
Figure 6-10. Compounds that reach the same level by Day 20 across a MET-3A culture and its 
reciprocal (MET-3B). (A) Compounds that display time trends that demonstrate a weak linear model 
in at least one of the runs. (B) Compounds that have time trends that are not linear. 
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Figure 6-11. Common point reached in only one run for MET-3A and MET-3B 
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 Table 6-6. Compounds that do not reach a 
common point between a culture and its 
reciprocal by Day 20 in either of the 
duplicate runs. 
MET-2A vs MET-2B MET-3A vs MET-3B 
Galactose Fructose 
Isovalerate Fumarate 
Phenylacetate Glycerol 
 Glycolate 
 Methanol 
 Methylamine 
 Serine 
 Thymine 
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 6.3.4 Discussion 
6.3.4.1 Profiling Variability 
Assessment of the metabolite profiles of replicate samples revealed that most compounds were 
quantified with a relative standard deviation of less than or equal to 15%. Since FDA regulations on 
bioanalytical method validation recommend 15% RSD, or 20% if at the lower limit of quantification, 
as the tolerance limit in assessments of precision132, the metabolite profiles can be considered to have 
relatively little variation. The compounds that demonstrated more spread tended to be compounds 
with only a few number of clusters in its NMR signal, a higher degree of convolution with other 
spectral signals, or the compound peaks were masked due to poor signal-to-noise ratios. Even though 
these, or any combination of these spectral characteristics can increase the variation in quantification, 
the precision was still high enough to be easily distinguished from other samples.  
6.3.4.2 Replicate Runs 
The run-to-run effects comment on the repeatability of culturing the same bacterial population. The 
multivariate model that described the metabolite profiles explained that only 8.3% of the total 
variation could be attributed to run-to-run variability. Comparing the metabolite profiles of each of 
the duplicate runs revealed that most compounds levels were reproduced across runs, and only one or 
two compounds had significantly different concentrations from one replicate run to the next.  
It should be noted that all time points from the growth of a culture were included in the run-
to-run comparisons since only one data point was available for each time point. A more accurate 
evaluation of repeatability would compare runs only at time-matched points, where each time point 
had at least 3 data points. The implications of grouping all three time-points together in making run-
run comparisons was that the test is more sensitive to compounds that remain constant over time 
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 within one run. Compounds that fluctuate largely between day 4 and day 20 of a given CSTR culture 
would be more likely identified as an insignificant difference with other culture runs. That being said, 
the replicate runs can still be differentiated by gross concentration differences in the metabolite 
profiles. 
6.3.4.3 Metabolite Profiles 
The metabolite profiles of the four bacterial communities were very similar to one another, with the 
greatest degree of similarity between a culture and its respective reciprocal. The same 41 compounds 
were observed in the metabolite profiles in all four cultures. The most apparent differences in 
metabolite profiles were evident when comparing the profiles between MET-2A-based cultures and 
MET-3A-based cultures. Overall, the total concentration of compounds profiled was greater in MET-
3-based cultures (MET-3A and MET-3B) compared to MET-2-based cultures (MET-2A and MET-
2B). Furthermore, there was a larger proportion of carboxylic acids in the profiles of MET-3-based 
cultures (~72%) than in the MET-2-based cultures (~60%). This difference was mostly attributed to 
acetate, where the average concentration observed in MET-3A-based cultures was 86 + 2 mM 
standard error, while the average concentration observed in MET-2A-based cultures was 49 + 3 mM 
standard error. The comparatively low concentrations of fatty acids and conjugate compounds in 
MET-3-based cultures (~9% in MET-3-based cultures and ~15% in MET-2-based cultures) was 
mostly due to lower levels of butyrate. The mean concentration of butyrate in MET-3A-based cultures 
was 15 + 1 mM standard error compared to 21 + 2 mM standard error found in MET-2A-based 
cultures. Concentrations of valerate and isovalerate were also considerably lower in MET-3A-based 
cultures but they were found at fairly low concentrations in all four cultures, so they only accounted 
for ~1-2% of the metabolite profiles.  
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 6.3.4.4 Defined Cultures vs Their Reciprocals 
In general, there was very little distinction between each defined culture and their respective 
reciprocal culture. In fact, an overview of the time course progression of the compound changes 
indicated the cultures and their biomass-varied counterparts reached similar metabolite profiles by the 
20th day post-inoculation. For some compounds, this progression happened linearly, while in others, 
the compounds experienced some fluctuation before reaching a common concentration point at day 
20. Only a select few compounds were not observed to reach a common point between a defined 
culture and its reciprocal cultures in either duplicate runs. While the convergence of compound 
concentrations by day 20 between a defined culture and its reciprocal culture was a first indication 
that the defined cultures tended towards a single metabolic steady state regardless of the biomass of 
species isolates in the inoculum, there are still aspects of this experiment that must be further 
investigated. First of all, it should be noted that the linearity was evaluated based on 3 time points of a 
given culture. For more robust evaluations on time series patterns, more time points should be 
evaluated, with multiple samples of each time point. This would enable more accurate modelling of 
the cultures’ metabolic activities. Moreover, previous investigations reported that fecal cultures 
grown in CSTR systems do not stabilize in terms of species composition until ~5 weeks after 
inoculation5. Therefore, the cultures should be observed for longer in the each bioreactor run to 
observe when a true metabolic steady state is actually reached, and to determine if the similarities in 
the metabolite profiles of a culture and its reciprocal would maintained.  
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 Chapter 7 Metabolomic Analysis of Human Fecal Microbiota 
Propagated In Vitro in a CSTR System 
7.1 Chapter Objective 
The purpose of this chapter was to demonstrate ways in which the metabolomic techniques and 
analyses used thus far can be applied to gain further understanding of the human gut microbiota. In 
the first experiment, metabolite profiles were used to describe feces-derived and defined in vitro 
communities. This study exemplified the potential of performing metabolomic analyses on in vitro 
gut microbial communities, as unique metabolic functions were identified in each bacterial culture. 
The second experiment supported the application of this metabolomic analysis for studying the 
human gut microbiota in a clinical and pharmaceutical framework. Several in vitro gut microbial 
communities were subjected to various types of perturbations, including antibiotics, a hormone and a 
defined community culture used to challenge the bioreactor culture. Examining the metabolomic 
responses to a wide range of perturbations set the preliminary groundwork in for raising attention to 
the metabolomic implications relevant to industrial and clinical research. 
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 7.2 Metabolomic Analysis of the Human Gut Microbiota: Comparison of 
Feces-Derived Communities and Defined Mixed Communities 
7.2.1 Journal Article Authorship 
Sandi Yen1, Julie A. K. McDonald2, Kathleen Schroeter2, Stanislav Sokolenko1, Eric J. M. Blondeel1, 
Emma Allen-Vercoe2#, Marc G. Aucoin1# 
1Waterloo Institute for Nanotechnology, Department of Chemical Engineering, University of 
Waterloo, 
Waterloo, Ontario, Canada, N2L 3G1 
2Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada, 
N1G 2W1 
#corresponding authors: Marc G. Aucoin maucoin@uwaterloo.ca, Emma Allen-Vercoe 
eav@uoguelph.ca 
7.2.2 Justification of Original Work 
With minor editorial changes to fulfill formatting requirements, this chapter is substantially as it has 
been submitted to the Journal of Proteome Research on October 31, 2014. The study was performed 
in collaboration with the Allen-Vercoe group at the University of Guelph. The partnership was 
formed where the Allen-Vercoe group brought forth expertise in culturing microbial communities 
representative of the human gut in an in vitro CSTR system and the Aucoin group extracted, analyzed 
and interpreted metabolomic data obtained from the microbial communities. Preparation and 
operation of the gut-mimicking CSTR system was performed by Julie McDonald and Kathleen 
Schroeter. They also collected raw fecal samples, prepared all community inocula, collected 
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 bioreactor and effluent samples, and processed the samples in preparation for metabolomic analysis. 
1D-1H NMR spectroscopy was performed by Sandi Yen. The manuscript was written by Sandi Yen. 
This work is included in this thesis because it applied the skills and analytical techniques developed 
from earlier studies presented in this thesis.  
7.2.3 Abstract 
The extensive impact of the human gut microbiota on its human host calls for a need to understand 
the types of communication that occur amongst the bacteria and its host. A metabolomics approach 
can provide a snapshot of the microbe-microbe interactions occurring, as well as variations in the 
microbes from different hosts. In this study, metabolite profiles from an anaerobic continuous stirred-
tank reactors (CSTR) system supporting the growth of several consortia of bacteria representative of 
the human gut were established and compared. Cell-free supernatant samples were analyzed by 1D-
1H Nuclear Magnetic Resonance (NMR) spectroscopy, producing spectra representative of the 
metabolic activity of a particular community at a given time. Using targeted profiling, specific 
metabolites were identified and quantified based on NMR analyses. Metabolite profiles discriminated 
each bacterial community examined, demonstrating that there are significant differences in the 
microbiota metabolome between each cultured community. We also found unique compounds that 
were identifying features of individual bacterial consortia. These findings are important because they 
demonstrate that metabolite profiles of gut microbial ecosystems can be constructed by targeted 
profiling of NMR spectra. Moreover, examination of these profiles sheds light on the type of 
microbes present in the gut and their metabolic interactions. 
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 7.2.4 Introduction 
In the wake of metagenomic research aiming to fully describe the gut microbiome, 
metabolomic research has emerged as a functional counterpart136 that provides insight into the 
metabolic activities engaged by whole communities of microorganisms. Metabolomics is the study of 
the entire set of compounds, or metabolites, produced by a given organism, referred to as a 
metabolome. As a reflection of enzymatic activities and metabolic pathways carried out by the 
organism137, the application of metabolomics to whole community bacterial cultures confers the 
ability to take a “snapshot” of the complex microbial population. Within the context of the human gut 
microbiota, the mixed culture metabolome not only reflects the metabolic activities of the enteric 
bacteria, but it also represents the bacterial compounds to which the human body is exposed.  
Metabolomic studies of the gut microbiota often use metabolites from fecal extracts to 
compile metabolomes that capture the gut bacteria-host interaction2,63,138. The metabolomic data 
obtained directly from stool samples contains metabolites from both host and microbial activities. 
Thus, while fecal metabolomics provide insight into the gut microbial-host co-metabolism, it is not 
the ideal source for studying the independent metabolic contributions from either the host or enteric 
bacteria. Furthermore, the composition of the gut microbiota varies depending on host age, nutrition, 
behaviour and health52,53,139. Therefore, while fecal metabolomic studies bring forth understanding of 
the microbial-mammalian metabolic axis, the exact conditions are difficult to recreate to further 
investigate potential relationships. Taking the approach of microbial metabolomics to study the gut 
microbiota, analysis of the extracellular metabolites (the ‘exometabolome’) produced by the enteric 
bacteria circumvents host biology variability and focuses the metabolomic analysis on the 
community’s metabolic state. 
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 The robustness of using metabolomic approaches to study the gut microbiota relies heavily on 
the acquisition of high-quality data. The most common analytical platforms used in quantifying 
metabolomes are mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy140. 
Both platforms have advantages and limitations that influence for which situations the analytical 
techniques are best suited. The methodology and application of MS and NMR in metabolomics have 
been extensively reviewed23,140–142. Within the scope of compiling enteric microbial metabolite 
profiles, 1H NMR spectroscopy is the platform of choice because it requires minimal pre-processing 
of samples, enabling rapid yet reproducible spectroscopic results29,39,143. Its signals provide structural 
information about the compounds, facilitating identification of known compounds and classification 
of unknown compounds. Furthermore, targeted profiling techniques have been developed for 
deconvolution of NMR spectra and provide a level of quantification and identification that was not 
previously possible with binning algorithms, the traditional tool in analyzing NMR spectra31,41. 
In this study, we employed metabolomic characterization of feces-derived bacteria 
propagated as various mixed cultures in a continuous stirred tank reactor (CSTR) that mimicked the 
environment of the distal regions of the human gastrointestinal tract5,144. With this approach, we built 
quantitative metabolite profiles of different gut bacterial communities. The purpose of this study was 
to describe the metabolome of bacterial communities propagated in a CSTR, and to evaluate 
identifying characteristics of different populations. In deciphering the ecological dynamics of the gut 
microbiota, further understanding of the interaction between the gut microbial ecosystem and the 
human body can be achieved. 
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 7.2.5 Materials and Methods 
7.2.5.1 Experiment overview 
The Research Ethics Board of the University of Guelph approved this study (REB#09AP011). This 
study was performed over 5 different bioreactor runs, where a run had one or more bioreactor vessels 
operating (Figure 7-1). All vessels within a run were inoculated from the same seeding sample. 
Conversely, each bioreactor run used different seeding sources, whether it was from a different donor, 
or from the same donor. Three healthy donors provided fresh fecal samples: donor A (male, 44 years-
old), donor B (female, 26 years-old) and donor C (male, 25 years-old). None of these donors had a 
recent history of antibiotic treatment or gastrointestinal disorders within the 9 months prior to 
collection of their samples. Runs 1 and 2 were inoculated with fecal extracts from donor A whereas 
Runs 3 and 4 were inoculated with fecal extracts from donor B and C respectively. Run 5 was 
inoculated with a defined mixed culture, called Microbial Ecosystem Therapeutic-2 (MET-2), which 
was a defined community consisting of strains derived from donor A’s feces (Table 7-1). Runs 1, 2, 3, 
and 4 were maintained for 48, 53, 41 and 53 days respectively, while Run 5 was maintained for 27 
days. Based on previous studies using this system the community cultures reached steady-state as 
early as 4 weeks after inoculation5. 
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Figure 7-1. Experiment overview. CSTR Bioreactor vessels were inoculated with a seeding culture 
that were derived from either a human fecal samples, or a defined mixed culture. Fecal samples were 
obtained from donors A, B and C, as denoted by DA, DB, and DC respectively. A cocktail of defined 
seeding cultures were used, termed Microbial Ecosystem Therapeutic-2 (MET-2). Bioreactors that 
were operated in parallel are considered to be part of a single Run (denoted as R1, R2 etc.), where the 
seeding culture in each bioreactor within a Run are derived from the same inoculant. Samples were 
collected from bioreactor effluent at various time points during bioreactor operation. 
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 Table 7-1. A list of cultured bacterial isolates from the feces of donor A included in the 
MET-2 defined community. 
Higher taxonomic 
group 
Closest species match, inferred by 
alignment of 16S rRNA sequence 
to GreenGenes database 
% identity to 
closest match 
Relative 
abundance4 
(by biomass) 
Actinobacteria 
Bifidobacterium longum 100 1 
Collinsella aerofaciens 100 0.5 
Microbacterium schleiferi 99.34 1.5 
Aldercreutzia equolifaciens 99.76 1 
Micrococcus luteus 97.04 1 
Bacteroidetes Bacteroides ovatus 100 0.5 Parabacteroides merdae 100 1 
Firmicutes 
Eubacterium rectale 100 1 
Blautia luti 98.91 1 
Roseburia hominis 99.04 1 
Roseburia lactaris 95.07 0.5 
Ruminococcus albus 96.96 1 
Eubacterium eligens 96.78 1 
Ruminococcus torques (two different 
strains) 
99.27 
100 
1 
1 
Roseburia intestinalis 100 1 
Eubacterium fissicatena 97.67 1 
Eubacterium ventriosum 97.37 1 
Blautia coccoides 99.85 0.25 
Blautia hydrogenotrophica 100 0.1 
Dorea longicatena 100 0.25 
Dorea formicigenerans 99.49 0.25 
Clostridium ramosum 96.14 0.25 
Eubacterium limosum 99.25 0.75 
Streptococcus thermophilus 100 0.25 
Bacillus simplex 98.7 0.25 
Coprococcus catus 99.19 0.25 
Flavonifractor plautii 96.21 0.25 
Streptococcus mitis 100 0.3 
Phascolarctobacterium sp. 99.85 0.1 
Proteobacteria Escherichia coli 100 0.25 Parasutterella excrementihominis 100 0.5 
 
4Relative abundance nits are presented as the equivalent of 1 X 10 µL loopful of bacterial culture scraped from 
petri dish plates. 
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 7.2.5.2 Bioreactor Operation and Inoculation 
Up to four 500-mL Multifors bioreactors (3 Multifors systems, Infors AG, Switzerland), with 
working volumes of 400 mL were operated as CSTRs. Conditions were set to mimic the distal human 
gut (37ºC, pH 7, gentle agitation, oxygen-free, and fed with a constant supply of mucin and insoluble 
starch substrates at a flow rate of ~400 mL/day). Vessels were maintained anaerobic by bubbling 
nitrogen. Operation and maintenance of the bioreactors were conducted as previously specified5. The 
bioreactors were inoculated with either the defined mixed culture, MET-2, or undefined mixed culture 
obtained from homogenized fecal samples from human donors. 100 mL of inoculum was added to 
300 mL of media to comprise a 10% w/v culture. Cultures were gently agitated pH adjusted to 6.9-
7.0. The media was prepared in-house, as previously described5. 
7.2.5.3 Preparation of Fecal Inocula and Defined Mixed Culture 
Fecal inocula were prepared as previously described5, where donors provided fresh fecal samples. 
The MET-2 consortium was developed by the Allen-Vercoe group of the University of Guelph as a 
simplified version of the gut microbiota of donor A, and was composed of 33 different strains of 
bacteria that were isolated from a fecal sample obtained from donor A (Table 7-1). These strains were 
isolated through plate culture of diluted fecal samples on various media types (deMann Rogosa & 
Sharpe agar, Brain Heart Infusion agar (Oxoid), Fastidious Anaerobe Agar (Lab90)), with incubation 
in an anaerobe chamber (Ruskinn) under an atmosphere of N2:CO2:H2 (90:5:5).  Isolated colonies 
were streak-purified and characterized by Sanger sequencing of their 16S rRNA genes with 
comparison to the Greengenes database (http://greengenes.lbl.gov/cgi-bin/nph-index.cgi). Each 
inoculum was prepared by scraping biomass from select plate cultures and suspending it in pre-
reduced CSTR growth medium (75 mL). 
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 7.2.5.4 Sample Collection and Processing 
Bioreactor effluent from Run 1 was pooled over a 10-day period and samples were taken from this 
pooled material. Samples from CSTR Runs 2-5 were collected on a daily basis; sampling volumes did 
not exceed 2.5% of the total working volume (so not to impact the chemostatic conditions of the 
bioreactor). Samples were stored at -80 °C, and thawed prior to analysis in a step wise manner (5 
hours in -40 °C, overnight in -20 °C and then on ice). Samples were centrifuged (3800 x g, 10 min) to 
remove cells, then subjected to ultracentrifugation (14650 x g, 4 °C) to remove media particulates. 
Finally, samples were filtered using 0.22 µm syringe filters (Acrodisc® Supor membrane, Pall 
Corporation, UK). 
7.2.5.5 NMR Spectra Acquisition and Processing 
Samples were diluted to contain 10% (v/v) internal standard in preparation for NMR spectroscopy. 
The internal standard used was a chemical shape indicator (CSI), a solution of 99.9% D2O with 5 mM 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) and 0.2% (w/v) sodium azide to inhibit bacterial 
contamination. Sample solutions were transferred to 5-mm glass NMR tubes (NE-UL5-7, New Era 
Enterprises Inc., Vineland, NJ, USA) and inserted into a Bruker Avance 600.13 MHz spectrometer 
with a Triple Resonance Probe (TXI 600) for scanning. Samples were stored at 4 °C. Prior to 
scanning, samples were allowed to warm to room temperature. NMR spectra were acquired using the 
first increment of a 1D NOESY pulse sequence with tmix of 100 ms, 4 second acquisition time, 1 s 
relaxation delay, and a spectral width of 12 ppm.  
Following acquisition, spectra were imported into Chenomx NMR Suite 7.5 (Chenomx Inc., 
Edmonton, Canada) for spectral processing and compound identification and quantification. Phase 
and baseline corrections were carried out manually referring to the internal standard, DSS, and by 
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 assessing clusters at random across the span of the spectra to make the appropriate adjustments. Shim 
and chemical shape correction was performed automatically by the software based on a manual 
comparison of ideal and observed DSS peaks. The known concentration of DSS was used to 
determine the concentration of all other compounds in the spectrum. Sample pH measurements that 
were obtained during the sample preparation stage were used for spectrum profiling. 
7.2.5.6 Metabolite Profiles 
Once spectral processing was completed, compounds were identified and quantified by targeted 
profiling using Chenomx NMR Suite, 7.0-7.7 (Chenomx Inc., AB). The identification process 
consisted of manually matching the projection of a predicted compound, selected from the software’s 
built-in 600 MHz compound library, to the processed 1D-1H NMR spectral signatures. Criteria for 
placing a compound on the spectrum included both the fit of the projected signature to spectral 
clusters and background information on metabolite properties, biofunction, pathways and uses. Such 
metabolite information was obtained from the Chenomx software database, The Human Metabolome 
Database (HMDB, www.hmdb.ca) and the Kyoto Encyclopedia of Genes and Genomes (KEGG, 
www.kegg.jp). Quantification of metabolite concentrations were determined by the area of the 
projected signal once it was fit to the peak centers during identification 39,41. As a post hoc evaluation 
of the metabolite profiles, each compound was assessed based on the number of clusters in the 
compound’s signal, the degree of convolution of the signal with other compounds’ signals and the 
signal to noise ratio. These three characteristics influence the amount of error associated with the 
identification and quantification process of targeted profiling. Therefore, only compounds that were 
ranked with high-confidence were included in subsequent analyses of the metabolite profiles. 
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 7.2.5.7 Statistical Analysis 
The metabolite profiles were analysed using Principal Component Analysis (PCA) to model the 
variance between different mixed cultures, and metabolites associated with observed variances. Mean 
centering (𝑥𝑥 − ?̅?𝑥) and unit variance scaling (𝑥𝑥/𝑠𝑠, where 𝑠𝑠 is the standard deviation of x 
concentrations) were applied to the metabolite profiles to easily compare the concentration changes 
and evaluate all compounds as equally weighted. Metabolite profiles were compared by pair-wise 
Tukey’s Honest Significant Difference (HSD) test where significance was defined by a Bonferroni 
correction to the alpha value (p < 0.008). Compounds were identified as a marker when the 
concentrations in one community’s metabolite profile were significantly different from that of all 
other populations’ profiles and where this cross-profile significance only occurred for one community 
culture. Since the concentrations in the metabolite profiles spanned several orders of magnitude, the 
compounds within a profile were separated into five bins (20+ mM, 10-20 mM, 1-10 mM, 0.1-1 mM 
and 0-0.1mM). These bins were defined by a kernel density estimation of compounds’ mean 
concentration, using a bandwidth of 0.031 (Figure A7). The reason for examining the compounds 
with other compounds of similar magnitude is two-fold. The first is that it allows clear contrast in 
seeing small increments in concentration changes when visualizing the profiles. The second is that 
large changes in high-concentration compounds are more likely to be influential than similar percent 
changes in low-concentration compounds. While this sort of weighting is not desired when analyzing 
variances and model-building with PCA, it is still important to acknowledge the effect size 
differences between different compounds when interpreting the changes. All statistical analysis was 
executed using R, a statistical computing and graphics tool145. All graphics were generated by the 
ggplot2 package146. 
 122 
 7.2.6 Results 
7.2.6.1 Multivariate Analysis 
In total, 40 metabolite profiles were acquired from the samples collected. PCA was used to visualize 
samples given the variation in metabolite profiles. This was done via a score plot (Figure 7-2), where 
each sample is represented by a point on the graph, and its coordinates on the graph demonstrates the 
relationship of that sample to others given the covariance matrix of the metabolite profiles. Samples 
from different donors clustered distinctly from each other, and samples of the same donor clustered 
together. Even the samples of donor A, which were obtained from two different runs, demonstrated 
similar metabolite profiles and clustered close together. Given that principal component (PC) 1 and 2 
cumulatively account for 64.8% of the total variation explained, while PC 3 accounts for only 11.3% 
of the total variation explained, it can be concluded that donor variability, rather than run-to-run 
variability, is the main contributor to the amount of variation observed in the metabolite profiles. 
Additionally, it became evident that the metabolite profiles derived from human fecal 
communities were more similar to each other than the profiles of defined communities, despite the 
latter being designed to resemble the consortia of one of the human donations. Profiles of human 
feces-derived cultures differed from profiles of the defined culture along PC1 on the x-axis, which 
accounted for 39.7% of the total variation. The compounds that drove the relationships depicted in the 
score was extracted from the corresponding loading plot, where the coordinate location of the 
compounds describes how those compounds contribute to those sample relationships (Figure A8B). 
The similarities and differences in cultures were also apparent through a global view of the metabolite 
profiles comparing mean compound concentrations across different donors (Figure 7-3). The 
compounds most influential in differentiating feces-derived communities and defined mixed cultures 
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 are listed in Table 7-2. Carboxylic acids and derivatives, fatty acids and conjugates, and amino acids 
and derivatives were the most common types of compounds that differentiated the two groupings. 
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Figure 7-2. Principal component analysis score of metabolite concentration profiles obtained from 
samples of bioreactor effluent. Metabolite concentrations have been mean centered and unit variance 
scaled. Seeding culture sources are represented by symbols, which are coloured by runs, where a run 
includes several bioreactor vessels seeded with the same inoculant and operating in parallel. Principal 
component (PC) 1 and PC 3 are represented along the x axis, while PC 2 and PC 4 are represented 
along the y-axis. PC 1 and PC 2 account for 39.7% and 25.1% of the total variation, respectively. PC 
3 and PC 4 account for 11.3% and 9.5% of the total variation respectively. 
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Figure 7-3. Metabolite profile comparison different donors. The mean compound concentrations 
(mM) of samples from the untreated conditions are presented for each donor. The profiles are split 
into five bins, as defined by kernel density plot of mean concentrations (Supplementary figure). (A) 
Bin range: mean ≥ 20 mM. (B) Bin range: 1 < mean < 10 mM. (C) Bin range: 10 < mean < 20 mM. 
(D) Bin range: 0.1 < mean < 1 mM. (E) Bin range: 0 < mean < 0.1 mM. 
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 Table 7-2. Compounds that differentiated donor-derived cultures and defined 
cultures as tested by the Mann-Whitney test at the 95% confidence level. 
 Compound5 P-value Compound Class 
Bin 1 Propionate 2.76E-06 Carboxylic Acids and Derivatives 
Bin 2 Valerate 8.62E-11 Fatty Acids and Conjugates 
Bin 3 Isobutyrate 8.62E-11 Carboxylic Acids and Derivatives 
 Isovalerate 8.62E-11 Fatty Acids and Conjugates 
 Glutamate 2.65E-07 Amino Acids and Derivatives 
Bin 4 Phenylacetate 8.62E-11 Phenylacetic Acid Derivatives 
 Methylamine 1.72E-10 Alkylamines 
 Urea 1.52E-09 Ureas 
 Asparagine 3.77E-08 Amino Acids and Derivatives 
 Choline 6.70E-08 Alcohols and Polyols 
 Succinate 1.44E-07 Carboxylic Acids and Derivatives 
 Pyroglutamate 2.38E-07 Pyrrolidines 
 Thymine 2.61E-07 Diazines 
 Glycolate 2.65E-07 Hydroxy Acids and Derivatives 
 Benzoate 3.78E-07 Benzoic Acid and Derivatives 
 Lysine 1.10E-05 Amino Acids and Derivatives 
 Proline 4.17E-05 Amino Acids and Derivatives 
 Serine 0.000155 Amino Acids and Derivatives 
 3-Phenylpropionate 0.000655 Cinnamic Acid Derivatives 
 Trimethylamine 0.017892 Alkylamines 
 Glucose 0.024295 Monosaccharides 
Bin 5 Tartrate 1.52E-09 Carboxylic Acids and Derivatives 
 Formate 6.73E-08 Carboxylic Acids and Derivatives 
 Histamine 1.10E-07 Azoles 
 p-Cresol 1.44E-07 Phenols and Derivatives 
 Dimethylamine 3.07E-07 Alkylamines 
 Acetone 3.70E-07 Carbonyl Compounds 
 2-Oxoisocaproate 9.72E-05 Fatty Acids and Conjugates 
 Malate 9.73E-05 Carboxylic Acids and Derivatives 
 Fumarate 9.73E-05 Fatty Acids and Conjugates 
 myo-Inositol 9.73E-05 Cyclic Alcohols and Derivatives 
 Sarcosine 9.73E-05 Amino Acids and Derivatives 
5Compounds are listed in order of increasing p-value within each compound bin. Bin 1: > 20 mM; 
Bin 2: > 10 mM, < 20 mM; Bin 3: > 1 mM, < 10 mM; Bin 4: > 0.1 mM, < 1 mM; Bin 5: > 0 mM. 
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  Pyruvate 0.000227 Keto-Acids and Derivatives 
 Tyramine 0.017207 Phenethylamines 
 Uracil 0.022443 Diazines 
 beta-Alanine 0.037663 Amino Acids and Derivatives 
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 7.2.6.2 Metabolite Profiles 
Amino acids and fatty acids were the two classes of compounds most commonly profiled in each of 
the cultures and the abundance of these compounds was a trait common to metabolite profiles of 
every bacterial community investigated. On average, feces-derived cultures had more compounds in 
their metabolite profiles compared to that of the defined culture; donor A, B and C had 47, 48 and 40 
different compounds respectively and MET-2 had 42 different compounds. When the frequency of 
each compound class in the metabolite profiles were weighted to the respective concentrations 
assigned, carboxylic acids and derivatives, fatty acids and conjugates and alcohols and polyols 
occupied the largest proportions of each culture’s profiles (Table 7-3) 
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 Table 7-3. Metabolite profile diversity of each bacterial culture. Proportion of each compound class 
(%) weighted to the compounds’ concentration. 
Compound Class Number of 
Compounds 
Bacterial Culture 
 
 A B C MET-2 
Carboxylic Acids and 
Derivatives 9 69.59801 74.72572 77.31247 72.48956 
Fatty Acids and Conjugates 5 15.95946 19.2173 11.08216 9.650773 
Alcohols and Polyols 4 11.324 3.840536 9.901108 13.1407 
Amino Acids and Derivatives 18 2.067571 1.280227 0.794359 2.670579 
Phenylacetic Acid Derivatives 1 0.323521 0.170689 0.250661 0.09505 
Alkylamines 3 0.316235 0.392174 0.295705 0.20722 
Hydroxy Acids and 
Derivatives 2 0.077436 0.142395 0.016511 0.206701 
Diazines 2 0.074816 0.046046 0.04838 0.099248 
Cinnamic Acid Derivatives 1 0.069176 0 0 0 
Benzoic Acid and Derivatives 1 0.055678 0.018187 0.077969 0.016401 
Pyrrolidines 1 0.027272 0.031161 0 0.614319 
Cyclic Alcohols and 
Derivatives 1 0.025528 0.022009 0 0 
Keto-Acids and Derivatives 1 0.024497 0.022676 0 0.038515 
Carbonyl Compounds 1 0.021668 0.00918 0.019653 0 
Phenethylamines 1 0.018246 0.035099 0.024367 0.027895 
Phenols and Derivatives 2 0.016894 0.046596 0.015592 0 
Azoles 1 0 0 0.018856 0.029123 
Monosaccharides 1 0 0 0.142208 0 
Ureas 1 0 0 0 0.713916 
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 In fact, the proportional distribution of all the compound classes were very similar between 
all four types of cultures. One of the few discrepancies between the cultures was that donor B-derived 
culture profiles contained 3.84% alcohols and polyols while all other cultures had ~10% or more of 
this class of compounds. While characteristics such as compound class composition and number of 
metabolites profiled could be generalized, each population of enteric bacteria still produced unique 
metabolite profiles that could be described based on several identifying features.  
Each of the communities’ metabolite profiles had unique features where certain metabolites 
could be identified as a marker for that particular bacteria population. 3-Phenylpropionate was unique 
to the metabolite profiles of donor A-derived cultures as it was not found in any other cultures’ 
metabolite profiles. Donor A-derived samples also had elevated levels of leucine, valine, isoleucine, 
methylamine, phenylalanine and methionine (p < 0.008). Mean methanol levels were much lower, 
while mean succinate, and dimethylamine levels were higher in donor A than all the other cultures, 
however this was not statistically significant due to relatively large standard deviations.  
Donor B culture had three markers that were unique to its metabolite profile. Pimelate and 
sebacate, both dicarboxylic acids, were found at 1.63 mM and 1.60 mM mean concentrations, 
respectively, but were absent in the profiles of communities other than Donor B. 4-
Hydroxyphenylacetate, an aromatic acid, was found only in donor B culture’s profile, though at very 
low concentrations (mean 0.023 mM). Other identifying features of donor B community’s metabolite 
profile was decreased levels of acetate and ethanol. Donor B cultures had an average concentration of 
48.6 mM of acetate and 0.91 mM of ethanol, whereas other communities had significantly greater 
levels of acetate and ethanol, in the range of 67.62-81.45 mM and 11.5-16.05 mM, respectively. The 
donor B community also had the highest levels of valerate and lactate of all the communities. The 
mean concentration of valerate in the metabolite profiles of donor B communities was 10.8 mM, 
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 while the mean of donor A, C and MET-2 communities were 5.02 mM, 4.41 mM and 0.80 mM, 
respectively. Similarly, the mean lactate concentration in donor B was 0.093 mM, while the mean 
lactate concentration in donor A and MET-2 communities were 0.028 mM and 0.023 mM 
respectively.  
Donor C was the only community that yielded metabolite profiles that did not contain any 
lactate. Similarly, donor C culture profiles did not contain any beta-alanine nor pyruvate, while all 
other cultures’ metabolite profiles had mean concentrations within the range of 0.015-0.026 mM and 
0.026-0.054 mM respectively. On the other hand, donor C culture’s profile was the only one that 
contained glucose (mean 0.23 mM).  
The MET-2 community was the only culture that produced a metabolite profile that contained 
tartrate and urea. Furthermore, MET-2 culture metabolite profiles contained significantly elevated 
levels of glutamate, pyroglutamate, asparagine, glycolate, choline, thymine and formate compared to 
donor A, B and C metabolite profiles (p < 0.008). Figure 7-4 provides further detail on these 
identifying markers.  
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Figure 7-4. Metabolites as identifying markers for metabolite profiles. 
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 7.2.7 Discussion 
7.2.7.1 Feces-Derived vs Defined Community Cultures 
Metabolite profiles of feces-derived samples were more similar to each other than MET-2 (defined 
community) samples. Given that the defined community was a subset of isolates derived from a fecal 
community and which therefore displayed less alpha diversity than its parent community147, 
differences in the metabolite profiles between defined and fecal communities were expected. 
According to multivariate analysis, where compounds are weighted equally, the compounds that were 
found at greater concentrations in MET-2 compared to fecal cultures were mostly low-concentration 
compounds (mean < 1 mM) (Figure A8B). The low concentrations of these compounds indicate that 
these metabolites could be intermediates in major pathways. While these compounds were 
statistically significant, their impact on the bacterial culture as a whole could be regarded as minimal. 
Glutamate was the only compound higher in MET-2 culture profiles (mean equal to 1.61 mM) 
compared to feces-derived culture profiles (means ranged from 0.26 to 0.62 mM). Glutamate is 
utilized by various species in Groups I through IV of the Clostridia class, forming acetate, butyrate, 
carbon dioxide, ammonia and hydrogen as products148,149. While acetate and butyrate were observed 
in abundance, the latter three compounds were not measured in the metabolite profiles due to their 
incompatibility with 1H NMR spectroscopy. On the other hand, glutamate synthesis is associated with 
osmoregulation150,151 and ammonia assimilation152 in anaerobic bacteria. Therefore, the difference in 
glutamate levels between the feces-derived and defined cultures could be indicative that the 
communities have differences in their propensity to perform these glutamate-associated biofunctions. 
Since the biofunctions associated by glutamate synthesis involve fluctuation of intracellular 
glutamate, those pathways are unlikely to be reflected in the metabolite profiles analyzed here, which 
represent the exometabolome only. Even though acetate and butyrate were end-products of glutamate 
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 breakdown, they were not observed to be at significantly lower levels in MET-2. This is likely due to 
the fact that acetate and butyrate are also by-products of other fermentation pathways, such as 
breakdown of other amino acids 149. Therefore, the concentration of acetate and butyrate observed is 
the cumulative result of the entire community’s metabolic reactions.  
Comparison between the two types of cultures also revealed that high-concentration 
compounds (mean > 1 mM) were found at decreased levels in defined cultures compared to fecal 
cultures. Since high-concentration compounds were the major components of the metabolite profiles, 
disparities in those compounds between the two groups are both significant and important. 
Propionate, valerate, and isovalerate have mean values of 34.7 mM, 6.74 mM, and 1.13 mM 
respectively in fecal cultures and 30.7 mM, 0.802 mM, and 0.236 mM respectively in the defined 
culture. Propionate, valerate, isobutyrate, and isovalerate are short chain and branched chain fatty 
acids (SCFA and BCFA respectively) previously reported to be produced by anaerobic bacteria of the 
distal GI tract74,153,154. Propionate fermentation occurs via the acrylate pathway in members of the 
Clostridium genus or via the succinate-propionate pathway in other bacteria such as Bacteroides 
fragilis155,156. Since these SCFA and BCFAs were not found in the metabolite profile of the CSTR 
growth medium, all the propionate, valerate, isobutyrate and isovalerate detected was produced by 
bacterial metabolic activities. 
7.2.7.2 Metabolite Profiles of Bacterial Communities 
The metabolite profiles can be broken down into metabolite classes as classified by HMDB (Table 3). 
The profiles can be viewed as a composition of chemical taxonomy classes proportional to the 
concentration of each compound. The proportion of compound classes that make up the metabolite 
profiles was consistent across all the bacterial cultures analyzed, where carboxylic acids and 
derivatives, fatty acids and conjugates and alcohols and polyols were present in the highest 
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 concentrations, cumulatively accounting for at least 95% of the metabolite profiles. Variability in the 
metabolite composition occurred in the remaining 2-5%% of the profiles. For example, amino acids 
occupied ~2% of the metabolite profiles in donor A-, and B-derived community and the defined 
community, but in the donor C-derived community made up only 0.79% of the metabolites. Less than 
4% of the metabolites from donor B-derived cultures were alcohols and polyols, but made up ~10% 
or more of the metabolites in the profiles from other cultures. Despite these small variations, the 
consistency of the metabolite profiles’ structure could be an indication that the intestinal communities 
share a functional steady state. Therefore, the metabolic interactions tend towards satisfying these 
functional roles, even when the microbial composition of the community are different. 
 While the general structure of the metabolite profiles based on the compounds’ chemical 
taxonomic classes could be a characteristic of communities of intestinal bacteria, it does not preclude 
the fact that there are important metabolic differences between various intestinal microbial 
ecosystems that are reflected in their metabolite profiles. Such are distinctive and could be used as 
identifying markers.  
7.2.7.3 Donor A 
The microbial ecosystem derived from donor A was elevated in compounds involved in the valine-
leucine-isoleucine metabolism pathway and the presence of 3-phenylpropionate (absent in all other 
fecal community samples, including MET-2) suggested an active phenylalanine metabolism 
pathway157,158. 3-Phenylpropionate is known to be produced by 13 different species in the 
Clostridiales order, including C. sporogenes, C. caproicum and C. botulinum (Clostridiaceae family), 
and C. bifermentans and C. sordellii, (Peptostreptococcaceae family)133,159, none of which are 
components of the MET-2 community (Table 1). Alternatively, 3-phenylpropionic acid has been 
demonstrated to be catabolized by Escherichia coli to produce acetaldehyde and pyruvate157. Given 
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 that MET-2 was designed to mimic the donor A community, and both communities contained E. coli, 
it can be assumed that both donor A and MET-2 communities would have similar, if any, 3-
phenylpropionate catabolism capabilities. Therefore, the absence of 3-phenylpropionate in all culture 
profiles except that of donor A’s was likely due to increased phenylalanine dissimilation capabilities, 
rather than decreased usage of 3-phenylpropionate.  
7.2.7.4 Donor B 
The metabolite profile of donor B could be distinguished by the presence of pimelate, sebacate and 4-
hydroxyphenylacetate. Derivatives of pimelate have been shown to be part of the lysine biosynthesis 
pathway in organisms such as E. coli and Bacillus subtilis and the biotin biosynthesis pathway in B. 
spaericus160,161. Bacteria that are able to oxidize long-chain dicarboxylic acid compounds, such as 
sebacate, are also capable of metabolizing a wide range of dibasic acids, like pimelate, suberate and 
azelate162. 4-Hydroxyphenylacetate is an aromatic acid that has been demonstrated to be part of the 
phenylalanine-tyrosine pathway of Klebsiella pneumoniae and the denitrifying pathway of 
Pseudomonas spp.163,164. Acetate and ethanol are produced by fermentation activities of enteric 
bacteria, and also act as the main substrate for sulfur-reducing enteric bacteria154,165. Given these 
observations, the donor B-derived community appeared to have greater dicarboxylic metabolism 
capabilities than the other communities studied, which in turn could be related to either increased 
levels of fermentation activity or decreased presence of sulfate-reducing bacteria. Valerate and lactate 
were identified as elevated in donor B-derived communities, and both are associated with 
fermentation; valerate is a SCFA produced from metabolism of carbohydrates and amino acids166 and 
lactate is a hydroxy acid that is produced alongside other organic acids during fermentation154,165.  
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 7.2.7.5 Donor C 
Interestingly, neither lactate nor pyruvate were detected in the donor C-derived community metabolite 
profile, even though these compounds were found in all other communities studied. These are 
common compounds within microbial communities, however, and we speculate that their 
concentrations were below the level of detection using our methods, rather than being completely 
absent. The donor C community metabolite profile was also the only one that still contained glucose. 
Since complex carbohydrates were the carbon source available in the feed medium, presence of 
glucose in the effluent samples was indicative of successful breakdown of these polysaccharides but 
reduced propensity to take up simple sugars. Thus, the absence of lactate and pyruvate as well as the 
presence of residual glucose all indicated that the donor C microbial community had not metabolized 
all of the simple sugar. The lack of beta-alanine was also unique to the donor C community. Several 
organisms, including C. sporogenes, follow a reductive pathway in degrading pyrimidines to produce 
beta-alanine167, and in some microorganisms beta-alanine can be subsequently broken down to be 
used as a nitrogen source168,169. As such, the absence of beta-alanine in the donor C profile could be 
attributed to either a non-reductive pathway of degrading pyrimidines or the inability to utilize beta-
alanine.  
7.2.7.6 MET-2 
MET-2 was the only bacterial population that had tartrate in its metabolite profiles. Tartrate is 
a dicarboxylic acid known to contribute to fecal pH170. Certain anaerobic bacteria, including some 
species found in feces, are able to breakdown tartrate to produce SCFAs, ethanol, lactate, carbon 
dioxide and hydrogen171–174. The production of tartrate has been studied extensively in Gluconobacter 
suboxydans, a strict aerobe, for industrial purposes175,176. While G. suboxydans is not a gut microbe, 
its tartrate biosynthesis pathway (from glucose, with glycolate as a by-product) could be similar to 
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 those in the MET-2 community. Indeed, glycolate was found in MET-2 profiles at levels an order of 
magnitude greater than in all other cultures. Based on the evidence that the presence of tartrate was 
unique to the MET-2 community, and that glycolate was elevated in the MET-2 culture, it appears 
that the MET-2 community has greater tartrate producing capabilities, rather than a diminished level 
of tartrate utilization.  
Urea was also a unique characteristic of the MET-2 culture. Urea is a waste product from 
both purine and amino acid degradation, and is usually degraded by bacterial urease to generate free 
ammonia177,178. Amino acid degradation products were detected in all studied cultures, but urea was 
only detected in MET-2. We speculate that because MET-2 has low diversity compared to fecal 
communities, the MET-2 culture lacked the ability to perform urea hydrolysis, rather than had an 
enhanced ability to break down amino acids.  
MET-2 cultures also had higher concentrations of glutamate, pyroglutamate, asparagine, 
choline, thymine, glycolate and formate. Glutamate and pyroglutamate both participate in glutamate 
metabolism, such as ammonia assimilation. Asparagine is known to be associated with generation of 
ammonia via an asparagine-aspartate deamidation pathway179,180. Therefore, an abundance of 
asparagine could be an indication of decreased activity along the asparagine degradation pathway. 
Another amino acid that was elevated in MET-2 cultures compared to other communities was choline. 
In anaerobic bacteria, choline utilization involves its enzymatic cleavage to produce trimethylamine, 
which can be subsequently used by methanogenic bacteria181–183. Significantly decreased levels of 
trimethylamine in the MET-2 samples compared to the donor B and C derived communities were 
most likely because there was a reduced capacity in the MET-2 community to cleave choline. 
Interestingly, the donor A community, from which MET-2 was derived, also had low levels of 
trimethylamine, indicating that this characteristic could be preserved in a derivative community.  
 139 
 Thymine is a pyrimidine that is utilized as a nitrogen source via either reductive or oxidative 
pathways184,185. Given that the MET-2 community exhibited pyrimidine levels over 3 times greater 
than that of the donor A samples, and 10 times greater than the donor B and C samples, we conclude 
that MET-2 was not able to catabolize thymine to the same extent as other community cultures. 
Glycolate and formate were also found to be significantly higher in MET-2 than other cultures. 
Glycolate, as well as formate, is involved in energy metabolism during fermentation of carbohydrates 
and degradation of amino acids149,186. Although, as described above, glycolate presence may be 
attributed to tartrate production. Even though both formate and glycolate were observed at a 
concentration less than 1 mM in MET-2 samples, this level was still relatively high compared to the 
profiles of donor A, B or C-derived communities. Subtle differences in metabolically linked 
compounds, such as glycolate and formate could be representative of differences in the metabolic 
interactions occurring within each culture. 
7.2.8 Conclusion 
Communities of colonic bacteria propagated in vitro were described by their metabolite profiles, 
which were built using 1D-1H NMR spectroscopy. Overall, the metabolite profiles were consistent in 
the proportions of compound classes, where carboxylic acids (69.6-77.3%), and fatty acids (9.7-
19.2%) were the most abundant types of metabolites. The two types of cultures (defined or feces-
derived) were seen to have different sugar metabolism capabilities, based on the levels of SCFAs 
(propionate and valerate) and BCFAs (isovalerate and isobutyrate). The simpler defined community, 
MET-2, was less proficient at carbohydrate metabolism compared to its feces-derived community 
counterparts. In general, more compounds were found in the feces-derived cultures, though many that 
were unique to the feces-derived cultures were found at very low concentrations, less than 0.1 mM. 
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 Ultimately, the features within each metabolic profile not only identified the community culture, but 
also allowed inferences on their respective metabolic capabilities to be made.  
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 7.3 Analysis of Perturbations to Human Fecal Microbiota Propagated In Vitro 
7.3.1 Experiment Objective 
Given that the metabolite profiles were demonstrated to reveal insight into the metabolic functions 
occurring in in vitro microbial communities, further experiments were conducted to assess the 
robustness of the communities’ functional roles. Several different perturbations were administered to 
feces-derived and defined communities after achieving steady state in the CSTRs. The objective of 
this study was to characterize the effects of different types of perturbations on bacterial communities 
based on their metabolite profiles. A wide range of perturbing agents was used to demonstrate the 
breadth of investigations to which this approach could be used. 
7.3.2 Justification of Treatment Condition 
7.3.2.1 Clindamycin 
Clindamycin is a broad spectrum antibiotic that is active against anaerobic bacteria, such as those 
found within the gastrointestinal system187. The antibiotic inhibits protein synthesis within the cell by 
binding to the 50S ribosomal subunits and preventing aminoacyl sRNA from binding to the 
messenger ribosome complex188. This mechanism of action is effective against most anaerobes as 
well as most aerobic gram-positive bacteria (Table A6), though its ineffectiveness against Clostridium 
difficile cautions clinicians to reserve the use of clindamycin for serious infections189,190. Due to its 
potency against gram-negative anaerobic bacteria, clindamycin is an appropriate antibiotic to target 
microflora in the oxygen depleted, distal parts of the GI tract190. 
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 7.3.2.2 Vancomycin 
Vancomycin is a broad spectrum antibiotic usually reserved for treating serious infections caused by 
β-lactam-resistant pathogens191. Like β-lactam antibiotics, vancomycin targets the mechanisms 
involved in biosynthesis of bacterial cell walls. While β-lactam antibiotics prevent the crosslinking of 
peptides to the peptidoglycans of the cell wall, vancomycin operates by specifically targeting the 
terminal peptides on the peptidoglycans required for transpeptidation reactions in forming the 
bacterial cell wall192,193.  
7.3.2.3 Norepinephrine 
Norepinephrine is a catecholamine that functions as a neurotransmitter or a hormone, depending on 
the area of the body in which the compound is produced. The production of norepinephrine is under 
control of the sympathetic nervous system, and activates the fight-or-flight response to influences 
heart rate and other physiological changes that cue the body for rapid metabolic change and physical 
movement194. As a hormone, norepinephrine travels through the blood to reach their target tissue to 
reinforce the sympathetic responses195. It has been documented that a substantial amount of the 
body’s total norepinephrine production and turnover is performed by mesentery organs, which 
includes the gastrointestinal tract, spleen and pancreas196. Since exposure to stress has been shown to 
induce a sustained increase in catecholamine levels, the effects of psychological stress on the gut 
microbiota have been probed regarding the integrity of the microflora and resistance to colonization 
of pathogenic organisms197–200. Specifically, studies in the literature suggest that norepinephrine 
increases in vitro growth of pathogenic gram negative bacteria found in the GI tract: Yersinia 
enterocolitica, Escherichia coli, and Pseudomonas aeruginosa201. It is of interest to investigate if the 
documented effects of norepinephrine on pure cultures manifest in the same way in community 
cultures and is able to influence the overall structure of the bioreactor microflora.  
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 7.3.2.4 Defined Bacterial Community 
A defined community of bacteria was developed by the Allen-Vercoe group of the University of 
Guelph as a simplified version of the gut microbiota. Referred to as MET-1, the mixed culture is 
composed of 33 different strains of bacteria that were isolated from a fecal sample obtained Donor D 
(Table A1). Using a subset of defined community to perturb the CSTR culture system allows one to 
monitor the test culture’s response to competition. 
7.3.3 Materials and Methods 
7.3.3.1 Overview of Bioreactor Setup 
This study was performed over 6 different bioreactor experimental ‘runs’, where any given run  had 
one or more bioreactor vessels operating. All vessels within a run propagated cultures from the same 
seeding source; that is, the inoculant for all vessels in each run was derived from the same inoculum. 
Conversely, different bioreactor runs used different inoculants. The inocula for Runs 1 and 2 were 
collected Donor A whereas the inocula for Run 3 was collected from Donor B. Run 5 was inoculated 
with a defined mixed culture, MET-2, modeled on the fecal community of Donor A (Figure 7-5). 
Runs 1, 2, and 3 were maintained for 48, 53, and 41 days respectively, while, Runs 5 was maintained 
for 27 days. Based on previous studies using this system the community cultures reached steady-state 
by ~5 weeks after inoculation5.  
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Figure 7-5. Experiment overview. The community culture grown in each bioreactor as labelled as 
DA=Donor A, DB=Donor B, DC=Donor C, MET 1=Microbial Ecosystem Therapeutic-1, MET-
2=Microbial Ecosystem Therapeutic-2, Clm=clindamycin, NE=norepinephrine, Van=vancomycin. 
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 7.3.3.2 Bioreactor Perturbations 
One of several perturbing agents were used to treat the mixed cultures by delivering the agent directly 
to the bioreactor vessel. In Run 2, the Donor-A derived culture (DA-N1) was administered 
norepinephrine (L-(-)-norepinephrine (+)-bitartrate salt monohydrate, Sigma Aldrich) to a final 
concentration of 100 mM every 12 hours starting from day 48 post-inoculation until day 52.5 post-
inoculation. Similarly, an equal volume of sterile water was added to the sister vessel, DA-N2, as a 
control. In Run 1, clindamycin (clindamycin 2-phosphate, Sigma Aldrich) was added the Donor A-
derived culture (DA-T2) every 12 hours from day 36 to day 40 post-inoculation. The final 
clindamycin concentration reached at each dosage was 12.6 µg/mL on day 36, 16.6 µg/mL on day 37, 
22.4 µg/mL on day 38, 124.7 µg/mL on day 39, and 203.8 µg/mL on day 40. At the same time, the 
culture DA-T1 was administered dosage-equivalent volumes of sterile water to be assessed as the 
control vessel. The culture DA-T4 was administered clindamycin from day 36 to day 40 post-
inoculation at the same dosages as DA-T2. Following clindamycin treatment, MET-1 was delivered 
to DA-T4 on day 42 post-inoculation. The MET-1 treatment was prepared as described in Chapter 3, 
and administered directly into the bioreactor vessel, being careful not to displace the resident 
bioreactor culture during the treatment delivery process. Concurrently, the DA-T3 community was 
administered clindamycin-dosage-equivalent volumes of sterile water from day 36-40 and on day 42, 
was the same MET-1 treatment as DA-T4 was delivered. In Run 3, the culture DB-T1 was 
administered clindamycin every 12 hours from day 36-40 at the same dosages as those given to DA-
T2. As the control vessel, DB-T2 was administered dosage-equivalent volumes every 12 hours from 
day 36-40. In run 5, the MET-2 culture was treated with vancomycin to a final concentration of 0.5 
mg/mL on day 26 post-inoculation. 
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 7.3.3.3 Sample collection and processing 
The bioreactor Runs 1, 2, and 3 were studied based on samples from the bioreactor effluent on a daily 
basis, except for samples from Run 1, where samples were collected from the effluent pooled over a 
period of 10 days. Runs 4, and 5 were sampled directly from the bioreactor, where sample volumes 
did not exceed 2.5% of the total working volume so not to impact the chemostatic conditions of the 
bioreactor. Samples were centrifuged (5000 rpm, 10 min) to remove cells, then subjected to 
ultracentrifugation (37 000 rpm, 4°C) to pellet media particulates. Finally, samples were filtered using 
0.22 µm syringe filters (Acrodisc® Supor membrane, Pall Corporation, UK) to remove bacterial cells. 
Samples were stored in 4°C until time of NMR analysis. 
7.3.3.4 Statistical analysis 
The metabolite profiles were analyzed using principal component analysis (PCA) to model the 
variance between different mixed cultures, and metabolites associated with observed variances. Mean 
centering (x-𝑥𝑥 − ?̅?𝑥) and unit variance scaling (𝑥𝑥/𝑠𝑠, where 𝑠𝑠 is the standard deviation of x 
concentrations) were applied to the metabolite profiles to easily compare the concentration changes 
and evaluate all compounds as equally weighted. Changes in specific compounds due to perturbations 
were assessed using the Mann-Whitney U test, at a 95% confidence level. Since the concentrations in 
the metabolite profiles spanned several orders of magnitude, the compounds within a profile were 
separated into five bins (20+ mM, 10-20 mM, 1-10 mM, 0.1-1 mM and 0-0.1mM). These bins were 
defined by a kernel density estimation of mean concentration of compounds in untreated samples, 
using a bandwidth of 0.03089 (Figure A7). The reason for examining the compounds with other 
compounds of similar magnitude is two-fold. The first is that it allows clear contrast in seeing small 
increments in concentration changes when visualizing the profiles. The second is that large changes in 
high-concentration compounds are more likely to be influential than similar percent changes in low-
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 concentration compounds. While this sort of weighting is not desired when analyzing variances and 
model-building with PCA, it is still important to acknowledge the effects size differences between 
different compounds when interpreting the changes. All statistical analysis was executed using R, a 
statistical computing and graphics tool. 
7.3.4 Results 
7.3.4.1 Antibiotic treatment 
Administration of clindamycin and vancomycin to different community cultures produced several 
changes in the metabolite profiles. Two different fecal communities were treated with clindamycin, 
one derived from donor A, and one from donor B. The effect of clindamycin treatment was a 
substantial change in many of the metabolites (Figure 7-6). In the high concentration compounds 
(mean >1 mM), which consisted of mostly short chain fatty acids (SCFA), long chain fatty acids 
(LCFA), branched chain fatty acids (BCFA) and alcohols, there were few drastic changes observed 
with clindamycin treatment. Most of the fatty acids decreased by a moderate amount, in the 20-50% 
range, except for acetate, which increased by 17% in the clindamycin-treated community from donor 
A. Ethanol and glutamate were the only compounds that increased by more than 100% after 
clindamycin treatment, and both increases were observed in the donor B community. In the Donor A 
community, the level of ethanol did not change significantly and glutamate increased by 63%. Of the 
all compounds profiled at lower concentrations (<1 mM), amino acids and some organic acids were 
affected the most, experiencing increases of greater than 100%. Succinate, a SCFA, increased by 
more than 100% after clindamycin treatment. Acetone, a carbonyl, and 2-oxoisocaproate, a fatty acid 
conjugate, were also low-concentration compounds that experienced large increases. Few low-
concentration compounds decreased in concentration with clindamycin treatment, but the ones that 
did only did so moderately. These included trimethylamine, methylamine, benzoate and 
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 dimethylamine. Some compounds, such as threonine, aspartate, serine, lysine, sarcosine and fumarate, 
saw significant increases in treatment of Donor B community, but no significant changes in treatment 
of Donor A community.  
The effects of vancomycin were examined by administering the antibiotic to a defined 
community, MET-2. The overall effects of this treatment were low to moderate decreases in high-
concentration compounds: acetate (-11%), propionate (-40%), butyrate (-37%), and isovalerate (-
43%). Additionally, there were large increases in several low-concentration compounds: alanine, 
valine, leucine, glycine, isoleucine, proline, phenylalanine, tyrosine, lactate, methionine, and formate 
(in order of decreasing mean concentration in untreated samples). Some low-concentration 
compounds were observed to decrease in concentration after treatment, including trimethylamine (-
47%), methylamine (-42%) benzoate (-63%), and tyramine (-33%), and lactate was completely 
eliminated with vancomycin treatment.  
7.3.4.2 Defined community 
The effects of challenging the resident community with a defined community were also investigated 
by administering MET-1, a community culture derived from Donor A. The metabolite profile of the 
Donor A culture remained largely unchanged after the bacterial community was challenged with 
MET-1 based on PCA of the metabolite profiles of the culture before and after introduction of the 
defined culture (Figure A9). However, there were still concentration differences apparent in the donor 
A profile after MET-1 treatment. High-concentration compounds (mean > 1 mM) either did not 
undergo significant changes with MET-1 treatment, or decreased by low-to-moderate amounts. The 
high-concentration compounds that decreased were propionate (-11%), ethanol (-32%), isobutyrate (-
12%), glutamate (-18%) and isovalerate (-7%). Methanol was the only high-concentration compound 
that exhibited a large decrease in concentration (92%) after MET-1 was introduced. The changes 
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 observed in low-concentration compounds were quite varied; observing both moderate increases and 
decreases in many compounds. Succinate, which was found at less than 1 mM prior to MET-1 
treatment, was that only SCFA that increased with MET-1 treatment, and it did so by more than 
100%. Similarly, dimethylamine was the only other low-concentration compound that increased by 
more than 100% after MET-1 treatment. On the other hand, asparagine, lysine and thymine were all 
completely eliminated after treatment. 
 The effects of treatment with a defined culture on a bacterial population in dysbiosis were 
evaluated by treating the Donor A culture with clindamycin followed by adding MET-1 to the culture. 
The metabolite profile of the culture after clindamycin and MET-1 treatment was comparable to that 
of cultures treated only with clindamycin according to the PCA score plot, where compounds were 
assigned equal weighting (Figure A9). In comparing the treatments’ profiles without scaling, it was 
evident that the concentration changes caused by the combination treatment resembled that of the 
clindamycin treatment, but with some characteristics of the MET-1 treatment profile (Figure 7-6). 
Most of the changes observed in high-concentration compounds followed the same trend in the 
clindamycin-MET-1 combination treatment, as clindamycin-only treatment of Donor A. For some 
compounds, like acetate and glutamate, the percent change was nearly identical for the combination 
treatment and clindamycin treatment. For other compounds, like butyrate and valerate, the percent 
differences was more exaggerated in the combination treatment than the clindamycin treatment, with 
42% and 73% decrease, respectively, in the combination treatment, compared to 30% and 24% 
decrease, respectively, in the clindamycin treatment. There were also compounds that followed the 
trend of MET-1 treatment, rather than the clindamycin treatment, as exemplified by propionate and 
isovalerate.  
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 Low-concentration compounds (<1 mM) also contained characteristics from both 
clindamycin treatment and MET-1 treatment profiles. In fact, about one third of the low-concentration 
compounds followed the same trends as the changes seen with clindamycin treatment and one-third 
followed that of MET-1 treatment. The remaining third of the compounds exhibited changes that were 
unique to the combination treatment, resembling neither the clindamycin treatment nor the MET-1 
treatment. Specifically, valine, leucine, and isoleucine did not change significantly when clindamycin 
was followed with introduction of MET-1 even though those compounds increased with both 
clindamycin-only and MET-1-only treatments. Glycolate (100+%), serine (40%), threonine (72%) 
and aspartate (86%) all increased after the combination treatment, but demonstrated no significant 
changes after clindamycin treatment, and moderate decreases with MET-1 treatment. 3-
Phenylpropionate, lactate and malate were also compounds that demonstrated concentration changes 
after administration of the combination treatment that were different from the changes observed when 
treated with each constituent perturbation agent alone.  
7.3.4.3 Norepinephrine treatment  
Exposure of norepinephrine, a stress hormone, to the Donor A-derived culture had a minor 
impact on the culture’s metabolite profiles, as reflected in the PCA of treated and non-treated profiles 
(Figure A9). In an overview of changes occurring across the entire profile (Figure 7-6), there were 
very few significant changes, giving further support that little changes occurred due to norepinephrine 
treatment. The few changes that did occur were observed in low-concentration compounds (mean < 1 
mM). These changes occurred in succinate (61%), malate (77%), 3-phenylproprionate (100+%), 
fumarate (100+%) and asparagine (-100%). 
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Figure 7-6. Treatment effects on metabolite profiles. The percent difference between mean 
compound concentration of treated samples and mean compound concentration of their non-perturbed 
counterparts. Norepinephrine, MET-2, clindamycin-MET-2 combination treatment and clindamycin 
treatment were administered to bioreactors inoculated with Donor A. Clindamycin treatment was also 
administered to bioreactors inoculated with Donor B. The two clindamycin conditions are identified 
by their respective donors as Clindamycin (A) and Clindamycin (B). Vancomycin was administered 
to a bioreactor growing the defined culture, MET-2. Positive percent differences are represented in 
blue, negative percent differences are represented in red, and non-significant differences are 
 152 
 represented in white. Compounds not found in either treatment or non-treated conditions for a 
particular profile are presented grey. Differences exceeding 100% are represented by a star (*) on 
blue, while differences exceeding -100% are represented by a star on red. Significance of compound 
changes due to treatment was tested by the Mann-Whitney U Test, where p-value > 0.05 were 
considered as non-significant. Compounds are organized according to the mean of untreated samples. 
(A) Bin range: mean ≥ 20 mM. (B) Bin range: 1 mM < mean < 10 mM. (C) Bin range: 10 mM < 
mean < 20 mM. (D) Bin range: 0.1 mM < mean < 1 mM. (E) Bin range: 0 mM < mean < 0.1 mM.  
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 7.3.5 Discussion 
7.3.5.1 Clindamycin treatment 
The impact of clindamycin on the metabolic output of both Donor A and Donor B communities was 
fairly consistent, with percent changes mirrored in almost every metabolite. The majority of 
compounds that increased by more than 100% after clindamycin treatment were amino acids. This 
indicates that pathways involving the metabolism of amino acids were strongly impacted by 
clindamycin treatment. Indeed, many changes in compound concentrations correspond with known 
metabolic pathways of anaerobic bacteria. For example, alanine and asparagine all increased more 
than 100% after clindamycin treatment; glutamate increased by 62.7% in Donor A and more than 
100% in Donor B. In B. fragilis, the alanine-aspartate-glutamate metabolism pathway is responsible 
for the breakdown and formation of each of those amino acids202. More generally, compounds 
involved in the glycine-serine-threonine metabolism increased after clindamycin treatment. Glycine, 
and methionine both increased by more than 100% after antibiotic treatment. Threonine and serine 
increased significantly in clindamycin treatment of Donor B culture, but no effect was observed in 
Donor A culture. Valine-leucine-isoleucine biosynthesis was another pathway where all three end 
products of the pathway increased by more than 100%. Aromatic amino acids such as phenylalanine, 
and tyrosine also increased. Given that clindamycin acts on the protein synthesis mechanisms of 
bacteria to inactivate most anaerobic and Gram-positive aerobic bacteria187,188,203, the increased 
amounts of free amino acids observed further supports that extensive impairment of amino acid 
metabolic pathways had occurred following clindamycin administration. 
Short chain fatty acids metabolism pathways were also affected by clindamycin treatment. 
This is apparent in the decreased levels of propionate, butyrate, valerate, isobutyrate and isovalerate. 
This supports findings from previous reports of decreases in fatty acid output levels of fecal bacteria 
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 in response to clindamycin treatment204. Production of short-chain fatty acids occurs due to 
carbohydrate fermentation by clostridia. Since, in general, members of the genus Clostridium, with 
the exception of C. difficile, are susceptible to clindamycin, decreased levels of short-chain fatty acids 
could be attributed to elimination of organisms that perform carbohydrate fermentation. Interestingly, 
succinate increased by more than 100% in both donor communities treated with clindamycin. Since 
succinate is a SCFA closely associated with energy metabolism pathways as well as carbohydrate 
fermentation in anaerobic bacteria, the large change in succinate levels could be a reflection of drastic 
shifts in the communities’ energy usage205,206. 
7.3.5.2 Vancomycin treatment 
Similar to clindamycin treatment, administration of vancomycin caused a reduction in SCFA: 
propionate, butyrate, and isovalerate. Other SCFAs observed in the metabolite profiles, valerate and 
isobutyrate, did not change significantly with treatment. This indicated that the antibiotic inactivated 
the organisms that were metabolizing carbohydrates and producing SCFAs, such as vancomycin-
sensitive bacteria from the Clostridium leptum and Clostridium coccoides clusters207. SCFAs, and 
lactate are fecal metabolites that have been previously reported to decrease with vancomycin 
treatment in mice models and human subjects208,209, even though the findings presented here 
demonstrated a large increase in lactate. The valine-leucine-isoleucine metabolism pathway as well as 
phenylalanine-tyrosine-tryptophan pathway were both well represented in the list of amino acids that 
increased after antibiotic treatment. These amino acid changes are in agreement with previous 
publications on the metabolomic effects of vancomycin on gut microbiota208. Glycine, serine and 
threonine, which are part of the same metabolism pathway, all increased after vancomycin treatment. 
Glycine is also involved in energy storage by acting as an oxidizing agent, and it is reduced to acetate 
and ammonia in one-carbon metabolism pathways149,210.  
 155 
 7.3.5.3 Challenge of Fecal Culture with Defined Community 
The impact of using a defined mixed culture, MET-1, to challenge an already-established fecal 
culture was investigated. In comparing fecal culture from Donor A before and after it was challenged 
with MET-1, the metabolite profiles were not impacted strongly by the presence of the defined 
culture. There were low to moderate decreases in SCFAs that had mean concentrations > 1 mM prior 
to treatment. This was an indication that the Donor A community’s ability to ferment carbohydrates 
was not strongly impacted by the introduction of MET-1. Even though succinate increased by over 
100%, such small concentrations were observed that the 100+% increase still only amounted to less 
than 1 mM. Despite from the small magnitude of change, the doubling of succinate should not be 
discounted as it could be an indication that MET-1 treatment had implications on Donor A 
community’s energy consumption or conservation pathways205. Methanol did not change significantly 
in all other treatment conditions tested, whereas there was a 91% decrease of methanol with MET-1 
treatment. While this was an observation unique to MET-1 treatment, the absolute change in 
methanol was only 0.7 mM, indicating that the overall impact on the metabolite profile, and the 
culture as a whole, was very little. Other metabolite-specific changes can be observed with 
introduction of MET-1, however, like methanol, the effect size of those changes were minimal. 
7.3.5.4 Challenge of Fecal Culture in Dysbiosis with Defined Community 
MET-1 was also introduced to Donor A fecal culture after it was treated with clindamycin. This was 
driven by the hypothesis that the defined community would be able to restore a culture in dysbiosis 
back to the original culture. The metabolite profiles revealed that while MET-1 was not able re-
establish the culture back to its original community, the profile of the clindamycin-MET-1 treated 
culture contained characteristics of the clindamycin-treated Donor A community, the MET-1 treated 
Donor A community as well as some characteristics unique to the combination treatment. Similar 
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 trends were observed in short-chain fatty acids such as acetate, butyrate, and valerate, indicating that 
impairment to carbohydrate fermentation pathways by clindamycin persisted even after introduction 
of MET-1. The increase in amino acids associated with the alanine-glutamate-aspartate pathway and 
phenylalanine-tyrosine-tryptophan pathway increased, just like the clindamycin-treated cultures. 
Therefore, certain amino acid degradation pathways impacted by clindamycin treatment were not 
recovered by the introduction of MET-1. 
On the other hand, common features between the MET-1 treatment profile and the 
combination treatment profile was evidence that some of the metabolic functions of MET-1 were 
established. For example, decreases in metabolically linked compounds trimethylamine, and 
methylamine211,212 observed in both MET-1-treated communities could mean that the pathway 
involved in the of these compounds became more active with the introduction of MET-1. Similarly, 
thymine and uracil, both catabolized by E. coli as carbon sources in nitrogen-restricted environments, 
decreased after MET-1 treatment and combination treatment213. Some amino acid metabolism in the 
combination-treated profile was more like the MET-1-treated profile than the clindamycin treated 
profiles. This included decreases in proline, and lysine, and an increases in methionine. The similar 
trends that proline and lysine follow in both MET-1 treatment and combination treatment condition 
suggested that MET-1 established its ability to breakdown nitrogen-rich amino acids. Even though 
free nitrogen and ammonia levels were not measured, the increase in catabolism of pyrimidines and 
nitrogen-rich amino acids were evidence that MET-1 conferred its nitrogen-utilisation capabilities to 
the Donor A community, even when it was perturbed with clindamycin.  
As mentioned earlier, the combination-treatment condition displayed some unique 
characteristics that were not observed in either MET-1 treatment or the combination treatment 
conditions. In particular, amino acids in the leucine-valine-isoleucine pathway remained the same 
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 after combination treatment, whereas clindamycin-treated only communities exhibited large increases 
and the MET-1-treated community exhibited moderate increases in those three compounds. The 
opposing effects of the combination treatment compared to the clindamycin treatment suggested that 
MET-1 had a remedial effect with respects to the degradation pathway of these amino acids. 
Furthermore, compounds of the glycine-serine-threonine pathway seemed to be sensitive to difference 
types of perturbations. Increases in serine and threonine was unique to the combination treatment; 
methionine increased moderately after both MET-1 treatment and the combination treatment; glycine 
increased by more than 100% in both combination treatment and clindamycin treatment, but not 
MET-1 treatment. 3-Phenylprionate decreased by 67% after the combination treatment, an effect not 
observed with either MET-1 treatment or clindamycin treatment. Since the Donor A community was 
previously found to harbour phenylalanine degradation capabilities, the decrease in 3-
phenylpropionate suggested that the combination treatment impaired the pathway responsible for 
converting phenylalanine to 3-phenylpropionate, an effect that did not occur with single perturbation 
treatments. Compounds closely associated with anaerobic energy metabolism, like glycolate, 
fumarate, lactate, malate and succinate186,205, also responded to the combination treatment differently 
than the MET-1 or clindamycin single-treatments. Glycolate, malate and fumarate all increased 
largely after the combination treatment, but either did not change significantly, or decreased 
moderately in the single-treatment conditions. 
Based on direct comparison of the combination-treated metabolite profiles with other 
treatment, the signatures of clindamycin treatment profiles were clearly evident. At the same time, it 
was apparent that MET-1 was able to confer some of its metabolic functions. Interestingly, some of 
the effects of clindamycin treatment was no longer evident after the combination treatment, 
suggesting that the MET-1 treatment re-established particular biofunctions that were impaired by the 
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 antibiotic. Since the metabolite profile of the Donor A community after the combination treatment 
appeared to be a mosaic of clindamycin treatment and MET-1 treatment, it suggested that the 
community was undergoing a dynamic, transitional stage, where the MET-1 community was in the 
process of establishing its functional role in the “deteriorated” Donor A community. It was speculated 
that if the MET-1 community was given more time to assert itself following clindamycin treatment, 
the metabolite profile of the combination-treated community would become distinct from either 
clindamycin or MET-1 treatment.  
The changes highlighted in the heat maps demonstrated how small changes in the metabolite 
profiles can yield insight into the changes happening to the community. At the same time, the impact 
of these changes on the profile as a whole is minimal. As a result, the metabolite profiles of Donor A 
community after combination treatment and after clindamycin treatment can still be considered to be 
very similar. 
7.3.5.5 Norepinephrine treatment 
Previous studies have shown that physiological stress can alter gut microbiota198. Norepinephrine, a 
catecholamine released in response to acute stress, is known to promote the growth of, and expression 
of virulence determinants by, some Gram-negative enteric bacteria, such as E. coli and Y. 
enterocolitica201, through bacterial signalling pathways. However, based on multivariate analysis the 
metabolic profiles of a norepinephrine-treated community did not differ notably from the control 
(untreated) community. A difference in succinate was one of the few changes seen in response to 
norepinephrine treatment, although this change was not as drastic in comparison to succinate 
fluctuations seen in response to antibiotic perturbation. One mechanism by which norepinephrine 
enhances growth of certain enteric organisms involves liberation of glycoprotein-bound iron ions by 
the catecholamine, rendering iron available to the bacteria to be taken up, promoting their growth. It 
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 is possible that the addition of norepinephrine to the bioreactor system did not have an effect on 
microbial community growth because iron was supplied in the form of hemin, which is readily taken 
up by anaerobic bacteria214,215, and not trapped in a protein-iron complex.   
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 Chapter 8 Conclusions 
8.1 Metabolomic analysis of Nutrient Solutions 
The targeted profiling technique used to build metabolite profiles of nutrient solutions was able to 
identify and quantify compounds based on their peak signals in 1H NMR spectra. Despite the manual 
spectral processing and peak assignment, the technique has been validated to be one that is 
reproducible and reliable39,41. Conducting metabolomic analysis on cell culture media provides insight 
into the nutrient content of the growth solution. Therefore, as a demonstration of the metabolomic 
analysis in the context of nutrient solutions, the metabolite make up of a defined media for 
mammalian CHO cells subjected to various treatments of UV irradiation was investigated. The 
findings from this study revealed that not only was the constructed metabolite profiles a 
comprehensive annotation of the nutrient solution, the profiles were also sensitive enough to quantify 
the minimal effects of UV treatment. Furthermore, this experiment demonstrated that the metabolite 
profiling technique would be an appropriate tool in observing changes in low-molecular weight 
compounds found in cell culture media. Therefore, the application of this technique can be expanded 
to investigating metabolites of spent media, from the growth of bacterial communities, such as those 
of the human gut microbiota. 
8.2 Standardization of Reporting on Fecal Water Metabolites 
Metabolomic studies of the human gut microbiota thus far have focused heavily on fecal samples. 
However, the minimal degree of standardization of obtaining NMR-based metabolomic data of 
feces62 and the complete lack of standardization in reporting the fecal metabolomic data have 
prevented cross-experimental comparisons. Therefore, with the purpose of determining an appropriate 
means of reporting fecal metabolome, various concentrations of human fecal water were analyzed. 
NMR-based analysis of these fecal water samples revealed that there was a direct linear relationship 
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 between fecal concentration and metabolite concentration. The implication of this is that the 
concentration of biomass used in preparing such samples must be well documented and transparent to 
all experiment stakeholders, or be reported as normalized values. Two methods of normalizing 
metabolite profiles were investigated: one where the concentrations were scaled to the mass of feces 
from which the metabolites were extracted, and the other, where the concentrations were scaled to an 
internal compound that was observed in abundance. While both normalization methods were equally 
effective, they both had advantages and disadvantages in their application. Furthermore, given the 
linear relationship between metabolite concentration and fecal concentration, the most suitable fecal-
water concentration would be defined by the intended analysis method. For the purposes of NMR-
based metabolite concentration, fecal concentration should be greater than 25% fecal concentration in 
order to ensure low concentration compounds are captured within the limit of quantification. 
Alternatively, it can be expressed that fecal water samples must contain at least ~7.3 mM of acetate to 
construct accurate and encompassing metabolite profiles. Beyond analytical considerations, practical 
limitations of sample preparation should also be taken into account. Since all samples must be passed 
through a 0.22 um filter, this may serve as an upper limit to the concentration of fecal water that can 
be processed. 
Based on these findings, it is recommended that acetate be used as a proxy to qualifying the 
contents of a fecal water sample. Acetate is an attractive identifying marker because it has been 
consistently found to be the most abundant compound in fecal water samples. According to the 
samples evaluated here, fecal water samples should be evaluated to contain at least 7.3 mM or 0.43 
g/L of acetate in order to qualify for metabolomic analysis by 1D-1H NMR. Describing a sample in 
terms of acetate content could be a more standardized method of describing fecal water samples. 
While 7.3 mM of acetate was the minimum requirement determined from this experiment, further 
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 study on other stool samples would be required to determine a generalized acetate threshold for fecal 
water samples. 
8.3 Metabolomic Evaluation of In Vitro Gut Bacterial Communities 
A wealth of insight has been gained on the human gut microbiota through the use of in vitro growth 
of the gut microbes as a community culture. These in vitro systems have been validated for their 
ability to preserve the in vivo gut bacterial community on the microbiological level11,68,75, but little 
work has been put forth to determine the metabolomic implications of these in vitro gut microbial 
cultures. In an effort to provide such metabolomic descriptions of in vitro gut bacterial communities, 
two experiments were conducted. The first centered on developing an appropriate procedure for 
preparing bioreactor samples for NMR-based metabolomic analysis. The second investigated the 
metabolomic impact of the microbial make-up of the fecal inoculant on its resulting in vitro bacterial 
community.  
8.3.1 Sample Preparation Procedure for Metabolomic Analysis 
Comparison of various procedures for the preparation of bioreactor samples for NMR-based 
metabolomic analysis determined that factors such as performing a “soft spin” to remove cell matter 
and syringe filtration had no significant effect on the metabolite profiles. On the other hand, the 
centrifugal force impacted the metabolite profile. It was found that increasing centrifugal force 
applied the effluent samples generally decreased compound concentrations in a linear fashion. These 
linear decreases, while significant, only occurred within 2% of the mean compound concentration and 
can be considered to be of little importance. The only compound to increase in concentration with 
centrifugal force applied was p-cresol, which increased by approximately 50% per 10 000 rpm 
applied. Furthermore, these effects were found to occur with high reproducibility. In conclusion, 
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 centrifugal force had significant, but minimal impact on the metabolite profile of the sample, but 
additional attention should be allocated to p-cresol. The large and predictable means by which this 
compound is impacted by ultracentrifugation means that a correction factor of 50% per 10 000 rpm 
should be applied to the compound’s concentration. Compensation for other compounds is not 
recommended as their trends were not observed at as high precision, and changes made to their 
concentrations due to sample processing steps are so small as to be considered negligible. 
8.3.2 Effects of Varying Inoculant Biomass Proportions 
There were four different community cultures evaluated in this experiment: two different defined 
cultures, MET-2A and MET-3A and their respective reciprocal cultures, MET-2B and MET-3B. The 
reciprocal cultures consisted of the same strains as the parent culture (MET-2A or MET-3A), but with 
different proportions of each strain in the inoculum. The objective of this experiment was to observe 
the metabolite profiles of the culture over time in a CSTR system and determine if similar metabolic 
states would be achieved regardless of inioculant biomass. After determining sources of variation to 
be mostly attributed to different inocula, rather than experimental parameters such as run variability 
or profiling variability, the effect of varying inoculum biomass was investigated. First of all, the total 
concentration of metabolites in a defined culture was similar to the total metabolite concentration in 
the profiles of the respective reciprocal population. Evaluation of the cultures over time revealed that 
the majority of compounds appeared to approach a common level by day 20 when comparing the 
MET-2A and MET-3A with their respective reciprocal cultures. In order to draw more accurate 
conclusions of the trends in metabolite profile changes over time, however, metabolite profiles should 
be assembled for more time points throughout the duration of the culture, with multiple samples per 
time point for an estimate of error and variation and also for a longer duration in order to evalutate 
acheivement of metabolic steady state.  
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 8.4 Metabolomic Characterization of In Vitro Gut Microbial Communities 
The advantages associated with studying the gut microbiota in an in vitro system combined with the 
metabolomic data available in these systems allows for a wide range of studies that contribute to 
metabolomic characterization the human gut microbiota. Therefore, two experiments were conducted 
with the aim of providing further insight into the metabolome of these bacterial communities. In 
“Metabolomic Analysis of Human Fecal Microbiota Propagated In Vitro in a CSTR System,” it was 
found that the metabolite profiles of the gut bacterial communities were generally composed of the 
same proportion of classifications of metabolites, regardless of the individual from whom the 
inoculating community was obtained. Despite these general similarities, the metabolite profiles were 
still able to distinguish one bacterial community from the next, even identifying differences in 
metabolic capabilities. These metabolomic characterizations were also applied to a defined 
community cultured in the same in vitro bioreactor system, revealing some functional differences 
between feces-derived and defined culture communities. 
Given that the metabolite profiles were able to identify individual bacterial communities and 
comment on their metabolic functions, it was of interest to observe the in vitro communities’ 
responses to various perturbations. For this purpose, several perturbation agents were administered to 
feces-derived or defined communities and metabolite profiles were used to identify the changes 
undergone by the cultures. These treatments included two antibiotic treatments (clindamycin and 
vancomycin); challenging the resident community with a defined community, MET-2; an antibiotic-
MET-2 combination treatment; and a norepinephrine treatment. It was found that amino acid and 
carbohydrate metabolism were the most sensitive to perturbation, as various changes in levels of 
associated amino acids and fatty acids were observed in all treatments except for norepinephrine 
treatment, which did not drastically impact the community’s metabolite profile. Succinate was a 
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 notable compound as it increased considerably after every treatment, even norepinephrine treatment. 
Due to succinate’s close association with central metabolic processes and is subject to large changes 
with perturbation, it could be the first indicator of a perturbation to the culture. From this study, it has 
been demonstrated that metabolite profiles of mixed cultures allows the differentiation of 
communities of different inoculant sources. These metabolite profiles also allow characterization of 
various perturbations, such as antibiotics, probiotic treatment and stress exposure, on those 
communities. 
The complex symbiotic relationship between microbial ecosystems residing in the human GI 
tract and human health emphasizes the importance of developing a comprehensive understanding of 
the interactions through alternative and complementary approaches. Studying the metabolome of the 
gut microbes is one such approach that has the capability of deciphering those interactions. In this 
body of work, an in vitro system of studying the human gut microbiota was subjected to metabolomic 
evaluation. Standardizing reports on fecal metabolomes and determining source of variation in 
metabolomic analyses are fundamental characterizations that appropriately contextualizes the findings 
presented here so they can be effectively communicated to other researchers. The metabolomic 
approach was further applied in analyzing the exometabolome found in the nutrient solutions in 
which these community cultures were grown. The metabolite profiles defined microbial metabolite 
products that commented on the summative outcome of the complex microbial interactions occurring 
within the gut microbiota. This is relevant to clinical and industrial research because this metabolomic 
characterization has the potential to bridge microbial activities with human health and physiology.  
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 Chapter 9 Recommendations 
The insights ascertained in this thesis contribute to the metabolomic understanding of the human gut 
microbiota by setting foundational work from which this approach can be further developed. For 
example, further metabolomic evaluation of the single-stage CSTR system can be performed. 
Comparison of the in vitro communities derived from two inocula that differed only in biomass 
proportions of the same bacterial species demonstrated that communities grown in the bioreactor 
systems were relatively robust, with the final ecological consortium driven by metabolic function, 
rather than the proportional composition of the inoculant. This finding suggested that the metabolic 
steady state was being approached as of 20 days post-inoculation. Some fluctuation in the metabolite 
levels indicated that the system was still dynamic, but convergence of profiles between a culture 
(MET-2A or MET-3A) and its reciprocal variant (MET-2B or MET-3B) was a hint that metabolic 
interactions were becoming more stable. Therefore, it would be worthwhile to conduct an experiment 
in which a metabolomic time-trend can establish metabolic steady state is achieved and how this 
compares to when ecological steady state is reached. 
 There is an evident gap in human gut microbial research, where advanced in vitro systems 
have been developed to study the ecology of the human gut microbiota, and at the same time, 
metabolomic understanding of the human gut microbiota have focused on fecal metabolites. A direct 
comparison of the fecal metabolome with the metabolome of the in vitro community cultured from 
the same fecal sample would be a good depiction of how the fecal communities change or are 
preserved in the in vitro system. This analysis would be a starting point for bridging that gap between 
in vitro gut microbiota research and our metabolomic understanding of that ecosystem. 
 The metabolite profile analysis of feces-derived communities and defined communities was 
able to confer a wealth of information regarding the gut microbiota. Not only did it highlight gross 
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 differences between each community, such as decreased levels carbohydrate fermentation in the 
defined community compared to its fecal counterpart, but specialized metabolic functions were 
identified to be unique to certain communities. Since the metabolomic data was able to divulge details 
on the metabolic interactions in the bacterial consortia, this approach can be applied to studying the 
human gut microbiota in clinical or pharmaceutical contexts. A wide range of perturbations were 
administered to the gut as a demonstration of such applications. From this preliminary experiment, it 
was demonstrated that amino acid metabolism and carbohydrate fermentation were the most 
dramatically influenced by antibiotic treatments. It is worth noting that the antibiotics used were 
administered to different kinds of bacterial communities (feces-derived or defined). Given that 
clindamycin and vancomycin targeted cells through different mechanisms of action – clindamycin 
inhibits the ribosomal mechanisms to halt protein interaction, while vancomycin interrupts 
biosynthesis of bacterial cell walls – it would be interesting to see how different classes of antibiotics 
impact one bacterial consortium.  
Furthermore, challenging a feces-derived community with a defined community and the 
combination treatment of clindamycin followed by challenging with a defined community also 
yielded interesting results. While the clindamycin-only treatment and the defined community-only 
treatment both produced unique metabolomic responses in the bacterial community, the combination 
treatment elicited a metabolite profile that resembled a hybrid of the two stand-alone treatments. This 
experiment would benefit from extending the time during which the microbial responses are 
monitored. In observing the in vitro cultures until steady-state is reached again, the full, long-term 
impact of the treatments, whether it be stand-alone or combination treatments, on the metabolic and 
ecologic makeup of the community would be captured. Additionally, the effect of recovery time on 
the final outcome in the combination treatment should be investigated. Such a study would reveal 
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 whether the stability of the community impacts the ability of the challenging consortia to establish 
itself within the residing community.  
The norepinephrine treatment was an example of using the in vitro communities to 
investigate host physiology on the gut microbiota. Even though host stress response have been show 
to impact bacterial physiology and the health of gut microbiota as a whole, those interactions were not 
reproduced with the when the in vitro feces-derived community was treated with norepinephrine. The 
reason for this discrepancy was hypothesized to be attributed the abundance of iron supplied in the 
media feed. Since iron was readily available throughout the culturing process, norepinephrine did not 
have any added benefit to the microbes that would typically capitalize on the norepinephrine-
facilitated release on iron ions was lost. 
The work presented in this thesis provides a kernel of insight into the contributions 
metabolomic studies could have on understanding the human gut microbiota. The recommendations 
stemming from this work focus on validating the bioreactor systems involved in propagating gut 
microbes in vitro as well as in deciphering metabolic interactions of those communities. 
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 Appendix A Supplementary Figures and Tables 
A.1 Materials and Methods 
Table A1. Cultured bacterial isolates for MET-1.6 
Higher taxonomic 
group Closest species match 
% Relative abundance (by 
biomass) 
Actinobacteria Bifidobacterium adolescentis 
(two different strains) 
99.79 
99.79 
1.5 
1.5 
Bifidobacterium longum (two 
different strains) 
99.86 
99.16 
0.5 
2 
Collinsella aerofaciens 98.73 1 
Bacteroides ovatus 99.52 1.5 
Parabacteroides distasonis 99.45 1.5 
Firmicutes Bacilli Lactobacillus casei/paracasei 99.47 1 
Lactobacillus casei 99.74 1 
Streptococcus mitis 99.79 0.75 
Clostridium 
cluster IV 
Eubacterium desmolans 94.9 1 
Faecalibacterium prausnitzii 99.17 2 
Clostridium 
cluster VIII 
Clostridium cocleatum 91.92 1 
Clostridium 
cluster IX 
Acidaminococcus intestini 100 1 
Clostridium 
cluster 
XIVa 
 
Blautia sp. 99.55 0.75 
Dorea longicatena 99.62 1 
(two different strains) 99.6 2 
Eubacterium eligens 98.15 2 
Eubacterium rectale 
(four different strains) 
99.59 
99.6 
99.19 
99.53 
2 
1.5 
1 
1 
Eubacterium ventriosum 100 1 
Lachnospira pectinoshiza 95.22 0.5 
Roseburia faecalis 99.65 1.5 
Roseburia intestinalis 100 1 
6Adapted from Table 2.3 of Development of an In Vitro Fermentation Model to Culture the Human Distal Gut 
Microbiota90. The species column refers to the closest species match, inferred by alignment of 16S rRNA 
sequence to GreenGenes database. The “%” column refers to the percent identity closest match. Units are 
presented as the equivalent of 1 X 10 µL loopful of bacterial culture scraped from petri dish plates. 
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 Ruminococcus torques 99.15 1 
(two different strains) 99.29 2 
Ruminococcus sp. 
(two different strains) 
97.35 
98.4 
1.5 
0.5 
Clostridium 
cluster XV 
Eubacterium limosum 97.05 1.5 
Proteobacteria Escherichia coli 
(two different strains) 
99.8 
99.6 
0.5 
- 
Raoultella sp. 99.4 1 
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 Table A2. Cultured bacterial isolates for MET-2.7 
Higher taxonomic 
group Closest species match % 
Relative abundance (by 
biomass) 
Actinobacteria 
Bifidobacterium longum 100 1 
Collinsella aerofaciens 100 0.5 
Microbacterium schleiferi 99.34 1.5 
Aldercreutzia equolifaciens 99.76 1 
Micrococcus luteus 97.04 1 
Bacteroidetes 
Bacteroides ovatus 100 0.5 
Parabacteroides merdae 100 1 
Firmicutes 
Eubacterium rectale 100 1 
Blautia luti 98.91 1 
Roseburia hominis 99.04 1 
Roseburia lactaris 95.07 0.5 
Ruminococcus albus 96.96 1 
Eubacterium eligens 96.78 1 
Ruminococcus torques (two 
different strains) 
99.27 1 
100 1 
Roseburia intestinalis 100 1 
Eubacterium fissicatena 97.67 1 
Eubacterium ventriosum 97.37 1 
Blautia coccoides 99.85 0.25 
Blautia hydrogenotrophica 100 0.1 
Dorea longicatena 100 0.25 
Dorea formicigenerans 99.49 0.25 
Clostridium ramosum 96.14 0.25 
Eubacterium limosum 99.25 0.75 
Streptococcus thermophilus 100 0.25 
Bacillus simplex 98.7 0.25 
Coprococcus catus 99.19 0.25 
Flavonifractor plautii 96.21 0.25 
7The species column refers to the closest species match, inferred by alignment of 16S rRNA sequence to 
GreenGenes database. The “%” column refers to the percent identity closest match. Units are presented as the 
equivalent of 1 X 10 µL loopful of bacterial culture scraped from petri dish plates. 
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 Streptococcus mitis 100 0.3 
Phascolarctobacterium sp. 99.85 0.1 
Proteobacteria 
Escherichia coli 100 0.25 
Parasutterella 
excrementihominis 100 0.5 
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 Table A3. Cultured bacterial isolates for MET-2A, MET-2B, MET-3A, and MET-3B.8 
Higher 
taxonomic 
group 
Closest species 
match % 
Relative abundance (by biomass) 
Donor D Donor A 
Run 30 Run 33 Run 31 Run 32 
MET
-2A 
MET
-2B 
MET
-2A* 
MET
-2B* 
MET
-3A 
MET
-3B 
MET
-3A* 
MET
-3B* 
Actinobacteria 
Bifidobacterium 
longum (three 
different strains) 
99.86 
99.16 
100.00 
1 
1.5 
- 
0.50 
0.75 
- 
1 
1.5 
- 
0.50 
0.75 
- 
- 
- 
1 
- 
- 
0.50 
- 
- 
1 
- 
- 
0.50 
Bifidobacterium 
adolescentis (two 
different strain)ǂ 
99.79 
99.79 
1 
1 
1 
1 
0.25 
1 
0.25 
1 
- 
- 
- 
- 
- 
- 
- 
- 
Collinsella 
aerofaciens (two 
different strains) 
98.73 
100.00 
0.50 
- 
1 
- 
0.50 
- 
1 
- 
- 
0.50 
- 
1 
- 
0.50 
- 
1 
Microbacterium 
schleiferi 99.34 - - - - 1.5 0.75 1.5 0.75 
Aldercreutzia 
equolfaciensǂ 99.76 - - - - 1 1 0.50 0.50 
Micrococcus luteus 97.04 - - - - 1 1 1 1 
Bacteroidetes 
Bacteroides ovatus 
(two different 
strains) 
99.52 
100.00 
0.50 
- 
1.5 
- 
0.50 
- 
1.5 
- 
- 
0.50 
- 
1.5 
- 
0.50 
- 
1.5 
Parabacteroides 
distasonis 99.45 1 1 1 1 - - - - 
Parabacteroides 
merdae 100.00 - - - - 1 1 1 1 
Firmicutes 
Eubacterium rectale 
(five different 
strains) 
99.59 
99.60 
99.19 
99.53 
100.00 
1 
1 
1 
0.50 
- 
0.25 
0.25 
1 
1 
- 
1 
1 
1 
0.50 
- 
0.25 
0.25 
1 
1 
- 
- 
- 
- 
- 
1 
- 
- 
- 
- 
0.25 
- 
- 
- 
- 
1 
- 
- 
- 
- 
0.25 
Blautia luti 98.91 - - - - 1 0.25 1 0.25 
Roseburia hominis 99.04 - - - - 1 1 1 1 
Roseburia lactaris 95.07 - - - - 0.50 1 0.50 1 
Faecalibacterium 
prausnitzii 99.17 1 0.25 1 0.25 - - - - 
8Adapted from Table 2.3 of Adaptation of a Single-Stage Chemostat System to Model Functional Aspects of the 
Human Distal Gut Microbiota91. The species column refers to the closest species match, inferred by alignment 
of 16S rRNA sequence to GreenGenes database. The “%” column refers to the percent identity closest match. 
Units are presented as the equivalent of 1 X 10 µL loopful of bacterial culture scraped from petri dish plates. ǂ 
Bacterial isolates that differed between inocula from replicate runs. *Has slight deviation in bacterial 
composition compared to original defined communities in Run 30 and Run 31 
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 Ruminococcus albus 96.96 - - - - 1 0.25 1 0.25 
Firmicutes 
Eubacterium eligens 
(2 different strains) 
98.15 
96.78 
1 
- 
0.25 
- 
1 
- 
0.25 
- 
- 
1 
- 
0.25 
- 
1 
- 
0.25 
Ruminococcus 
torques (four 
different strains) 
99.15 
99.29 
99.27 
100.00 
1.5 
1.5 
- 
- 
0.50 
0.75 
- 
- 
1.5 
1.5 
- 
- 
0.50 
0.75 
- 
- 
- 
- 
1.5 
1.5 
- 
- 
0.50 
0.75 
- 
- 
1.5 
1.5 
- 
- 
0.50 
0.75 
Roseburia 
intestinalis (two 
different strains) 
100.00 
100.00 
1 
- 
1 
- 
1 
- 
1 
- 
- 
1 
- 
1 
- 
1 
- 
1 
Roseburia faecalis 99.65 1 1 1 1 - - - - 
Eubacterium 
fissicatena 97.67 - - - - 1 1 1 1 
Eubacterium 
ventriosum (two 
different strains)ǂ 
100.00 
97.37 
1 
- 
1 
- 
0.10 
- 
0.10 
- 
- 
1 
- 
1 
- 
0.25 
- 
0.25 
Ruminococcus 
obeum (two 
different strains) 
99.55 
97.35 
0.50 
0.25 
1.5 
1 
0.50 
0.25 
1.5 
1 
- 
- 
- 
- 
- 
- 
- 
- 
Ruminococcus 
producta 98.40 0.25 0.50 0.25 0.50 - - - - 
Blautia coccoides 99.85 - - - - 0.25 0.50 0.25 0.50 
Blautia 
hydrogenotrophica 100.00 - - - - 0.10 0.50 0.10 0.50 
Dorea longicatena 
(three different 
strains) 
99.62 
99.60 
100.00 
0.25 
0.25 
- 
1.5 
1 
- 
0.25 
0.25 
- 
1.5 
1 
- 
- 
- 
0.25 
- 
- 
1 
- 
- 
0.25 
- 
- 
1 
Dorea 
formicigenerans 99.49 - - - - 0.25 1.5 0.25 1.5 
Clostridium 
cocleatumǂ 91.92 0.25 1 0.25 0.50 - - - - 
Clostridium 
ramosum 96.14 - - - - 0.25 1 0.25 1 
Eubacterium 
limosum (two 
different strains) 
97.05 
99.25 
0.75 
- 
1.5 
- 
0.75 
- 
1.5 
- 
- 
0.75 
- 
1.5 
- 
0.75 
- 
1.5 
Lactobacillus casei 99.74 0.25 1 0.25 1 - - - - 
Streptococcus 
thermophilus 100.00 - - - - 0.25 1 0.25 1 
Lactobacillus 
paracasei 99.47 0.25 1 0.25 1 - - - - 
Bacillus simplex 98.70 - - - - 0.25 1 0.25 1 
Firmicutes Coprococcus catus 99.19 - - - - 0.25 1 0.25 1 Eubacterium 94.90 0.25 1 0.25 1 - - - - 
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 desmolans 
Flavonifractor 
plautii 96.21 - - - - 0.25 1 0.25 1 
Streptococcus mitis 
(two different 
strains) 
99.79 
100.00 
0.30 
- 
0.30 
- 
0.30 
- 
0.30 
- 
- 
0.30 
- 
0.30 
- 
0.30 
- 
0.30 
Acidaminococcus 
intestini 100.00 1.5 0.75 1.5 0.75 - - - - 
Phascolarctobacteri
um sp. 99.85 - - - - 0.10 0.05 0.10 0.05 
Proteobacteria 
Escherichia coli 
(two different 
strains) 
99.80 
100.00 
0.25 
- 
0.50 
- 
0.25 
- 
0.50 
- 
- 
0.25 
- 
0.50 
- 
0.25 
- 
0.50 
Raoultella sp. 99.40 0.50 0.25 0.50 0.25 - - - - 
Parasutterella 
excrementihominis 100.00 - - - - 0.5 0.25 0.5 0.25 
 
  
 196 
 A.2 Standardization of Fecal Water Samples and Analysis 
 
Figure A1. NMR Spectra of fecal water at various concentrations (0.85-1.05 ppm). Includes the 
NMR signature or partial signature of isobutyrate, propionate, isoleucine, valine, leucine, 2-
oxoisocaproate, isovalerate, and butyrate from left to right. Inset is zoomed view of 0.90-1.01 ppm, 
includes NMR signatures or partial signatures of isoleucine, valine, leucine and 2-oxoisocaproate 
from left to right. 
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Figure A2. Profiling confidence impacted for certain compounds. Purple represents spectrum of 
34.33% fecal water, and light green represents spectrum of 8.670% fecal water. For p-cresol, grey 
line represents the subtraction line between the 8.670% spectrum and area of profiled compounds in 
that spectrum. The p-Cresol signal, highlighted in red, represents the profiling of that compound fitted 
to the 8.670% sample spectrum. For all other compounds, the grey line represents the subtraction line 
between 34.33% fecal water and the area of all compounds profiled in that spectrum. The compound 
signals for pyroglutamate, arabinose and choline, highlighted in red, represent the profiling 
assignment of those compounds fitted to the 34.33% sample spectrum. Reason for demonstrating 
pyroglutamate, arabinose and choline relative to the high-concentration spectrum is because those 
compounds are not easily visualized in the low-concentration sample spectrum, due to low signal-to-
noise ratio. Note: only compound clusters that were used in facilitating compound identification and 
quantifications are depicted. 
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 A.3 Sample Preparation Procedure for Metabolomic Analysis 
 
Figure A3. Significance of terms in each iteration of model simplification, with model 1 being the 
most complex model, and model 4 being the simplest model. Significant terms indicated with a star 
(*). 
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Figure A4. Evaluation of profiling precision based on relative standard deviation of compound 
concentrations observed in single-step filtered samples from Experiment 2. 
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 Table A4. Compounds that did not demonstrate significant linear trend with 
changes in centrifugal force, based on simplest MLR model. 
Compound Slope Standard error T statistic P value 
3-Phenylpropionate -9.61E-08 5.07E-08 -1.89346 0.064462 
beta-Alanine -4.98E-08 4.71E-08 -1.05815 0.295394 
Choline 8.49E-10 3.59E-09 0.236667 0.813943 
Pyroglutamate -2.38E-07 1.48E-07 -1.61043 0.114001 
Tyramine 2.39E-08 3.26E-08 0.734012 0.466588 
Xanthine -3.17E-08 3.69E-08 -0.85923 0.394576 
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 Table A5. Compounds that demonstrated the same trends in concentration change with 
ultracentrifuge speed in both Experiment 1 and Experiment 2. 
Compound Experiment Bias Standard Error T Statistic P-value 
2-Hydroxyisovalerate -0.00165 0.000561 -2.94227 0.005046 
2-Oxoglutarate -0.00253 0.001059 -2.38909 0.020956 
2-Oxoisocaproate -0.00024 0.000843 -0.28491 0.776966 
3-Phenylpropionate -0.00038 0.001903 -0.19831 0.843658 
Acetate 2.170932 0.753433 2.881389 0.005949 
Alanine -0.01835 0.016419 -1.11733 0.269532 
Asparagine -0.00698 0.00222 -3.14535 0.002875 
Butyrate 0.197922 0.089398 2.213936 0.031721 
Choline 0.000274 0.000135 2.038151 0.047184 
Dimethylamine 0.001538 0.000924 1.663707 0.102826 
Ethanol 0.258782 0.102993 2.512618 0.015474 
Formate 0.001515 0.002143 0.707101 0.483071 
Fumarate -6.57E-05 0.000249 -0.26356 0.793271 
Galactose -0.00855 0.004827 -1.77141 0.082977 
Glucose -0.00346 0.004161 -0.83057 0.410415 
Glutamate 0.013564 0.014769 0.918433 0.363082 
Glycolate 0.001112 0.002222 0.500279 0.619213 
Hydroxyacetone -0.00176 0.000749 -2.35505 0.022747 
Isobutyrate 0.028285 0.016396 1.725171 0.091067 
Isoleucine -0.00475 0.010084 -0.47081 0.639952 
Isopropanol 0.001274 0.002859 0.445497 0.658006 
Isovalerate -0.00559 0.008376 -0.66739 0.507788 
Malate 0.002312 0.002725 0.848437 0.400495 
Methanol 0.005318 0.002503 2.124866 0.038885 
Methionine 0.001398 0.002021 0.691921 0.492391 
Methylamine 0.006067 0.002394 2.53447 0.014652 
p-Cresol 0.008506 0.003623 2.347627 0.023155 
Proline 0.012527 0.003986 3.142632 0.002898 
Serine 0.005399 0.003212 1.681038 0.09939 
Succinate 0.065393 0.019404 3.37 0.00151 
Threonine 6.22E-05 0.003425 0.018166 0.985584 
Thymine 0.000269 0.00145 0.185337 0.853762 
Trimethylamine 3.07E-05 0.000618 0.049737 0.960542 
Tyramine -0.00107 0.001222 -0.87233 0.387465 
Tyrosine 0.013931 0.004123 3.378554 0.001473 
Valerate 0.007871 0.028608 0.275138 0.784416 
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 Valine -0.02753 0.013235 -2.07976 0.043027 
Xanthine 0.003677 0.001385 2.655878 0.010767 
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 A.4 Effects of Varying Inoculant Biomass Proportions 
 
Figure A5. Density plot of the relative standard deviation of triplicate samples. 
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Figure A6. Profile overview of MET-2A and MET-3A and their reciprocal cultures, MET-2B and 
MET-3B, respectively. 
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 A.5 METABOLOMIC ANALYSIS OF THE HUMAN GUT MICROBIOTA: 
COMPARISON OF FECES-DERIVED COMMUNITIES AND DEFINED MIXED 
COMMUNITIES 
 
Figure A7. Kernel density plot of mean concentrations of untreated samples collected during steady 
state, bandwidth=0.03043. Inset is the kernel density plot of mean concentrations greater than or 
equal to 0.1 mM and less than or equal to 20 mM, bandwidth = 0.135. The clusters observed in these 
plots were used to define the bin in which the compounds would be grouped. 
  
 207 
  
Figure A8. (A) PCA Score plot of metabolite profiles of donor A, B, C and MET-2 cultures. (B) PCA 
loading plot of metabolite profiles of donor A, B C and MET-2 cultures. Data is mean centered and 
scaled by unit variance. Bin 1: mean ≥ 20 mM; Bin 2: 10 < mean < 20 mM; Bin 3: 1 < mean < 10 
mM; Bin 4: 0.1 < mean < 1 mM; Bin 5: 0 < mean < 0. 
  
 208 
 A.6 Analysis of Perturbations to Human Fecal Microbiota Propagated In Vitro 
Table A6. List of microorganisms sensitive to 
clindamycin. Adapted from Spizek et al, 2004216 
Organism Minimum Inhibitory 
concentration (µg/mL) 
Gram-positive  
Bacillus anthracis 0.25–5.0 
Staphylococcus aureus 0.04–1.6 
Sta. epidermidis 0.1–0.2 
Streptococcus agalactiae 0.02–0.1 
Str. pneumoniae 0.002–0.1 
Str. pyogenes 0.01–0.2 
Str. viridans 0.005–0.2 
Gram-negative  
Escherichia coli 64 
Haemophilus influenzae 0.5–16.0 
Klebsiella pneumoniae 125 
Neisseria gonorhoeae 0.5–4.0 
N. meningitis 4 
Proteus vulgaris 250 
Pseudomonas aeruginosa 1000 
Salmonella schottmuelleri 64 
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Figure A9. PCA model of metabolite profiles of Donor A, B, and MET-2, as well as profiles of each 
respective community culture after various treatments. (A) Score plot. (B) Loading plot. 
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 Appendix B Calculations 
Appendix B1. Relative Standard Deviation (RSD) 
𝑅𝑅𝑅𝑅𝑅𝑅 =  𝑠𝑠
?̅?𝑥
× 100             ;             𝑠𝑠 =  �∑(𝑥𝑥𝑒𝑒 − ?̅?𝑥)2
𝑖𝑖 − 1  
 
Appendix B2. Equation for multiple linear regression. 
The following equation was used to model each compound: 
𝑦𝑦𝑒𝑒 = 𝛽𝛽1𝑥𝑥𝑒𝑒1 +  𝛽𝛽2𝑥𝑥2 +  𝛽𝛽3𝑥𝑥3 + 𝛽𝛽3𝑥𝑥1𝑥𝑥2 + 𝛽𝛽2𝑥𝑥1𝑥𝑥3 + 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 +  𝜀𝜀   
Where 𝑥𝑥1 is ultracentrifuge speed, 𝑥𝑥2 is experiment, 𝑥𝑥3 is type of pre-processing step used, 𝜀𝜀 is the 
error and 𝑖𝑖 = 1 …𝑖𝑖 samples. 
 
Appendix B3. Bonferroni correction on statistical significance when performing multiple 
comparisons. 
𝛼𝛼𝑐𝑐𝑐𝑐𝑒𝑒𝑒𝑒𝑠𝑠𝑐𝑐𝑒𝑒𝑠𝑠𝑠𝑠 =  𝛼𝛼𝑖𝑖 
Where n is the number of times the statistical test is applied. 
 
Appendix B4. Percent change in concentration per 10 000 rpm 
𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖ℎ𝑎𝑎𝑖𝑖𝑎𝑎𝑖𝑖 =  �𝛽𝛽1 ∗ 10000
𝑦𝑦10000
� × 100 
Where the response at rpm=10000, 𝑦𝑦10000, and coefficient, 𝛽𝛽1, are from the MLR equation presented 
in Appendix B2. 
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 Appendix B5. Analysis of Variance (ANOVA) about the mean. MSresidual = Mean square within 
group, MSamong = Mean square between groups, nj=number of observations within the jth group, 
q=number of groups. 
𝑥𝑥.𝚥𝚥��� =  1𝑖𝑖𝑗𝑗�𝑥𝑥𝑒𝑒𝑗𝑗𝑒𝑒𝑗𝑗𝑒𝑒=1            ;            ?̅?𝑥𝑔𝑔𝑔𝑔𝑐𝑐𝑔𝑔𝑔𝑔𝑔𝑔 =  1𝑖𝑖��𝑥𝑥𝑒𝑒𝑗𝑗
𝑒𝑒𝑗𝑗
𝑒𝑒=1
𝑞𝑞
𝑗𝑗=1
           ;            𝑖𝑖 =  �𝑖𝑖𝑗𝑗𝑞𝑞
𝑗𝑗=1
 
𝑅𝑅𝑅𝑅𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑠𝑠𝑟𝑟𝑔𝑔𝑔𝑔 =  ��𝑥𝑥𝑒𝑒𝑗𝑗 − 𝑥𝑥.𝑗𝑗�2
𝑒𝑒
         ;           𝑀𝑀𝑅𝑅𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑠𝑠𝑟𝑟𝑔𝑔𝑔𝑔 = 𝑅𝑅𝑅𝑅𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑠𝑠𝑟𝑟𝑔𝑔𝑔𝑔𝑖𝑖𝑗𝑗 − 𝑞𝑞  
𝑅𝑅𝑅𝑅𝑔𝑔𝑒𝑒𝑐𝑐𝑒𝑒𝑔𝑔 =  ��𝑥𝑥.𝑗𝑗 − 𝑥𝑥𝑔𝑔𝑔𝑔𝑐𝑐𝑔𝑔𝑔𝑔𝑔𝑔�2           ;            𝑀𝑀𝑅𝑅𝑔𝑔𝑒𝑒𝑐𝑐𝑒𝑒𝑔𝑔 = 𝑅𝑅𝑅𝑅𝑔𝑔𝑒𝑒𝑐𝑐𝑒𝑒𝑔𝑔𝑞𝑞 − 1  
𝐹𝐹 𝑣𝑣𝑎𝑎𝑣𝑣𝑣𝑣𝑖𝑖 = 𝑀𝑀𝑅𝑅𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑠𝑠𝑟𝑟𝑔𝑔𝑔𝑔
𝑀𝑀𝑅𝑅𝑔𝑔𝑒𝑒𝑐𝑐𝑒𝑒𝑔𝑔
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 Appendix C Programming 
 213 
C.1 Standardization of Fecal Water Samples and Analysis
Data source.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #Data source
3
4 require (RSQLite )
5 require ( reshape2 )
6
7 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
8 source ( ’ funct ion−summary p r ep ro c e s s i ng .R ’ )
9
10 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R Sc r i p t s/Data source
f i l e s ’ )
11
12 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
13 raw <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R
Sc r i p t s/Data source f i l e s / concen t ra t i on s x2−f e c a l water . csv ’ )
14
15 d <− raw [ [ ’ data ’ ] ]
16 d . melt <− melt (d)
17 d . melt$value <− d . melt$value/0 .9 #ad ju s t i n g f o r sample d i l u t i o n with 10% DSS
18
19 raw2 <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R
Sc r i p t s/Data source f i l e s / concen t ra t i on s x1 , x2 , x3−f e c a l water . csv ’ )
20
21 d2 <− raw2 [ [ ’ data ’ ] ]
22 d2 . melt <− melt ( d2 )
23 d2 . melt$value <− d2 . melt$value/0 .9
24
25 raw3 <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R
Sc r i p t s/Data source f i l e s / concent ra t i ons−f e c a l samples Er ic SY. csv ’ )
26
27 d3 <− raw3 [ [ ’ data ’ ] ]
28 d3 . melt <− melt ( d3 )
29 d3 . melt$value <− d3 . melt$value/0 .9
30
31 #Qua l i f i e r−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
32 q u a l i f i e r <− data . frame ( f i l e=d$ f i l e )
33 q u a l i f i e r $sampleID <− q u a l i f i e r $ f i l e
34 q u a l i f i e r $sampleID <− gsub ( ’ .∗ ( [A−Z ] ) (?= x) .∗ ’ , ’ \\1 ’ , q u a l i f i e r $sampleID , p e r l=
TRUE)
35
36 q u a l i f i e r $scan <− q u a l i f i e r $ f i l e
37 q u a l i f i e r $scan <− gsub ( ’ .∗(?<=[A−Z ] x ) ( [0 −9 ]{1 ,2} ) .∗ ’ , ’ \\1 ’ , q u a l i f i e r $scan , p e r l=
TRUE)
38
39 q u a l i f i e r $prof i le . no <− q u a l i f i e r $ f i l e
40 q u a l i f i e r $prof i le . no <− gsub ( ’ .∗ ( [0 −9 ] ) (?=\\ . cnx ) . ∗ ’ , ’ \\1 ’ ,
41 q u a l i f i e r $prof i le . no , p e r l=TRUE)
42
43 q u a l i f i e r $c . i n i t i a l <− c ( rep ( 8 . 2 , 2) , rep ( 5 . 6 , 2) , rep ( 9 . 1 , 2) , rep ( 2 0 . 6 , 2) ,
44 rep ( 1 5 . 2 , 2) , rep ( 2 . 6 , 2) )
45 q u a l i f i e r $v . i n i t i a l <− c ( rep (30 ,6 ) , rep (60 , 4) , rep (30 , 2) )
46 q u a l i f i e r $ concent ra t i on <− round( q u a l i f i e r $c . i n i t i a l / q u a l i f i e r $v . i n i t i a l , 4 )
47
48 q u a l i f i e r $rep <− c ( rep (c ( 1 , 2 ) , 6 ) )
49 q u a l i f i e r $date <− ’ June 5 , 2014 ’
50
51 q u a l i f i e r 2 <− data . frame ( f i l e=d2$ f i l e )
52 q u a l i f i e r 2 $sampleID <− q u a l i f i e r 2 $ f i l e
53 q u a l i f i e r 2 $sampleID <− gsub ( ’ .∗ ( [A−Z ] ) (?= x) .∗ ’ , ’ \\1 ’ , q u a l i f i e r 2 $sampleID , p e r l=
TRUE)
54
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55 q u a l i f i e r 2 $scan <− q u a l i f i e r 2 $ f i l e
56 q u a l i f i e r 2 $scan <− gsub ( ’ .∗(?<=[A−Z ] x ) ( [0 −9 ]{1 ,2} ) .∗ ’ , ’ \\1 ’ , q u a l i f i e r 2 $scan ,
p e r l=TRUE)
57
58 q u a l i f i e r 2 $prof i le . no <− q u a l i f i e r 2 $ f i l e
59 q u a l i f i e r 2 $prof i le . no <− gsub ( ’ .∗ ( [0 −9 ] ) (?=\\ . cnx ) . ∗ ’ , ’ \\1 ’ ,
60 q u a l i f i e r 2 $prof i le . no , p e r l=TRUE)
61
62 q u a l i f i e r 2 $c . i n i t i a l <− c ( rep (c ( rep ( 8 . 2 , 2) , rep ( 5 . 6 , 2) , rep ( 9 . 1 , 2) , rep ( 2 0 . 6 , 2)
,
63 rep ( 1 5 . 2 , 2) , rep ( 2 . 6 , 2) ) , 3 ) )
64 q u a l i f i e r 2 $v . i n i t i a l <− c ( rep (c ( rep (30 ,6 ) , rep (60 , 4) , rep (30 , 2) ) , 3 ) )
65 q u a l i f i e r 2 $ concent ra t i on <− round( q u a l i f i e r 2 $c . i n i t i a l / q u a l i f i e r 2 $v . i n i t i a l , 4 )
66 q u a l i f i e r 2 $rep <− c ( rep (c ( rep (c ( 1 , 2 ) , 6 ) ) , 3 ) )
67 #Compound rank−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
68 rank <− read . csv ( ’Compound rank−f e c a l water . csv ’ )
69 rank <− rank [ , 1 : 4 ]
70
71 # Create the connect ion (no f i l e needed ) −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
72
73 # Choose d r i v e r
74 drv = dbDriver ( ’ SQLite ’ )
75
76 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
77 con = dbConnect ( drv , ’ data . db ’ )
78
79 # Creating database t a b l e s
80 data . table <− dbWriteTable ( con , ’Data ’ , d . melt , ove rwr i t e=TRUE)
81 data . table
82
83 data2 . table <− dbWriteTable ( con , ’ Data2 ’ , d2 . melt , ove rwr i t e=TRUE)
84 data2 . table
85
86 data3 . table <− dbWriteTable ( con , ’ Data3 ’ , d3 . melt , ove rwr i t e=TRUE)
87 data3 . table
88
89 q u a l i f i e r . table <− dbWriteTable ( con , ’ Qu a l i f i e r ’ , q u a l i f i e r , ove rwr i t e=TRUE)
90 q u a l i f i e r . table
91
92 q u a l i f i e r 2 . table <− dbWriteTable ( con , ’ Qua l i f i e r 2 ’ , q u a l i f i e r 2 , ove rwr i t e=TRUE)
93 q u a l i f i e r 2 . table
94
95 rank . table <− dbWriteTable ( con , ’Rank ’ , rank , ove rwr i t e=TRUE)
96 rank . table
97
98 t ab l e s <− dbGetQuery ( con , ”SELECT ∗ FROM s q l i t e master WHERE type=’ tab le ’ ; ” )
99 print ( t ab l e s )
100
101 dbDisconnect ( con )
Fecal concentration analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Analys i s
3
4 #load ing requ i red packages
5 require ( ggp lot2 )
6 require ( reshape2 )
7 require (RSQLite )
8
9 #sourc ing requ i red func t i ons
10 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
11 source ( ’ funct ion−data cleanup .R ’ )
12 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
13
14 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n samples/Experiment 2/R
Sc r i p t s/Functions ’ )
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15 source ( ’ c o r r e l a t i o n .R ’ )
16
17 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R Sc r i p t s/Analys i s ’ )
18
19 source ( ’ . . /Functions/ l i n e a r model .R ’ )
20
21 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
22 #Input data
23 # Choose d r i v e r
24 drv <− dbDriver ( ’ SQLite ’ )
25
26 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
27 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
28
29 input <− dbGetQuery ( con , ”SELECT q . SampleID , q . concentrat ion , q . rep ,
30 d . va r i ab l e , d . va lue
31 FROM Data d INNER JOIN Qua l i f i e r q
32 ON d . f i l e = q . f i l e
33 INNER JOIN Rank r
34 ON d . va r i ab l e = r .Compound
35 WHERE r . Conf idence = 1
36 ORDER BY q . sampleID ; ” )
37
38
39 dbDisconnect ( con )
40
41 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
42 c l ean <− data cleanup ( input , convert .NA=TRUE)
43 c l ean$rep <− as . character ( c l ean$rep )
44
45 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
46 stat <− d e s c r i p t i v e . stat ( c lean , data . type=’ long ’ , variable=c ( ’ v a r i ab l e ’ , ’
c oncent ra t i on ’ ) )
47
48 #Overview−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
49 p <− ggp lot ( stat , aes ( x=concentrat ion , y=value ) ) +
50 geom point ( aes ( co l our=rep ) , alpha =0.8) +
51 xlab ( ’ Fecal water concent ra t i on ( g/mL) ’ ) +
52 ylab ( ’Compound concent ra t i on (mM) ’ ) +
53 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=6) +
54 theme bw(14) +
55 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
56
57 ggsave ( ’ . . /Plot s/Overview x2 . png ’ , p , he ight=30, width=30, un i t s=’cm ’ )
58
59 #Linear r e l a t i on s h i p−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
60 lm . t e s t <− ddply ( stat , ’ v a r i a b l e ’ , lm custom , group=’ concent ra t i on ’ , va lue=’ avg ’ )
61 lm . s i g <− lm . t e s t [ lm . t e s t$ s l ope . p <=0.05 ,]
62
63 #cor r e l a t i on
64 co r r . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , c o r r custom , x=’ concent ra t i on ’ , y=’ avg ’ )
65 co r r . s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l <= 0 . 0 5 , ]
66
67 plot . stat <− cbind (lm . t e s t , c o r r . r e s u l t $ es t imate )
68 colnames (plot . stat ) [ 1 0 ] <− ’ c o r r . e s t imate ’
69 plot . stat$ l i n e t yp e <− ’ ns ’
70 plot . stat$ l i n e t yp e [ plot . stat$ s l ope . p <= 0.05 &
71 plot . stat$ co r r . e s t imate > 0 . 6 0 ] <− ’ s ’
72
73 p . lm <− ggp lot ( stat , aes ( x=concentrat ion , y=value ) ) +
74 #geom poin t ( aes ( co lour=rep ) , a lpha =0.6) +
75 geom point ( aes ( y=avg ) , co l ou r=’ black ’ , alpha =0.8) +
76 geom abline (data=plot . stat , aes ( i n t e r c e p t=int , s l ope=s lope , l i n e t yp e=l i n e t yp e ) ) +
77 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
78 xlab ( ’ Fecal concent ra t i on ( g/mL) ’ ) +
79 ylab ( ’Compound concent ra t i on (mM) ’ ) +
80 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=6) +
81 theme bw(9) +
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82 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
83
84 ggsave ( ’ . . /Plot s/Re la t i on sh ip x2 c . png ’ , he ight =25, width=22, un i t s=’cm ’ )
85
86 #Lowest concentrat ions−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
87 low <− stat [ stat$ concent ra t i on == 0 . 3 433 , ]
88 low . cmpd <− unique ( low [ , c ( ’ v a r i ab l e ’ , ’ avg ’ ) ] )
89 low . cmpd <− low . cmpd [ order ( low . cmpd$avg ) , ]
Normalization analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
////
2 #normal i z ing f o r f e c a l water concentra t ion
3
4 #load ing requ i red packages
5 require ( ggp lot2 )
6 require ( reshape2 )
7 require (RSQLite )
8 require ( gr idExtra )
9
10 #sourc ing requ i red func t i ons
11 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
12 source ( ’ funct ion−data cleanup .R ’ )
13 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
14
15 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n samples/Experiment 2/R
Sc r i p t s/Functions ’ )
16 source ( ’ c o r r e l a t i o n .R ’ )
17
18 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Fecal water samples/R Sc r i p t s/Analys i s ’ )
19
20 source ( ’ . . /Functions/ l i n e a r model .R ’ )
21 source ( ’ . . /Functions/ s t a t custom .R ’ )
22 source ( ’ . . /Functions/normal ize .R ’ )
23 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
24 #Input data
25 # Choose d r i v e r
26 drv <− dbDriver ( ’ SQLite ’ )
27
28 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
29 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
30
31 input <− dbGetQuery ( con , ”SELECT q . SampleID , q . concentrat ion , q . rep ,
32 d . va r i ab l e , d . va lue
33 FROM Data d INNER JOIN Qua l i f i e r q
34 ON d . f i l e = q . f i l e
35 INNER JOIN Rank r
36 ON d . va r i ab l e = r .Compound
37 WHERE r . Conf idence = 1
38 ORDER BY q . sampleID ; ” )
39
40 input2 <− dbGetQuery ( con , ”SELECT ∗ FROM Data3 d3 INNER JOIN Rank r
41 ON d3 . v a r i a b l e = r .Compound
42 WHERE r . Conf idence = 1 ; ” )
43
44 dbDisconnect ( con )
45
46 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
47 c l ean <− data cleanup ( input , convert .NA=TRUE)
48 c l ean$rep <− as . character ( c l ean$rep )
49
50 #expor t in e x c e l
51 ca s t <− dcast ( c lean , sampleID+concent ra t i on+rep˜variable , va lue . var=’ value ’ )
52 #wri t e . csv ( f i l e =’C:/Users/Sandi/Dropbox/Pro jec t s/Fecal water samples/R Scr i p t s/
Resu l t s/ f e c a l water data . csv ’ , ca s t )
53
54 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
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55 stat <− d e s c r i p t i v e . stat ( c lean , data . type=’ long ’ ,
56 variable=c ( ’ v a r i ab l e ’ , ’ c oncent ra t i on ’ ) )
57
58 #Linear r e l a t i o n s h i p between me tabo l i t e concentra t ion with f e c a l water
concentrat ion−−−−−−−−
59 lm . t e s t <− ddply ( stat , ’ v a r i a b l e ’ , lm custom , group=’ concent ra t i on ’ , va lue=’ avg ’ )
60 lm . s i g <− lm . t e s t [ lm . t e s t$ s l ope . p <=0.05 ,]
61
62 #cor r e l a t i on
63 co r r . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , c o r r custom , x=’ concent ra t i on ’ , y=’ avg ’ )
64 co r r . s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l <= 0 . 0 5 , ]
65
66 plot . stat <− cbind (lm . t e s t , c o r r . r e s u l t $ es t imate )
67 colnames (plot . stat ) [ 1 0 ] <− ’ c o r r . e s t imate ’
68 plot . stat$ l i n e t yp e <− ’ ns ’
69 plot . stat$ l i n e t yp e [ plot . stat$ s l ope . p <= 0.05 &
70 plot . stat$ co r r . e s t imate > 0 . 6 0 ] <− ’ s ’
71
72 p . lm <− ggp lot ( stat , aes ( x=concentrat ion , y=value ) ) +
73 geom point ( aes ( co l our=rep ) , alpha =0.6) +
74 geom point ( aes ( y=avg ) , co l ou r=’ black ’ , alpha =0.8) +
75 geom abline (data=plot . stat , aes ( i n t e r c e p t=int , s l ope=s lope , l i n e t yp e=l i n e t yp e ) ) +
76 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
77 xlab ( ’ Fecal water concent ra t i on ( g/mL) ’ ) +
78 ylab ( ’Compound concent ra t i on (mM) ’ ) +
79 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=6) +
80 theme bw(14) +
81 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
82
83 #Normalizing me tabo l i t e concentra t ion fo r f e c a l water concentrat ion−−−−−−−−−−−−−−−−
84 #exper s s ing compound concentra t ion as per g o f f e c e s
85 c l ean$norm <− c l ean$value/ c l ean$ concent ra t i on/1000
86
87 #Do the s tandard i zed concentra t ions have s l ope s i g n i f i c a n t l y d i f f e r e n t than zero
88 lm . norm <− ddply ( c lean , ’ v a r i ab l e ’ ,lm custom , group=’ concent ra t i on ’ , va lue=’norm ’ )
89 lm . norm$ l i n e t yp e <− ’ ns ’
90 lm . norm$ l i n e t yp e [ lm . norm$ s l ope . p <=0.05] <− ’ s ’
91
92 #Vi sua l i z i n g normalized va lues−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
93 p <− ggp lot ( c lean , aes ( x=concentrat ion , y=norm) ) +
94 geom point ( aes ( co l our=rep ) , alpha =0.8) +
95 geom abline (data=lm . norm , aes ( i n t e r c e p t=int , s l ope=s lope , l i n e t yp e=l i n e t yp e ) ) +
96 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
97 xlab ( ’ Fecal water concent ra t i on ( g/mL) ’ ) +
98 ylab ( ’ Standardized Compound conce t r a t i on (mmol/g f e c e s ) ’ ) +
99 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=6) +
100 theme bw(14) +
101 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
102
103 #ggsave ( ’ . . /Plo t s/Normalized Overview . png ’ , p , h e i g h t =30, width=30, un i t s=’cm’ )
104
105
106 #look ing at what the s l o p e s o f normalized va lue s are
107 png ( ’ . . /Plot s/Normalized s l op e s . png ’ , un i t s=’cm ’ , he ight=8, width=12, r e s =240)
108 plot (density (lm . norm$ s l ope ) , main=’ ’ , sub=’N=39, Bandwidth=0.001 ’ ,
109 xlab=’ Slope (mM/g o f f e c e s ) ’ )
110 dev . of f ( )
111
112
113 p . norm <− ggp lot (norm . stat , aes ( x=variable , y=norm) ) +
114 stat boxplot ( ) +
115 geom point ( ) +
116 xlab ( ’Compound ’ ) +
117 ylab ( ’ Normalized Compound Concentrat ion (mmol/g f e c e s ) ’ ) +
118 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ ,ncol=5) +
119 theme bw(14) +
120 scale x d i s c r e t e ( labels=NULL) +
121 theme ( axis . t i c k s . x=element blank ( ) )
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122
123 ggsave ( ’ . . /Plot s/Normalized concent ra t i on b . png ’ , p . norm ,
124 he ight=35, width=30, un i t s=’cm ’ )
125
126 #Normalizing me tabo l i t e concentra t ion g iven mM vs g/mL r e l a t i o n s h i p as a score
−−−−−−−−−−−−−−−−−−
127 c l ean$ s l ope <− NA
128 for ( i in lm . t e s t$variable ) {
129 s <− lm . t e s t$ s l ope [ lm . t e s t$variable==i ]
130 c l ean$ s l ope [ c l ean$variable == i ] <− s
131 }
132
133 c l ean$ s c o r e <− c l ean$value/ c l ean$ s l ope/ c l ean$ concent ra t i on/1000
134
135 #Do the normalized scores have s l ope s i g n i f i c a n t l y d i f f e r e n t than zero
136 lm . s c o r e <− ddply ( c lean , ’ v a r i ab l e ’ ,lm custom , group=’ concent ra t i on ’ , va lue=’ s co r e ’ )
137 lm . s c o r e$ l i n e t yp e <− ’ ns ’
138 lm . s c o r e$ l i n e t yp e [ lm . s c o r e$ s l ope . p <=0.05] <− ’ s ’
139
140
141 p <− ggp lot ( c lean , aes ( x=concentrat ion , y=sco r e ) ) +
142 geom point ( aes ( co l our=rep ) , alpha =0.8) +
143 geom abline (data=lm . s core , aes ( i n t e r c e p t=int , s l ope=s lope , l i n e t yp e=l i n e t yp e ) ) +
144 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
145 xlab ( ’ Fecal water concent ra t i on ( g/mL) ’ ) +
146 ylab ( ’ Normalized Score o f Compound Concetrat ion ’ ) +
147 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=6) +
148 theme bw(14) +
149 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
150
151 #ggsave ( ’ . . /Plo t s/Normalized Score Overview . png ’ , p , h e i g h t =30, width=30, un i t s=’cm
’ )
152
153 #Comparing Normalized p r o f i l e to prev ious f e c a l sample p r o f i l e s−−−−−−−−−−−−−−−−−−−−
154
155 c l ean2 <− data cleanup ( input2 , convert .NA=TRUE)
156 c l ean2$rep <− as . character ( c l ean$rep )
157 s t a t2 <− d e s c r i p t i v e . stat ( c lean2 , data . type=’ long ’ , variable=’ va r i ab l e ’ )
158
159 s t a t2$ s c a l ed <− s t a t2$value/100
160 s t a t2$ s c a l ed [ s t a t 2$variable == ’ Ethanol ’ ] <− s t a t2$ s c a l ed [ s t a t 2$variable == ’
Ethanol ’ ]/50
161 s t a t2$expt <− ’ Pre l iminary experiment ’
162 norm . stat$expt <− ’ Smal l e s t Poop experiment ’
163
164 pf <− ggp lot ( s tat2 , aes ( x=variable , y=sca led , co l ou r=expt ) , alpha =0.8) +
165 stat boxplot (data=norm . stat , aes ( y=norm) ) +
166 geom point (data=norm . stat , aes ( y=norm) ) +
167 stat boxplot ( ) +
168 geom point ( ) +
169 xlab ( ’Compound ’ ) +
170 ylab ( ’Compound Concentrat ion ’ ) +
171 theme bw(14) +
172 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
173 legend . p o s i t i o n=’ none ’ )
174 #ggsave ( ’ . . /Plo t s/Old f e c a l samples . png ’ , pf , h e i g h t =15, width=35, un i t s=’cm’ )
175
176 #Normalizing by h i g h e s t concentra t ion compound ( Acetate )−−−−−−−−−−−−−−−−−−−−−−−
177 cmpd . norm <− ddply ( stat , ’ c oncent ra t i on ’ , norm custom ,
178 norm=’ Acetate ’ , norm . va l=’ avg ’ ,norm . name=’norm . ac e ta t e ’ )
179 cmpd . norm <− ddply (cmpd . norm , ’ concent ra t i on ’ , norm custom ,
180 norm=’ Propionate ’ , norm . va l=’ avg ’ ,norm . name=’norm . prop ionate ’ )
181 cmpd . norm <− ddply (cmpd . norm , ’ concent ra t i on ’ , norm custom ,
182 norm=’ Butyrate ’ , norm . va l=’ avg ’ ,norm . name=’norm . butyrate ’ )
183
184 norm <− melt (cmpd . norm , id . vars=c ( ’ sampleID ’ , ’ concent ra t i on ’ , ’ rep ’ , ’ v a r i a b l e ’ ) ,
185 measure . vars=c ( ’ va lue ’ , ’ avg ’ , ’ norm . ace ta t e ’ , ’ norm . prop ionate ’ ,
186 ’norm . butyrate ’ ) ,
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187 variable . name=’norm . type ’ )
188
189 norm <− norm [ !norm$norm . type %in% c ( ’ va lue ’ , ’ avg ’ ) , ]
190
191 cmpd . stat <− ddply (norm , ’norm . type ’ , d e s c r i p t i v e . stat , data . type=’ long ’ ,
192 variable=c ( ’ v a r i ab l e ’ , ’ c oncent ra t i on ’ ) )
193
194 #Compare f e c e s norm and ace ta t e normal izat ion−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
195 #Gett ing d e s c r i p t i v e s t a t s o f the normalized va lue s
196 stat func <− function (d , va lue ) {
197 stdev <− sd (d [ , va lue ] )
198 avg <− mean(d [ , va lue ] )
199 ymax <− max(d [ , va lue ] )
200 ymin <− min(d [ , va lue ] )
201 se <− stdev/sqrt (nrow(d) )
202 out <− data . frame ( avg=avg , stdev=stdev , se=se , ymax=ymax , ymin=ymin )
203 return ( out )
204 }
205
206 f e c e . stat <− ddply ( c lean , ’ v a r i ab l e ’ , stat func , va lue=’norm ’ )
207 acet . stat <− ddply (cmpd . norm , ’ v a r i a b l e ’ , stat func , va lue=’norm . ac e ta t e ’ )
208
209 d i f f . stat <− data . frame ( variable=f e c e . stat$variable , f e c . sd=f e c e . stat$stdev ,
210 f e c . se=f e c e . stat$se , ace . sd=acet . stat$stdev ,
211 ace . se=acet . stat$se )
212 d i f f . stat$d i f f . se <− d i f f . stat$ f e c . se−d i f f . stat$ace . se
213 d i f f . stat$d i f f . sd <− d i f f . stat$ f e c . sd−d i f f . stat$ace . sd
214
215 f e c e . stat$norm . type <− ’ f e c ’
216 acet . stat$norm . type <− ’ norm . ace ta t e ’
217
218 norm . stat <− rbind ( f e c e . stat , ace t . stat )
219
220 #Comparing Normalized p r o f i l e to non−norm values−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
221 p . data <− c l ean
222 p . data$ s c a l . va l <− p . data$value/100
223 p . data <− melt (p . data , measure . vars=c ( ’ va lue ’ , ’ norm ’ , ’ s c a l . va l ’ ) )
224 colnames (p . data ) [ 5 ] <− ’ data . type ’
225 p . data <− p . data [ p . data$data . type != ’ va lue ’ , ]
226 #p . data <− merge (p . data , norm . s t a t [ norm . s t a t$norm . type==’fec ’ , ] , by=’ va r i a b l e ’ )
227
228 p . f e c e s <− ggp lot (p . data , aes ( x=variable , y=value , co l ou r=data . type ) ) +
229 stat boxplot ( ) +
230 #geom poin t ( po s i t i on=po s i t i on dodge ( width=1)) +
231 ylab ( ’Compound Concentrat ion ’ ) +
232 theme bw(8) +
233 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
234 axis . t i t l e . x=element blank ( ) ,
235 legend . p o s i t i o n=c (0 .5 , −0 .35) ,
236 legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
237 legend .margin=uni t (0 , ’cm ’ ) ,
238 panel .margin=uni t (c ( 0 . 3 , 0 . 1 , 0 , 0 . 1 ) , ’cm ’ ) )
239
240 plot . data <−cmpd . stat [ cmpd . stat$norm . type==’norm . ac e ta t e ’ , ]
241 p . a c e ta t e <− ggp lot (plot . data , aes ( x=variable , y=value ) ) +
242 stat boxplot ( aes (ymax=ymax , ymin=ymin ) ) +
243 #geom poin t () +
244 theme bw(8) +
245 xlab ( ’Compound ’ ) +
246 ylab ( ’Compound concent ra t i on (% Acetate ) ’ ) +
247 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
248 panel .margin=uni t (c ( 0 , 0 . 1 , 0 . 2 , 0 . 1 ) , ’cm ’ ) )
249
250 g <− arrangeGrob (p . f e c e s , p . acetate , ncol=1, nrow=2, he ight=c ( 0 . 5 , 0 . 5 ) )
251
252 png ( f i l e=’ . . /Plot s/norm compare . png ’ , width=18, he ight=18, un i t s=’cm ’ , r e s =300)
253 print ( g )
254 grid . text ( ’A ’ , x=0.0345 ,y=0.98)
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255 grid . text ( ’B ’ , x=0.0345 ,y=0.51)
256 dev . of f ( )
257
258 #Inner j o in two norma l i za t ions in to one d f f o r p l o t t i n g−−−−−−−−−−−−−−−−−−−−−−−
259 p . data <− data . frame ( variable=clean$variable ,
260 concent ra t i on=c l ean$ concentrat ion ,
261 rep=clean$rep ,
262 f e c=c l ean$norm)
263
264 p . data <− merge(p . data , cmpd . norm [ , c ( ’ v a r i ab l e ’ , ’ c oncent ra t i on ’ , ’ rep ’ ,
265 ’norm . ac e ta t e ’ ) ] ,
266 by=c ( ’ v a r i ab l e ’ , ’ c oncent ra t i on ’ , ’ rep ’ ) )
267
268 p . data <− melt (p . data , id . vars=c ( ’ v a r i ab l e ’ , ’ c oncent ra t i on ’ , ’ rep ’ ) ,
269 measure . vars=c ( ’ f e c ’ , ’ norm . ace ta t e ’ ) )
270
271 colnames (p . data ) [ 4 : 5 ] <− c ( ’norm . type ’ , ’ norm . va l ’ )
272
273 p . data <− merge(p . data , norm . stat , by=c ( ’ v a r i ab l e ’ , ’ norm . type ’ ) )
274
275 p . f e c <− ggp lot (p . data [ p . data$norm . type==’ f e c ’ , ] , aes ( x=variable , y=norm . va l ) ) +
276 geom pointrange ( aes ( y=avg , ymin=ymin , ymax=ymax) , s i z e =0.3)+
277 #s t a t boxp l o t ( ) +
278 theme bw(10) +
279 #x lab ( ’Compound ’ ) +
280 ylab ( ’ Nomalized concent ra t i on (mM/g f e c e s ) ’ ) +
281 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
282 axis . t i t l e . x=element blank ( ) ,
283 plot .margin=uni t (c ( 0 . 8 , 0 . 5 , 0 , 0 . 2 ) , ”cm” ) )
284
285 #ggsave ( ’ . . /Plo t s/norm range−f e c e s . png ’ , p . fec , h e i g h t =11.5 , width=18, un i t s=’cm’ )
286
287 p . ace <− ggp lot (p . data [ p . data$norm . type==’norm . ac e ta t e ’ , ] , aes ( x=variable , y=norm .
va l ) ) +
288 geom pointrange ( aes ( y=avg , ymin=ymin , ymax=ymax) , s i z e =0.3)+
289 #s t a t boxp l o t ( ) +
290 theme bw(10) +
291 xlab ( ’Compound ’ ) +
292 ylab ( ’ Nomalized concent ra t i on (% ace ta t e ) ’ ) +
293 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
294 plot .margin=uni t (c ( 0 , 0 . 5 , 0 . 2 , 0 . 2 ) , ”cm” ) )
295
296 #ggsave ( ’ . . /Plo t s/norm range−ace ta t e . png ’ , p . ace , h e i g h t =11.5 , width=18, un i t s=’cm
’ )
297
298 g <− arrangeGrob (p . f ec , p . ace , ncol=1, nrow=2, he ight=c ( 0 . 5 , 0 . 5 ) )
299
300 png ( f i l e=’ . . /Plot s/norm range . png ’ , width=15, he ight=18, un i t s=’cm ’ , r e s =300)
301 print ( g )
302 grid . text ( ’A ’ , x=0.0345 ,y=0.98)
303 grid . text ( ’B ’ , x=0.0345 ,y=0.51)
304 dev . of f ( )
305 #Compare d i f f e r e n c e compound normal i za t ions−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
306
307 p . norm <− ggp lot (cmpd . stat , aes ( x=variable , y=value , co l ou r=norm . type ) ) +
308 stat boxplot ( aes (ymax=ymax , ymin=ymin ) ) +
309 geom point ( p o s i t i o n=po s i t i o n dodge ( width=0.8) ) +
310 theme bw(14) +
311 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
312
313 ggsave ( ’ . . /Plot s/Normalize by d i f f compounds . png ’ , p . norm ,
314 he ight=15, width=35, un i t s=’cm ’ )
315
316 #p l o t t i n g only ace ta t e normalized and poop nomalized
317 plot . data <−cmpd . stat [ cmpd . stat$norm . type==’norm . ac e ta t e ’ , ]
318 plot . data2 <− norm . stat
319 plot . data2$norm2 <− plot . data2$norm∗25
320
221
321 p . a c e ta t e <− ggp lot (plot . data , aes ( x=variable , y=value ) ) +
322 #s t a t boxp l o t ( data=p l o t . data2 , aes ( y=norm2) , co lour=’grey60 ’ ) +
323 #geom poin t ( data=p l o t . data2 , aes ( y=norm2) , co lour=’grey60 ’ ) +
324 stat boxplot ( aes (ymax=ymax , ymin=ymin ) ) +
325 geom point ( ) +
326 theme bw(14) +
327 xlab ( ’Compound ’ ) +
328 ylab ( ’Compound concent ra t i on (% Acetate ) ’ ) +
329 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
330
331 ggsave ( ’ . . /Plot s/Normalize by ace ta t e . png ’ , p . acetate ,
332 he ight=15, width=35, un i t s=’cm ’ )
333
334 pa2 <− ggp lot (plot . data , aes ( x=variable , y=value ) ) +
335 stat boxplot ( aes (ymax=ymax , ymin=ymin ) ) +
336 geom point ( ) +
337 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=5) +
338 theme bw(14)+
339 xlab ( ’Compound ’ ) +
340 ylab ( ’ Normalized Compound Concentrat ion (% Acetate ) ’ ) +
341 scale x d i s c r e t e ( labels=NULL) +
342 theme ( axis . t i c k s . x=element blank ( ) )
343
344 ggsave ( ’ . . /Plot s/Normalize by acetate−concen t ra t i on s2 . png ’ , pa2 ,
345 he ight=35, width=30, un i t s=’cm ’ )
C.2 Gut-mimicking CSTR Eﬄuent Sample Preparation and
Analysisprep protocol
Data source.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Data source f o r UC Expt 3
3
4
5 #sourc ing requ i red func t i ons
6 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
7 source ( ’ funct ion−summary p r ep ro c e s s i ng .R ’ )
8
9 #load ing requ i red packages
10 require ( reshape2 )
11 require (RSQLite )
12
13 #Se t t i n g working d i r e c t o r y
14 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Data source f i l e s ’ )
15
16 #preproces s ing raw data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
17 #Experiment 1
18 raw1 <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n
Samples/Experiment 1/Resu l t s/R Sc r i p t s/Data source f i l e s / concent ra t i ons−UC Expt
1 . csv ’ )
19 data1 <− raw1 [ [ ’ data ’ ] ]
20 data . melt1 <− melt ( data1 )
21 data . melt1$value <− data . melt1$value/0 .9
22
23 mw <− raw1 [ [ ’mol . wt ’ ] ]
24 mw1 <− as . data . frame ( t (mw) )
25 mw1$variable <− rownames(mw1)
26 mw1$Weight <− as .numeric (as . character (mw1$Weight ) )
27
28
29 #Experiment 2
222
30 raw2 <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n
samples/Experiment 2/R Sc r i p t s/Data source f i l e s / concen t ra t i on s x2−UC Expt 2 .
csv ’ )
31 data2 <− raw2 [ [ ’ data ’ ] ]
32 data . melt2 <− melt ( data2 )
33 data . melt2$value <− data . melt2$value/0 .9
34
35 mw <− raw2 [ [ ’mol . wt ’ ] ]
36 mw2 <− as . data . frame ( t (mw) )
37 mw2$variable <− rownames(mw2)
38 mw2$Weight <− as .numeric (as . character (mw2$Weight ) )
39
40 #Experiment 3
41 raw3 <− summary . p r ep roce s s ( ’ concent ra t i ons−UC Expt 3 . csv ’ )
42 data3 <− raw3 [ [ ’ data ’ ] ]
43 data . melt3 <− melt ( data3 )
44 data . melt3$value <− data . melt3$value/0 .9
45
46 mw <− raw1 [ [ ’mol . wt ’ ] ]
47 mw3 <− as . data . frame ( t (mw) )
48 mw3$variable <− rownames(mw3)
49 mw3$Weight <− as .numeric (as . character (mw3$Weight ) )
50
51 #Prel iminary experiment
52 raw . pre l im <− summary . p r ep roce s s ( ’C: /Users/Sandi/Dropbox/Pro j e c t s/
Ul t r a c en t r i f u g a t i o n samples/Pre l iminary Experiment/R s c r i p t s /Data source f i l e s /
D5−Ul t r a c en t r i f u g a t i o n concent ra t i on summary 2 . csv ’ )
53 data . pre l im <− raw . pre l im [ [ ’ data ’ ] ]
54 pre l im . melt <− melt (data . pre l im )
55 pre l im . melt$value <− pre l im . melt$value/0 .9
56
57 mw <− raw1 [ [ ’mol . wt ’ ] ]
58 mw. pre l im <− as . data . frame ( t (mw) )
59 mw. pre l im$variable <− rownames(mw. pre l im )
60 mw. pre l im$Weight <− as .numeric (as . character (mw. pre l im$Weight ) )
61
62 data <− rbind (data . melt1 , data . melt2 , data . melt3 , pre l im . melt )
63
64 mw <− unique ( rbind (mw1, mw2, mw3, mw. pre l im ) )
65 #Qua l i f i e r s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
66 #f i l e == f i l e name from batch expor t
67 #scan == scan number wi th in Expt
68 #sample == sample ID wi th in UC Expt
69 #sampleID == sample ID wi th in UC pro j e c t −− unique across exp t s
70 #type == grouping t r i p l i c a t e samples wi th in UC Expt −− not unique across exp t s
71 #grp == grouping t r i p l i c a t e sampels across p r o j e c t (UC Expt 1 and 2 combined )
72 # −− unique across exp t s
73 #rep == r e p l i c a t e number
74 #c l a s s == proces s ing procedure used
75 #speed == speed at which samples was u l t r a c e n t r i f u g e d
76 #process == presence o f pre sp in or no
77 #f i l t e r == f i l t e r s i z e
78 #expt == experiment number
79
80 #Experiment 1−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
81 q u a l i f i e r 1 <− data . frame ( f i l e=data1$ f i l e )
82
83 q u a l i f i e r 1 $scan <− q u a l i f i e r 1 $ f i l e
84 q u a l i f i e r 1 $scan <− gsub ( ’ .∗(?<=x) ( [0 −9 ]{1 ,2} ) . ∗ ’ , ’ \\1 ’ ,
85 q u a l i f i e r 1 $scan , p e r l=TRUE)
86
87 scan <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/
Experiment 1/Resu l t s/R Sc r i p t s/Data source f i l e s /scan order . csv ’ , header=FALSE)
88 scan <− scan [ 2 :nrow( scan ) , ]
89 col . name <− as . character (as .matrix ( scan [ 1 , ] ) )
90 colnames ( scan ) <− col . name
91 scan <− scan [ 2 :nrow( scan ) , ]
92 scan [ , ’ Scan Order ’ ] <− as .numeric ( scan [ , ’ Scan Order ’ ] )
223
93 scan$sampleID <− as . character ( scan$sample )
94
95 type <− c ( )
96 for ( i in 1 : 9 ) {
97 temp <− rep (LETTERS[ i ] , 3)
98 type <− c ( type , temp)
99 }
100
101 grp <− c ( )
102 for ( i in 1 : 18 ) {
103 temp <− rep (LETTERS[ i ] , 3)
104 grp <− c ( grp , temp)
105 }
106
107 scan$type <− type
108 scan$grp <− grp [ 1 :nrow( scan ) ]
109 scan$rep <− c ( rep ( 1 : 3 , 9) )
110 scan$class <− c ( rep ( ’ I ’ , 15) , rep ( ’ I I ’ , 6 ) , rep ( ’ I I I ’ , 6 ) )
111 scan$speed <− c ( rep (10000 ,3) , rep (20000 ,3) , rep (30000 ,3) , rep (40000 ,3) , rep
(50000 ,3) ,
112 rep (10000 ,3) , rep (50000 ,3) , rep ( 0 , 6 ) )
113 scan$proce s s <− c ( rep ( ’ pre−sp in ’ ,15) , rep ( ’ no pre−sp in ’ , 6 ) , rep ( ’ pre−sp in ’ , 6 ) )
114 scan$ f i l t e r <− c ( rep ( ’ 0 .22 ’ ,21) , rep ( ’ s e r i a l ’ , 3 ) , rep ( ’ 0 .22 ’ , 3 ) )
115
116 scan <− scan [ order ( scan [ , ’ Scan Order ’ ] ) , ]
117
118 q u a l i f i e r 1 <− cbind ( q u a l i f i e r 1 , scan )
119 q u a l i f i e r 1 <− q u a l i f i e r 1 [ , ! colnames ( q u a l i f i e r 1 ) %in% c ( ’ sample name ’ ,
120 ’ Scan Order ’ ) ]
121
122 q u a l i f i e r 1 $expt <− ’ expt1 ’
123 q u a l i f i e r 1 $sampleID <− factor ( q u a l i f i e r 1 $sampleID ,
124 levels=c (LETTERS[ 1 : 2 6 ] ,
125 paste (LETTERS[ 1 ] ,LETTERS[ 1 ] , sep=’ ’ ) ) )
126 q u a l i f i e r 1 <− q u a l i f i e r 1 [ order ( q u a l i f i e r 1 $sampleID ) , ]
127
128 #Experiment 2−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
129 q u a l i f i e r 2 <− data . frame ( f i l e=data2$ f i l e )
130 q u a l i f i e r 2 $scan <− q u a l i f i e r 2 $ f i l e
131 q u a l i f i e r 2 $scan <− gsub ( ’ .∗ ( [0−9]{2}) (?= x2 \\ . cnx ) . ∗ ’ , ’ \\1 ’ , q u a l i f i e r 2 $scan , p e r l
=TRUE)
132 q u a l i f i e r 2 $scan <− gsub ( ’ .∗ ( [0−9]{1}) (?= x2 \\ . cnx ) . ∗ ’ , ’ \\1 ’ , q u a l i f i e r 2 $scan , p e r l
=TRUE)
133 q u a l i f i e r 2 $sample <− q u a l i f i e r 2 $ f i l e
134 q u a l i f i e r 2 $sample <− gsub ( ’ ( [A−Z ]{1 , 2} ) (?= x [0−9]{1 ,2} ) . ∗ ’ , ’ \\1 ’ ,
135 q u a l i f i e r 2 $sample , p e r l=TRUE)
136
137 q u a l i f i e r 2 $sample <− factor ( q u a l i f i e r 2 $sample ,
138 levels=c (LETTERS[ 1 : 2 6 ] ,
139 paste (LETTERS[ 1 ] ,LETTERS[ 1 ] , sep=’ ’ ) ) )
140 q u a l i f i e r 2 <− q u a l i f i e r 2 [ order ( q u a l i f i e r 2 $sample ) , ]
141
142
143 sampleID <− c (paste (LETTERS[ 1 ] ,LETTERS[ 2 : 2 6 ] , sep=’ ’ ) ,
144 paste (LETTERS[ 2 ] ,LETTERS[ 1 : 2 6 ] , sep=’ ’ ) ,
145 paste (LETTERS[ 3 ] ,LETTERS[ 1 : 2 6 ] , sep=’ ’ ) )
146
147 q u a l i f i e r 2 $sampleID <− sampleID [ 1 :nrow( q u a l i f i e r 2 ) ]
148
149 q u a l i f i e r 2 $type <− type
150 q u a l i f i e r 2 $grp <− grp [nrow( scan )+1:nrow( q u a l i f i e r 2 ) ]
151 q u a l i f i e r 2 $rep <− c ( rep ( 1 : 3 , 9) )
152 q u a l i f i e r 2 $class <− c ( rep ( ’ I ’ , 15) , rep ( ’ I I ’ , 6 ) , rep ( ’ I I I ’ , 6 ) )
153 q u a l i f i e r 2 $speed <− c ( rep (10000 ,3) , rep (20000 ,3) , rep (30000 ,3) , rep (40000 ,3) , rep
(50000 ,3) ,
154 rep (10000 ,3) , rep (50000 ,3) , rep ( 0 , 6 ) )
155 q u a l i f i e r 2 $proce s s <− c ( rep ( ’ pre−sp in ’ ,15) , rep ( ’ no pre−sp in ’ , 6 ) , rep ( ’ pre−sp in ’
, 6 ) )
224
156 q u a l i f i e r 2 $ f i l t e r <− c ( rep ( ’ 0 .22 ’ ,21) , rep ( ’ s e r i a l ’ , 3 ) , rep ( ’ 0 .22 ’ , 3 ) )
157 q u a l i f i e r 2 $expt <− ’ expt2 ’
158
159 #Experiment 3−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
160 q u a l i f i e r 3 <− data . frame ( f i l e=data3$ f i l e , scan=data3$ f i l e )
161 q u a l i f i e r 3 $scan <− gsub ( ’ .∗(?<= x) ( [0 −9 ]{1 ,2} ) . ∗ ’ , ’ \\1 ’ , q u a l i f i e r 3 $scan ,
162 p e r l=TRUE)
163
164 scan . order <− read . csv ( ’ scan order . csv ’ )
165 scan . order <− scan . order [ , 2 : 3 ]
166
167 q u a l i f i e r 3 $sample <− scan . order [ , 2 ]
168 q u a l i f i e r 3 <− q u a l i f i e r 3 [ order ( q u a l i f i e r 3 $sample ) , ]
169
170 q u a l i f i e r 3 $sampleID <− sampleID [ (nrow( q u a l i f i e r 2 )+1) :
171 (nrow( q u a l i f i e r 2 )+nrow( q u a l i f i e r 3 ) ) ]
172
173 q u a l i f i e r 3 $type <− c ( rep ( ’A ’ , 8 ) , unlist ( lapply (LETTERS[ 2 : 6 ] , rep , 3) ) )
174 q u a l i f i e r 3 $grp <− c ( rep ( ’S ’ , 8 ) , unlist ( lapply (LETTERS[ 2 0 : 2 4 ] , rep , 3) ) )
175 q u a l i f i e r 3 $rep <− c ( 1 : 8 , rep ( 1 : 3 , 5 ) )
176 q u a l i f i e r 3 $class <− c ( rep ( ’ I I I ’ , 8 ) , rep ( ’ I ’ , 15) )
177
178 sample . i n f o <− lapply ( seq (50000 , 10000 , −10000) , rep , t imes=3)
179 q u a l i f i e r 3 $speed <− c ( rep ( 0 , 8 ) , unlist (sample . i n f o ) )
180
181 q u a l i f i e r 3 $proce s s <− ’ no pre−sp in ’
182 q u a l i f i e r 3 $ f i l t e r <− c ( rep ( ’ s e r i a l ’ , 8 ) , rep ( 0 . 2 2 , 1 5 ) )
183 q u a l i f i e r 3 $expt <− ’ expt3 ’
184
185 #Prel iminary experiment−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
186 q u a l i f i e r . pre l im <− data . frame ( f i l e=data . pre l im$ f i l e )
187 q u a l i f i e r . pre l im$scan <− c ( 1 , 2 )
188 q u a l i f i e r . pre l im$sample <− LETTERS[ 1 :nrow( q u a l i f i e r . pre l im ) ]
189 q u a l i f i e r . pre l im$sampleID <− sampleID [ (nrow( q u a l i f i e r 2 )+nrow( q u a l i f i e r 3 )+1) :
190 (nrow( q u a l i f i e r 2 )+nrow( q u a l i f i e r 3 )+
191 nrow( q u a l i f i e r . pre l im ) ) ]
192 q u a l i f i e r . pre l im$type <− LETTERS[ 1 : length (unique (data . pre l im$ f i l e ) ) ]
193 q u a l i f i e r . pre l im$grp <− LETTERS[ ( length (unique ( q u a l i f i e r 1 $grp ) )+
194 length (unique ( q u a l i f i e r 2 $grp ) )+1) :
195 ( length (unique ( q u a l i f i e r 1 $grp ) )+
196 length (unique ( q u a l i f i e r 2 $grp ) )+
197 length (unique ( q u a l i f i e r . pre l im$ f i l e ) ) ) ]
198 q u a l i f i e r . pre l im$rep <− rep ( 1 , 2 )
199 q u a l i f i e r . pre l im$class <− c ( ’ I I ’ , ’ I I I ’ )
200 q u a l i f i e r . pre l im$speed <− c (50000 , 0)
201 q u a l i f i e r . pre l im$proce s s <− c ( ’ no pre−sp in ’ , ’ pre−sp in ’ )
202 q u a l i f i e r . pre l im$ f i l t e r <− c ( 0 . 2 2 , ’ s e r i a l ’ )
203 q u a l i f i e r . pre l im$expt <− ’ p r e l im inary ’
204
205 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
206 q u a l i f i e r <− rbind ( q u a l i f i e r 1 , q u a l i f i e r 2 , q u a l i f i e r 3 , q u a l i f i e r . pre l im )
207 q u a l i f i e r $sampleID <− as . character ( q u a l i f i e r $sampleID )
208
209 #Rank−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
210 #Experiment 1
211 rank1 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/
Experiment 1/Resu l t s/R Sc r i p t s/Data source f i l e s /compound ranking . csv ’ ,
encoding=’UTF−8 ’ )
212 rank1 <− rank1 [ , 1 : 4 ]
213 rank1$expt <− ’ expt1 ’
214
215 #Experiment 2
216 rank2 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n samples/
Experiment 2/R Sc r i p t s/Data source f i l e s /Compound rank−UC Expt 2 . csv ’ , encoding
=’UTF−8 ’ )
217 rank2 <− rank2 [ , 1 : 4 ]
218 rank2$expt <− ’ expt2 ’
219
225
220 #Experiment 3
221 rank3 <− read . csv ( ’Compound rank−UC Expt 3 . csv ’ )
222 rank3 <− rank3 [ , 1 : 4 ]
223 rank3$expt <− ’ expt3 ’
224
225 #Prel iminary experiment
226 rank . pre l im <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n
samples/Pre l iminary Experiment/R s c r i p t s /Data source f i l e s /Compound annotat ion .
csv ’ , encoding=’UTF−8 ’ )
227 rank . pre l im <− rank . pre l im [ , c ( 1 : 3 , 5 ) ]
228 rank . pre l im$expt <− ’ p r e l im inary ’
229
230 rank <− rbind ( rank1 , rank2 , rank3 , rank . pre l im )
231
232 #Compound info−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
233 i n f o <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data
source f i l e s /Database−Compound c l a s s e s . csv ’ )
234
235 # Create the connect ion (no f i l e needed ) −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
236
237 # Choose d r i v e r
238 drv = dbDriver ( ’ SQLite ’ )
239
240 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
241 con = dbConnect ( drv , ’ data . db ’ )
242
243 # Creating database t a b l e s
244 uc . table <− dbWriteTable ( con , ’UC3 data ’ , data , ove rwr i t e=TRUE)
245 uc . table
246
247 q u a l i f i e r . table <− dbWriteTable ( con , ’ Qu a l i f i e r ’ , q u a l i f i e r , ove rwr i t e=TRUE)
248 q u a l i f i e r . table
249
250 rank . table <− dbWriteTable ( con , ’Rank ’ , rank , ove rwr i t e=TRUE)
251 rank . table
252
253 i n f o . table <− dbWriteTable ( con , ’Cmpd i n f o ’ , in fo , ove rwr i t e=TRUE)
254 i n f o . table
255
256 mw. table <− dbWriteTable ( con , ’Mol wt ’ , mw, ove rwr i t e=TRUE)
257 mw. table
258
259 t ab l e s <− dbGetQuery ( con , ”SELECT ∗ FROM s q l i t e master WHERE type=’ tab le ’ ; ” )
260 print ( t ab l e s )
261
262 dbDisconnect ( con )
Profiling precision analysis.R
1 #///////////////////////////////////////////////////////////////////////////////
2 #Ul t r a c en t r i f u g e Experiment 3 − Analys i s o f p r o f i l i n g v a r i a b i l i t y
3
4 #Pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
5 #Se t t i n g working d i r e c t o r y
6 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data source
f i l e s / ’ )
7
8 #Sourcing requ i red func t i ons
9 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
10 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
11
12 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 2/R
Sc r i p t s/Functions ’ )
13 source ( ’ ./ANOVA−mean .R ’ )
14 source ( ’ ./kruska l w a l l i s .R ’ )
15 source ( ’ ./ l i n e a r model .R ’ )
16 source ( ’ ./tukey .R ’ )
17 source ( ’ ./ c o r r e l a t i o n .R ’ )
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18
19 #load ing requ i red packages
20 require (RSQLite )
21 require ( reshape2 )
22 require ( p ly r )
23 require ( ggp lot2 )
24
25 #s e t t i n g working d i r e c t o r y
26 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
27 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
28 #Input data
29 # Choose d r i v e r
30 drv <− dbDriver ( ’ SQLite ’ )
31
32 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
33 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
34
35 expt3 <− dbGetQuery ( con , ”SELECT q . sampleID , q . type , q . grp , q . rep , q . c l a s s ,
36 q . speed , q . process , q . f i l t e r , q . expt , c . Type , m.Weight ,
37 d . va r i ab l e , d . va lue
38 FROM UC3 Data d INNER JOIN Qua l i f i e r q
39 ON d . f i l e = q . f i l e
40 INNER JOIN Rank r
41 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
42 INNER JOIN Cmpd i n f o c
43 ON d . va r i ab l e = c .Compound
44 INNER JOIN Mol wt m
45 ON d . va r i ab l e = m. va r i ab l e
46 WHERE r . Conf idence = 1 AND q . expt = ’ expt3 ’
47 AND q . type = ’A’
48 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
49 ORDER BY q . type ; ” )
50
51 dbDisconnect ( con )
52
53 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
54 c l ean <− data cleanup ( expt3 , convert .NA=TRUE)
55
56 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
57 stat <− d e s c r i p t i v e . stat ( c lean , data . type=’ long ’ , variable=c ( ’ type ’ , ’ v a r i ab l e ’ ) )
58
59 #Re la t i v e standard dev ia t ion−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
60
61 stat$ rsd <− stat$ stdev/stat$avg∗100
62
63 plot (density ( stat$rsd , bw=1) )
64
65 png ( f i l ename=’ . . /Plot s/p r e c i s i on−RSD. png ’ ,
66 width=10, he ight=7, un i t s=’cm ’ , r e s =240)
67 plot (density ( stat$rsd , bw=1) , main=’ ’ )
68 dev . of f ( )
69
70 high . rsd <− unique ( stat [ stat$ rsd > 15 ,c ( ’ v a r i ab l e ’ , ’ r sd ’ ) ] )
71 write . csv ( f i l e=’ . . /Resu l t s/p r e s c i s i o n−rsd . csv ’ , high . rsd )
Factor effects-mlr analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Comparison o f p r o f i l e s from Expt 3 , amd Expt 2
3 #look ing at e f f e c t s o f a l l exp lana tory v a r i a b l e s ( process , speed , exp t )
4
5 #pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
6 #Se t t i n g working d i r e c t o r y
7 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
8
9 #Sourcing requ i red func t i ons
227
10 source ( ’ funct ion−data cleanup .R ’ )
11 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
12
13 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 2/R
Sc r i p t s/Functions ’ )
14 source ( ’ ./ANOVA−mean .R ’ )
15 source ( ’ ./kruska l w a l l i s .R ’ )
16 source ( ’ ./ l i n e a r model .R ’ )
17 source ( ’ ./tukey .R ’ )
18 source ( ’ ./ c o r r e l a t i o n .R ’ )
19
20 #load ing requ i red packages
21 require (RSQLite )
22 require ( reshape2 )
23 require ( p ly r )
24 require ( ggp lot2 )
25
26 #s e t t i n g working d i r e c t o r y
27 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
28 source ( ’ . . /Functions/mul t ip l e l i n e a r r e g r e s s i o n .R ’ )
29 source ( ’ . . /Functions/mlr p r ed i c t i on .R ’ )
30 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
31 #Input data
32 # Choose d r i v e r
33 drv <− dbDriver ( ’ SQLite ’ )
34
35 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
36 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
37
38 input <− dbGetQuery ( con , ”SELECT q . SampleID , q . type , q . grp , q . rep , q . c l a s s ,
39 q . speed , q . process , q . f i l t e r , q . expt , c . Type , m.Weight ,
40 d . va r i ab l e , d . va lue
41 FROM UC3 Data d INNER JOIN Qua l i f i e r q
42 ON d . f i l e = q . f i l e
43 INNER JOIN Rank r
44 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
45 INNER JOIN Cmpd i n f o c
46 ON d . va r i ab l e = c .Compound
47 INNER JOIN Mol wt m
48 ON d . va r i ab l e = m. va r i ab l e
49 WHERE
50 (q . expt = ’ expt2 ’ AND r . Conf idence = 1) OR
51 (q . expt = ’ expt3 ’ AND r . Conf idence = 1)
52 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
53 ORDER BY q . expt ; ” )
54 dbDisconnect ( con )
55
56 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
57 c l ean <− data cleanup ( input , convert .NA=TRUE)
58
59 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
60 stat <− ddply ( c lean , ’ expt ’ , d e s c r i p t i v e . stat , data . type=’ long ’ ,
61 variable=c ( ’ type ’ , ’ v a r i ab l e ’ ) )
62
63 #Removing compounds found only in one o f Expt 2 and Expt 3−−−−−−−−−−−−−−−−−−−−−−−
64 expt2 . var <− unique ( stat$variable [ stat$expt==’ expt2 ’ ] )
65 expt3 . var <− unique ( stat$variable [ stat$expt==’ expt3 ’ ] )
66
67 remove <− expt2 . var [ ! expt2 . var %in% expt3 . var ]
68 sub <− stat [ stat$variable != remove , ]
69 #General to s imp l e s t mlr model−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
70 check model <− function (d , f1 , f 2 ) {
71 m1 <− lm( formula=f1 , data=d)
72 m2 <− lm( formula=f2 , data=d)
73 compare <− anova(m1, m2)
228
74 out <− compare [ 2 , 6 ]
75 return ( out )
76 }
77
78 bon f e r r on i <− 0 .05/length (unique (sub$variable ) )
79 mlr1 <−ddply (sub , ’ v a r i a b l e ’ , mlr custom ,
80 f=’ va lue˜speed+expt+proce s s+speed : p roce s s+speed : expt ’ )
81 mlr1$ l a b e l <− ’ ’
82 mlr1$ l a b e l [ mlr1 [ , ’ Pr(>| t | ) ’ ] <bon f e r r on i ] <− ’∗ ’
83 mlr1$model <− −0.3/2
84
85 mlr2 <− ddply (sub , ’ v a r i a b l e ’ , mlr custom ,
86 f=’ va lue˜speed+expt+proce s s+speed : expt ’ ) #remove speed : process
87 mlr2$ l a b e l <− ’ ’
88 mlr2$ l a b e l [ mlr2 [ , ’ Pr(>| t | ) ’ ] <bon f e r r on i ] <− ’∗ ’
89 mlr2$model <− −0.1/2
90
91 #compare mlr1 and mlr2
92 m1m2 <−ddply (sub , ’ v a r i a b l e ’ , check model ,
93 f 1=’ va lue˜speed+expt+proce s s+speed : p roce s s+speed : expt ’ ,
94 f2=’ va lue˜speed+expt+proce s s+speed : expt ’ )
95
96 mlr3 <− ddply (sub , ’ v a r i a b l e ’ , mlr custom ,
97 f=’ va lue˜speed+expt+speed : expt ’ ) #remove process
98 mlr3$ l a b e l <− ’ ’
99 mlr3$ l a b e l [ mlr3 [ , ’ Pr(>| t | ) ’ ] <bon f e r r on i ] <− ’∗ ’
100 mlr3$model <− 0 .1/2
101
102 m2m3 <− ddply (sub , ’ v a r i a b l e ’ , check model ,
103 f1=’ va lue˜speed+expt+proce s s+speed : expt ’ ,
104 f2=’ va lue˜speed+expt+speed : expt ’ )
105
106 mlr4 <− ddply (sub , ’ v a r i a b l e ’ , mlr custom ,
107 f=’ va lue˜speed+expt ’ ) #remove speed : exp t
108 mlr4$ l a b e l <− ’ ’
109 mlr4$ l a b e l [ mlr4 [ , ’ Pr(>| t | ) ’ ] <bon f e r r on i ] <− ’∗ ’
110 mlr4$model <− 0 .3/2
111
112 m3m4 <− ddply (sub , ’ v a r i a b l e ’ , check model ,
113 f1=’ va lue˜speed+expt+speed : expt ’ ,
114 f2=’ va lue˜speed+expt ’ )
115
116 #v i s u a l i z i n g s i g n i f i c a n c e o f terms−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
117 plot . data <− rbind (mlr1 , mlr2 , mlr3 , mlr4 )
118 plot . data <− plot . data [ plot . data$rname != ’ ( I n t e r c ep t ) ’ , ]
119 plot . data$rname <− factor (plot . data$rname , levels=c ( ’ speed ’ , ’ exptexpt3 ’ ,
120 ’ proces spre−sp in ’ , ’ speed : exptexpt3 ’ ,
121 ’ speed : proces spre−sp in ’ ) )
122 var . l e v e l <− rev (unique (plot . data$variable ) )
123 plot . data$variable <− factor (plot . data$variable , levels=var . l e v e l )
124
125 rname . code <− data . frame ( rname=unique (plot . data$rname ) ,
126 rname . code=c ( 1 , 2 , 3 , 5 , 4 ) )
127
128 plot . data <− merge(plot . data , rname . code , by=’ rname ’ )
129 plot . data$x <− plot . data$model + plot . data$rname . code
130
131 var . code <− data . frame ( variable=var . l e v e l )
132 var . code$var . code <− rev (as .numeric (var . code$variable ) )
133 plot . data <− merge(plot . data , var . code , by=’ va r i ab l e ’ )
134 plot . data$y <− plot . data$var . code
135 plot . data$var . code [ plot . data$ l a b e l != ’∗ ’ ] <− NA
136
137 plot . data$model <− factor (plot . data$model)
138
139 p <− ggp lot (plot . data , aes ( x=x , y=var . code ) ) +
140 geom point ( aes ( co l our=model) , shape=42, s i z e =5) +
141 scale x d i s c r e t e ( breaks =1:5 , labels=c ( ’ Speed ’ , ’ Experiment ’ , ’ Pre−Process ’ ,
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142 ’ Speed−Experiment\ n In t e r a c t i on ’ ,
143 ’ Speed−Pre−proce s s \ n In t e r a c t i on ’ ) ) +
144 coord c a r t e s i a n ( xlim = c ( 0 . 5 , 5 . 5 ) ) +
145 scale co l ou r d i s c r e t e (name=’MLR Model ’ , labels=c (paste ( ’model ’ , 1 : 4 , sep=’ ’ ) ) ) +
146 scale y cont inuous ( breaks=var . code$var . code , labels=var . code$variable ) +
147 xlab ( ’ E f f e c t ’ ) +
148 ylab ( ’Compound ’ ) +
149 theme bw(11) +
150 theme ( axis . t i c k s . x=element blank ( ) ,
151 panel . grid . minor . x=element blank ( ) , panel . grid . major . x=element blank ( ) ,
152 panel . grid . minor . y=element blank ( ) )
153
154 ggsave ( ’ . . /Plot s/Factor e f f e c t s −mlr ana l y s i s/ s imp l i f y i n g mlr−model compare2 . png ’ , p
,
155 he ight=20, width=22, un i t s=’cm ’ )
156
157 #Pred ic t ion from MLR−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
158 mlr4 . predict <− ddply (sub , ’ v a r i a b l e ’ , mlr predict , f= ’ va lue˜speed+expt ’ )
159
160 #abso l u t e changes−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
161 va lue s <− unique ( mlr4 . predict [ , c ( ’ speed ’ , ’ v a r i ab l e ’ , ’ avg ’ , ’ p r ed i c t i on ’ ) ] )
162
163 ran <− ddply ( values , ’ v a r i ab l e ’ , mutate , r . avg1=range ( avg ) [ 1 ] , r . avg2=range ( avg )
[ 2 ] ,
164 r . pred1=range ( p r ed i c t i o n ) [ 1 ] , r . pred2=range ( p r ed i c t i o n ) [ 2 ] )
165 ran <− unique ( ran )
166 ran$d i f f . avg <− ran$ r . avg2−ran$ r . avg1
167 ran$d i f f . pred <− ran$ r . pred2−ran$r . pred1
168
169 d i f f <− unique ( ran [ ran$variable %in% c ( ’ Phenyla lan ine ’ , ’ Tyros ine ’ , ’p−Creso l ’ ) ,
170 c ( ’ v a r i ab l e ’ , ’ d i f f . avg ’ , ’ d i f f . pred ’ ) ] )
171
172 abs . s l ope <− mlr4 [ mlr4$variable %in% c ( ’ Phenyla lan ine ’ , ’ Tyros ine ’ , ’p−Creso l ’ ) , ]
173 #Perecent decrease per 10 000 rpm−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
174 va lue s <− unique ( mlr4 . predict [ mlr4 . predict$class==’ I ’ ,
175 c ( ’ expt ’ , ’ speed ’ , ’ v a r i a b l e ’ , ’ avg ’ , ’ p r ed i c t i on ’ ) ] )
176 pred custom <− function (d , formula ) {
177 m <− lm(d , formula=formula )
178 s <− summary(m)
179 out <− d
180 out$ s l ope <− s$coef f ic ients [ 2 , 1 ]
181 out$ i n t <− s$coef f ic ients [ 1 , 1 ]
182 return ( out )
183 }
184 lm . pred <− ddply ( values , c ( ’ v a r i ab l e ’ , ’ expt ’ ) , pred custom ,
185 formula=” pr ed i c t i on˜speed ” )
186
187 per . d i f f custom <− function (d) {
188 d$per . d i f f <− NA
189 for ( i in 2 :nrow(d) ) {
190 d$per . d i f f [ i ] <− d$ s l ope [ i ]∗10000/d$p r ed i c t i o n [ d$speed==10000]∗100
191 }
192 return (d)
193 }
194
195 lm . pred <− ddply (lm . pred , c ( ’ v a r i ab l e ’ , ’ expt ’ ) , per . d i f f custom )
196
197 export <− unique (lm . pred [ ! i s .na(lm . pred$per . d i f f ) ,c ( ’ expt ’ , ’ v a r i ab l e ’ , ’ per . d i f f ’ ) ] )
198 #wri t e . csv ( f i l e = ’ . ./Resu l t s/Percent change per 10 000 rpm2 . csv ’ , expor t )
199
200 per . stat <− export [ export$variable != ’p−Creso l ’ , ]
201 avg . per1 <− mean( per . stat$per . d i f f [ per . stat$expt==’ expt2 ’ ] )
202 avg . per2 <− mean( per . stat$per . d i f f [ per . stat$expt==’ expt3 ’ ] )
203 sd . per1 <− sd ( per . stat$per . d i f f [ per . stat$expt==’ expt2 ’ ] )
204 sd . per2 <− sd ( per . stat$per . d i f f [ per . stat$expt==’ expt3 ’ ] )
205 #combos o f s i g n i f i c a n t terms−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
206 speed . s i g <− mlr4 [ mlr4$rname == ’ speed ’ & mlr4 [ , ’ Pr(>| t | ) ’ ] <bonfe r ron i , ]
207 speed . n s i g <− mlr4 [ mlr4$rname == ’ speed ’ & mlr4 [ , ’ Pr(>| t | ) ’ ] >=bonfe r ron i , ]
230
208 expt . s i g <− mlr4 [ mlr4$rname == ’ exptexpt3 ’ & mlr4 [ , ’ Pr(>| t | ) ’ ] <bonfe r ron i , ]
209 expt . n s i g <− mlr4 [ mlr4$rname == ’ exptexpt3 ’ & mlr4 [ , ’ Pr(>| t | ) ’ ] >=bonfe r ron i , ]
210
211 #p l o t t i n g compounds with s i g b ias−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
212 b ia s <− mlr4 . predict [ mlr4 . predict$variable %in% unique ( expt . s i g$variable ) , ]
213 b ia s$ l i n e t yp e <− ’ s ’
214 b ia s$ l i n e t yp e [ b i a s$variable %in% unique ( speed . n s i g$variable ) ] <− ’ n ’
215
216 p . b i a s <− ggp lot ( bias , aes ( x=speed , y=value , co l ou r=expt ) ) +
217 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
218 geom point ( ) +
219 geom l i n e ( aes ( x=speed , y=pred i c t i on , l i n e t yp e=l i n e t yp e ) ) +
220 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ ) +
221 scale l i n e t yp e manual ( va lue s=c ( 5 , 1 ) , guide=FALSE) +
222 scale x cont inuous ( breaks=seq (0 , 50000 , 10000) , labels=c ( 0 : 5 ) ) +
223 scale co l ou r d i s c r e t e (name=’ Experiment ’ , labels=c ( ’ Experiment 1 ’ , ’ Experiment 2 ’ ) )
+
224 theme bw(11) +
225 xlab ( ’ U l t r a c en t r i f u g e speed (10000 rpm) ’ ) +
226 ylab ( ’ Concentrat ion (mM) ’ ) +
227 theme ( legend . p o s i t i o n=’ bottom ’ )
228
229 ggsave ( ’ . . /Plot s/Factor e f f e c t s −mlr ana l y s i s/mlr4−b ia s4 . png ’ , p . b ias ,
230 he ight=20, width=20, un i t s=’cm ’ )
231
232 #Explor ing b ia sed compounds−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
233 b ia s .model <− mlr4 [ mlr4$variable %in% unique ( expt . s i g$variable ) , ]
234
235 importance <− data . frame ( variable=unique ( b i a s .model$variable ) ,
236 i n t e r c e p t=b ia s .model$Estimate [ b i a s .model$rname==’ (
In t e r c ep t ) ’ ] ,
237 b i a s=b ia s .model$Estimate [ b i a s .model$rname==’ exptexpt3 ’ ] ,
238 se=bia s .model [ , ’ Std . Error ’ ] [ b i a s .model$rname==’ exptexpt3 ’
] )
239 importance$impt <− abs ( importance$b ia s/ importance$ i n t e r c e p t∗100)
240 importance$impt . se <− abs ( importance$se/ importance$ i n t e r c e p t∗100)
241
242 #expor t ing f i l e s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
243 write . csv ( f i l e=’ . . /Resu l t s/Bias importance . csv ’ , importance )
244 write . csv ( f i l e=’ . . /Resu l t s/ f a c t o r e f f e c t−expt s i g . csv ’ , expt . s i g )
245
246 #Plo t t i n g compounds with s i g n i f i c a n t s l ope ( speed )−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
247 speed <− mlr4 . predict [ mlr4 . predict$variable %in% unique ( speed . s i g$variable ) , ]
248
249 p <− ggp lot ( speed , aes ( x=speed , y=value , co l ou r=expt ) ) +
250 geom point ( s i z e =1.5) +
251 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
252 geom l i n e ( aes ( x=speed , y=p r ed i c t i o n ) ) +
253 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=5) +
254 scale x cont inuous ( breaks=seq (0 , 50000 , 10000) , labels=c ( 0 : 5 ) ) +
255 scale co l ou r d i s c r e t e (name=’ Experiment ’ , labels=c ( ’ Experiment 1 ’ , ’ Experiment 2 ’ ) )
+
256 theme bw(10) +
257 xlab ( ’ U l t r a c en t r i f u g e speed (10000 rpm) ’ ) +
258 ylab ( ’ Concentrat ion (mM) ’ ) +
259 theme ( legend . p o s i t i o n=’ bottom ’ )
260
261 ggsave ( ’ . . /Plot s/Factor e f f e c t s −mlr ana l y s i s/mlr4−speed3 . png ’ , p ,
262 he ight=25, width=20, un i t s=’cm ’ )
263
264 #expor t speed i n s i g
265 speed . n s i g <− mlr4 [ mlr4$rname==’ speed ’ &mlr4 [ , ’ Pr(>| t | ) ’ ] > 0 . 0 6 , ]
266
267 write . csv ( f i l e=’ . . /Resu l t s/ f a c t o r e f f e c t−speed ns i g . csv ’ , speed . n s i g )
Processing method analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
231
2 #Ul t r a c en t r i f u g e Experiment 3 − Analys i s o f e f f e c t s o f proces s ing methods
3 #u l t r a c e n t r i f u g a t i o n vs f i l t r a t i o n
4
5 #Pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
6 #Se t t i n g working d i r e c t o r y
7 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data source
f i l e s / ’ )
8
9 #Sourcing requ i red func t i ons
10 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
11 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
12
13 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 2/R
Sc r i p t s/Functions ’ )
14 source ( ’ ./ANOVA−mean .R ’ )
15 source ( ’ ./kruska l w a l l i s .R ’ )
16 source ( ’ ./ l i n e a r model .R ’ )
17 source ( ’ ./tukey .R ’ )
18 source ( ’ ./ c o r r e l a t i o n .R ’ )
19
20 #load ing requ i red packages
21 require (RSQLite )
22 require ( reshape2 )
23 require ( p ly r )
24 require ( ggp lot2 )
25
26 #s e t t i n g working d i r e c t o r y
27 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
28 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
29 #Input data
30 # Choose d r i v e r
31 drv <− dbDriver ( ’ SQLite ’ )
32
33 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
34 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
35
36 expt3 <− dbGetQuery ( con , ”SELECT q . sampleID , q . type , q . grp , q . rep , q . c l a s s ,
37 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
38 FROM UC3 Data d INNER JOIN Qua l i f i e r q
39 ON d . f i l e = q . f i l e
40 INNER JOIN Rank r
41 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
42 WHERE r . Conf idence = 1 AND q . expt = ’ expt3 ’
43 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
44 ORDER BY q . type ; ” )
45
46 dbDisconnect ( con )
47
48 #Data c lean up
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
49 c l ean <− data cleanup ( expt3 , convert .NA=TRUE)
50
51 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
52 stat <− d e s c r i p t i v e . stat ( c lean , data . type=’ long ’ , variable=c ( ’ type ’ , ’ v a r i ab l e ’ ) )
53
54 #Pro f i l e overview−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
55 plot . data <− stat
56 plot . data$ l a b e l [ stat$type %in% LETTERS [ 2 : 6 ] ] <− ’ u l t r a c e n t r i f u g e ’
57 plot . data$ l a b e l [ stat$type == ’A ’ ] <− ’ s e r i a l f i l t e r ’
58 #p l o t . data$ type <− f a c t o r ( p l o t . data$ type , l e v e l s=c ( ’H’ , ’ I ’ ,LETTERS[ 1 : 5 ] ) )
59
60 p <− ggp lot (plot . data , aes ( x=speed , y=avg , co l our=l a b e l ) ) +
61 geom point ( aes ( y=value ) ) +
62 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
63 f a c e t wrap (˜variable , scale=’ f r e e ’ ) +
64 scale co l ou r d i s c r e t e (name=’ Process ’ , guide=guide legend ( r e v e r s e=TRUE) ) +
65 theme bw(14) +
232
66 xlab ( ’ Sample ’ ) +
67 ylab ( ’ Concentrat ion (mM) ’ )
68
69 ggsave ( ’ . . /Plot s/Proce s s ing method comparison/P r o f i l e overview . png ’ , p ,
70 he ight=30, width=40, un i t s=’cm ’ )
71
72 #ANOVA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73
74 #f i l t r a t i o n proces se s vs u l t r a c e n t r i f u g e proces se s
75 anova <− ddply ( stat , ’ v a r i a b l e ’ , aov custom , ’ c l a s s ’ )
76 s i g . anova <− anova [ anova$p . va l <= 0 . 0 5 , ]
77 write . csv ( f i l e=’ . . /Resu l t s/anova−proce s s . csv ’ , s i g . anova)
78
79 #tukey ’ s HSD t e s t on f i l t r a t i o n vs UC proces se s
80 tukey . data <− stat [ stat$variable %in% s i g . anova$variable , ]
81 tukey <− ddply ( tukey . data , ’ v a r i a b l e ’ , tukey custom , ’ type ’ )
82
83 bon f e r r on i <− 0 .05/length (unique ( tukey . data$type ) )
84 s i g . tukey <− tukey [ tukey$p . va l <= bonfe r ron i , ]
85 i n s i g . tukey <− tukey [ tukey$p . va l > bonfe r ron i , ]
86
87 #See which compounds do not d i f f e r s i g n i f i c a n t l y between
88 #f i l t e r −processed and low speed
89 d i f f <− s i g . tukey [ s i g . tukey$g1 %in% c ( ’S ’ , ’X ’ ) &
90 s i g . tukey$g2 %in% c ( ’S ’ , ’X ’ ) , ]
91 same <− i n s i g . tukey [ i n s i g . tukey$g1 %in% c ( ’S ’ , ’X ’ ) &
92 i n s i g . tukey$g2 %in% c ( ’S ’ , ’X ’ ) , ]
93 write . csv ( f i l e=’ . . /Resu l t s/tukey−proce s s . csv ’ , same )
94
95 #look ing to see i f f i l t r a t i o n samples are s im i l a r to low UC speeds
96 low <− ddply ( stat [ stat$speed <= 30000 , ] , ’ v a r i ab l e ’ , aov custom , ’ speed ’ )
97 s i g . low <− low [ low$p . va l <= 0 . 0 5 , ]
98 i n s i g . low <− low [ low$p . va l > 0 . 0 5 , ]
99 write . csv ( f i l e=’ . . /Resu l t s/anova−proce s s f i l t vs low speed . csv ’ , s i g . low )
100
101 #l i n e a r r e l a t i on s h i p s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
102 #see ing i f l i n e a r r e l a t i o n s h i p s are maintained even when inc l ud ing
103 #f i l t r a t i o n samples −−> t r e a t i n g f i l t r a t i o n samples as u l t r a f i l t r a t i o n speed 0
104 #lumping s e r i a l f i l t r a t i o n and s ing l e−s t age f i l t r a t i o n toge ther , s ince they do not
105 #d i f f e r t ha t much
106
107 lm . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , lm custom , ’ speed ’ )
108 lm . s i g <− lm . r e s u l t [ lm . r e s u l t $ s l ope . p <= 0 . 0 5 , ]
109 lm . r e s u l t $ l i n e t yp e <− ’ ns ’
110 lm . r e s u l t $ l i n e t yp e [ lm . r e s u l t $variable %in% lm . s i g$variable ] <− ’ s ’
111
112 #compounds t ha t were l i n e a r in UC samples
113 uc . lm <− read . csv ( ’ . . /Resu l t s/ c o r r e l a t i o n−speed . csv ’ )
114 uc . lm <− as . character ( uc . lm$variable )
115
116 #see ing i f they are s t i l l l i n e a r with add i t i on o f f i l t r a t i o n samples
117 #any uc . lm stop be ing l i n e a r ?
118 any( uc . lm [ ! uc . lm %in% lm . s i g$variable ] ) #no
119 #any compounds become l i n e a r a f t e r in t roduc t i on o f f i l t e r −processed samples?
120 lm . s i g [ !lm . s i g$variable %in% uc . lm , ]
121
122 co r r . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , c o r r custom ,
123 x=’ speed ’ , y=’ va lue ’ , methods=’ pearson ’ )
124 co r r . s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l <= 0 . 0 5 , ]
125 co r r . i n s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l > 0 . 0 5 , ]
126 write . csv ( f i l e=’ . . /Resu l t s/ c o r r e l a t i o n−proce s s . csv ’ , c o r r . s i g )
127
128 #cor r e l a t i on o f compounds t ha t were l i n e a r in UC ana l y s i s
129 com . co r r <− co r r . s i g [ c o r r . s i g$variable %in% uc . lm , ]
130 uncom . co r r <− co r r . s i g [ ! co r r . s i g$variable %in% uc . lm , ]
131 write . csv ( f i l e=’ . . /Resu l t s/common co r r e l a t i o n−proce s s . csv ’ , com . co r r )
132 write . csv ( f i l e=’ . . /Resu l t s/uncommon co r r e l a t i o n−proce s s . csv ’ , uncom . co r r )
133
233
134 p . lm <− ggp lot (plot . data , aes ( x=speed , y=avg , co l our=l a b e l ) ) +
135 geom abline (data=lm . r e s u l t , aes ( s l ope=slope , i n t e r c e p t=int ,
136 l i n e t yp e=l i n e t yp e ) , co l ou r=’ grey50 ’ , ) +
137 geom point ( aes ( y=value ) , p o s i t i o n=po s i t i o n dodge ( width=8000) ) +
138 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) , p o s i t i o n=po s i t i o n dodge ( ) ) +
139 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
140 scale x cont inuous ( breaks=seq (0 , 50000 , 10000) ) +
141 f a c e t wrap (˜variable , scale=’ f r e e ’ , ncol=7) +
142 theme bw(14) +
143 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ) +
144 xlab ( ’ U l t r a c e n t r i f u g a t i o n Speed (rpm) ’ ) +
145 ylab ( ’Mean Concentrat ion (mM) ’ )
146
147 ggsave ( ’ . . /Plot s/Proce s s ing method comparison/Linear r e l a t i o n s h i p . png ’ , p . lm ,
148 he ight=40, width=35, un i t s=’cm ’ )
Centrifugal force analysis.R
1 #///////////////////////////////////////////////////////////////////////////////
2 #Ul t r a c en t r i f u g e Experiment 3 − Analys i s o f e f f e c t s o f c e n t r i f u g a l f o r ce
3 #d i f f e r e n t speeds
4
5 #Pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
6 #Se t t i n g working d i r e c t o r y
7 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data source
f i l e s / ’ )
8
9 #Sourcing requ i red func t i ons
10 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
11 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
12
13 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 2/R
Sc r i p t s/Functions ’ )
14 source ( ’ ./ANOVA−mean .R ’ )
15 source ( ’ ./kruska l w a l l i s .R ’ )
16 source ( ’ ./ l i n e a r model .R ’ )
17 source ( ’ ./tukey .R ’ )
18 source ( ’ ./ c o r r e l a t i o n .R ’ )
19
20 #load ing requ i red packages
21 require (RSQLite )
22 require ( reshape2 )
23 require ( p ly r )
24 require ( ggp lot2 )
25
26 #s e t t i n g working d i r e c t o r y
27 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
28 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
29 #Input data
30 # Choose d r i v e r
31 drv <− dbDriver ( ’ SQLite ’ )
32
33 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
34 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
35
36 expt3 <− dbGetQuery ( con , ”SELECT q . sampleID , q . type , q . grp , q . rep , q . c l a s s ,
37 q . speed , q . process , q . f i l t e r , q . expt , c . Type , m.Weight ,
38 d . va r i ab l e , d . va lue
39 FROM UC3 Data d INNER JOIN Qua l i f i e r q
40 ON d . f i l e = q . f i l e
41 INNER JOIN Rank r
42 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
43 INNER JOIN Cmpd i n f o c
44 ON d . va r i ab l e = c .Compound
45 INNER JOIN Mol wt m
46 ON d . va r i ab l e = m. va r i ab l e
47 WHERE r . Conf idence = 1 AND q . expt = ’ expt3 ’
234
48 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
49 ORDER BY q . type ; ” )
50
51 dbDisconnect ( con )
52
53 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
54 c l ean <− data cleanup ( expt3 , convert .NA=TRUE)
55
56 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
57 stat <− d e s c r i p t i v e . stat ( c lean , data . type=’ long ’ , variable=c ( ’ type ’ , ’ v a r i ab l e ’ ) )
58
59 #p r o f i l e overview−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
60 #p l o t t i n g compound l e v e l s at d i f f UC speeds
61 p . uc <− ggp lot ( stat , aes ( x=speed , y=avg ) ) +
62 geom point ( aes ( y=value ) ) +
63 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
64 f a c e t wrap (˜variable , scale=’ f r e e ’ ) +
65 theme bw(14) +
66 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ) +
67 xlab ( ’ U l t r a c e n t r i f u g a t i o n Speed (rpm) ’ ) +
68 ylab ( ’Mean Concentrat ion (mM) ’ )
69
70 ggsave ( ’ . . /Plot s/Speed comparison/P r o f i l e overview2 . png ’ , p . uc , he ight =35,width=40,
un i t s=’cm ’ )
71
72 #Linear r e l a t i on s h i p−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73 #Looking f o r l i n e a r r e l a t i o n s h i p between concentra t ion and speed
74
75 lm . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , lm custom , ’ speed ’ )
76 lm . r e s u l t $ l i n e t yp e <− ’ ns ’
77 lm . r e s u l t $ l i n e t yp e [ lm . r e s u l t $ s l ope . p < 0 . 0 6 ] <− ’ s ’
78
79 lm . s i g <− lm . r e s u l t [ lm . r e s u l t $ s l ope . p < 0 . 0 6 , ]
80 lm . n s i g <− lm . r e s u l t [ !lm . r e s u l t $variable %in% lm . s i g$variable , ]
81 #wri t e . csv ( f i l e = ’ . ./Resu l t s/lm non−s i g n i f i c a n t . csv ’ , lm . ns i g )
82
83 #cor r e l a t i on
84 co r r . r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , c o r r custom ,
85 x=’ speed ’ , y=’ va lue ’ , methods=’ pearson ’ )
86 co r r . s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l <= 0 . 0 5 , ]
87 co r r . i n s i g <− co r r . r e s u l t [ c o r r . r e s u l t $p . va l > 0 . 0 5 , ]
88 #wri t e . csv ( f i l e = ’ . ./Resu l t s/ co r r e l a t i on−speed2 . csv ’ , corr . s i g )
89 #wri t e . csv ( f i l e = ’ . ./Resu l t s/weak cor r e l a t i on−speed2 . csv ’ , corr . i n s i g )
90
91 #p l o t t i n g lm−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
92 p . lm <− ggp lot ( stat , aes ( x=speed , y=avg ) ) +
93 geom point ( aes ( y=value ) ) +
94 #geom errorbar ( aes (ymax=ymax , ymin=ymin) ) +
95 stat smooth ( aes ( y=value ) , method=’ lm ’ , co l ou r=’ grey85 ’ ) +
96 geom abline (data=lm . r e s u l t , aes ( s l ope=slope , i n t e r c e p t=int ,
97 co l ou r=l ine type , l i n e t yp e=l i n e t yp e ) ) +
98 scale l i n e t yp e manual ( va lue s=c ( 2 , 1 ) ) +
99 scale co l ou r manual ( va lue s=c ( ’ b lack ’ , ’ red ’ ) ) +
100 scale x cont inuous ( breaks=seq (10000 , 50000 , 10000) ) +
101 f a c e t wrap (˜variable , scale=’ f r e e ’ ) +
102 theme bw(14) +
103 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ) +
104 xlab ( ’ U l t r a c e n t r i f u g a t i o n Speed (rpm) ’ ) +
105 ylab ( ’Mean Concentrat ion (mM) ’ )
106
107 ggsave ( ’ . . /Plot s/Speed comparison/ l i n e a r r e l a t i o n s h i p 4 . png ’ , p . lm ,
108 he ight=35, width=40, un i t s=’cm ’ )
109
110 plot . data <− stat [ stat$variable %in% unique (lm . s i g$variable ) , ]
111 p . s ig lm <− ggp lot (plot . data , aes ( speed , y=avg ) ) +
112 geom point ( aes ( y=value ) ) +
113 stat smooth ( aes ( y=value ) , method=’ lm ’ , co l ou r=’ black ’ ) +
114 scale x cont inuous ( breaks=seq (0 , 50000 , 10000) ) +
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115 f a c e t wrap (˜variable , scale=’ f r e e ’ , ncol=6) +
116 theme bw(14) +
117 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ) +
118 xlab ( ’ U l t r a c en t r i f u g e Speed (rpm) ’ ) +
119 ylab ( ’Mean Concentrat ion (mM) ’ )
120
121 ggsave ( ’ . . /Plot s/Speed comparison/ s i g l i n e a r r e l a t i o n s h i p 2 . png ’ , p . s iglm ,
122 he ight=40, width=35, un i t s=’cm ’ )
123
124 #Sources o f var ia t i on−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
125 #Kruskal w a l l i s t e s t
126 kw <− ddply ( stat , ’ v a r i a b l e ’ , k ruska l custom , ’ type ’ )
127 kw . s i g <− kw [kw$p . va l <= 0 . 0 5 , ]
128 unique (kw$variable )
129
130 #ANOVA
131 anova <− ddply ( stat , ’ v a r i a b l e ’ , aov custom , ’ type ’ )
132 anova . s i g <− anova [ anova$p . va l <= 0 . 0 5 , ]
133 write . csv ( f i l e=’ . . /Resu l t s/uc anova . csv ’ , anova . s i g )
134
135 #Post hoc , Tukey ’ s HSD to see where d i f f e r e n c e i s coming from
136 s i g . data <− stat [ stat$variable %in% anova . s i g$variable , ]
137 tukey <− ddply ( s i g . data , ’ v a r i a b l e ’ , tukey custom , ’ type ’ )
138 tukey . s i g <− tukey [ tukey$p . va l < 0 . 0 5 , ]
139
140 plot . data <− stat [ stat$variable %in% anova . s i g$variable , ]
141 lm . anova <− lm . r e s u l t [ lm . r e s u l t $variable %in% anova . s i g$variable , ]
142
143 p . anova <− ggp lot (plot . data , aes ( x=speed , y=avg ) ) +
144 geom point ( aes ( y=value ) ) +
145 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
146 geom abline (data=lm . anova , aes ( s l ope=s lope , i n t e r c e p t=int ,
147 co l our=l ine type , l i n e t yp e=l i n e t yp e ) ) +
148 scale co l ou r manual ( va lue s=’ red ’ ) +
149 scale x cont inuous ( breaks=seq (0 ,50000 ,10000) ) +
150 f a c e t wrap (˜variable , scale=’ f r e e ’ , ncol=5) +
151 theme bw(14) +
152 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ) +
153 xlab ( ’ U l t r a c e n t r i f u g a t i o n Speed (rpm) ’ ) +
154 ylab ( ’Mean Concentrat ion (mM) ’ )
155
156 ggsave ( ’ . . /Plot s/Speed comparison/UC−anova2 . png ’ , p . anova ,
157 he ight=30,width=25, un i t s=’cm ’ )
158
159 #Range o f changes as percent o f avg−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
160 r <− stat
161 r <− ddply ( r , ’ v a r i ab l e ’ , mutate , t . avg=mean( va lue ) , max=max( avg ) , min=min( avg ) )
162 r <− ddply ( r , ’ v a r i ab l e ’ , mutate , p .max=(max−t . avg )/t . avg∗100 ,
163 p .min=(min−t . avg )/t . avg∗100)
164
165 p . range <− unique ( r [ , c ( ’ v a r i ab l e ’ , ’Type ’ , ’Weight ’ , ’ t . avg ’ , ’ p .max ’ , ’ p . min ’ ) ] )
166 p . range$ s l ope = NULL
167 p . range$ i n t = NULL
168
169 for ( i in unique (p . range$variable ) ) {
170 p . range$ s l ope [ p . range$variable==i ] <− lm . r e s u l t $ s l ope [ lm . r e s u l t $variable==i ]
171 p . range$ i n t [ p . range$variable==i ] <− lm . r e s u l t $ i n t [ lm . r e s u l t $variable==i ]
172 }
173
174 percent custom <− function (d , s l ope=’ s l ope ’ , i n t=’ i n t ’ , x ) {
175 y <− d [ , s l ope ] ∗x+d [ , i n t ]
176 per <− ( y [2]−y [ 1 ] ) /y [ 1 ] ∗100
177
178 out <− d
179 out$perc . change <− per
180 out$abs . change <− abs ( per )
181 return ( out )
182 }
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183
184 percent <− ddply (p . range , ’ v a r i ab l e ’ , percent custom ,
185 x=seq (10000 , 50000 , 10000) )
186
187 #wri t e . csv ( f i l e = ’ . ./Resu l t s/Percent change per 10 000 rpm . csv ’ , percent )
188
189 #abso l u t e changes−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
190 va lue s <− unique ( r [ , c ( ’ speed ’ , ’ v a r i ab l e ’ , ’ avg ’ ) ] )
191
192 r2 <− ddply ( values , ’ v a r i ab l e ’ , mutate , r .max=range ( avg ) [ 2 ] , r .min=range ( avg ) [ 1 ] )
193 r2 <− unique ( r2 [ , c ( ’ v a r i ab l e ’ , ’ r .max ’ , ’ r . min ’ ) ] )
194 r2$d i f f <− r2$ r .max−r2$ r .min
195
196 #con t ro l prec i s ion−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
197 c t r l <− stat [ stat$speed == 0 , ]
198 c t r l <− ddply ( c t r l , ’ v a r i a b l e ’ , mutate ,
199 max=max( va lue ) , min=min( va lue ) )
200 c t r l <− ddply ( c t r l , ’ v a r i ab l e ’ , mutate , p .max=(max−avg )/avg∗100 ,
201 p .min=(min−avg )/avg∗100 , p . range=(max−min)/avg∗100)
202 c t r l <− unique ( c t r l [ , c ( ’ v a r i ab l e ’ , ’ avg ’ , ’ s e ’ , ’max ’ , ’min ’ , ’ p .max ’ , ’ p . min ’ , ’p . range ’ )
] )
203
204 #see i f percent change can be ca t e go r i z e d in to −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
205 #compound c l a s s or molecular weight
206 percent . s i g <− percent [ percent$variable %in% lm . s i g$variable , ]
207
208 s i g . dec <− percent . s i g [ percent . s i g$perc . change < 0 , ]
209
210 percent . stat <− data . frame ( avg=mean( s i g . dec$abs . change ) ,
211 stdev=sd ( s i g . dec$abs . change ) ,
212 max=max( s i g . dec$abs . change ) ,
213 min=min( s i g . dec$abs . change ) )
214
215 wt . lm <− lm(data=s i g . dec , formula=Weight˜abs . change )
216 wt . f i t <− anova(wt . lm)
217
218 wt . c o r r <− cor . t e s t ( s i g . dec$Weight , percent$abs . change )
219
220 p . percent <− ggp lot ( s i g . dec , aes ( x=Weight , y=abs . change ) ) +
221 stat smooth (method=’ lm ’ )+
222 geom point ( ) +
223 geom text ( aes ( l a b e l=variable ) ) +
224 theme bw(14) +
225 xlab ( ’ Molecular weight ( g/mol ) ’ ) +
226 ylab ( ’ Absolute Pecent Decrease ’ ) +
227
228 ggsave ( ’ . . /Plot s/ trend by weight . png ’ , p . percent , he ight=15, width=30, un i t s=’cm ’ )
229
230 class . lm <− lm(data=percent , formula=Type˜abs . change )
231
232 p . percent2 <− ggp lot ( s i g . dec , aes ( x=Type , y=abs . change ) ) +
233 stat boxplot ( ) +
234 geom point ( ) +
235 theme bw(14) +
236 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
Cross-experiment analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Comparison o f p r o f i l e s from Expt 3 , Expt 1 , Expt 2 and pre l iminary expt
3
4 #pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
5 #Se t t i n g working d i r e c t o r y
6 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
7
8 #Sourcing requ i red func t i ons
9 source ( ’ funct ion−data cleanup .R ’ )
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10 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
11
12 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 2/R
Sc r i p t s/Functions ’ )
13 source ( ’ ./ANOVA−mean .R ’ )
14 source ( ’ ./kruska l w a l l i s .R ’ )
15 source ( ’ ./ l i n e a r model .R ’ )
16 source ( ’ ./tukey .R ’ )
17 source ( ’ ./ c o r r e l a t i o n .R ’ )
18
19 #load ing requ i red packages
20 require (RSQLite )
21 require ( reshape2 )
22 require ( p ly r )
23 require ( ggp lot2 )
24
25 #s e t t i n g working d i r e c t o r y
26 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
27 source ( ’ . . /Functions/mul t ip l e l i n e a r r e g r e s s i o n .R ’ )
28 source ( ’ . . /Functions/mlr p r ed i c t i on .R ’ )
29 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
30 #Input data
31 # Choose d r i v e r
32 drv <− dbDriver ( ’ SQLite ’ )
33
34 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
35 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
36
37 input <− dbGetQuery ( con , ”SELECT q . SampleID , q . type , q . grp , q . rep , q . c l a s s ,
38 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
39 FROM UC3 Data d INNER JOIN Qua l i f i e r q
40 ON d . f i l e = q . f i l e
41 INNER JOIN Rank r
42 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
43 WHERE
44 (q . expt == ’ expt1 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
45 (q . expt == ’ expt2 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
46 q . expt IN ( ’ expt3 ’ , ’ pre l iminary ’ ) AND r . Conf idence = 1
47 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
48 ORDER BY q . type ; ” )
49
50 input2 <− dbGetQuery ( con , ”SELECT q . SampleID , q . type , q . grp , q . rep , q . c l a s s ,
51 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
52 FROM UC3 Data d INNER JOIN Qua l i f i e r q
53 ON d . f i l e = q . f i l e
54 INNER JOIN Rank r
55 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
56 WHERE
57 (q . expt == ’ expt2 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
58 q . expt = ’ expt3 ’ AND r . Conf idence = 1
59 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
60 ORDER BY q . type ; ” )
61
62
63 dbDisconnect ( con )
64
65 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
66 c l ean <− data cleanup ( input2 , convert .NA=TRUE)
67
68 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
69 stat <− ddply ( c lean , ’ expt ’ , d e s c r i p t i v e . stat , data . type=’ long ’ ,
70 variable=c ( ’ type ’ , ’ v a r i ab l e ’ ) )
71
72 #p r o f i l e overview−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73 p . uc2 <− ggp lot ( stat , aes ( x=speed , y=avg , co l our=expt ) ) +
74 geom point ( aes ( y=value ) , alpha =0.8) +
75 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
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76 f a c e t wrap (˜variable , scale=’ f r e e ’ ) +
77 theme bw(14) +
78 theme ( axis . text . x=element text ( ang le=−45, h ju s t =0, v ju s t=1) ,
79 legend . p o s i t i o n=’ bottom ’ ) +
80 xlab ( ’ U l t r a c e n t r i f u g a t i o n Speed (rpm) ’ ) +
81 ylab ( ’Mean Concentrat ion (mM) ’ )
82
83 ggsave ( ’ . . /Plot s/Cross−experiment comparison/Combined expt−expt2 , expt3 2 . png ’ ,
84 p . uc2 , he ight =35,width=35, un i t s=’cm ’ )
85
86 #Removing compounds found only in one o f Expt 2 and Expt 3−−−−−−−−−−−−−−−−−−−−−−−
87 expt2 . var <− unique ( stat$variable [ stat$expt==’ expt2 ’ ] )
88 expt3 . var <− unique ( stat$variable [ stat$expt==’ expt3 ’ ] )
89
90 remove <− expt2 . var [ ! expt2 . var %in% expt3 . var ]
91 sub <− stat [ stat$variable != remove , ]
92
93 #Gett ing equat ion fo r mu l t i p l e l i n e a r r e g r e s s i on plane−−−−−−−−−−−−−−−−−−−−−−−−−−−−
94 #check ing f o r b i a s and i n t e r a c t i on
95 mlr <− ddply (sub , ’ v a r i a b l e ’ , mlr custom , f=’ value˜speed+expt+speed : expt ’ )
96
97 #compounds with i n s i g n i f i c a n t s l ope
98 ns i g . s l ope <− mlr [ mlr [ , ’ Pr(>| t | ) ’ ] > 0 .05 & mlr$rname == ’ speed ’ , ]
99
100 #removing compounds with i n s i g n i f i c a n t s l ope (don ’ t need to be p l o t t e d )
101 mlr . sub <− mlr [ !mlr$variable %in% unique ( n s i g . s l ope$variable ) , ]
102
103 #ge t t i n g compounds with only s i g n i f i c a n t b ias , i n t e r a c t i on or both
104 s . b i a s <− unique (mlr . sub$variable [ mlr . sub [ , ’ Pr(>| t | ) ’ ] < 0 .06
105 & mlr . sub$rname == ’ exptexpt3 ’ ] )
106 n . intxn <− unique (mlr . sub$variable [ mlr . sub [ , ’ Pr(>| t | ) ’ ] > 0 .06
107 & mlr . sub$rname == ’ speed : exptexpt3 ’ ] )
108 n . b i a s <− unique (mlr . sub$variable [ mlr . sub [ , ’ Pr(>| t | ) ’ ] > 0 .06
109 & mlr . sub$rname == ’ exptexpt3 ’ ] )
110 s . intxn <− unique (mlr . sub$variable [ mlr . sub [ , ’ Pr(>| t | ) ’ ] < 0 .06
111 & mlr . sub$rname == ’ speed : exptexpt3 ’ ] )
112
113 b ia s <− unique (mlr . sub$variable [ mlr . sub$variable %in% s . b i a s
114 & mlr . sub$variable %in% n . intxn ] )
115 intxn <− unique (mlr . sub$variable [ mlr . sub$variable %in% n . b i a s
116 & mlr . sub$variable %in% s . intxn ] )
117 both <− unique (mlr . sub$variable [ mlr . sub$variable %in% s . b i a s
118 & mlr . sub$variable %in% s . intxn ] )
119 ne i t h e r <− unique (mlr . sub$variable [ mlr . sub$variable %in% n . b i a s
120 & mlr . sub$variable %in% n . intxn ] )
121
122 #Export ing compounds t ha t f o l l owed same trend in both experiments
123 export . n e i t h e r <− mlr . sub [ mlr . sub$variable %in% ne i ther , c ( 1 , 5 , 6 ) ]
124 export . n e i t h e r <− dcast ( export . ne i the r , variable˜rname , va lue . var=’Pr(>| t | ) ’ )
125 write . csv ( f i l e=’ . . /Resu l t s/mlr ne i t h e r . csv ’ , export . n e i t h e r )
126
127 #pred i c t i n g va lue s a long the mu l t i p l e l i n e a r r e g r e s s i ong plane−−−−−−−−−−−−−−−−−−−−
128 mlr . predict <− ddply (sub , ’ v a r i a b l e ’ , mlr predict , f= ’ va lue˜speed+expt+speed : expt ’ )
129
130 #v i s u a l i z i n g b i a s and in t e rac t i on−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
131 plot . data <− mlr . predict
132 plot . data . b i a s <− plot . data [ plot . data$variable %in% bias , ]
133 plot . data . intxn <− plot . data [ plot . data$variable %in% intxn , ]
134 plot . data . both <− plot . data [ plot . data$variable %in% both , ]
135 plot . data . n e i t h e r <− plot . data [ plot . data$variable %in% ne i the r , ]
136
137 p <− ggp lot (plot . data . both , aes ( x=speed , y=value , co l ou r=expt ) ) +
138 geom point ( ) +
139 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
140 geom l i n e ( aes ( x=speed , y=p r ed i c t i o n ) ) +
141 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ ) +
142 scale x cont inuous ( breaks=seq (0 , 50000 , 10000) ) +
143 scale co l ou r d i s c r e t e (name=’ Experiment ’ , labels=c ( ’ Experiment 1 ’ , ’ Experiment 2 ’ ) )
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+
144 theme bw(11) +
145 xlab ( ’ U l t r a c en t r i f u g e speed (rpm) ’ ) +
146 ylab ( ’ Concentrat ion (mM) ’ ) +
147 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
148
149 ggsave ( ’ . . /Plot s/Cross−experiment comparison/mul t ip l e l i n e a r r e g r e s s i o n/mlr b i a s
and i n t e r a c t i o n 2 . png ’ , p ,
150 he ight =10.5 , width=18, un i t s=’cm ’ )
Cross-experiment analysis-pca.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Cross−experiment ana ly s i s−pca
3 #Comparison o f p r o f i l e s from Expt 1 , Expt 2 and pre l iminary expt
4
5 #pre−amble−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
6
7 #load ing requr i ed packages
8 require (RSQLite )
9 require ( ggp lot2 )
10
11 #sourc ing requ i red func t i ons
12 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/ ’ )
13 source ( ’ funct ion−pca .R ’ )
14 source ( ’ funct ion−p l o t t i n g 2D sco r e .R ’ )
15 source ( ’ funct ion−p l o t t i n g 2D load ing .R ’ )
16 source ( ’ funct ion−pca d i a gno s t i c s .R ’ )
17 source ( ’ funct ion−data cleanup .R ’ )
18 source ( ’ funct ion−s c a l i n g .R ’ )
19
20
21 #s e t t i n g working d i r e c t o r y
22 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Ul t r a c en t r i f u g a t i o n Samples/Experiment 3/R
Sc r i p t s/Analys i s ’ )
23 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
24 #Input data
25 # Choose d r i v e r
26 drv <− dbDriver ( ’ SQLite ’ )
27
28 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
29 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
30
31 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . type , q . grp , q . rep , q . c l a s s ,
32 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
33 FROM UC3 Data d INNER JOIN Qua l i f i e r q
34 ON d . f i l e = q . f i l e
35 INNER JOIN Rank r
36 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
37 WHERE
38 (q . expt == ’ expt1 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
39 (q . expt == ’ expt2 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
40 q . expt IN ( ’ expt3 ’ , ’ pre l iminary ’ ) AND r . Conf idence = 1
41 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
42 ORDER BY q . type ; ” )
43
44 input2 <− dbGetQuery ( con , ”SELECT q . SampleID , q . type , q . grp , q . rep , q . c l a s s ,
45 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
46 FROM UC3 Data d INNER JOIN Qua l i f i e r q
47 ON d . f i l e = q . f i l e
48 INNER JOIN Rank r
49 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
50 WHERE
51 (q . expt == ’ expt2 ’ AND q . c l a s s != ’ I I ’ AND r . Conf idence = 1) OR
52 q . expt = ’ expt3 ’ AND r . Conf idence = 1
53 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
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54 ORDER BY q . type ; ” )
55
56 expt3 <− dbGetQuery ( con , ”SELECT q . SampleID , q . type , q . grp , q . rep , q . c l a s s ,
57 q . speed , q . process , q . f i l t e r , q . expt , d . va r i ab l e , d . va lue
58 FROM UC3 Data d INNER JOIN Qua l i f i e r q
59 ON d . f i l e = q . f i l e
60 INNER JOIN Rank r
61 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
62 WHERE
63 q . expt = ’ expt3 ’ AND r . Conf idence = 1
64 AND NOT (d . v a r i a b l e = ’Formate ’ AND d . value > 0 . 3 )
65 ORDER BY q . type ; ” )
66 dbDisconnect ( con )
67
68
69 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
70 c l ean <− data cleanup ( expt3 , convert .NA=FALSE)
71
72 #performing the PCA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73 pca . data = perform pca ( c lean , sampleID=’ sampleID ’ ,
74 variable=’ va r i ab l e ’ , va lue=’ va lue ’ ,
75 form . y=c ( ’ sampleID ’ , ’ type ’ , ’ grp ’ , ’ rep ’ , ’ c l a s s ’ ,
76 ’ speed ’ , ’ p roc e s s ’ , ’ f i l t e r ’ , ’ expt ’ ) ,
77 form . x=’ va r i ab l e ’ ,
78 scale=’UV’ , c en t e r=TRUE, convert .NA=TRUE)
79
80 #performing d i a gno s t i c s on PCA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
81 d i a gno s t i c . r e s u l t s = s c r e e plot ( pca . data )
82
83 #unpacking the d i a gno s t i c r e s u l t s
84 d i a gno s t i c . number = d i a gno s t i c . r e s u l t s [ [ ’ number ’ ] ]
85 d i a gno s t i c . exp la ined = d i a gno s t i c . r e s u l t s [ [ ’ exp la ined ’ ] ]
86 d i a gno s t i c . plot = d i agno s t i c . r e s u l t s [ [ ’ p l o t ’ ] ]
87 d i a gno s t i c . plot = d i agno s t i c . plot + g g t i t l e ( ’ Scree Plot (UVN) ’ )
88
89 #pr in t i n g out d i a gno s t i c r e s u l t s
90 print ( d i a gno s t i c . number )
91 print ( d i a gno s t i c . exp la ined )
92 print ( d i a gno s t i c . plot )
93
94 #p l o t t i n g PCA−processed data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
95 #Score p l o t 2D
96 # Note : Arguments f o r score p l o t func t i on are
97 # (pca data , q u a l i f i e r data , PCs=1:4 , co lour=NULL, shape=NULL, s i z e=NULL,
98 # l a b e l=NULL, t i t l e=NULL, legend . o r i=’ hor i zon ta l ’ , b l a c k whi te=FALSE)
99
100 s co r e plot = sco r e plot 2d( pca . data , PCs=1:4 ,
101 co l our=’ speed ’ , shape=’ expt ’ ,
102 legend . o r i= ’ v e r t i c a l ’ ,
103 black white=FALSE)
104
105 p . s c o r e <− s c o r e plot [ [ ’ p ’ ] ]
106 c o l l e c t e d . data <− s c o r e plot [ [ ’ c o l l e c t e d . data ’ ] ]
107
108 p . s c o r e = p . s co r e +
109 #sca l e shape d i s c r e t e (name=’Process condi t ion ’ ,
110 # l a b e l s=c ( ’ Pre−spun , UC−processed ’ ,
111 # ’Not pre−spun , UC−processed ’ , ’ F i l t e r−processed ’ ) )
+
112 scale shape d i s c r e t e (name=’Pre−proce s s treatment ’ , labels=c ( ’ Pre−spun ’ , ’Not pre−
spun ’ ) ) +
113 #sca l e shape d i s c r e t e (name=’Experiment ’ , l a b e l s=c ( ’ Experiment 1 ’ , ’ Experiment 2 ’ , ’
Prel iminary ’ ) ) +
114 gu ides ( co l our=guide co lourbar ( ’ Speed (rpm) ’ ) ) +
115 theme bw(14)
116
117 ggsave ( ’ . . /Plot s/Cross−experiment comparison/pca/ score−expt3 . png ’ ,p . score ,
118 he ight=10, width=25, un i t s=’cm ’ )
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C.3 Effects of Varying Inoculum Biomass Proportions
Data source.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Creating database f o r Biomass Samples
3
4 #sourc ing requ i red func t i ons
5 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
6 source ( ’ funct ion−summary p r ep ro c e s s i ng .R ’ )
7
8 #load ing requ i red packages
9 require ( reshape2 )
10 require (RSQLite )
11
12 #Se t t i n g working d i r e c t o r y
13 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass samples/R Sc r i p t s/Data source f i l e s ’
)
14
15 #preproces s ing raw data
16 raw <− summary . p r ep roce s s ( ’ c oncen t ra t i on s2 . csv ’ )
17
18 data <− raw [ [ ’ data ’ ] ]
19
20 melt . data <− melt (data )
21 melt . data$value <− melt . data$value/0 .9
22
23 #Writing q u a l i f i e r s
24 #reading sample names and scan order
25 sample . l i s t <− read . csv ( ’ Sample l i s t . csv ’ )
26 scan <− read . csv ( ’ Scan order . csv ’ )
27
28 #de f i n in g p r o f i l e s according to scan order
29 q u a l i f i e r <− data . frame ( f i l e=data$ f i l e , sampleID=scan$sampleID )
30
31 #re−order ing by sample ID
32 q u a l i f i e r <− q u a l i f i e r [ order ( q u a l i f i e r $sampleID ) , ]
33
34 #adding sample name to q u a l i f i e r
35 q u a l i f i e r $sample name <− sample . l i s t $sample name
36
37 q u a l i f i e r $run <− q u a l i f i e r $sample name
38 q u a l i f i e r $run <− gsub ( ’ .∗(?<=Run ) ( [0−9]{2}) . ∗ ’ , ’ \\1 ’ , q u a l i f i e r $run , p e r l=TRUE)
39
40 q u a l i f i e r $ v e s s e l <− q u a l i f i e r $sample name
41 q u a l i f i e r $ v e s s e l <− gsub ( ’ .∗(?<=V) ( [0 −9 ] ) .∗ ’ , ’ \\1 ’ , q u a l i f i e r $ve s s e l , p e r l=TRUE)
42
43 q u a l i f i e r $donor <− q u a l i f i e r $sample name
44 q u a l i f i e r $donor <− gsub ( ’ .∗(?<=, ) ( [A−Z0−9]{2 ,4}) .∗ ’ , ’ \\1 ’ ,
45 q u a l i f i e r $donor , p e r l=TRUE)
46
47 q u a l i f i e r $day <− q u a l i f i e r $sample name
48 q u a l i f i e r $day <− gsub ( ’ .∗(?<=Day ) ( [0 −9 ]{1 ,2} ) . ∗ ’ , ’ \\1 ’ , q u a l i f i e r $day , p e r l=TRUE)
49 q u a l i f i e r $day [ q u a l i f i e r $day == ’Media c on t r o l ’ ] <− 0
50
51 #Compound Ranking
52 rank <− read . csv ( ’Compound ranking . csv ’ , encoding=’UTF−8 ’ )
53 rank <− rank [ , 1 : 7 ]
54
55 #Compound in f o
56 #metabo l i t e pathway
57 path . data <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/
Data source f i l e s /Compound pathway annotat ion . csv ’ ,
58 header=FALSE)
59 path . data <− path . data [ 1 : 1 5 3 , ]
60
61 #Gett ing compound types
62 cmpd . type <− data . frame (Compound=t (path . data [ 1 , 2 : ncol (path . data ) ] ) ,
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63 Type=t (path . data [ 2 , 2 : ncol (path . data ) ] ) )
64 colnames (cmpd . type ) <− c ( ’Compound ’ , ’Type ’ )
65
66 # Create the connect ion (no f i l e needed ) −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
67
68 # Choose d r i v e r
69 drv = dbDriver ( ’ SQLite ’ )
70
71 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
72 con = dbConnect ( drv , ’ data . db ’ )
73
74 # Creating database t a b l e s
75 data . table <− dbWriteTable ( con , ’Data ’ , melt . data , ove rwr i t e=TRUE)
76
77 q u a l i f i e r . table <− dbWriteTable ( con , ’ Qu a l i f i e r ’ , q u a l i f i e r , ove rwr i t e=TRUE)
78
79 rank . table <− dbWriteTable ( con , ’Rank ’ , rank , ove rwr i t e=TRUE)
80
81 cmpd . table <− dbWriteTable ( con , ’Cmpd i n f o ’ , cmpd . type , ove rwr i t e=TRUE)
82
83 t ab l e s <− dbGetQuery ( con , ”SELECT ∗ FROM s q l i t e master WHERE type=’ tab le ’ ; ” )
84 print ( t ab l e s )
85
86 dbDisconnect ( con )
profiling variability analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
//////
2 #Pro f i l i n g v a r i a b i l i t y an l a y s i s
3
4 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
5 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
6 source ( ’ funct ion−data cleanup .R ’ )
7
8 #load ing requ i red packages
9 require (RSQLite )
10 require ( p ly r )
11
12 #s e t t i n g working d i r e c t o r y
13 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass Samples/R Sc r i p t s/Analys i s ’ )
14
15 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
16 #Choose d r i v e r
17 drv <− dbDriver ( ’ SQLite ’ )
18
19 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
20 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
21
22 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
23 d . va r i ab l e , d . va lue
24 FROM Data d INNER JOIN Qua l i f i e r q
25 ON d . f i l e=q . f i l e
26 INNER JOIN Rank r
27 ON d . va r i ab l e = r .Compound
28 WHERE r . Conf idence = 1
29 AND q . sampleID IN ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ )
30 ORDER BY q . sampleID ; ” )
31
32 dbDisconnect ( con )
33
34 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
35 #Remove DSS, contminants and compounds o f zero concentra t ion
36 c l ean . data <− data cleanup ( input , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
37 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ ) ,
38 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
39 convert .NA=TRUE)
40
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41 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
42 #f i r s t a s s i gn ing genera l sampleID
43 c l ean . data$set <− c l ean . data$sampleID
44 c l ean . data$set <− gsub ( ’ ˆ ( [A−Z ] ) (?=[0−9]) . ∗ ’ , ’ \\1 ’ , c l ean . data$set , p e r l=TRUE)
45
46 stat <− ddply ( c l ean . data , ’ s e t ’ , d e s c r i p t i v e . stat , data . type=’ long ’ ,
47 variable=’ va r i ab l e ’ , )
48
49 #Residuals−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
50 stat$ r e s <− stat$value−stat$avg
51
52 #Student i z ed r e s i d ua l
53 stat$ s r e s <− abs ( stat$ r e s )/stat$ stdev
54
55 #p l o t ( dens i t y ( s t a t$ s r e s ) )
56
57 #ge t t i n g sum of r e s i d u a l s f o r v a r i a b l e
58 custom r e s i d u a l <− function (data ) {
59 out <− ddply (data , ’ v a r i a b l e ’ , mutate , sum . r e s=sum( r e s ) )
60 return ( out )
61 }
62
63 stat <− ddply ( stat , ’ s e t ’ , custom r e s i d u a l )
64
65 #p l o t ( dens i t y ( s t a t$sum . res ) )
66
67 #Range−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
68 #ge t t i n g range o f v a r i a b l e concen t ra t ions
69 custom range <− function (data ) {
70 d <− data
71 out <− ddply (d , ’ v a r i a b l e ’ , mutate , min=min( va lue ) , max=max( va lue ) )
72 out$range <− out$min−out$max
73 return ( out )
74
75 }
76 stat <− ddply ( stat , ’ s e t ’ , custom range )
77
78 #range as percent o f mean
79 stat$prange <− abs ( stat$range )/stat$avg∗100
80 plot (density ( stat$prange ) )
81
82 png ( f i l ename=’ . . /Resu l t s/Percent range2 . png ’ ,
83 width=10, he ight=7, un i t s=’cm ’ , r e s =240)
84 plot (density ( stat$prange ) , main=’ ’ )
85 dev . of f ( )
86
87 prange <− unique ( stat [ , c (6 , 8 , ncol ( stat ) ) ] )
88 l r ange <− prange [ prange$prange >= 25 , ]
89 l r ange <− l r ange [ order ( l r ange$prange ) , ]
90 write . csv ( f i l e=’ . . /Resu l t s/Percent range2 . csv ’ , x=l range )
91
92 #Re la t i v e standard dev ia t ion−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
93 stat$ rsd <− stat$ stdev/stat$avg∗100
94
95 plot (density ( stat$rsd , bw=1) )
96
97 png ( f i l ename=’ . . /Plot s/ p r e c i s i o n/RSD. png ’ ,
98 width=10, he ight=7, un i t s=’cm ’ , r e s =240)
99 plot (density ( stat$rsd , bw=1) , main=’ ’ )
100 dev . of f ( )
101
102 high . rsd <− unique ( stat [ stat$ rsd > 15 ,c ( ’ s e t ’ , ’ v a r i a b l e ’ , ’ r sd ’ ) ] )
103 write . csv ( f i l e=’ . . /Resu l t s/ rsd . csv ’ , high . rsd )
104 #Compounds with va lue s g r ea t e r than 2∗sd−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
105 stat$sd2 <− 2∗stat$ stdev
106
107 sd1 <− stat [ abs ( stat$ r e s ) > stat$stdev , ]
108 sd2 <− stat [ abs ( stat$ r e s ) > stat$sd2 , ]
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109
110 sub . stat <− unique ( stat [ , c ( 8 , 2 : 6 , 9 : ncol ( stat ) ) ] )
111
112 #Prec i s ion an l a y s i s ANOVA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
113 aov custom <− function (data , group ) {
114 d <− data
115
116 grand <− mean(d$value ) #grand mean
117
118 s s . grp <− ddply (d , group , mutate , avg=mean( va lue ) ) #within−group mean
119 s s . grp$grand <− grand #adding grand mean
120
121 s s r <− sum( ( s s . grp$value − s s . grp$avg )∗∗2) #sum of sqr o f w i th in groups
122 s sa <− sum( ( s s . grp$avg − s s . grp$grand )∗∗2) #sum of sqr o f between groups
123
124 d f r <− nrow(d)−length (unique (d [ , group ] ) ) #n−q
125 dfa <− length (unique (d [ , group ] ) )−1 #q−1
126
127 msa <− s sa/dfa #mean square between group
128 msr <− s s r/d f r #mean square wi th in group
129
130 f <− msa/msr #f s t a t i s t i c
131 p . va l <− 1−pf ( f , dfa , d f r )
132 out <− data . frame ( variable=unique (d$variable ) , f . va l=f , p . va l=p . va l )
133 return ( out )
134 }
135
136 anova <− ddply ( c l ean . data , ’ v a r i a b l e ’ , aov custom , ’ s e t ’ )
137
138 s . anova <− anova [ anova$p . va l <=0.05 ,]
139
140 write . csv ( f i l e=’ . . /Resu l t s/ANOVA−t r i p l i c a t e s 2 . csv ’ , s . anova)
141 #p l o t ( dens i t y ( anova$ f . v a l ) )
142 p <− ggp lot ( stat , aes ( x=set , y=value ) ) +
143 geom point ( ) +
144 stat boxplot ( aes (ymax=ymax , ymin=ymin ) ) +
145 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ ) +
146 theme bw(14)
147
148 #Student ’ s t−t e s t−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
149 custom t <− function (data , group ) {
150 grps <− unique (data [ , group ] )
151 g1 <− data [ data [ , group ] == grps [ 1 ] , ]
152 g2 <− data [ data [ , group ] == grps [ 2 ] , ]
153
154 t <− t . t e s t ( g1$value , g2$value )
155 out <− data . frame ( s t a t i s t i c=t$ s t a t i s t i c , p . va l=t$p . va lue )
156 return ( out )
157 }
158
159 t <− ddply ( stat , ’ v a r i a b l e ’ , custom t , ’ s e t ’ )
160 s . t <− t [ t$p . va l <= 0 . 0 5 , ]
161
162 write . csv ( f i l e=’ . . /Resu l t s/p r e c i s i on−t . csv ’ , s . t )
duplicate variabilty analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Dupl ica te run v a r i a b i l i t y ana l y s i s
3
4 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
5 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
6 source ( ’ funct ion−data cleanup .R ’ )
7
8 #load ing requ i red packages
9 require (RSQLite )
10 require ( p ly r )
11 require ( ggp lot2 )
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12
13 #s e t t i n g working d i r e c t o r y
14 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass Samples/R Sc r i p t s/Analys i s ’ )
15
16 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
17 #Choose d r i v e r
18 drv <− dbDriver ( ’ SQLite ’ )
19
20 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
21 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
22
23 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
24 d . va r i ab l e , d . va lue
25 FROM Data d INNER JOIN Qua l i f i e r q
26 ON d . f i l e=q . f i l e
27 INNER JOIN Rank r
28 ON d . va r i ab l e = r .Compound
29 WHERE r . Conf idence = 1 AND q . run != ’Media cont ro l ’
30 ORDER BY q . sampleID ; ” )
31
32 input1 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
33 d . va r i ab l e , d . va lue
34 FROM Data d INNER JOIN Qua l i f i e r q
35 ON d . f i l e=q . f i l e
36 INNER JOIN Rank r
37 ON d . va r i ab l e = r .Compound
38 WHERE r . Conf idence = 1
39 AND q . run IN ( ’ 30 ’ , ’ 33 ’ )
40 ORDER BY q . sampleID ; ” )
41
42 input2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
43 d . va r i ab l e , d . va lue
44 FROM Data d INNER JOIN Qua l i f i e r q
45 ON d . f i l e=q . f i l e
46 INNER JOIN Rank r
47 ON d . va r i ab l e = r .Compound
48 WHERE r . Conf idence = 1
49 AND q . run IN ( ’ 31 ’ , ’ 32 ’ )
50 ORDER BY q . sampleID ; ” )
51
52 dbDisconnect ( con )
53
54 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
55 #Remove DSS, contminants and compounds o f zero concentra t ion
56 c l ean . data <− data cleanup ( input , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
57 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ ) ,
58 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
59 convert .NA=TRUE)
60
61 #Ca lcu l a t ing mean va lue s o f t r i p l i c a t e s in se t2 and input−−−−−−−−−−−−−−−−−−−−−−−
62 i f (any( c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ ) ) ) {
63 H. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ ) , ]
64 R. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’R1 ’ , ’R2 ’ , ’R3 ’ ) , ]
65
66 H <− ddply (H. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
67 H$sampleID <− ’H ’
68 H <− unique (H[ , −7 ] )
69 colnames (H) [ 7 ] <− ’ va lue ’
70
71 R <− ddply (R. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
72 R$sampleID <− ’R ’
73 R <− unique (R[ , −7 ] )
74 colnames (R) [ 7 ] <− ’ va lue ’
75
76 #removing H1,H2,H3,R1,R2,R3
77 c l ean . data <− c l ean . data [ ! c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3
’ ) , ]
78 #adding mean H and R
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79 c l ean . data <− rbind ( c l ean . data , H, R)
80 print ( ’ here ’ )
81 }
82
83
84 #cas t i n g data to g i v e non−p r o f i l e d compounds concentra t ion o f zero
85 data . c a s t <− dcast ( c l ean . data , sampleID+run+v e s s e l+donor+day˜variable ,
86 va lue . var=’ value ’ )
87
88 data . c a s t [ i s .na(data . c a s t ) ] <− 0
89
90 #mel t ing back to work with
91 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ ) )
92
93 #adding ID fo r donor−run combo
94 data . melt$donor . run <− paste (data . melt$donor , data . melt$run , sep=’ . ’ )
95
96 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
97 #s t a t <− d e s c r i p t i v e . s t a t ( data . melt , data . type=’ long ’ , v a r i a b l e =’ va r i a b l e ’ )
98
99 stat <− ddply (data . melt , c ( ’ v a r i ab l e ’ , ’ donor ’ , ’ run ’ ) , d e s c r i p t i v e . stat ,
100 data . type=’ long ’ , variable=’ va r i ab l e ’ )
101
102 stat <− ddply ( stat , c ( ’ v a r i ab l e ’ , ’ donor ’ ) , mutate , run . avg=mean( va lue ) )
103 stat$per . d i f f <− abs ( ( stat$avg−stat$run . avg ) )/stat$run . avg∗100
104
105 #ANOVA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
106 aov custom <− function (data , group ) {
107 d <− data
108
109 grand <− mean(d$value ) #grand mean
110
111 s s . grp <− ddply (d , group , mutate , avg=mean( va lue ) ) #within−group mean
112 s s . grp$grand <− grand #adding grand mean
113
114 s s r <− sum( ( s s . grp$value − s s . grp$avg )∗∗2) #sum of sqr o f w i th in groups
115 s sa <− sum( ( s s . grp$avg − s s . grp$grand )∗∗2) #sum of sqr o f between groups
116
117 d f r <− nrow(d)−length (unique (d [ , group ] ) ) #n−q
118 dfa <− length (unique (d [ , group ] ) )−1 #q−1
119
120 msa <− s sa/dfa #mean square between group
121 msr <− s s r/d f r #mean square wi th in group
122
123 f <− msa/msr #f s t a t i s t i c
124 p . va l <− 1−pf ( f , dfa , d f r )
125 #out <− data . frame ( v a r i a b l e=unique (d$ v a r i a b l e ) , f . v a l=f , p . va l=p . va l )
126 out <− d
127 out$ f . va l <− f
128 out$p . va l <− p . va l
129 return ( out )
130 }
131
132 anova <− ddply ( stat , c ( ’ v a r i ab l e ’ , ’ donor ’ ) , aov custom , group=’ run ’ )
133 s . anova <− anova [ anova$p . va l <= 0.05 & ! i s .na(anova$p . va l ) , ]
134 #wri t e . csv ( f i l e = ’ . ./Resu l t s/Run comparison−31 vs 32. csv ’ , s . anova )
135
136 #Tukey with bon fer ron i correc t ion−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
137 tukey custom <− function (data , group ) {
138 grps <− unique (data [ , group ] )
139 pa i r <− combn( grps , 2 )
140 out <− c ( )
141 for ( i in 1 : ncol ( pa i r ) ) {
142 grp1 <− data [ data [ , group ] == pa i r [ 1 , i ] , ]
143 grp2 <− data [ data [ , group ] == pa i r [ 2 , i ] , ]
144 grp <− rbind ( grp1 , grp2 ) #both groups be ing compared
145
146 grand <− mean(data$value ) #grand mean
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147 s s . grp <− ddply ( grp , group , mutate , avg=mean( va lue ) ) #within−group mean
148 s s . grp$grand <− grand #adding grand mean
149 s s r <− sum( ( s s . grp$value − s s . grp$avg )∗∗2) #sum of sqr o f w i th in groups
150 d f r <− nrow(data )−length (unique (data [ , group ] ) ) #n−q ; n=# of observa t ions ,
151 #q= # of groups
152 msr <− s s r/d f r
153
154 avg1 <− mean( grp1$value )
155 avg2 <− mean( grp2$value )
156
157 n <− nrow( grp1 ) #number o f ob s e r va t i on s in a group ( t h i s i s parametric t e s t )
158 q <− length (unique (data [ , group ] ) ) #number o f groups
159 se <− sqrt (msr/n)
160 q . stat <− (max(c ( avg1 , avg2 ) )−min(c ( avg1 , avg2 ) ) )/se
161 p . va l <− ptukey (q . stat , q , df=dfr , lower . t a i l=FALSE)
162
163 #pr in t ( pa i r [ , i ] )
164 #pr in t ( grp1$va lue )
165 #pr in t ( grp2$va lue )
166 #pr in t (msr)
167 #pr in t ( se )
168 #pr in t (p . va l )
169 #cat ( ’\n\n ’ )
170 output <− data . frame ( g1=pa i r [ 1 , i ] , g2=pa i r [ 2 , i ] , p . va l=p . va l )
171
172 out <− rbind ( out , output )
173
174 }
175 return ( out )
176 }
177
178 tukey <− ddply (data . melt , ’ v a r i a b l e ’ , tukey custom , group=’ donor . run ’ )
179 bon f e r r on i <− 0 .05/6
180 s . tukey <− tukey [ tukey$p . va l <= bon f e r r on i & ! i s .na( tukey$p . va l ) , ]
181
182 #t−t e s t−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
183 t custom <− function (data , group ) {
184
185 grps <− unique (data [ , group ] )
186
187 grp1 <− data [ data [ , group ] == grps [ 1 ] , ]
188 grp2 <− data [ data [ , group ] == grps [ 2 ] , ]
189 grp <− rbind ( grp1 , grp2 ) #both groups be ing compared
190
191 r e s u l t <− t . t e s t ( grp1$value , grp2$value )
192 p . va l <− r e s u l t $p . va lue
193 s t a t i s t i c <− r e s u l t $ s t a t i s t i c
194 output <− data . frame ( g1=unique ( grp1 [ , group ] ) , g2=unique ( grp2 [ , group ] ) ,
195 stat=s t a t i s t i c , p . va l=p . va l )
196
197 return ( output )
198 }
199
200 t . r e s u l t <− ddply ( stat , c ( ’ v a r i ab l e ’ , ’ donor ’ ) , t custom , group=’ run ’ )
201 t . s i g <− t . r e s u l t [ t . r e s u l t $p . va l <= 0.05 & ! i s .na( t . r e s u l t $p . va l ) , ]
202
203 bon f e r r on i <− 0 .05/sqrt ( length (unique ( stat$variable ) )+length (unique ( stat$donor ) ) )
204 t . s i g 2 <− t . r e s u l t [ t . r e s u l t $p . va l <= bon f e r r on i & ! i s .na( t . r e s u l t $p . va l ) , ]
205
206 for ( i in c ( ’RP ’ , ’RRP’ , ’RP2 ’ , ’RRP2 ’ ) ) {
207 d1 <− unique ( stat [ stat$donor==i , c ( ’ v a r i ab l e ’ , ’ donor ’ , ’ per . d i f f ’ ) ] )
208 d2 <− t . s i g [ t . s i g$donor == i , ]
209 export <− merge( d2 , d1 ,by=’ va r i ab l e ’ )
210 export <− unique ( export [ , c ( ’ donor . y ’ , ’ v a r i a b l e ’ , ’ s t a t ’ , ’ p . va l ’ , ’ per . d i f f ’ ) ] )
211 write . csv ( f i l e=paste ( ’ . . /Resu l t s/run v a r i a b i l i t y − ’ , i , ’ . csv ’ , sep=’ ’ ) , export )
212 }
213 write . csv ( f i l e=’ . . /Resu l t s/run v a r i a b i l i t y −t bon f e r r on i . csv ’ , t . s i g 2 )
214
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215 stat . s i g <− stat [ stat$variable %in% unique ( t . s i g$variable ) , ]
216 stat . s i g 2 <− stat [ stat$variable %in% unique ( t . s i g 2$variable ) , ]
217
218 t . l i s t <− l i s t ( rp=unique ( t . s i g$variable [ t . s i g$donor==’RP ’ ] ) ,
219 rrp=unique ( t . s i g$variable [ t . s i g$donor==’RRP’ ] ) ,
220 rp2=unique ( t . s i g$variable [ t . s i g$donor==’RP2 ’ ] ) ,
221 rrp2=unique ( t . s i g$variable [ t . s i g$donor==’RRP2 ’ ] ) )
222
223
224 #Boxplot−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
225 #s i g n i f i c a n t by t t e s t
226 donor <− c ( ’RP ’ , ’RRP’ , ’RP2 ’ , ’RRP2 ’ )
227 he ight <− c (15 , 10 , 8 , 10)
228 width <− c (20 ,20 ,15 ,20 )
229 n . col <− c ( 4 , 4 , 3 , 4 )
230 for ( i in 1 : length ( donor ) ) {
231 pbox . data <− stat [ stat$donor == donor [ i ] & stat$variable %in% t . l i s t [ [ i ] ] , ]
232
233 p .box <− ggp lot ( pbox . data , aes ( x=run , y=value ) ) +
234 stat boxplot ( ) +
235 geom point ( ) +
236 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=n . col [ i ] ) +
237 theme bw(14) +
238 xlab ( ’Run ’ ) +
239 ylab ( ’ Concentrat ion (mM) ’ )
240
241 #ggsave ( ’ . . /Plo t s/Run v a r i a b i l i t y /anova2−s i g 30 vs 33. png ’ , p . box , h e i g h t =15,
width=25, un i t s=’cm’ )
242
243 ggsave (paste ( ’ . . /Plot s/Run v a r i a b i l i t y /anova ’ , i , ’ . png ’ ) , p .box ,
244 he ight=he ight [ i ] , width=width [ i ] , un i t s=’cm ’ )
245 }
pca analysis.R
1 #/////////////////////////////////////////////////////////////////////////////////
2 #PCA Analys i s o f Biomass samples
3
4 #sourc ing requ i red func t i ons
5 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
6 source ( ’ funct ion−data cleanup .R ’ )
7 source ( ’ funct ion−pca .R ’ )
8 source ( ’ funct ion−pca d i a gno s t i c s .R ’ )
9 source ( ’ funct ion−p l o t t i n g 2D sco r e .R ’ )
10 source ( ’ funct ion−p l o t t i n g 2D load ing .R ’ )
11
12 #load ing requ i red packages
13 require (RSQLite )
14 require ( p ly r )
15
16 #s e t t i n g working d i r e c t o r y
17 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass Samples/R Sc r i p t s/Analys i s ’ )
18
19 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
20 #Choose d r i v e r
21 drv <− dbDriver ( ’ SQLite ’ )
22
23 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
24 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
25
26 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
27 d . va r i ab l e , d . va lue
28 FROM Data d INNER JOIN Qua l i f i e r q
29 ON d . f i l e=q . f i l e
30 INNER JOIN Rank r
31 ON d . va r i ab l e = r .Compound
32 WHERE r . Conf idence = 1
33 ORDER BY q . sampleID ; ” )
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34
35 input2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
36 d . va r i ab l e , d . va lue
37 FROM Data d INNER JOIN Qua l i f i e r q
38 ON d . f i l e=q . f i l e
39 INNER JOIN Rank r
40 ON d . va r i ab l e = r .Compound
41 WHERE r . Conf idence = 1 AND q . run != ’Media cont ro l ’
42 ORDER BY q . sampleID ; ” )
43
44 s e t1 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
45 d . va r i ab l e , d . va lue
46 FROM Data d INNER JOIN Qua l i f i e r q
47 ON d . f i l e=q . f i l e
48 INNER JOIN Rank r
49 ON d . va r i ab l e = r .Compound
50 WHERE r . Conf idence = 1 AND q . run IN (30 ,33)
51 ORDER BY q . sampleID ; ” )
52
53 s e t2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
54 d . va r i ab l e , d . va lue
55 FROM Data d INNER JOIN Qua l i f i e r q
56 ON d . f i l e=q . f i l e
57 INNER JOIN Rank r
58 ON d . va r i ab l e = r .Compound
59 WHERE r . Conf idence = 1 AND q . run IN (31 ,32)
60 ORDER BY q . sampleID ; ” )
61
62 s e t3 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
63 d . va r i ab l e , d . va lue
64 FROM Data d INNER JOIN Qua l i f i e r q
65 ON d . f i l e=q . f i l e
66 INNER JOIN Rank r
67 ON d . va r i ab l e = r .Compound
68 WHERE r . Conf idence = 1 AND q . sampleID IN ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’
R1 ’ , ’R2 ’ , ’R3 ’ )
69 ORDER BY q . sampleID ; ” )
70
71 dbDisconnect ( con )
72
73 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
74 #Remove DSS, contminants and compounds o f zero concentra t ion
75 c l ean . data <− data cleanup ( set3 , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
76 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ ) ,
77 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
78 convert .NA=FALSE)
79 i f (FALSE) {
80 export . data <− dcast ( c l ean . data , formula=sampleID+run+v e s s e l+donor+day˜variable ,
81 va lue . var=’ value ’ )
82 write . csv ( f i l e=’ . . /metabo l i t e data2 . csv ’ , export . data )
83 }
84
85 #Ca lcu l a t ing mean va lue s o f t r i p l i c a t e s in se t2 and input−−−−−−−−−−−−−−−−−−−−−−−
86 i f (any( c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ ) ) ) {
87 H. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ ) , ]
88 R. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’R1 ’ , ’R2 ’ , ’R3 ’ ) , ]
89
90 H <− ddply (H. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
91 H$sampleID <− ’H ’
92 H <− unique (H[ , −7 ] )
93 colnames (H) [ 7 ] <− ’ va lue ’
94
95 R <− ddply (R. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
96 R$sampleID <− ’R ’
97 R <− unique (R[ , −7 ] )
98 colnames (R) [ 7 ] <− ’ va lue ’
99
100 #removing H1,H2,H3,R1,R2,R3
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101 c l ean . data <− c l ean . data [ ! c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3
’ ) , ]
102 #adding mean H and R
103 c l ean . data <− rbind ( c l ean . data , H, R)
104 print ( ’ here ’ )
105 }
106
107 #adding columns o f coded run and donor l a b e l s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
108 c l ean . data$d <− c l ean . data$donor
109 c l ean . data$d <− gsub ( ’RRP2 ’ , ’MET−3B ’ , c l ean . data$d)
110 c l ean . data$d <− gsub ( ’RP2 ’ , ’MET−3A ’ , c l ean . data$d)
111 c l ean . data$d <− gsub ( ’RRP’ , ’MET−2B ’ , c l ean . data$d)
112 c l ean . data$d <− gsub ( ’RP ’ , ’MET−2A ’ , c l ean . data$d)
113 c l ean . data$ r <− c l ean . data$run
114 c l ean . data$ r <− gsub ( ’ 30 ’ , 1 , c l ean . data$ r )
115 c l ean . data$ r <− gsub ( ’ 33 ’ , 3 , c l ean . data$ r )
116 c l ean . data$ r <− gsub ( ’ 31 ’ , 2 , c l ean . data$ r )
117 c l ean . data$ r <− gsub ( ’ 32 ’ , 4 , c l ean . data$ r )
118 #Performing PCA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
119 pca . data <− perform pca ( c l ean . data , sampleID=’ sampleID ’ , variable=’ va r i ab l e ’ ,
120 value=’ value ’ ,
121 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ , ’ r ’ , ’ d ’ ) ,
122 form . x=’ va r i ab l e ’ , scale=’UV’ , c en t e r=TRUE, convert .NA=TRUE
)
123
124 #Export ing pca data f o r Kathleen−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
125 i f (FALSE) {
126 pca .names <− names( pca . data )
127 for ( i in 1 : length ( pca .names) ) {
128 write . csv ( f i l e=paste ( ’ . . /Resu l t s/ ’ , pca .names [ i ] , ’− t r i p l i c a t e s . csv ’ , sep=’ ’ ) ,
pca . data [ [ i ] ] )
129 }
130
131 pca .summary <− as .matrix (summary( pca . data ) )
132 write . csv ( f i l e=’ . . /Resu l t s/summary−t r i p l i c a t e s . csv ’ , pca .summary [ [ 6 ] ] )
133 }
134 #performing d i a gno s t i c s on PCA−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
135 d i a gno s t i c . r e s u l t s = s c r e e plot ( pca . data )
136
137 #unpacking the d i a gno s t i c r e s u l t s
138 d i a gno s t i c . number = d i a gno s t i c . r e s u l t s [ [ ’ number ’ ] ]
139 d i a gno s t i c . exp la ined = d i a gno s t i c . r e s u l t s [ [ ’ exp la ined ’ ] ]
140 d i a gno s t i c . plot = d i agno s t i c . r e s u l t s [ [ ’ p l o t ’ ] ]
141 d i a gno s t i c . plot = d i agno s t i c . plot + g g t i t l e ( ’ Scree Plot (UVN) ’ )
142
143 #pr in t i n g out d i a gno s t i c r e s u l t s
144 print ( d i a gno s t i c . number )
145 print ( d i a gno s t i c . exp la ined )
146 print ( d i a gno s t i c . plot )
147
148 #p l o t t i n g PCA−processed data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
149 #Score p l o t 2D
150 # Note : Arguments f o r score p l o t func t i on are
151 # (pca data , q u a l i f i e r data , PCs=1:4 , co lour=NULL, shape=NULL, s i z e=NULL,
152 # l a b e l=NULL, t i t l e=NULL, legend . o r i=’ hor i zon ta l ’ , b l a c k whi te=FALSE)
153
154 s co r e plot = sco r e plot 2d( pca . data , PCs=1:4 ,
155 co l our=’ r ’ , shape=’d ’ , l a b e l=’ day ’ ,
156 legend . o r i= ’ ho r i z on t a l ’ ,
157 black white=FALSE)
158
159 p . s c o r e <− s c o r e plot [ [ ’ p ’ ] ]
160 p . s c o r e <− p . s co r e +
161 scale co l ou r manual ( va lue s=c ( ’ f o r e s t g r e e n ’ , ’ darkorange2 ’ ) ,name=’Run ’ ) + #se t 3
162 #sca l e co lour manual ( va lue s=c ( ’ cora l2 ’ , ’ darkorange2 ’ ,
163 # ’ corn f l owerb lue ’ , ’ f o r e s t g r een ’ ) ,name=’Run ’ ) +
164 scale shape d i s c r e t e (name=’Donor ’ )
165 c o l l e c t e d . data <− s c o r e plot [ [ ’ c o l l e c t e d . data ’ ] ]
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166
167 ggsave ( ’ . . /Plot s/pca p l o t s/ r e p l i c a t e s 3 . png ’ , p . score , he ight=15, width=25, un i t s=’
cm ’ )
168
169 #Loading p l o t 2D−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
170
171 # Note : Arguments f o r l oad ing p l o t func t i on are ( pca data , PCs=1:4 , l a b e l=NULL,
t i t l e=NULL,
172 # view mode=’compressed ’ )
173
174 #I f you want a l l compound l a b e l s shown , enter a l l paths in l a b e l argument
175 a l l paths = rownames( pca . data$ r o t a t i on )
176
177 #I f you want a l l and only compound wi th in the sub s e t o f o b s e r va t i ons processed in
the PCA funct ion , can crea t e a temperary group c a l l e d ’a ’ to enter in f o r the
l a b e l argument
178 #a = pathway l i s t $Carb [ pathway l i s t $Organic %in% rownames ( pca processed data$
r o t a t i on ) ]
179
180 load ing plot = load ing plot 2d( pca . data , PCs=1:4 , l a b e l=a l l paths ,
181 t i t l e=’ 2D Loading Plot−\nUV ’ , view mode = ’
compressed ’ )
182
183 p . load <− l oad ing plot [ [ ’ p ’ ] ]
184 load . data <− l oad ing plot [ [ ’ c o l l e c t e d . data ’ ] ]
185
186 print (p . load )
187 ggsave ( ’ . . /Resu l t s/ set1−l oad ing . png ’ , p . load , he ight=30, width=50, un i t s=’cm ’ )
profile diversity analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Pro f i l e d i v e r s i t y o f Biomass samples
3
4 #sourc ing requ i red func t i ons
5 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
6 source ( ’ funct ion−data cleanup .R ’ )
7 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
8
9 #load ing requ i red packages
10 require (RSQLite )
11 require ( ggp lot2 )
12 require ( gr idExtra )
13 require (RODBC)
14
15 #s e t t i n g working d i r e c t o r y
16 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass Samples/R Sc r i p t s/Analys i s ’ )
17
18 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
19 #Choose d r i v e r
20 drv <− dbDriver ( ’ SQLite ’ )
21
22 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
23 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
24
25 cmpd . i n f o <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
26 d . va r i ab l e , d . value , c . Type
27 FROM Cmpd i n f o c INNER JOIN Data d
28 ON c .Compound=d . va r i ab l e
29 INNER JOIN Qua l i f i e r q
30 ON d . f i l e=q . f i l e
31 INNER JOIN Rank r
32 ON r .Compound=d . va r i ab l e
33 WHERE r . Conf idence = 1
34 ORDER BY q . sampleID” )
35
36 dbDisconnect ( con )
37
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38 # Create connect ion and s e l e c t i n g database
39 con <− odbcConnect ( ’MySQLDSN’ )
40
41 input <− sqlQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
42 d . va r i ab l e , d . value , t . tax c l a s s
43 FROM biomass . data d INNER JOIN biomass . q u a l i f i e r q
44 ON d . f i l e=q . f i l e
45 INNER JOIN gene ra l . tax t
46 ON d . va r i ab l e=t . syn
47 INNER JOIN biomass . rank r
48 ON r . compound=d . va r i ab l e
49 WHERE r . con f idence = 1
50 ORDER by q . sampleID ; ” )
51
52 odbcClose ( con )
53 #data cleanup−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
54 #Remove DSS, contminants and compounds o f zero concentra t ion
55 c l ean . data <− data cleanup ( input , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
56 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ , ’Type ’ )
,
57 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
58 convert .NA=TRUE)
59
60 #Ca lcu l a t ing mean va lue s o f t r i p l i c a t e s in se t2 and input−−−−−−−−−−−−−−−−−−−−−−−
61 i f (any( c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ ) ) ) {
62 H. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ ) , ]
63 R. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’R1 ’ , ’R2 ’ , ’R3 ’ ) , ]
64
65 H <− ddply (H. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
66 H$sampleID <− ’H ’
67 H <− unique (H[ , −7 ] )
68 colnames (H) [ 8 ] <− ’ va lue ’
69
70 R <− ddply (R. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
71 R$sampleID <− ’R ’
72 R <− unique (R[ , −7 ] )
73 colnames (R) [ 8 ] <− ’ va lue ’
74
75 #removing H1,H2,H3,R1,R2,R3
76 c l ean . data <− c l ean . data [ ! c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3
’ ) , ]
77 #adding mean H and R
78 c l ean . data <− rbind ( c l ean . data , H, R)
79 print ( ’ here ’ )
80 }
81
82 #Adding ex t ra q u a l i f i e r to id RP−based cu l t u r e s and RP2−based cu l t u re s−−−−−−−−−
83 c l ean . data$ cu l t u r e . type <− ’RP ’
84 c l ean . data$ cu l t u r e . type [ c l ean . data$run %in% c (31 ,32) ] <− ’RP2 ’
85 c l ean . data$ cu l t u r e . type [ c l ean . data$run == ’Media c on t r o l ’ ] <− ’ media ’
86
87 #adding columns o f coded run and donor l a b e l s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
88 c l ean . data$d <− c l ean . data$donor
89 c l ean . data$d <− gsub ( ’RRP2 ’ , ’MET−3B ’ , c l ean . data$d)
90 c l ean . data$d <− gsub ( ’RP2 ’ , ’MET−3A ’ , c l ean . data$d)
91 c l ean . data$d <− gsub ( ’RRP’ , ’MET−2B ’ , c l ean . data$d)
92 c l ean . data$d <− gsub ( ’RP ’ , ’MET−2A ’ , c l ean . data$d)
93 c l ean . data$ r <− c l ean . data$run
94 c l ean . data$ r <− gsub ( ’ 30 ’ , 1 , c l ean . data$ r )
95 c l ean . data$ r <− gsub ( ’ 33 ’ , 3 , c l ean . data$ r )
96 c l ean . data$ r <− gsub ( ’ 31 ’ , 2 , c l ean . data$ r )
97 c l ean . data$ r <− gsub ( ’ 32 ’ , 4 , c l ean . data$ r )
98
99 #ge t t i n g s t a t s on each cu l t u r e type
100 stat <− ddply ( c l ean . data , c ( ’ v a r i ab l e ’ , ’ c u l t u r e . type ’ ) , d e s c r i p t i v e . stat ,
101 data . type=’ long ’ , variable=’ va r i ab l e ’ )
102
103 #t o t a l compound concentra t ions−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
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104 rp <− c l ean . data [ c l ean . data$donor==’RP ’ , ]
105 rrp <− c l ean . data [ c l ean . data$donor==’RRP’ , ]
106 rp2 <− c l ean . data [ c l ean . data$donor==’RP2 ’ , ]
107 rrp2 <− c l ean . data [ c l ean . data$donor==’RRP2 ’ , ]
108 t o t a l <− data . frame ( rp30=sum( rp$value [ rp$run==’ 30 ’ ] ) ,
109 rp33=sum( rp$value [ rp$run==’ 33 ’ ] ) ,
110 rrp30=sum( rrp$value [ r rp$run==’ 30 ’ ] ) ,
111 rrp33=sum( rrp$value [ r rp$run==’ 33 ’ ] ) ,
112 rp2 .31=sum( rp2$value [ rp2$run ==’ 31 ’ ] ) ,
113 rp2 .32=sum( rp2$value [ rp2$run ==’ 32 ’ ] ) ,
114 rrp2 .31=sum( rrp2$value [ rrp2$run ==’ 31 ’ ] ) ,
115 rrp2 .32=sum( rrp2$value [ rrp2$run ==’ 32 ’ ] ) )
116 write . csv ( f i l e=’ . . /Resu l t s/ t o t a l p r o f i l e concen t ra t i on s3 . csv ’ , t o t a l )
117
118 #Compound in f o − propor t ion o f compound types−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
119 cmpd . i n f o 2 <− unique ( c l ean . data [ , c ( ’ v a r i ab l e ’ , ’ donor ’ , ’ tax c l a s s ’ , ’ d ’ ) ] )
120 cmpd . table <− table (cmpd . i n f o 2$tax class )/5
121 perc . table <− cmpd . table/sum(cmpd . table )
122
123 #propor t ion o f compound types weighted to concentrat ion−−−−−−−−−−−−−−−−−−−−−−−
124 custom perc <− function (data ) {
125 output <− ddply (data , ’ sampleID ’ , mutate , prof i le . t o t a l=sum( value , na .rm=TRUE) )
126 out <− ddply ( output , c ( ’ sampleID ’ , ’ tax c l a s s ’ ) , mutate ,
127 tax class . t o t a l=sum( value , na .rm=TRUE) )
128 out <− ddply ( out , ’ tax c l a s s ’ , mutate , tax class . avg= mean(unique ( tax class . t o t a l
) ) )
129 out$perc <− round( out$tax class . t o t a l/out$prof i le . t o t a l∗100 ,3)
130 out <− ddply ( out , ’ tax c l a s s ’ , mutate , perc . avg=mean(unique ( perc ) ) )
131 out$perc . avg <− round( out$perc . avg , 3)
132 return ( out )
133 }
134
135 cmpd . i n f o 3 <− ddply ( stat [ stat$sampleID != ’Y ’ , ] , ’ donor ’ , custom perc )
136
137 cmpd . i n f o 4 <− unique (cmpd . i n f o 3 [ , c ( ’ donor ’ , ’ d ’ , ’ tax c l a s s ’ , ’ perc . avg ’ ) ] )
138 cmpd . i n f o 4$donor <− factor (cmpd . i n f o 4$donor , levels=c ( ’RP ’ , ’RRP’ , ’RP2 ’ , ’RRP2 ’ ) )
139
140 #cas t f o r expor t
141 cmpd . i n f o 5 <− dcast (cmpd . in fo4 , tax class˜donor , va lue . var=’ perc . avg ’ )
142 cmpd . i n f o 5 <− cmpd . i n f o 5 [ order (cmpd . i n f o 5$RP, dec r ea s ing=TRUE) , ]
143
144 #wri t e . csv (cmpd . info5 , f i l e = ’ . ./Resu l t s/ p r o f i l e d i v e r s i t y 3 . csv ’ )
145
146 #look ing at compounds t ha t d i f f e r between cu l t u r e types−−−−−−−−−−−−−−−−−−−
147 var . carb <− as . character (unique (cmpd . i n f o 3$variable [
148 cmpd . i n f o 3$tax class == ’ Carboxyl ic Acids and Der i va t i v e s ’ ] ) )
149
150 carb . ac id <− unique (cmpd . i n f o 3 [ cmpd . i n f o 3$variable %in% var . carb ,
151 c ( ’ donor ’ , ’ run ’ , ’ c u l t u r e . type ’ , ’ v a r i ab l e ’ , ’ tax c l a s s ’ ,
152 ’ avg ’ , ’ s e ’ , ’ p r o f i l e . t o t a l ’ ) ] )
153
154 var . f a t <− as . character (unique (cmpd . i n f o 3$variable [
155 cmpd . i n f o 3$tax class ==’ Fatty Acids and Conjugates ’ ] ) )
156
157 f a t t y . ac id <− unique (cmpd . i n f o 3 [ cmpd . i n f o 3$variable %in% var . f a t ,
158 c ( ’ donor ’ , ’ run ’ , ’ c u l t u r e . type ’ , ’ v a r i ab l e ’ , ’ tax c l a s s ’ ,
159 ’ avg ’ , ’ s e ’ , ’ p r o f i l e . t o t a l ’ ) ] )
160
161 #percentage o f i n d i v i d u a l compounds
162 carb . perc <− carb . ac id [ order ( carb . ac id$variable ) , ]
163
164 #f i r s t g e t t i n g mean p r o f i l e t o t a l s f o r each cu l t u r e type
165 carb . perc <− ddply ( carb . perc , c ( ’ v a r i ab l e ’ , ’ c u l t u r e . type ’ ) , mutate ,
166 avg . p ro f . t o t = mean( prof i le . t o t a l ) )
167
168 carb . perc <− unique ( carb . perc [ , colnames ( carb . perc ) != ’ p r o f i l e . t o t a l ’ ] )
169 carb . perc$cmpd . perc <− carb . perc$avg/carb . perc$avg . p ro f . t o t∗100
170
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171 f a t . perc <− f a t t y . ac id [ order ( f a t t y . ac id$variable ) , ]
172
173 #f i r s t g e t t i n g mean p r o f i l e t o t a l s f o r each cu l t u r e type
174 f a t . perc <− ddply ( f a t . perc , c ( ’ v a r i ab l e ’ , ’ c u l t u r e . type ’ ) , mutate ,
175 avg . p ro f . t o t = mean( prof i le . t o t a l ) )
176
177 f a t . perc <− unique ( f a t . perc [ , colnames ( f a t . perc ) != ’ p r o f i l e . t o t a l ’ ] )
178 f a t . perc$cmpd . perc <− f a t . perc$avg/ f a t . perc$avg . p ro f . t o t∗100
179
180 #v i s u a l i z i n g proport ions−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
181 plot . data <− unique (cmpd . i n f o 3 [ , c ( ’d ’ , ’ tax c l a s s ’ , ’ tax c l a s s . avg ’ , ’ perc . avg ’ ) ] )
182 #p l o t . data$donor <− f a c t o r ( p l o t . data$donor , l e v e l s=c ( ’RP’ , ’RRP’ , ’RP2’ , ’RRP2’ ) )
183 plot . data <− plot . data [ order (plot . data$tax class . avg ) , ]
184 plot . data$tax class <− factor (plot . data$tax class , levels=unique (plot . data$tax
class ) , ordered=TRUE)
185
186 f i l l . va l <− rev (c ( ’ c o r a l 2 ’ , ’ dodgerblue4 ’ , ’ s eagreen ’ , ’ ye l low2 ’ , ’ hotpink2 ’ , ’ brown3 ’ ,
187 ’ co rn f l owe rb lue ’ , ’ darkorange2 ’ , ’ s eagreen2 ’ , ’ purple3 ’ , ’ tan4 ’ ,
188 ’ b i sque3 ’ , ’ s l a t e g r ay ’ ) )
189
190 p <− ggp lot (plot . data , aes ( x=d) ) +
191 geom bar ( stat=’ i d e n t i t y ’ , aes ( y=tax class . avg , f i l l =tax class ) ) +
192 scale f i l l manual ( va lue s= f i l l . val ,
193 guide=guide legend ( r e v e r s e=TRUE,
194 t i t l e=’Compound Class ’ ) ) +
195 xlab ( ’Community Culture ’ ) +
196 ylab ( ’ Class St ruc ture o f Metabo l i te P r o f i l e s \n( weighted to concent ra t i on ) ’ ) +
197 theme bw(9) +
198 theme ( legend . key . s i z e=uni t ( 0 . 3 5 , ’cm ’ ) )
199
200 ggsave ( ’ . . /Plot s/ p r o f i l e d i v e r s i t y 3 . png . png ’ , p , he ight=10, width=15, un i t s=’cm ’ )
donor comparison.R
1 #/////////////////////////////////////////////////////////////////////////////////
2 #Donor comparison
3
4 #load ing requ i red packages
5 require ( ggp lot2 )
6 require ( reshape2 )
7 require ( p ly r )
8 require (RSQLite )
9
10 #Sourcing requ i red func t i ons
11 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/ ’ )
12 source ( ’ funct ion−data cleanup .R ’ )
13 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
14
15 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass samples/R Sc r i p t s/Analys i s/ ’ )
16
17 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
18 #Choose d r i v e r
19 drv <− dbDriver ( ’ SQLite ’ )
20
21 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
22 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
23
24 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
25 d . va r i ab l e , d . va lue
26 FROM Data d INNER JOIN Qua l i f i e r q
27 ON d . f i l e=q . f i l e
28 INNER JOIN Rank r
29 ON d . va r i ab l e = r .Compound
30 WHERE r . Conf idence = 1 AND q . run != ’Media cont ro l ’
31 ORDER BY q . sampleID ; ” )
32
33 dbDisconnect ( con )
34
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35 #Data c lean up−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
36 #Remove DSS, contminants and compounds o f zero concentra t ion
37 c l ean . data <− data cleanup ( input , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
38 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ ) ,
39 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
40 convert .NA=TRUE)
41
42 #Ca lcu l a t ing mean va lue s o f t r i p l i c a t e s in se t2 and input−−−−−−−−−−−−−−−−−−−−−−−
43 i f (any( c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ ) ) ) {
44 H. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ ) , ]
45 R. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’R1 ’ , ’R2 ’ , ’R3 ’ ) , ]
46
47 H <− ddply (H. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
48 H$sampleID <− ’H ’
49 H <− unique (H[ , −7 ] )
50 colnames (H) [ 7 ] <− ’ va lue ’
51
52 R <− ddply (R. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
53 R$sampleID <− ’R ’
54 R <− unique (R[ , −7 ] )
55 colnames (R) [ 7 ] <− ’ va lue ’
56
57 #removing H1,H2,H3,R1,R2,R3
58 c l ean . data <− c l ean . data [ ! c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3
’ ) , ]
59 #adding mean H and R
60 c l ean . data <− rbind ( c l ean . data , H, R)
61 print ( ’ here ’ )
62 }
63
64 #adding columns o f coded run and donor l a b e l s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
65 c l ean . data$d <− c l ean . data$donor
66 c l ean . data$d <− gsub ( ’RRP2 ’ , ’MET−3B ’ , c l ean . data$d)
67 c l ean . data$d <− gsub ( ’RP2 ’ , ’MET−3A ’ , c l ean . data$d)
68 c l ean . data$d <− gsub ( ’RRP’ , ’MET−2B ’ , c l ean . data$d)
69 c l ean . data$d <− gsub ( ’RP ’ , ’MET−2A ’ , c l ean . data$d)
70 c l ean . data$ r <− c l ean . data$run
71 c l ean . data$ r <− gsub ( ’ 30 ’ , 1 , c l ean . data$ r )
72 c l ean . data$ r <− gsub ( ’ 33 ’ , 3 , c l ean . data$ r )
73 c l ean . data$ r <− gsub ( ’ 31 ’ , 2 , c l ean . data$ r )
74 c l ean . data$ r <− gsub ( ’ 32 ’ , 4 , c l ean . data$ r )
75
76 #cas t i n g data to g i v e non−p r o f i l e d compounds concentra t ion o f zero
77 data . c a s t <− dcast ( c l ean . data , sampleID+run+v e s s e l+donor+day+d+r˜variable ,
78 va lue . var=’ value ’ )
79
80 data . c a s t [ i s .na(data . c a s t ) ] <− 0
81
82 #mel t ing back to work with
83 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ , ’ d ’ ,
’ r ’ ) )
84
85 #adding ID fo r donor−run combo
86 data . melt$donor . run <− paste (data . melt$donor , data . melt$run , sep=’ . ’ )
87
88 #Desc r i p t i v e s t a t i s t i c s −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
89 stat <− d e s c r i p t i v e . stat (data . melt , data . type=’ long ’ , variable=’ va r i ab l e ’ )
90
91 #Plot o f RP vs RP2−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
92 plot . data <− stat
93 plot . data$x . code <− NULL
94 plot . data$x . code [ plot . data$donor %in% c ( ’RP ’ , ’RRP’ ) ] <− 1
95 plot . data$x . code [ plot . data$donor %in% c ( ’RP2 ’ , ’RRP2 ’ ) ] <− 2
96 plot . data$x <− plot . data$x
97 plot . data$x [ plot . data$run==’ 30 ’ ] <− plot . data$x [ plot . data$run==’ 30 ’ ] − 0 .18
98 plot . data$x [ plot . data$run==’ 33 ’ ] <− plot . data$x [ plot . data$run==’ 33 ’ ] + 0 .18
99 plot . data$x [ plot . data$run==’ 31 ’ ] <− plot . data$x [ plot . data$run==’ 31 ’ ] − 0 .18
100 plot . data$x [ plot . data$run==’ 32 ’ ] <− plot . data$x [ plot . data$run==’ 32 ’ ] + 0 .18
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101
102 #p l o t . data$run <− f a c t o r ( p l o t . data$run , l e v e l s=c ( ’30 ’ , ’ 33 ’ , ’ 31 ’ , ’ 32 ’ ) )
103 #p l o t . data$donor <− f a c t o r ( p l o t . data$donor , l e v e l s=c ( ’RP’ , ’RRP’ , ’RP2’ , ’RRP2’ ) )
104 cu l tu r e <− plot . data [ plot . data$donor %in% c ( ’RP ’ , ’RP2 ’ ) , ]
105 r e c i p r o c a l <− plot . data [ plot . data$donor %in% c ( ’RRP’ , ’RRP2 ’ ) , ]
106
107
108 p <− ggp lot (plot . data , aes ( x=x , y=value , co l ou r=r , l i n e t yp e=d) ) +
109 geom point ( aes (ymax=ymax , ymin=ymin ) ) +
110 stat boxplot (data=cul ture , alpha =0.6) +
111 stat boxplot (data=re c i p r o c a l , alpha =0.6) +
112 scale x cont inuous ( breaks=c ( 1 , 2 ) , l a b e l=c ( ’MET−2 ’ , ’MET−3 ’ ) ) +
113 scale l i n e t yp e manual ( va lue s=c ( 1 , 3 , 1 , 3 ) , name=’ Def ined cu l t u r e ’ ) +
114 theme bw(12) +
115 f a c e t wrap (˜variable , scale=’ f r e e y ’ , ncol=6) +
116 scale co l ou r manual ( va lue s=c ( ’ l i g h t c o r a l ’ , ’ cha r t r eu se4 ’ , ’ cyan3 ’ , ’ darkorange ’ ) ,
117 name=’Run ’ ) +
118 xlab ( ’ Def ined Culture ’ ) +
119 ylab ( ’ Concentrat ion (mM) ’ ) +
120 theme ( legend . p o s i t i o n=’ bottom ’ )
121
122
123 ggsave ( ’ . . /Plot s/donor d i f f e r e n c e s 4 . png ’ , p , he ight=25, width=23, un i t s=’cm ’ )
time course analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Time−course ana l y s i s o f Biomass samples
3
4 #sourc ing requ i red func t i ons
5 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions ’ )
6 source ( ’ funct ion−data cleanup .R ’ )
7 source ( ’ . . /Functions/ funct ion−ex t r a c t legend .R ’ )
8 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
9
10 #load ing requ i red packages
11 require (RSQLite )
12 require ( ggp lot2 )
13 require ( gr idExtra )
14 require ( p ly r )
15 require ( grid )
16
17
18 #s e t t i n g working d i r e c t o r y
19 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Biomass Samples/R Sc r i p t s/Analys i s ’ )
20
21 #Input data−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
22 #Choose d r i v e r
23 drv <− dbDriver ( ’ SQLite ’ )
24
25 #Create connecct ion ( f o r SQLite , t h i s i s a f i l e )
26 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
27
28 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
29 d . va r i ab l e , d . va lue
30 FROM Data d INNER JOIN Qua l i f i e r q
31 ON d . f i l e=q . f i l e
32 INNER JOIN Rank r
33 ON r .Compound=d . va r i ab l e
34 WHERE r . Conf idence = 1
35 ORDER BY q . sampleID ; ” )
36
37 input2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
38 d . va r i ab l e , d . va lue
39 FROM Data d INNER JOIN Qua l i f i e r q
40 ON d . f i l e=q . f i l e
41 INNER JOIN Rank r
42 ON r .Compound=d . va r i ab l e
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43 WHERE r . Conf idence = 1
44 AND q . run != ’Media cont ro l ’
45 ORDER BY q . sampleID ; ” )
46
47 s e t1 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
48 d . va r i ab l e , d . va lue
49 FROM Data d INNER JOIN Qua l i f i e r q
50 ON d . f i l e=q . f i l e
51 INNER JOIN Rank r
52 ON r .Compound=d . va r i ab l e
53 WHERE r . Conf idence = 1
54 AND q . run IN (30 ,33 , ’Media cont ro l ’ )
55 ORDER BY q . sampleID ; ” )
56
57 s e t2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
58 d . va r i ab l e , d . va lue
59 FROM Data d INNER JOIN Qua l i f i e r q
60 ON d . f i l e=q . f i l e
61 INNER JOIN Rank r
62 ON r .Compound=d . va r i ab l e
63 WHERE r . Conf idence = 1
64 AND q . run IN (31 ,32 , ’Media cont ro l ’ )
65 ORDER BY q . sampleID ; ” )
66
67 cmpd . i n f o <− dbGetQuery ( con , ”SELECT q . sampleID , q . run , q . v e s s e l , q . donor , q . day ,
68 d . va r i ab l e , d . value , c . Type
69 FROM Cmpd i n f o c INNER JOIN Data d
70 ON c .Compound=d . va r i ab l e
71 INNER JOIN Qua l i f i e r q
72 ON d . f i l e=q . f i l e
73 ORDER BY q . sampleID” )
74
75 dbDisconnect ( con )
76
77 #data cleanup−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
78 #Remove DSS, contminants and compounds o f zero concentra t ion
79 c l ean . data <− data cleanup ( set1 , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
80 form . y=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ , ’Type ’ )
,
81 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE,
82 convert .NA=TRUE)
83
84 #Ca lcu l a t ing mean va lue s o f t r i p l i c a t e s in se t2 and input−−−−−−−−−−−−−−−−−−−−−−−
85 i f (any( c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3 ’ ) ) ) {
86
87 H. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ ) , ]
88 R. rep <− c l ean . data [ c l ean . data$sampleID %in% c ( ’R1 ’ , ’R2 ’ , ’R3 ’ ) , ]
89
90 H <− ddply (H. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
91 H$sampleID <− ’H ’
92 H <− unique (H[ , −7 ] )
93 colnames (H) [ 7 ] <− ’ va lue ’
94
95 R <− ddply (R. rep , ’ v a r i a b l e ’ , mutate , avg=mean( va lue ) )
96 R$sampleID <− ’R ’
97 R <− unique (R[ , −7 ] )
98 colnames (R) [ 7 ] <− ’ va lue ’
99
100 #removing H1,H2,H3,R1,R2,R3
101 c l ean . data <− c l ean . data [ ! c l ean . data$sampleID %in% c ( ’H1 ’ , ’H2 ’ , ’H3 ’ , ’R1 ’ , ’R2 ’ , ’R3
’ ) , ]
102 #adding mean H and R
103 c l ean . data <− rbind ( c l ean . data , H, R)
104
105 print ( ’ here ’ )
106 }
107
108 #adding columns o f coded run and donor l a b e l s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
258
109 c l ean . data$d <− c l ean . data$donor
110 c l ean . data$d <− gsub ( ’RRP2 ’ , ’MET−3B ’ , c l ean . data$d)
111 c l ean . data$d <− gsub ( ’RP2 ’ , ’MET−3A ’ , c l ean . data$d)
112 c l ean . data$d <− gsub ( ’RRP’ , ’MET−2B ’ , c l ean . data$d)
113 c l ean . data$d <− gsub ( ’RP ’ , ’MET−2A ’ , c l ean . data$d)
114 c l ean . data$ r <− c l ean . data$run
115 c l ean . data$ r <− gsub ( ’ 30 ’ , 1 , c l ean . data$ r )
116 c l ean . data$ r <− gsub ( ’ 33 ’ , 3 , c l ean . data$ r )
117 c l ean . data$ r <− gsub ( ’ 31 ’ , 2 , c l ean . data$ r )
118 c l ean . data$ r <− gsub ( ’ 32 ’ , 4 , c l ean . data$ r )
119
120 #cas t i n g data to g i v e non−p r o f i l e d compounds concentra t ion o f zero
121 data . c a s t <− dcast ( c l ean . data , sampleID+run+v e s s e l+donor+day+d+r˜variable ,
122 value . var=’ value ’ )
123
124 data . c a s t [ i s .na(data . c a s t ) ] <− 0
125
126 #mel t ing back to work with
127 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ run ’ , ’ v e s s e l ’ , ’ donor ’ , ’ day ’ , ’ d ’ ,
’ r ’ ) )
128
129 #adding ID fo r donor−run combo
130 data . melt$donor . run <− paste (data . melt$donor , data . melt$run , sep=’ . ’ )
131
132 #ID for run r e p l i c a t e s
133 data . melt$run . rep <− data . melt$donor . run
134 data . melt$run . rep [ data . melt$run . rep %in% c ( ’RP.30 ’ , ’RP.33 ’ , ’RRP.30 ’ , ’RRP.33 ’ ) ] <−
’ 30 .33 ’
135 data . melt$run . rep [ data . melt$run . rep %in% c ( ’RP2.31 ’ , ’RP2.32 ’ , ’RRP2.31 ’ , ’RRP2.32 ’ ) ]
<− ’ 31 .32 ’
136
137 #conver t ing day to numeric
138 data . melt$day <− as .numeric (data . melt$day )
139
140 #Plo t t i n g over time−bar
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
141 plot . l i s t <− l i s t ( )
142 for ( i in unique (data . melt$variable ) ) {
143 plot . data <− data . melt [ data . melt$variable == i , ]
144 plot . data$run <− factor (plot . data$run , levels=c ( ’Media c on t r o l ’ , ’ 30 ’ , ’ 33 ’ , ’ 31 ’ , ’
32 ’ ) )
145 plot . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=donor , y=value , f i l l =day , shape=run ) ) +
146 geom bar ( p o s i t i o n=’ dodge ’ , stat=’ i d e n t i t y ’ ) +
147 f a c e t wrap (˜ run , s c a l e s=’ f r e e x ’ , nrow=1) +
148 theme bw(12) +
149 g g t i t l e ( i ) +
150 theme ( legend . p o s i t i o n=’ none ’ ,
151 t i t l e=element text ( s i z e =8) ,
152 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
153
154 }
155
156 l . plot <− ggp lot (plot . data , aes ( x=donor , y=value , f i l l =day , shape=run ) ) +
157 geom bar ( p o s i t i o n=’ dodge ’ , stat=’ i d e n t i t y ’ ) +
158 f a c e t wrap (˜ run , s c a l e s=’ f r e e x ’ , nrow=1) +
159 theme bw(14)
160 legend <− g legend ( l . plot )
161
162 png ( f i l ename=’ . . /Plot s/Time−bar p l o t s . png ’ , width=50, he ight=60, un i t s=’cm ’ , r e s
=240)
163 do . ca l l ( grid . arrange , plot . l i s t )
164 dev . of f ( )
165
166 #Looking f o r l i n e a r i t y
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
167 custom l i n e a r <− function (data , group ) {
168 aov . lm <− d lp ly (data , group , aov , formula=value˜day )
169 out <− l dp ly (aov . lm , anova)
259
170 return ( out )
171 }
172
173 lm . run <− ddply (data . melt , ’ v a r i a b l e ’ , custom l i n e a r , ’ run ’ )
174 s . lm . run <− lm . run [ lm . run [ , ’ Pr(>F) ’ ] <= 0.1 & ! i s .na(lm . run [ , ’ Pr(>F) ’ ] ) , ]
175
176 lm . dr <− ddply (data . melt , ’ v a r i a b l e ’ , custom l i n e a r , ’ donor . run ’ )
177 s . lm . dr <− lm . dr [ lm . dr [ , ’ Pr(>F) ’ ] <=0.1 & ! i s .na(lm . dr [ , ’ Pr(>F) ’ ] ) , ]
178
179 #Plo t t i n g over time−s ca t t e r
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
180
181 p . s c a t t e r <− ggp lot (data . melt , aes ( x=day , y=value , shape=donor , co l ou r=run ) ) +
182 geom point ( ) +
183 geom path ( ) +
184 f a c e t wrap (˜ variable , s c a l e s=’ f r e e ’ ) +
185 scale co l ou r manual ( va lue s=c ( ’ cha r t r eu se4 ’ , ’ darkorange ’ , ’ b lue ’ ) ) +
186 theme bw(12) +
187 theme ( t i t l e=element text ( s i z e =8) ,
188 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
189
190 ggsave ( f i l e=’ . . /Plot s/Time course/Run 31 and 32/Al l compounds2 . png ’ , p . s c a t t e r ,
191 he ight=25, width=30, un i t s=’cm ’ )
192
193 #Compounds showing l i n e a r i t y as de f ined by runs−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
194 lm . run <− data . melt [ data . melt$variable %in% unique ( s . lm . run$variable ) , ]
195
196 p . lm . run <− ggp lot (lm . run , aes ( x=day , y=value , shape=donor , co l ou r=run ) ) +
197 geom point ( ) +
198 geom path ( ) +
199 f a c e t wrap (˜ variable , s c a l e s=’ f r e e ’ ) +
200 theme bw(12) +
201 theme ( t i t l e=element text ( s i z e =8) ,
202 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
203
204 ggsave ( f i l e=’ . . /Plot s/Time course/Run 31 and 32/ l i n e a r−run . png ’ , p . lm . run ,
205 he ight=15, width=25, un i t s=’cm ’ )
206
207 #Compounds showing l i n e a r i t y as de f ined by donors wi th in runs−−−−−−−−−−−−−−−−
208 lm . dr <− data . melt [ data . melt$variable %in% unique ( s . lm . dr$variable ) , ]
209
210 p . lm . dr <− ggp lot (lm . dr , aes ( x=day , y=value , shape=donor , co l ou r=run ) ) +
211 geom point ( ) +
212 geom path ( ) +
213 f a c e t wrap (˜ variable , s c a l e s=’ f r e e ’ ) +
214 theme bw(12) +
215 theme ( t i t l e=element text ( s i z e =8) ,
216 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
217
218 ggsave ( f i l e=’ . . /Plot s/Time course/Run 30 and 33/ l i n e a r−donor with in runs . png ’ , p . lm
. dr ,
219 he ight=20, width=30, un i t s=’cm ’ )
220
221 #Reaching common poin t Run 30 and 33−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
222 comm. lm <− c ( ’ Alanine ’ , ’ Asparagine ’ , ’ Aspartate ’ , ’ Betaine ’ , ’ Ethanol ’ , ’ Fructose ’ ,
223 ’ Glyce ro l ’ , ’ G lyco la te ’ , ’ Hydroxyacetone ’ , ’ Propionate ’ , ’Thymine ’ ,
224 ’ Urac i l ’ , ’ Va le rate ’ )
225
226 comm. notlm <− c ( ’ Glucose ’ , ’ Phenyla lan ine ’ , ’ Succ inate ’ , ’ Threonine ’ , ’ Tyros ine ’ ,
227 ’ Xylose ’ )
228
229 one .comm <− c ( ’ Acetate ’ , ’ Butyrate ’ , ’ Chol ine ’ , ’ Fumarate ’ , ’ Glyc ine ’ , ’ I s obuty ra t e ’ ,
230 ’ I s o l e u c i n e ’ , ’ Leucine ’ , ’ Lys ine ’ , ’Methanol ’ , ’ Methionine ’ , ’Methylamine ’
,
231 ’ Pro l i n e ’ , ’ S e r ine ’ , ’ Trimethylamine ’ , ’ Val ine ’ )
232
233 cmpd . l i s t <− l i s t (comm. lm , comm. notlm , one .comm)
234
260
235 p . l i s t <− l i s t ( )
236 ncol <− c ( 4 , 3 , 4 )
237 width <− c (17 , 15 , 20)
238 he ight <− c (12 , 10 , 20)
239
240 for ( i in 1 : length (cmpd . l i s t ) ) {
241 plot . data <− data . melt [ data . melt$variable %in% cmpd . l i s t [ [ i ] ] , ]
242 plot . data <− plot . data [ plot . data$run != ’Media c on t r o l ’ , ]
243
244 p . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=day , y=value , shape=d , co l our=r ) ) +
245 geom point ( ) +
246 geom path ( ) +
247 theme bw(11) +
248 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=ncol [ i ] ) +
249 scale co l ou r d i s c r e t e (name=’Run ’ ) +
250 scale shape d i s c r e t e (name=’Donor ’ ) +
251 scale x cont inuous ( breaks=c (6 , 14 , 20 ) ) +
252 xlab ( ’Day ’ ) +
253 ylab ( ’ Concentrat ion (mM) ’ ) +
254 theme ( legend . d i r e c t i o n=’ ho r i z on t a l ’ , legend . p o s i t i o n=’ bottom ’ ,
255 legend .box=’ ho r i z on t a l ’ )
256 }
257
258 vp <− viewport ( x=0.5 , y=0.5 , width=uni t (17 , ’cm ’ ) , he ight=uni t (18 , ’cm ’ ) )
259
260 png ( f i l ename=’ . . /Plot s/Time course/Run 30 and 33/common point2 . png ’ ,
261 width=17, he ight=25, un i t s=’cm ’ , r e s =300 , p o i n t s i z e =11)
262 plot .new( )
263 pushViewport ( vp )
264 print (p . l i s t [ [ 1 ] ] , vp=viewport ( x=0.5 , y=0.75 , width=uni t (17 , ’cm ’ ) ,
265 he ight=uni t (16 , ’cm ’ ) ) )
266 print (p . l i s t [ [ 2 ] ] , vp=viewport ( x=0.385 , y=0.12 , width=uni t (13 , ’cm ’ ) ,
267 he ight=uni t (10 , ’cm ’ ) ) )
268 grid . text ( ’A ’ , x=0.03 , y=1.155 , gp=gpar ( cex=1.5) )
269 grid . text ( ’B ’ , x=0.03 , y=0.36 , gp=gpar ( cex=1.5) )
270 dev . of f ( )
271
272 ggsave ( ’ . . /Plot s/Time course/Run 30 and 33/common point−one run2 . png ’ , p . l i s t [ [ 3 ] ] ,
273 width=18, he ight=18, un i t s=’cm ’ )
274
275 #Reaching common poin t Run 31 and 32−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
276 comm. lm <− c ( ’ Alanine ’ , ’ Asparagine ’ , ’ Glutamate ’ , ’ Glyc ine ’ , ’ P ro l i n e ’ )
277
278 comm. notlm <− c ( ’ Butyrate ’ , ’ Glucose ’ , ’ Galactose ’ , ’ Glutamate ’ , ’ Hydroxyacetone ’ ,
279 ’ I s obuty ra t e ’ , ’ I s o l e u c i n e ’ , ’ I s o v a l e r a t e ’ , ’ Methionine ’ ,
280 ’ Phenyla lan ine ’ , ’ Propionate ’ , ’ Tyros ine ’ , ’ Urace l ’ , ’ Va le rate ’ ,
281 ’ Val ine ’ , ’ Xylose ’ )
282
283 one .comm <− c ( ’ Acetate ’ , ’ Aspartate ’ , ’ Benzoate ’ , ’ Betaine ’ , ’ Chol ine ’ , ’ Ethanol ’ ,
284 ’ Leucine ’ , ’Methanol ’ , ’ Phenylacetate ’ , ’ Pyroglutamate ’ ,
285 ’ Trimethylamine ’ )
286
287 cmpd . l i s t <− l i s t (comm. lm , comm. notlm , one .comm)
288
289 p . l i s t <− l i s t ( )
290 ncol <− c ( 5 , 5 , 4 )
291 width <− c (20 , 17 , 18)
292 he ight <− c (5 , 16 , 12)
293 for ( i in 1 : length (cmpd . l i s t ) ) {
294 plot . data <− data . melt [ data . melt$variable %in% cmpd . l i s t [ [ i ] ] , ]
295 plot . data <− plot . data [ plot . data$run != ’Media c on t r o l ’ , ]
296
297 p . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=day , y=value , shape=d , co l our=r ) ) +
298 geom point ( ) +
299 geom path ( ) +
300 theme bw(11) +
301 f a c e t wrap (˜variable , s c a l e s=’ f r e e ’ , ncol=ncol [ i ] ) +
302 scale co l ou r manual ( va lue s=c ( ’ cha r t r eu se4 ’ , ’ darkorange ’ ) , name=’Run ’ ) +
261
303 scale shape d i s c r e t e (name=’Donor ’ ) +
304 scale x cont inuous ( breaks=c (6 , 14 , 20 ) ) +
305 xlab ( ’Day ’ ) +
306 ylab ( ’ Concentrat ion (mM) ’ ) +
307 theme ( legend . d i r e c t i o n=’ ho r i z on t a l ’ , legend . p o s i t i o n=’ bottom ’ ,
308 legend .box=’ ho r i z on t a l ’ )
309 }
310
311 vp <− viewport ( x=0.5 , y=0.5 , width=uni t (17 , ’cm ’ ) , he ight=uni t (15 , ’cm ’ ) )
312
313 png ( f i l ename=’ . . /Plot s/Time course/Run 31 and 32/common point2 . png ’ ,
314 width=17, he ight=25, un i t s=’cm ’ , r e s =300 , p o i n t s i z e =11)
315 plot .new( )
316 pushViewport ( vp )
317 print (p . l i s t [ [ 1 ] ] , vp=viewport ( x=0.5 , y=1.1 , width=1, he ight =0.4) )
318 print (p . l i s t [ [ 2 ] ] , vp=viewport ( x=0.5 , y=0.57 , width=1, he ight =0.85) )
319 grid . text ( ’A ’ , x=0.03 , y=1.3 , gp=gpar ( cex=1.5) )
320 grid . text ( ’B ’ , x=0.03 , y=0.95 , gp=gpar ( cex=1.5) )
321 dev . of f ( )
322
323 ggsave ( ’ . . /Plot s/Time course/Run 31 and 32/common point−one run2 . png ’ , p . l i s t [ [ 3 ] ] ,
324 width=width [ 3 ] , he ight=15, un i t s=’cm ’ )
C.4 Metabolomic Analysis of Human Fecal Microbiota
Data source.R
1 #/////////////////////////////////////////////////////////////////////////////////
2 #This i s a database o f a l l donors and repoopu la te c u l t u r e s
3
4 #load ing requ i red packages
5 require (RSQLite )
6 require ( reshape2 )
7
8 #Se t t i n g working d i r e c t o r y
9 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data source
f i l e s / ’ )
10
11 #Sourcing requ i red func t i ons
12 source ( ’ . . / f un c t i on s/ funct ion−summary p r ep ro c e s s i ng .R ’ )
13
14 #Gett ing raw data f i l e s from each p ro j e c t
15 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
16 #Uric ac id p ro j e c t
17
18 rp2 . ua . raw <− summary . p r ep roce s s ( f i l e . name=’C:/Users/Sandi/Dropbox/Pro j e c t s/Uric
ac id Pro j e c t/Resu l t s/Expt 1 and 2−UA NMR/R Sc r i p t s/Data source f i l e s /UA Expt 2
summary2 . csv ’ )
19
20 rp2 . ua <− rp2 . ua . raw [ [ ’ data ’ ] ]
21 molwt . rp2 . ua <− rp2 . ua . raw [ [ ’mol . wt ’ ] ]
22
23 rp2 . ua . melt <− melt ( rp2 . ua , id . vars=’ f i l e ’ )
24
25 d9 . raw <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Uric ac id Pro j e c t/
Resu l t s/Expt 1 and 2−UA NMR/R Sc r i p t s/Data source f i l e s /UA Expt 1 summary2 . csv ’
)
26
27 d9 <− d9 . raw [ [ ’ data ’ ] ]
28 molwt . d9 <− d9 . raw [ [ ’mol . wt ’ ] ]
29
30 d9 . melt <− melt (d9 , id . vars=’ f i l e ’ )
262
31 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
32 #Repoopulate samples
33 rp1 . raw <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Repoopulate samples/
R s c r i p t s /Data source f i l e s /Concentrat ions−RepoopI mM3. csv ’ )
34
35 rp1 <− rp1 . raw [ [ ’ data ’ ] ]
36 molwt . rp1 <− rp1 . raw [ [ ’mol . wt ’ ] ]
37
38 rp1 . melt <− melt ( rp1 , id . vars=’ f i l e ’ )
39
40 rp2 . raw <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Repoopulate samples/
R s c r i p t s /Data source f i l e s /Concentrat ions−RepoopII mM2. csv ’ )
41
42 rp2 <− rp2 . raw [ [ ’ data ’ ] ]
43 molwt . rp2 <− rp2 . raw [ [ ’mol . wt ’ ] ]
44
45 rp2 . melt <− melt ( rp2 , id . vars=’ f i l e ’ )
46 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
47 #Liquid Gold samples
48 l g . raw <− summary . p r ep roce s s ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s
/V 3.0/Data source f i l e s /D5 D8 summary mM3. csv ’ )
49
50 l g <− l g . raw [ [ ’ data ’ ] ]
51 molwt . l g <− l g . raw [ [ ’mol . wt ’ ] ]
52
53
54 l g . melt <− melt ( lg , id . vars=’ f i l e ’ )
55 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
56 #put t i n g a l l samples t o g e t h e r in to one data frame
57 data <− rbind ( rp2 . ua . melt , d9 . melt , rp1 . melt , rp2 . melt , l g . melt )
58 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
59 #ge t t i n g molecular weight o f compounds
60 cmpd . molwt <− unique (as . data . frame ( t (cbind (molwt . rp2 . ua , molwt . d9 ,
61 molwt . rp1 , molwt . rp2 , molwt . l g ) ) ) )
62 cmpd . molwt$variable <− rownames(cmpd . molwt )
63
64 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
65 #Making Qua l i f i e r s
66 q . rp2 . ua <− data . frame ( f i l e=rp2 . ua$ f i l e ,
67 sampleID=LETTERS[ 1 : 1 7 ] ,
68 donor=rep ( ’RP2 ’ ,17) ,
69 v e s s e l=c (0 , rep ( 1 , 6 ) , rep (2 , 10) ) ,
70 DPI=rep (NA, 17) ,
71 phase=c (0 , rep ( 1 , 3 ) , rep ( 2 , 3 ) , rep ( 3 , 7 ) , rep ( 4 , 3 ) ) ,
72 hour=c ( I (−24)
, 0 , 24 , 32 , 48 , 72 , 80 , 0 . 25 , 0 . 5 , 1 , 2 , 4 , 24 , 32 , 48 , 72 , 80 ) ,
73 dose=c (0 , rep (360 ,3 ) , rep (720 ,3 ) , rep (360 ,10) ) ,
74 dose . type=c (NA, ’ sp ike ’ , rep ( ’ f e ed ’ ,15) ) ,
75 expt=rep ( ’UA Expt2 ’ ,17) )
76
77 q . rp2 . ua$scan <− NA
78 q . rp2 . ua$ treatment <− c ( rep ( ’UA’ ,14) , rep ( ’ Vancomycin ’ , 3 ) )
79 q . rp2 . ua$run <− 5
80 q . rp2 . ua$gen . t r e a t <− c ( rep ( ’None ’ , 14) , rep ( ’ Vancomycin ’ , 3 ) )
81 q . rp2 . ua$ s t a t e <− ’ s s ’
82
83 #making donor o f c l a s s charac ter
84 q . rp2 . ua$donor <− as . character (q . rp2 . ua$donor )
263
85
86 q . d9 <− data . frame ( f i l e=d9$ f i l e ,
87 sampleID=LETTERS[ 1 8 : 2 5 ] ,
88 donor=rep ( ’C ’ , 8 ) ,
89 v e s s e l=rep ( 3 , 8 ) ,
90 DPI=c (40 ,41 ,44 ,45 ,48 ,49 ,52 ,53 ) ,
91 phase=rep (NA, 8 ) ,
92 hour=rep (NA, 8 ) ,
93 dose=c ( rep ( 0 , 2 ) , rep (360 ,6 ) ) ,
94 dose . type=rep ( ’ f e ed ’ , 8 ) ,
95 expt=rep ( ’UA Expt1 ’ , 8 ) )
96
97 #adding columns to match other q u a l i f i e r s e t s
98 q . d9$scan <− NA
99 q . d9$ treatment <− c ( rep ( ’None ’ , 2 ) , rep ( ’UA’ ,nrow(q . d9 )−2) )
100 q . d9$run <− 4
101 q . d9$gen . t r e a t <− rep ( ’None ’ , nrow(q . d9 ) )
102 q . d9$ s t a t e <− ’ s s ’
103
104 #making donor o f c l a s s charac ter
105 q . d9$donor <− as . character (q . d9$donor )
106
107 q . rp1 <− data . frame ( f i l e=rp1$ f i l e ,
108 sampleID=paste ( ’RP1 .D ’ ,c ( 0 , 3 , 5 , 7 , 10 ) , sep=’ ’ ) ,
109 DPI=c ( 0 , 3 , 5 , 7 , 10 ) ,
110 donor=rep ( ’RP1 ’ , 5 ) ,
111 expt=rep ( ’RP1 ’ , 5 ) )
112
113 #adding columns to match other q u a l i f i e r s e t s
114 q . rp1$ v e s s e l <− NA
115 q . rp1$phase <− NA
116 q . rp1$dose <− NA
117 q . rp1$dose . type <− NA
118 q . rp1$scan <− NA
119 q . rp1$ treatment <− rep ( ’ none ’ ,nrow(q . rp1 ) )
120 q . rp1$run <− 6
121 q . rp1$hour <− NA
122 q . rp1$gen . t r e a t <− rep ( ’None ’ , nrow(q . rp1 ) )
123 q . rp1$ s t a t e <− c ( ’ uss ’ , rep ( ’ s s ’ , 4 ) )
124
125 #making donor o f c l a s s charac ter
126 q . rp1$donor <− as . character (q . rp1$donor )
127
128 q . rp2 <− data . frame ( f i l e=rp2$ f i l e ,
129 sampleID= paste ( ’RP2 .V ’ ,c ( 1 , 2 ) , sep=’ ’ ) ,
130 DPI=rep (NA, 2) ,
131 donor=rep ( ’RP2 ’ , 2 ) ,
132 expt=rep ( ’RP2 ’ , 2) )
133
134 #adding columns to match other q u a l i f i e r s e t s
135 q . rp2$ v e s s e l <− NA
136 q . rp2$phase <− NA
137 q . rp2$dose <− NA
138 q . rp2$dose . type <− NA
139 q . rp2$scan <− NA
140 q . rp2$ treatment <− rep ( ’None ’ , nrow(q . rp2 ) )
141 q . rp2$run <− 7
142 q . rp2$hour <− NA
143 q . rp2$gen . t r e a t <− rep ( ’None ’ , nrow(q . rp2 ) )
144 q . rp2$ s t a t e <− ’ s s ’
145
146 #making donor o f c l a s s charac ter
147 q . rp2$donor <− as . character (q . rp2$donor )
148
149 q . l g <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Data
source f i l e s /Liquid gold q u a l i f i e r . csv ’ ,
150 header=TRUE, check .names=FALSE, encoding=’UTF−8 ’ )
151 q . l g$expt <− NA
264
152 q . l g$expt [q . l g$Donor == ’A ’ ] <− ’ L iquid gold D5 ’
153 q . l g$expt [q . l g$Donor == ’B ’ ] <− ’ L iquid gold D8 ’
154 q . l g <− q . l g [ , colnames (q . l g ) != ’ Plot . Treat ’ ]
155 colnames (q . l g ) <− c ( ’ f i l e ’ , ’ scan ’ , ’ donor ’ , ’ run ’ , ’ treatment ’ , ’DPI ’ , ’ s t a t e ’ , ’ v e s s e l ’ ,
156 ’ gen . t r e a t ’ , ’ sampleID ’ , ’ expt ’ )
157
158 q . l g$run [q . l g$run == 1 ] <− 8
159 q . l g$run [q . l g$run == 2 ] <− 1
160 q . l g$run [q . l g$run == 3 ] <− 2
161 q . l g$run [q . l g$run == 4 ] <− 3
162
163 #adding columns to match other q u a l i f i e r s e t s
164 q . l g$phase <− NA
165 q . l g$dose <− NA
166 q . l g$hour <− NA
167 q . l g$dose . type <− NA
168
169
170 #making donor o f c l a s s charac ter
171 q . l g$donor <− as . character (q . l g$donor )
172
173 #put t i n g a l l q u a l i f i e r s t o g e t h e r
174 q u a l i f i e r <− rbind (q . rp2 . ua , q . d9 , q . rp1 , q . rp2 , q . l g )
175 q u a l i f i e r $expt <− as . character ( q u a l i f i e r $expt )
176 q u a l i f i e r $ v e s s e l <− as . character ( q u a l i f i e r $ v e s s e l )
177 q u a l i f i e r $ s t a t e <− as . character ( q u a l i f i e r $ s t a t e )
178
179 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
180 #Gett ing compound annotat ions
181 rank . rp2 . ua <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Uric ac id Pro j e c t/Resu l t s/
Expt 1 and 2−UA NMR/R Sc r i p t s/Data source f i l e s /Compound annotat ions−RepoopII−
UA. csv ’ ,
182 encoding=’UTF−8 ’ )
183 rank . rp2 . ua <− rank . rp2 . ua [ , 1 : 7 ]
184 rank . rp2 . ua$expt <− ’UA Expt2 ’
185
186 rank . d9 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Uric ac id Pro j e c t/Resu l t s/Expt
1 and 2−UA NMR/R Sc r i p t s/Data source f i l e s /Compound annotat ions−Donor 9 . csv ’ ,
187 encoding=’UTF−8 ’ )
188 rank . d9 <− rank . d9 [ , 1 : 7 ]
189 rank . d9$expt <− ’UA Expt1 ’
190
191 rank . rp1 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Repoopulate samples/R s c r i p t s
/Data source f i l e s /Compound annotat ions−RepoopI . csv ’ ,
192 encoding=’UTF−8 ’ )
193 rank . rp1 <− rank . rp1 [ , 1 : 7 ]
194 rank . rp1$expt <− ’RP1 ’
195
196 rank . rp2 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Repoopulate samples/R s c r i p t s
/Data source f i l e s /Compound annotat ions−RepoopII . csv ’ ,
197 encoding=’UTF−8 ’ )
198 rank . rp2 <− rank . rp2 [ , 1 : 7 ]
199 rank . rp2$expt <− ’RP2 ’
200
201 rank . d5 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 2.0/
data source f i l e s /Export−l i q u i d gold conf idence−D5 . csv ’ ,
202 header=TRUE, encoding=’UTF−8 ’ )
203 rank . d5 <− rank . d5 [ , 1 : 7 ]
204 colnames (rank . d5 ) <− c ( ’Compound ’ , ’ C lu s t e r s ’ , ’ Convolution ’ , ’ Cons i s tency ’ , ’
Conf idence ’ , ’X . . o f . P r o f i l e s ’ , ’X . . o f . P r o f i l e s ’ )
205 rank . d5$expt <− ’ L iquid gold D5 ’
206
207 rank . d8 <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 2.0/
data source f i l e s /Export−l i q u i d gold conf idence−D8 . csv ’ ,
208 header=TRUE, encoding=’UTF−8 ’ )
209 rank . d8 <− rank . d8 [ , 1 : 7 ]
265
210 colnames (rank . d8 ) <− c ( ’Compound ’ , ’ C lu s t e r s ’ , ’ Convolution ’ , ’ Cons i s tency ’ , ’
Conf idence ’ , ’X . . o f . P r o f i l e s ’ , ’X . . o f . P r o f i l e s ’ )
211 rank . d8$expt <− ’ L iquid gold D8 ’
212
213
214 #put t i n g a l l rankings t o g e t h e r
215 rank <− rbind (rank . rp2 . ua , rank . d9 , rank . rp1 , rank . rp2 , rank . d5 , rank . d8 )
216 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
217 #metabo l i t e pathway
218 path . data <− read . csv ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/
Data source f i l e s /Compound pathway annotat ion . csv ’ ,
219 header=FALSE)
220 path . data <− path . data [ 1 : 1 5 3 , ]
221
222 #Gett ing compound types
223 cmpd . type <− data . frame (Compound=t (path . data [ 1 , 2 : ncol (path . data ) ] ) ,
224 Type=t (path . data [ 2 , 2 : ncol (path . data ) ] ) )
225 colnames (cmpd . type ) <− c ( ’Compound ’ , ’Type ’ )
226
227 #Categor i z ing pathways
228 main .path <− data . frame (main=c ( rep ( ’ Carbohydrates ’ , 12) ,
229 rep ( ’ Catecholamines ’ , 5) ,
230 rep ( ’ Vitamins ’ , 8) ,
231 rep ( ’ An t i b i o t i c s ’ , 3 ) ,
232 rep ( ’ L ip id s ’ , 9 ) ,
233 rep ( ’Amino ac id s ’ , 28) ,
234 rep ( ’ Purine , Pyrimidine ’ , 4) ,
235 rep ( ’ Fatty ac id s ’ , 6) ,
236 rep ( ’ Organic a c id s ’ , 9) ,
237 rep ( ’ Pro te in s ’ , 5) ,
238 rep ( ’ Ino rgan i c Compounds ’ , 4) ,
239 rep ( ’ S t e ro id Hormones ’ , 4) ,
240 rep ( ’ Centra l Metabol ic Pathways ’ , 8) ,
241 rep ( ’ Aromatic Compounds ’ , 8 ) ,
242 rep ( ’ Neurotransmit te r s ’ , 3 ) ,
243 rep ( ’ Cytochromes ’ , 3) ,
244 rep ( ’ Other ’ , 31) ) ,
245 path=path . data [ 4 :nrow(path . data ) , 1 ] )
246
247 # removing pathway headings from ex c e l ver s ion
248 main <− main .path[−c (1 , 13 ,18 ,26 ,29 ,38 ,66 ,70 ,
249 76 ,85 ,90 ,94 ,98 ,106 ,114 ,117 ,120) , ]
250
251 #Gett ing pathway assignment f o r each compound
252 col . name <− as . character (as .matrix (path . data [ 1 , 2 : ncol (path . data ) ] ) )
253 row . name <− as . character (as .matrix (path . data [ 4 :nrow(path . data ) , 1 ] ) )
254
255 path <− path . data [ 4 :nrow(path . data ) , 2 : ncol (path . data ) ]
256 colnames (path ) <− col . name
257 rownames(path ) <− row . name
258 path <− path[−c (1 , 13 ,18 ,26 ,29 ,38 ,66 ,70 ,
259 76 ,85 ,90 ,94 ,98 ,106 ,114 ,117 ,120) , ]
260
261 pathway <− c ( )
262 for ( i in 1 : ncol (path ) ) {
263 temp <− path [ i ]
264 yes <− rownames( temp) [ temp [ 1 ] == ’Y ’ ]
265 out <− data . frame (Compound=rep (colnames ( temp) , length ( yes ) ) , Pathway=yes )
266 pathway <− rbind ( pathway , out )
267 }
268
269 # Create the connect ion (no f i l e needed ) −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
270
271 # Choose d r i v e r
272 drv = dbDriver ( ’ SQLite ’ )
273
266
274 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
275 con = dbConnect ( drv , ’ data . db ’ )
276
277 # Creating database t a b l e s
278 data . table <− dbWriteTable ( con , ’Data ’ , data , ove rwr i t e=TRUE)
279
280 q u a l i f i e r . table <− dbWriteTable ( con , ’ Qu a l i f i e r ’ , q u a l i f i e r , ove rwr i t e=TRUE)
281
282 q . rp2 . ua . table <− dbWriteTable ( con , ’Q RP2 UA’ , q . rp2 . ua , ove rwr i t e=TRUE)
283 q . d9 . table <− dbWriteTable ( con , ’Q D9 ’ , q . d9 , ove rwr i t e=TRUE)
284 q . rp1 . table <− dbWriteTable ( con , ’Q RP1 ’ , q . rp1 , ove rwr i t e=TRUE)
285 q . rp2 . table <− dbWriteTable ( con , ’Q RP2 ’ , q . rp2 , ove rwr i t e=TRUE)
286 q . l g . table <− dbWriteTable ( con , ’Q LG ’ , q . lg , ove rwr i t e=TRUE)
287
288 rank . table <− dbWriteTable ( con , ’Rank ’ , rank , ove rwr i t e=TRUE)
289
290 molwt . table <− dbWriteTable ( con , ’Mol wt ’ , cmpd . molwt , ove rwr i t e=TRUE)
291
292 cmpdtype . table <− dbWriteTable ( con , ’Cmpd type ’ , cmpd . type , ove rwr i t e=TRUE)
293
294 main . table <− dbWriteTable ( con , ’Main pathway ’ , main , ove rwr i t e=TRUE)
295
296 path . table <− dbWriteTable ( con , ’Pathway ’ , pathway , ove rwr i t e=TRUE)
297
298 t ab l e s <− dbGetQuery ( con , ”SELECT ∗ FROM s q l i t e master WHERE type=’ tab le ’ ; ” )
299 print ( t ab l e s )
300
301 dbDisconnect ( con )
PCA analysis.R
1 #/////////////////////////////////////////////////////////////////////////////////
2 #Modif ied f o r Manuscript A
3 #Analys i s to compare samples across p r o j e c t s
4
5 #load ing requr i ed packages
6 require (RSQLite )
7 require ( ggp lot2 )
8
9 #sourc ing requ i red func t i ons
10 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/ ’ )
11 source ( ’ funct ion−pca .R ’ )
12 source ( ’ funct ion−p l o t t i n g 2D sco r e .R ’ )
13 source ( ’ funct ion−p l o t t i n g 2D load ing .R ’ )
14 source ( ’ funct ion−pca d i a gno s t i c s .R ’ )
15 source ( ’ funct ion−data cleanup .R ’ )
16 source ( ’ funct ion−s c a l i n g .R ’ )
17
18 #s e t t i n g working d i r e c t o r y
19 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript A ’
)
20
21 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
22 #Input data
23 # Choose d r i v e r
24 drv <− dbDriver ( ’ SQLite ’ )
25
26 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
27 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
28
29 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
30 q . hour , q . phase , q . dose , q . treatment , q . gen t reat , q . expt ,
31 d . va r i ab l e , d . va lue
32 FROM Data d INNER JOIN Qua l i f i e r q
33 ON d . f i l e = q . f i l e
34 INNER JOIN Rank r
35 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
36 INNER JOIN Cmpd type c
267
37 ON r .Compound = c .Compound
38 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
39 AND (q . run != 8 OR q . run IS NULL)
40 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
41 AND q . s t a t e = ’ ss ’
42 AND q . donor != ’RP1’
43 AND q . expt != ’RP2’
44 ORDER BY q . sampleID ; ” )
45
46 dbDisconnect ( con )
47 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
48 #conver t ing f a c t o r s to appropr ia te c l a s s e s
49 input$run <− as . character ( input$run )
50
51 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
52 #Performing c learnup func t ion to remove DSS, contaminants and compounds o f
53 #zero concentra t ion
54
55 c l ean . data <− data cleanup ( input , ’ sampleID ’ , ’ v a r i ab l e ’ , ’ va lue ’ ,
56 form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ , ’DPI ’ ,
57 ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ , ’ gen t r e a t ’ ,
58 ’ expt ’ ) ,
59 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE)
60
61 c l ean . data$dr <− paste ( c l ean . data$donor , c l ean . data$run , sep=’ . ’ )
62 c l ean . data$dr <− factor ( c l ean . data$dr , levels=c ( ’A. 1 ’ , ’A. 2 ’ , ’B. 3 ’ , ’C. 4 ’ , ’RP2. 5 ’ ) )
63 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
64 #performing the PCA
65 pca . data = perform pca ( c l ean . data , sampleID=’ sampleID ’ ,
66 variable=’ va r i ab l e ’ , va lue=’ va lue ’ ,
67 form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ , ’DPI ’ ,
68 ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ , ’ gen t r e a t ’ ,
69 ’ expt ’ , ’ dr ’ ) ,
70 form . x=’ va r i ab l e ’ ,
71 scale=’UV’ , c en t e r=TRUE, convert .NA=TRUE)
72 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73 #performing d i a gno s t i c s on PCA
74 d i a gno s t i c . r e s u l t s = s c r e e plot ( pca . data )
75
76 #unpacking the d i a gno s t i c r e s u l t s
77 d i a gno s t i c . number = d i a gno s t i c . r e s u l t s [ [ ’ number ’ ] ]
78 d i a gno s t i c . exp la ined = d i a gno s t i c . r e s u l t s [ [ ’ exp la ined ’ ] ]
79 d i a gno s t i c . plot = d i agno s t i c . r e s u l t s [ [ ’ p l o t ’ ] ]
80 d i a gno s t i c . plot = d i agno s t i c . plot + g g t i t l e ( ’ Scree Plot (UVN) ’ )
81
82 #pr in t i n g out d i a gno s t i c r e s u l t s
83 print ( d i a gno s t i c . number )
84 print ( d i a gno s t i c . exp la ined )
85 print ( d i a gno s t i c . plot )
86 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
87 #p l o t t i n g PCA−processed data
88 #Score p l o t 2D
89 # Note : Arguments f o r score p l o t func t i on are
90 # (pca data , q u a l i f i e r data , PCs=1:4 , co lour=NULL, shape=NULL, s i z e=NULL,
91 # l a b e l=NULL, t i t l e=NULL, legend . o r i=’ hor i zon ta l ’ , b l a c k whi te=FALSE)
92
93 s co r e plot = sco r e plot 2d( pca . data , PCs=1:4 ,
94 shape=’ dr ’ ,
95 legend . o r i= ’ ho r i z on t a l ’ ,
96 ou t l i n e=FALSE, black white=FALSE)
97
98 p . s c o r e <− s c o r e plot [ [ ’ p ’ ] ]
99 c o l l e c t e d . data <− s c o r e plot [ [ ’ c o l l e c t e d . data ’ ] ]
100
101 e l l i p s e custom <− function (d) {
102
103 #Ca lcu l a t ing e l l i p s e f o r 95% conf idence
104 e l l i p s eSD = cor (d$x . value , d$y . va lue )
268
105 e l l i p s eD f = as . data . frame ( e l l i p s e ( e l l i p seSD , scale=c ( sd (d$x . va lue ) ,
106 sd (d$y . va lue ) ) ,
107 cent r e=colMeans (d [ , c ( ’ x . va lue ’ , ’ y . va lue ’ ) ] ) ,
108 t=2) )
109 return ( e l l i p s eD f )
110 }
111
112 e .path <− ddply ( c o l l e c t e d . data , ’ view ’ , e l l i p s e custom )
113
114
115 #Drawing an e l l i p s e f o r 95% conf idence
116 p . s c o r e = p . s co r e +
117 # geom path ( data=e . path , aes ( x=x , y=y ) , l i n e t y p e =2, a lpha =0.5) +
118 # sca l e co lour manual ( va lue s=c ( ’ b lack ’ , ’ darkorange1 ’ , ’ corn f l owerb lue ’ ,
119 # ’ b lack ’ , ’ char treuse ’ , ’ b lue ’ , ’ grey30 ’ ) ,
120 # guide legend ( t i t l e =’Run ’ ) ,
121 # l a b e l s=c ( ’NA’ , ’ 1 ’ , ’ 2 ’ , ’ 3 ’ , ’ 4 ’ , ’ 5 ’ , ’ 6 ’ ) ) +
122 #sca l e co lour manual ( va lue s=c ( ’ deeppink1 ’ , ’ darkorange1 ’ , ’ cyan4 ’ ,
123 # ’ darkorchid4 ’ , ’ chartreuse ’ , ’ b lue ’ , ’ grey30 ’ ) ,
124 # guide legend ( t i t l e =’Run ’ ) , l a b e l s=c (1 : 5 ) ) +
125 scale shape manual (name=’ ’ , labels=c ( ’Donor A (Run 1) ’ , ’Donor A (Run 2) ’ ,
126 ’Donor B ’ , ’Donor C ’ , ’MET−2 ’ ) ,
127 va lue s=c ( 16 , 17 , 7 , 3 , 5 ) ) +
128 gu ides ( col=guide legend ( byrow=TRUE) )
129
130 ggsave ( ’ . . /Plot s/PCA p l o t s/Pro f i l e s−s co r e5 . png ’ , p . score , he ight=15, width=25,
un i t s=’cm ’ )
131
132 t i f f ( f i l e=’C: /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/Manuscript/Manuscript A/
Journal o f Proteome Research/Figure 2 . t i f ’ ,
133 width=7, he ight=10/2 . 54 , un i t s=’ in ’ , r e s =300 ,)
134 print (p . s c o r e )
135 dev . of f ( )
136 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
137 #Loading p l o t 2D
138 # Note : Arguments f o r l oad ing p l o t func t i on are ( pca data , PCs=1:4 , l a b e l=NULL,
t i t l e=NULL,
139 # view mode=’compressed ’ )
140
141 #I f you want a l l compound l a b e l s shown , enter a l l paths in l a b e l argument
142 a l l paths = rownames( pca . data$ r o t a t i on )
143
144 source ( ’ ./Functions/de f ined binning .R ’ )
145 bin <− de f ined binning ( )
146
147 #I f you want a l l and only compound wi th in the sub s e t o f o b s e r va t i ons processed in
the PCA funct ion , can crea t e a temperary group c a l l e d ’a ’ to enter in f o r the
l a b e l argument
148 #a = pathway l i s t $Carb [ pathway l i s t $Organic %in% rownames ( pca processed data$
r o t a t i on ) ]
149 load ing plot = load ing plot 2d( pca . data , PCs=1:4 , l a b e l=a l l paths ,
150 t i t l e=NULL, ou t l i n e=FALSE, view mode = ’ compressed ’ )
151
152 p . load <− l oad ing plot [ [ ’ p ’ ] ]
153 load . data <− l oad ing plot [ [ ’ c o l l e c t e d . data ’ ] ]
154
155 load . data$bin <− NA
156 for ( i in bin$variable ) {
157 load . data$bin [ load . data$Text == i ] <− as . character ( bin$bin [ bin$variable == i ] )
158 }
159
160 p . load <− p . load +
161 geom point (data=load . data , aes ( x=xPC, y=yPC, shape=bin ) , s i z e =1) +
162 geom text (data=load . data , aes ( x=xPC, y=yPC, l a b e l=Text ) ,
163 h ju s t =−0.1 , v ju s t =0, s i z e =1, co l ou r=’ grey50 ’ ) +
164 scale co l ou r manual ( va lue s=c ( ’ deeppink1 ’ , ’ darkorange1 ’ , ’ cyan4 ’ ,
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165 ’ darkorch id4 ’ , ’ cha r t r eu s e ’ ) ,
166 guide legend ( t i t l e=’Bin ’ ) ) +
167 scale shape manual (name=’Bin ’ , va lue s=rev (c ( 16 , 17 , 7 , 3 , 5 ) ) ) +
168 theme ( legend . p o s i t i o n=’ bottom ’ )
169
170 ggsave ( ’ . . /Plot s/PCA p l o t s/Pro f i l e s−l oad ing5 . png ’ , p . load ,
171 he ight=12∗ 1 . 5 , width=18∗2 , un i t s=’cm ’ )
172
173 #EPS−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
174 p <− ggp lot ( load . data , aes (xPC, yPC, shape=bin ) ) +
175 geom text ( aes ( l a b e l=Text ) , s i z e =4, h ju s t =−0.1 , v ju s t =0.4 , co l ou r=’ grey50 ’ ) +
176 geom point ( s i z e =3) +
177 scale shape manual (name=’Bin ’ , va lue s=rev (c ( 16 , 17 , 7 , 3 , 5 ) ) ) +
178 f a c e t wrap (˜ View , ncol=min( f loor ( length ( 1 : 4 )/2) , 3) ) +
179 xlab ( ’PC sco r e ’ ) +
180 ylab ( ’PC sco r e ’ ) +
181 theme bw(12) +
182 theme ( axis . t i t l e . x = element text ( s i z e =14, f a c e=’ bold ’ ) ,
183 axis . t i t l e . y = element text ( s i z e =14, f a c e=’ bold ’ ) ,
184 #ax i s . t e x t = element t e x t ( s i z e =12, co lour=’ b lack ’ ) ,
185 legend . t i t l e = element text ( s i z e =14) ,
186 legend . text = element text ( s i z e =14) ,
187 legend . key = element rect ( co l ou r=’ white ’ ) ,
188 legend .margin = unit (0 , ”cm” ) ,
189 panel . border=element rect ( s i z e =2, co l our=’ black ’ ) ,
190 s t r i p . text . x = element text ( s i z e =12, f a c e=’ bold ’ ) ,
191 legend . p o s i t i o n=’ bottom ’ )
192 #Drawing o r i g i n
193 p = p + geom v l i n e ( x i n t e r c ep t =0, alpha =0.3)
194 p = p + geom h l i n e ( y i n t e r c ep t =0, alpha =0.3)
195
196 #Ca lcu l a t ing p l o t l im i t s
197 x l im i t = max(abs ( load . data$xPC) )∗1 .15
198 y l im i t = max(abs ( load . data$yPC) )∗1 .1
199
200 #Se t t i n g l im i t s
201 p = p + xlim(−x l imi t , x l im i t )
202 p = p + ylim(−y l imi t , y l im i t )
203
204
205 ggsave ( ’ . . /Plot s/PCA p l o t s/temp . png ’ , p , he ight )
206
207 t i f f ( f i l ename=’C: /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/Manuscript/Manuscript A/
Journal o f Proteome Research/Figure S2 . t i f ’ ,
208 width=15∗2/2 . 54 , he ight=12∗2/2 . 54 , un i t s=’ in ’ , r e s =300 ,
209 p o i n t s i z e =10)
210 grid . arrange (p . score , p , nrow=2)
211 grid . text ( ’A ’ , x=uni t ( 0 . 7 , ’cm ’ ) , y=uni t ( 23 . 25 , ’cm ’ ) , gp=gpar ( cex=2) )
212 grid . text ( ’B ’ , x=uni t ( 0 . 7 , ’cm ’ ) , y=uni t ( 1 1 . 3 , ’cm ’ ) , gp=gpar ( cex=2) )
213 dev . of f ( )
Profile diveristy analysis.R
1 #///////////////////////////////////////////////////////////////////////////////
2 #Modif ied f o r Liquid Gold Manuscript A
3 #Pro f i l e d i v e r s i t y
4
5 #Se t t i n g working d i r e c t o r y
6 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Analys i s ’ )
7
8 #load ing requ i red packages
9 require (RSQLite )
10 require ( ggp lot2 )
11 require ( p ly r )
12 require ( reshape2 )
13 require ( gr idExtra )
14
15 #sourc ing requ i red func t i ons
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16 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
17 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
18 source ( ’ . . /Functions/ funct ion−s c a l i n g .R ’ )
19 source ( ’ . . /Functions/ funct ion−ex t r a c t legend .R ’ )
20 source ( ’ . . /Functions/ funct ion−mul t ip l o t .R ’ )
21 source ( ’ . . /Functions/ funct ion−heat map bin .R ’ )
22 source ( ’ . . /Functions/ funct ion−de f ined binning .R ’ )
23 source ( ’ . . /Functions/ funct ion−s i e g e l tukey t e s t .R ’ )
24 source ( ’ . . /Functions/ funct ion−weighted compound c l a s s .R ’ )
25
26
27 #s e t t i n g working d i r e c t o r y
28 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript A ’
)
29
30 #Input data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
31 # Choose d r i v e r
32 drv <− dbDriver ( ’ SQLite ’ )
33
34 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
35 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
36
37 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
38 q . hour , q . phase , q . dose , q . treatment , q . gen t reat , q . expt ,
39 d . va r i ab l e , d . value , c . Type
40 FROM Data d INNER JOIN Qua l i f i e r q
41 ON d . f i l e = q . f i l e
42 INNER JOIN Rank r
43 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
44 INNER JOIN Cmpd type c
45 ON r .Compound = c .Compound
46 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
47 AND (q . run != 8 OR q . run IS NULL)
48 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
49 AND q . s t a t e = ’ ss ’
50 AND q . donor != ’RP1’
51 AND q . expt != ’RP2’
52 ORDER BY q . sampleID ; ” )
53
54 cmpd . i n f o <− dbGetQuery ( con , ”SELECT c .Compound , c . Type , p . Pathway , m. main
55 FROM Cmpd type c INNER JOIN Pathway p
56 ON c .Compound = p .Compound
57 INNER JOIN Main pathway m
58 ON p . Pathway = m. path
59 ORDER BY c .Compound” )
60
61 dbDisconnect ( con )
62
63 #data cleanup
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
64
65 #Performing data cleanup to remove zero va lue compounds
66 #al so ca s t s data in to wide format
67 c l ean <− data cleanup ( input , convert .NA=TRUE)
68
69
70 #Ordering compound c l a s s e s by abundance−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
71 rp <− input [ input$donor ==’RP2 ’ , ]
72 d <− input [ input$donor != ’RP2 ’ , ]
73
74 div . data <− c l ean
75 div . table <− as . data . frame ( table ( div . data$Type) )
76 div . table <− div . table [ order ( div . table$Freq , de c r ea s ing=TRUE) , ]
77 var1 . levels <− as . character ( div . table$Var1 )
78 div . data$Type <− factor ( div . data$Type , levels=var1 . levels , ordered=TRUE)
79
80 #Plo t t i n g p r o f i l e d i v e r s i t y −−> what t imes o f compounds are the p r o f i l e s made o f
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81 p <− ggp lot ( div . data , aes ( x=donor , f i l l =Type ) ) +
82 geom bar ( stat=’ bin ’ ) +
83 theme bw(14)
84 ggsave ( ’ . /Plot s/P r o f i l e d i v e r s i t y / p r o f i l e d i v e r s i t y order2 . png ’ , p , he ight=20,
width=15, un i t s=’cm ’ )
85
86 #Abundance o f compound sca l ed to concentrat ions−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
87 div <− ddply ( div . data , ’ donor ’ , custom perc , ’Type ’ )
88
89 p . div <− ggp lot ( div , aes ( x=donor , y=class . avg , f i l l =Type ) ) +
90 geom bar ( stat=’ i d e n t i t y ’ ) +
91 theme bw(14)
92
93 #expor t compount propor t ions
94 div . ca s t <− dcast ( div , formula=Type˜donor , va lue . var=’ perc ’ )
95 write . csv ( f i l e=’ . /Resu l t s/P r o f i l e d i v e r s i t y−weighted . csv ’ , d iv . ca s t )
96
97 #Percentage o f p r o f i l e s i s made o f each compound c la s s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
98 #( not s ca l ed to concentra t ion )
99 custom table <− function (data ) {
100 table <− as . data . frame ( table (data$Type) )
101 prop <− table$Freq/sum( table$Freq )∗100
102 type <− data . frame ( donor=unique (data$donor ) , type=table$Var1 , prop )
103 return ( type )
104 }
105 table <− ddply ( c lean , ’ donor ’ , custom table )
106 type . data <− dcast ( table , donor ˜ type , va lue . var=’ prop ’ )
107 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y 2 . csv ’ , x=type . data )
Profile analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
/////////
2 #Modif ied f o r Manuscript A
3 #Cross−experiment ana l y s i s
4
5 #Se t t i n g working d i r e c t o r y
6 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Analys i s ’ )
7
8 #load ing requ i red packages
9 require (RSQLite )
10 require ( ggp lot2 )
11 require ( p ly r )
12 require ( reshape2 )
13 require ( gr idExtra )
14 require ( grid )
15 require ( gr idBase )
16
17 #sourc ing requ i red func t i ons
18 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
19 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
20 source ( ’ . . /Functions/ funct ion−s c a l i n g .R ’ )
21 source ( ’ . . /Functions/ funct ion−ex t r a c t legend .R ’ )
22 source ( ’ . . /Functions/ funct ion−mul t ip l o t .R ’ )
23 source ( ’ . . /Functions/ funct ion−heat map bin .R ’ )
24
25
26 #Input data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
27 # Choose d r i v e r
28 drv <− dbDriver ( ’ SQLite ’ )
29
30 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
31 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
32
33 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
34 q . hour , q . phase , q . dose , q . treatment , q . gen t reat ,
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35 q . expt , d . va r i ab l e , d . va lue
36 FROM Data d INNER JOIN Qua l i f i e r q
37 ON d . f i l e = q . f i l e
38 INNER JOIN Rank r
39 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
40 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
41 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
42 AND q . s t a t e = ’ ss ’
43 AND (q . run != 8 OR q . run IS NULL)
44 AND q . donor != ’RP1’
45 AND q . expt != ’RP2’
46 ORDER BY q . sampleID ; ” )
47
48 cmpd . i n f o <− dbGetQuery ( con , ”SELECT c .Compound , c . Type , p . Pathway , m. main
49 FROM Cmpd type c INNER JOIN Pathway p
50 ON c .Compound = p .Compound
51 INNER JOIN Main pathway m
52 ON p . Pathway = m. path
53 ORDER BY c .Compound” )
54
55 dbDisconnect ( con )
56
57 #Se t t i n g working d i r e c t o r y
58 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript A/
Analys i s ’ )
59
60 #data cleanup
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
61
62 #Performing data cleanup to remove zero va lue compounds
63 #al so ca s t s data in to wide format
64 c l ean <− data cleanup ( input , form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
65 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
66 ’ gen t r e a t ’ , ’ expt ’ ) ,
67 form . x=’ va r i ab l e ’ , convert .NA=TRUE)
68
69 #make sure a l l compounds have a va lue f o r each donor
70 data . c a s t <− dcast ( c lean , formula=sampleID+donor+run+v e s s e l+DPI+hour+phase+dose+
71 treatment+gen t r e a t+expt˜variable , va lue . var=’ value ’ )
72
73 data . c a s t [ i s .na(data . c a s t ) ] <− 0
74
75 #mel t ing back to long format
76 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
77 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
78 ’ gen t r e a t ’ , ’ expt ’ ) )
79
80 #separa t ing out q u a l i f i e r and data
81 q u a l i f i e r <− data . melt [ , 1 : 1 1 ]
82 x . data <− data . melt [ , 1 2 : 1 3 ]
83
84 #de s c r i p t i v e s t a t s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
85 #Gett ing d e s c r i p t i v e s t a t s f o r each donor
86 stat <− ddply (data . melt , ’ donor ’ , d e s c r i p t i v e . stat , data . type=’ long ’ , variable=’
va r i ab l e ’ ,
87 q u a l i f i e r=q u a l i f i e r , scale . data=FALSE)
88 #wri t e . csv ( f i l e =’check s t a t . csv ’ , s t a t )
89
90 #dens i t y p lo t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
91 #ge t t i n g kerna l d ens i t y p l o t o f va lue s
92 p . dens <− ggp lot ( stat [ stat$avg >= 0.1 & stat$avg <=20 ,]) +
93 geom density ( aes ( x=avg ) ) +
94 theme bw(16)
95
96 plot (density ( stat$avg ) )
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98 plot (density ( stat$avg ) )
99 png ( f i l e=’ . . /Plot s/bin dens i ty . png ’ , he ight=10, width=15, un i t s=’cm ’ , r e s =240)
100 plot (density ( stat$avg ) , main=’ ’ , x lab=’Mean Concentrat ion (mM) ’ ,
101 sub=’bw=0.03089 ’ )
102 dev . of f ( )
103
104 temp <− stat$avg [ stat$avg >=0.1 & stat$avg <=20]
105 plot (density ( temp) ) #bw=0.135
106
107 png ( f i l e=’ . . /Plot s/bin dens i ty−i n s e t . png ’ , he ight =7.5 , width=10, un i t s=’cm ’ , r e s
=240)
108 plot (density ( stat$avg [ stat$avg >=0.1 & stat$avg <=20]) ,
109 main=’ ’ , x lab=’ ’ , y lab=’ ’ , cex=10, xaxt=’n ’ )
110 axis (1 , at=seq ( 0 , 20 , 5 ) , labels=c ( 0 . 1 , seq ( 5 , 20 , 5 ) ) )
111 dev . of f ( )
112
113 vp <− viewport ( x=0.55 , y=0.3 , width=0.95 , he ight =0.95)
114 vp . i n s e t <− viewport ( x=0.55 , y=0.8 , width=uni t (12 , ’cm ’ ) ,
115 he ight=uni t ( 8 . 5 , ’cm ’ ) )
116 t i f f ( f i l ename=’C: /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/Manuscript/Manuscript A/
Journal o f Proteome Research/Figure S1 . t i f ’ ,
117 width=7, he ight =5.5 , un i t s=’ in ’ , r e s =300 ,
118 p o i n t s i z e =10)
119 plot .new( )
120 pushViewport ( vp )
121 plot (density ( stat$avg ) , main=’ ’ , x lab=’Mean Concentrat ion (mM) ’ ,
122 sub=’bw=0.03089 ’ )
123 pushViewport ( vp . i n s e t )
124 par (new=TRUE, f i g=gridFIG ( ) )
125 plot (density ( stat$avg [ stat$avg >=0.1 & stat$avg <=20]) ,
126 main=’ ’ , x lab=’ ’ , y lab=’ ’ , cex=10, xaxt=’n ’ )
127 axis (1 , at=seq ( 0 , 20 , 5 ) , labels=c ( 0 . 1 , seq ( 5 , 20 , 5 ) ) )
128 upViewport ( )
129 grid . l ines ( x=c ( 0 . 8 5 , 0 . 2 6 ) , y=c ( 0 . 6 4 , 0 . 3 7 5 ) )
130 grid . l ines ( x=c ( 0 . 2 9 8 , 0 . 0 6 2 ) , y=c ( 0 . 6 4 , 0 . 4 5 ) )
131 dev . of f ( )
132
133 #Binning
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
134 #Assigning data to b ins
135 bin . data <− bin . heatmap ( stat , bin=c ( 2 0 , 1 0 , 1 , 0 . 1 , 0 ) , ’ v a r i a b l e ’ ,
136 order . data=stat , order . var=’ va r i ab l e ’ , order . va lue=’ avg ’ )
137
138 uni . l i s t <− bin . data [ [ ’ uni . l i s t ’ ] ]
139 ordered . data <− bin . data [ [ ’ ordered . data ’ ] ]
140 ordered . data$donor <− factor (ordered . data$donor , levels=c ( ’RP2 ’ , ’A ’ , ’B ’ , ’C ’ ) )
141
142 #Padded v a r i a b l e names
143 ordered . data$pad <− s p r i n t f ( ’%022s ’ , as . character (ordered . data$variable ) )
144
145 pad . l i s t <− l i s t ( )
146 for ( i in 1 : length ( uni . l i s t ) ) {
147 pad . temp <− s p r i n t f ( ’%022s ’ , as . character ( uni . l i s t [ [ i ] ] ) )
148 pad . l i s t [ [ i ] ] <− pad . temp
149 }
150
151 pad . order <− c ( )
152 for ( i in 1 : length ( pad . l i s t ) ) {
153 temp <− as . character ( pad . l i s t [ [ i ] ] )
154 pad . order <− c ( pad . order , temp)
155 }
156
157
158 #p l o t t i n g heat maps
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
159 #p l o t t i n g heat maps by bin
160 plot . l i s t <− l i s t ( )
161 legend . l i s t <− l i s t ( )
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162 f i g . l i s t <− l i s t ( )
163 f i g . l e g <− l i s t ( )
164
165
166 f i g . width <− c ( 7 . 7 , 7 . 5 , 7 . 8 , 8 . 8 , 9 . 4 )
167 f i g . he ight <− c ( 2 . 6 5 , 3 . 1 , 4 . 7 , 1 3 . 5 , 1 0 . 9 )
168 margin <− l i s t (c ( 0 , 0 . 2 , 0 . 5 , 0 . 8 ) ,
169 c ( 0 , 0 . 2 , 0 . 5 , 0 . 8 ) ,
170 c ( 0 , 0 . 2 , 0 . 3 , 0 . 4 ) ,
171 c ( 0 , 0 . 2 , 0 , 0 ) ,
172 c ( 0 , 0 . 2 , 0 , 0 ) )
173
174 for ( i in 1 : length ( uni . l i s t ) ) {
175 plot . data <− ordered . data [ ordered . data$variable %in% uni . l i s t [ [ i ] ] , ]
176
177 #s e t t i n g compound order
178 plot . data$pad <− factor (as . character (plot . data$pad ) ,
179 levels=rev ( pad . order [ pad . order %in% pad . l i s t [ [ i ] ] ] ) ,
ordered=TRUE)
180
181 plot . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=donor , y=pad ) ) +
182 geom t i l e ( aes ( f i l l =avg ) , co l ou r=’ grey90 ’ ) +
183 scale f i l l g rad i en t ( low=’ grey90 ’ , high=’ grey0 ’ ,
184 name=’Mean\nConcentrat ion (mM) ’ ) +
185 scale x d i s c r e t e ( labels=c ( ’MET−2 ’ , ’A ’ , ’B ’ , ’C ’ ) ) +
186 theme bw(10) +
187 xlab ( ’Donor ’ ) +
188 theme ( legend . p o s i t i o n=c ( 0 . 5 2 , 0 . 5 ) , legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
189 legend . key . width=uni t (1 , ’cm ’ ) ,
190 legend . key . he ight=uni t ( 0 . 3 , ’cm ’ ) ,
191 legend . text=element text ( s i z e =7.5) ,
192 legend . t i t l e=element text ( s i z e =7.5) ,
193 axis . t i t l e . y=element blank ( ) ,
194 plot .margin=uni t (margin [ [ i ] ] , ’cm ’ ) )
195
196
197 legend . l i s t [ [ i ] ] <− g legend (plot . l i s t [ [ i ] ] )
198
199 f i g . l i s t [ [ i ] ] <− grid . arrange ( legend . l i s t [ [ i ] ] ,
200 plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
201 he i gh t s=c ( 0 . 1 , 0 . 9 ) )
202
203 #save as pane l s
204 i f (FALSE) {
205 png ( f i l ename=paste ( ’ . . /Plot s/P r o f i l e s / p r o f i l e 4 bin ’ , i , ’ . png ’ , sep=’ ’ ) ,
206 he ight=f i g . he ight [ i ] , width=f i g . width [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e
=10)
207 f i g . l i s t [ [ i ] ] <− grid . arrange (plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
208 dev . of f ( )
209
210 png ( f i l ename=paste ( ’ . . /Plot s/P r o f i l e s / p r o f i l e 4 bin l e g ’ , i , ’ . png ’ , sep=’ ’ ) ,
211 he ight=1, width=l e g . width [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e =10)
212 f i g . l e g [ [ i ] ] <− grid . arrange ( legend . l i s t [ [ i ] ] )
213 dev . of f ( )
214 }
215
216 }
217
218 #Se t t i n g p l o t dimensions
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
219
220 w <− l i s t (c ( 1 0 , 7 . 7 ) , #1
221 c ( 1 0 , 7 . 5 ) , #2
222 c ( 1 0 , 7 . 8 ) , #3
223 c ( 1 0 , 8 . 8 ) , #4
224 c ( 1 0 , 9 . 4 ) ) #5
225
226 h <− l i s t (c ( 1 , 2 . 5 ) , #1
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227 c ( 1 , 2 . 9 ) , #2
228 c ( 1 , 4 . 5 ) , #3
229 c ( 1 , 1 3 . 5 ) , #4
230 c ( 1 , 1 0 . 3 ) ) #5
231
232 #EPS−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
233 t i f f ( f i l ename=’C: /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/Manuscript/Manuscript A/
Journal o f Proteome Research/Figure 3 . t i f ’ ,
234 width=7, he ight=sum(c (h [ [ 4 ] ] , h [ [ 3 ] ] ) / 2 . 54 ) , un i t s=’ in ’ , r e s =300 ,
235 p o i n t s i z e =11)
236 grid . arrange ( arrangeGrob ( legend . l i s t [ [ 1 ] ] ,
237 plot . l i s t [ [ 1 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
238 legend . l i s t [ [ 2 ] ] ,
239 plot . l i s t [ [ 2 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
240 legend . l i s t [ [ 5 ] ] ,
241 plot . l i s t [ [ 5 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
242 ncol=1, he i gh t s=c (h [ [ 1 ] ] , h [ [ 2 ] ] , h [ [ 5 ] ] ) ,
243 widths=c (w [ [ 1 ] ] , w [ [ 2 ] ] ,w [ [ 5 ] ] ) ) ,
244 arrangeGrob ( legend . l i s t [ [ 3 ] ] ,
245 plot . l i s t [ [ 3 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
246 legend . l i s t [ [ 4 ] ] ,
247 plot . l i s t [ [ 4 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
248 ncol=1, he i gh t s=c (h [ [ 3 ] ] , h [ [ 4 ] ] ) ,
249 widths=c (w [ [ 3 ] ] , w [ [ 4 ] ] ) ) ,
250 ncol=2)
251 grid . text ( ’A ’ , x=uni t ( 0 . 2 5 , ’cm ’ ) , y=uni t ( 19 . 45 , ’cm ’ ) , gp=gpar ( cex=1.5) )
252 grid . text ( ’B ’ , x=uni t ( 0 . 2 5 , ’cm ’ ) , y=uni t ( 1 5 . 7 , ’cm ’ ) , gp=gpar ( cex=1.5) )
253 grid . text ( ’E ’ , x=uni t ( 0 . 2 5 , ’cm ’ ) , y=uni t ( 11 . 52 , ’cm ’ ) , gp=gpar ( cex=1.5) )
254 grid . text ( ’C ’ , x=uni t ( 9 . 1 , ’cm ’ ) , y=uni t ( 19 . 45 , ’cm ’ ) , gp=gpar ( cex=1.5) )
255 grid . text ( ’D ’ , x=uni t ( 9 . 1 , ’cm ’ ) , y=uni t (14 , ’cm ’ ) , gp=gpar ( cex=1.5) )
256 dev . of f ( )
257
258 #Mann Whitney t e s t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
259 #see ing what compounds d i f f e r b/w donor and RPs
260 mw custom <− function (data , va lue=’ va lue ’ ) {
261
262 d <− data [ data$donor %in% c ( ’A ’ , ’B ’ , ’C ’ ) , ]
263 rp <− data [ data$donor == ’RP2 ’ , ]
264 out <− c ( )
265 t e s t . r e s u l t=wi lcox . t e s t (d [ , va lue ] , rp [ , va lue ] )
266
267 output <− rp
268
269 output$p . va l <− t e s t . r e s u l t $p . va lue
270 output$stat <− t e s t . r e s u l t $ s t a t i s t i c
271
272 out <− rbind ( out , output )
273 return ( out )
274 }
275
276
277 mw. r e s u l t <− ddply ( stat , ’ v a r i a b l e ’ , mw custom )
278
279 s i g <− mw. r e s u l t [mw. r e s u l t $p . va l <= 0 . 0 5 , ]
280
281
282 s i g . bin <− uni . l i s t
283
284 #Putt ing s i g n i f i c a n t compounds in bin order−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
285 s i g . order <− l i s t ( )
286 for ( i in 1 : length ( s i g . bin ) ) {
287 s i g . data <− s i g [ s i g$variable %in% s i g . bin [ [ i ] ] , ]
288 s i g . data <− unique ( s i g . data [ , c ( ’ v a r i ab l e ’ , ’ p . va l ’ ) ] )
289
290 type <− cmpd . i n f o [ cmpd . i n f o$Compound %in% unique ( s i g . data$variable ) , ]
291 for ( j in unique ( type$Compound) ) {
292 type$p . va l [ type$Compound == j ] <− s i g . data$p . va l [ s i g . data$variable == j ]
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293 #pr in t ( ’ end1 ’ )
294 }
295
296 #type$Compound <− f a c t o r ( type$Compound ,
297 # l e v e l s=rev ( l e v e l s ( s i g . b in [ [ i ] ] ) ) , order=TRUE)
298 #type <− type [ order ( type$Compound) , ]
299 type <− type [ order ( type$p . val , d e c r ea s i ng=FALSE) , ]
300
301 s i g . order [ [ i ] ] <−type
302 #pr in t ( ’ end2 ’ )
303
304 }
305
306 #Putt ing a l l in one dataframe −− Compound Type
307 s i g . a l l . cmpd <− do . ca l l ( rbind . data . frame , s i g . order )
308 s i g . a l l . cmpd <− unique ( s i g . a l l . cmpd [ , c ( 1 , 5 , 2 ) ] )
309 table ( s i g . a l l . cmpd$Type)
310
311 #Putt ing a l l in one dataframe −− Pathway
312 s i g . a l l .path <− do . ca l l ( rbind . data . frame , s i g . order )
313 s i g . a l l .path <− unique ( s i g . a l l .path [ , c ( 1 , 5 , 3 ) ] )
314 table ( s i g . a l l .path$Pathway )
315
316 #wri t e . csv ( f i l e = ’ . ./Resu l t s/donor−pva lue2 . csv ’ , s i g . a l l )
317
318 #expor t ing each bin s epa ra t e l y
319 for ( i in 1 : length ( s i g . order ) ) {
320 s i g .write <− s i g . order [ [ i ] ]
321 #wri t e . csv ( f i l e=pas te ( ’ . . /Resu l t s/donor−pvalue ’ , i , ’ 2 . csv ’ , sep= ’ ’) , s i g . wr i t e )
322 }
323
324 #Seeing how the se compounds d i f f e r across donors−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
325 d <− s i g . a l l
326
327 out <− data . frame (A=NULL, B=NULL, C=NULL, RP2=NULL)
328 for ( i in d$Compound) {
329 avg <− unique ( stat [ stat$variable == i , c ( ’ donor ’ , ’ avg ’ ) ] )
330 tmp <− as . data . frame ( t ( avg ) )
331 va l <− tmp [ 2 , ]
332 colnames ( va l ) <− as . character (as .matrix (tmp [ 1 , ] ) )
333 va l$variable <− i
334 out <− rbind ( out , va l )
335 }
336
337 d <− cbind (d , out )
338
339 #Gett ing mean concentra t ions o f each group−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
340 a <− stat [ stat$variable %in% s i g . a l l $Compound , ]
341
342 rp <− a [ a$donor == ’RP2 ’ , ]
343 dn <− a [ a$donor %in% c ( ’A ’ , ’B ’ , ’C ’ ) , ]
344
345 rp$donor . type <− ’ rp ’
346 dn$donor . type <− ’ d ’
347
348 rp <− ddply ( rp , ’ v a r i ab l e ’ , mutate , rp . avg=mean(unique ( avg ) ) )
349 dn <− ddply (dn , ’ v a r i ab l e ’ , mutate , dn . avg=mean(unique ( avg ) ) )
350
351 rp2 <− unique ( rp [ , c ( ’ donor . type ’ , ’ v a r i a b l e ’ , ’ rp . avg ’ ) ] )
352 dn2 <− unique (dn [ , c ( ’ donor . type ’ , ’ v a r i a b l e ’ , ’ dn . avg ’ ) ] )
353
354 b <− cbind ( rp2 [ c ( ’ v a r i ab l e ’ , ’ rp . avg ’ ) ] , ’ dn . avg ’=dn2$dn . avg )
355
356 source ( ’ . . /Functions/de f ined binning .R ’ )
357 bin . i n f o <− de f ined binning ( )
358 b$bin <− NULL
359 for ( i in b$variable )b$bin [ b$variable == i ] <− bin . i n f o$bin [ bin . i n f o$variable==i ]
360
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361 h . rp <− b [ b$rp . avg > b$dn . avg , ]
362 l . rp <− b [ b$rp . avg < b$dn . avg , ]
363
364 #Visua l i z e in p l o t form−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
365 d . melt <− melt (d , id . vars=c ( ’Compound ’ , ’ v a r i ab l e ’ , ’Type ’ , ’ p . va l ’ ) ,
366 measure . vars=c ( ’A ’ , ’B ’ , ’C ’ , ’RP2 ’ ) , variable . name=’ donor ’ )
367 d . melt$value <− as .numeric (d . melt$value )
368
369 plot . var <− unique (d . melt$variable )
370 plot . var <− factor (plot . var , levels=unlist ( uni . l i s t ) )
371 plot . var <− plot . var [ order (plot . var ) ]
372 plot . var <− as . character (plot . var )
373
374 plot . function <− function ( . x , dat , var , variable ) {
375 plot . data <− dat [ dat [ , variable]==var [ . x ] , ]
376 p <− ggp lot (plot . data , aes ( x=donor , y=variable ) ) +
377 geom t i l e ( aes ( f i l l =value ) ) +
378 geom text ( aes ( f i l l =value , l a b e l=round(plot . data$value , 3 ) ) ) +
379 scale f i l l g rad i en t ( low=’ white ’ , high=’ blue ’ ) +
380 theme bw(14) +
381 theme ( axis . t i t l e . y=element blank ( ) )
382 return (p)
383 }
384 p <− lapply ( 1 : length (plot . var ) , plot . function ,
385 dat=d . melt , var=plot . var , variable=’ va r i ab l e ’ )
386
387 png ( ’ . . /Plot s/ t e s t . png ’ , he ight =100 , width=15, un i t s=’cm ’ , r e s =240)
388 do . ca l l ( grid . arrange , c (p , ncol=1) )
389 dev . of f ( )
390 #pathway ana ly s i s−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
391 path . table <− as . data . frame ( table (data$Pathway ) )
392 path . table <− path . table [ order (path . table$Freq , de c r ea s ing=TRUE) , ]
393 #wri t e . csv ( f i l e = ’ . ./Resu l t s/donor−pathway . csv ’ , path . t a b l e )
394
395 main . table <− as . data . frame ( table (data$main ) )
396 main . table <− main . table [ order (main . table$Freq , de c r ea s ing=TRUE) , ]
397 #wri t e . csv ( f i l e = ’ . ./Resu l t s/donor−main pathway . csv ’ , main . t a b l e )
398
399 data$main . count <− NA
400 for ( i in unique (main . table$Var1 ) ) {
401 data$main . count [ data$main == i ] <− main . table$Freq [ main . table$Var1 == i ]
402 }
403
404 data$path . count <− NA
405 for ( i in unique (path . table$Var1 ) ) {
406 data$path . count [ data$Pathway == i ] <− path . table$Freq [path . table$Var1 == i ]
407 }
408
409 data <− data [ order(−data$path . count ) , ]
410 path . l e v e l <− unique (data$Pathway )
411 data$Pathway <− factor (data$Pathway , levels=rev (path . l e v e l ) , ordered=TRUE)
412 cmpd . l e v e l <− unique (data$Compound)
413 data$Compound <− factor (data$Compound , levels=cmpd . l e v e l , ordered=TRUE)
414
415 p .path <− ggp lot (data [ data$main %in% c ( ’Amino ac id s ’ , ’ Organic a c i d s ’ ,
416 ’ Vitamins ’ , ’ Centra l Metabol ic Pathways ’ ,
417 ’ L ip id s ’ , ’ Purine , Pyrimidine ’ , ’ Fatty ac id s ’ )
, ] ,
418 aes ( x=main , f i l l =Pathway ) ) +
419 geom bar ( stat=’ bin ’ , co l ou r=’ black ’ ) +
420 theme bw(14) +
421 theme ( axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45))
Biomarker analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Analys i s f o r biomarkers unique to each donor
3 #Created f o r Liquid Gold Manuscript A
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4 #( not in r e gu l a r Liquid Gold manuscript R ana ly ses )
5
6 #Se t t i n g working d i r e c t o r y
7 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Analys i s ’ )
8
9 #load ing requ i red packages
10 require (RSQLite )
11 require ( ggp lot2 )
12 require ( p ly r )
13 require ( reshape2 )
14 require ( gr idExtra )
15 require ( s t r i n g r )
16
17 #sourc ing requ i red func t i ons
18 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
19 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
20 source ( ’ . . /Functions/ funct ion−s c a l i n g .R ’ )
21 source ( ’ . . /Functions/ funct ion−ex t r a c t legend .R ’ )
22 source ( ’ . . /Functions/ funct ion−mul t ip l o t .R ’ )
23 source ( ’ . . /Functions/ funct ion−heat map bin .R ’ )
24 source ( ’ . . /Functions/ funct ion−de f ined binning .R ’ )
25 source ( ’ . . /Functions/ funct ion−s i e g e l tukey t e s t .R ’ )
26
27
28 #s e t t i n g working d i r e c t o r y
29 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript A ’
)
30
31 #Input data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
32 # Choose d r i v e r
33 drv <− dbDriver ( ’ SQLite ’ )
34
35 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
36 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
37
38 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
39 q . hour , q . phase , q . dose , q . treatment , q . gen t reat , q . expt ,
40 d . va r i ab l e , d . value , c . Type
41 FROM Data d INNER JOIN Qua l i f i e r q
42 ON d . f i l e = q . f i l e
43 INNER JOIN Rank r
44 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
45 INNER JOIN Cmpd type c
46 ON r .Compound = c .Compound
47 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
48 AND (q . run != 8 OR q . run IS NULL)
49 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
50 AND q . s t a t e = ’ ss ’
51 AND q . donor != ’RP1’
52 AND q . expt != ’RP2’
53 ORDER BY q . sampleID ; ” )
54
55 cmpd . i n f o <− dbGetQuery ( con , ”SELECT c .Compound , c . Type , p . Pathway , m. main
56 FROM Cmpd type c INNER JOIN Pathway p
57 ON c .Compound = p .Compound
58 INNER JOIN Main pathway m
59 ON p . Pathway = m. path
60 ORDER BY c .Compound” )
61
62 dbDisconnect ( con )
63
64 #data cleanup
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
65
66 #Performing data cleanup to remove zero va lue compounds
67 #al so ca s t s data in to wide format
68 c l ean <− data cleanup ( input , convert .NA=TRUE)
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69
70 #make sure a l l compounds have a va lue f o r each donor
71 data . c a s t <− dcast ( c lean , formula=sampleID+donor+run+v e s s e l+DPI+hour+phase+dose+
72 treatment+gen t r e a t+expt˜variable , va lue . var=’ value ’ )
73
74 data . c a s t [ i s .na(data . c a s t ) ] <− 0
75
76 #mel t ing back to long format
77 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
78 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
79 ’ gen t r e a t ’ , ’ expt ’ ) )
80
81 #de s c r i p t i v e s t a t s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
82 #Gett ing d e s c r i p t i v e s t a t s f o r each donor
83 stat <− ddply (data . melt , ’ donor ’ , d e s c r i p t i v e . stat , data . type=’ long ’ , variable=’
va r i ab l e ’ ,
84 q u a l i f i e r=NULL, scale . data=FALSE)
85
86 #Metabo l i t e markers−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
87 #markers i d e n t i f i e d v i s u a l l y
88 co i <− c ( ’3−Phenylpropionate ’ , ’ Leucine ’ , ’ Val ine ’ , ’ I s o l e u c i n e ’ ,
89 ’Methylamine ’ , ’ Methionine ’ , ’ Phenyla lan ine ’ , ’Methanol ’ , ’ Succ inate ’ , ’
Dimethylamine ’ , ##Donor A
90
91 ’ Pimelate ’ , ’ Sebacate ’ , ’4−Hydroxyphenylacetate ’ , ’ Acetate ’ , ’ Ethanol ’ ,
92 ’ Va le rate ’ , ’ Lactate ’ , ##Donor B
93
94 ’ beta−Alanine ’ , ’ Pyruvate ’ , ’ Glucose ’ ,##Donor C, low in Lactate too
95
96 ’ Tartrate ’ , ’ Urea ’ , ’ Glutamate ’ , ’ Pyroglutamate ’ , ’ Asparagine ’ , ’ G lyco la te ’ ,
97 ’ Chol ine ’ , ’Thymine ’ , ’ Formate ’ , ’ I s o v a l e r a t e ’ , ’ I s obuty ra t e ’ , ’p−Creso l ’ ,
98 ’ Lys ine ’ ) ##RP2
99
100 co i <− factor ( co i , levels=coi , ordered=TRUE)
101
102 #Seeing i f same compounds p icked by anova
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
103 #tukey f a i l s becuase too few data po in t s
104 source ( ’ . . /Functions/ funct ion−tukey .R ’ )
105 source ( ’ . . /Functions/ funct ion−anova custom .R ’ )
106
107 anova <− ddply ( stat , ’ v a r i a b l e ’ , aov custom , group=’ donor ’ )
108 s . anova <− anova [ anova$p . va l <= 0.05 & ! i s .na(anova$p . va l ) , ]
109
110 tukey <− ddply ( stat , ’ v a r i a b l e ’ , tukey custom , group=’ donor ’ )
111 s . tukey <− tukey [ tukey$p . va l <= tukey$bon . va l | i s .na( tukey$p . va l ) , ]
112 #wri t e . csv ( f i l e =’Resu l t s/ tukey−s i g . csv ’ , s . tukey )
113
114 #see i f bon fe r ron i co r r ec t i on p icked anything not in co i
115 bon . tukey <− s . tukey [ ! s . tukey$variable %in% coi , ]
116
117 #Check i f bon fe r ron i co r r ec t i on cut out any co i
118 cut . tukey <− c o i [ ! c o i %in% unique ( s . tukey$variable ) ]
119 cut . tukey <− tukey [ tukey$variable %in% cut . tukey , ]
120
121 ##bonfer ron i cut out compounds found only in one donor AND had l a r g e spread
122 ##these compounds s t i l l need to be d i s cus s ed
123
124 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−tukey bon f e r r on i . csv ’ , s . tukey )
125
126 #ge t t i n g compounds where one group i s s i g n i f i c a n t l y d i f f e r e n t from every s i n g l e
group
127 marker custom <− function (data ) {
128 donor <− c (as . character (data$g1 ) , as . character (data$g2 ) )
129 t <− as . data . frame ( table ( donor ) )
130 t$variable <− unique (data$variable )
131 marker <− t [ t$Freq == 3 , ]
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132 out <− marker [ , c ( ’ v a r i ab l e ’ , ’ donor ’ ) ]
133 return ( out )
134 }
135
136 marker . tukey <− ddply ( s . tukey , ’ v a r i a b l e ’ , marker custom )
137
138 #Gett ing markers t ha t only have one donor t ha t i s d i f f e r e n t from every s i n g l e o ther
group
139 table . marker <− as . data . frame ( table (as . character (marker . tukey$variable ) ) )
140 uni . marker <− as . character ( table . marker$Var1 [ table . marker$Freq == 1 ] )
141
142 marker . tukey2 <− marker . tukey [ marker . tukey$variable %in% uni . marker , ]
143
144 #compare to those done by v i s u a l i n spec t i on
145
146
147 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−marker tukey . csv ’ , marker . tukey )
148 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−marker2 tukey . csv ’ , marker . tukey2 )
149 #Seeing i f same compounds p icked by t−t e s t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
150 #t−t e s t wi th Bonferroni co r r ec t i on
151 t custom <− function (data , group ) {
152
153 grps <− unique (data [ , group ] )
154 pa i r <− combn( grps , 2 )
155
156 out <− c ( )
157 for ( i in 1 : ncol ( pa i r ) ) {
158 grp1 <− data [ data [ , group ] == pa i r [ 1 , i ] , ]
159 grp2 <− data [ data [ , group ] == pa i r [ 2 , i ] , ]
160 grp <− rbind ( grp1 , grp2 ) #both groups be ing compared
161
162 r e s u l t <− t . t e s t ( grp1$value , grp2$value )
163 p . va l <− r e s u l t $p . va lue
164 s t a t i s t i c <− r e s u l t $ s t a t i s t i c
165 output <− data . frame ( g1=pa i r [ 1 , i ] , g2=pa i r [ 2 , i ] , stat=s t a t i s t i c , p . va l=p . va l )
166
167 out <− rbind ( out , output )
168 }
169 return ( out )
170 }
171
172 t . r e s u l t <− ddply ( stat , ’ v a r i ab l e ’ , t custom , group=’ donor ’ )
173
174 pa i r <− combn(unique ( stat$donor ) ,2 )
175 bon f e r r on i <− 0 .05/ncol ( pa i r )
176
177 s i g . t <− t . r e s u l t [ t . r e s u l t $p . va l <= bon f e r r on i & ! i s .na( t . r e s u l t $p . va l ) , ]
178
179 #see i f bon fe r ron i co r r ec t i on p icked anything not in co i
180 bon <− s i g . t [ ! s i g . t$variable %in% coi , ]
181
182 #Check i f bon fe r ron i co r r ec t i on cut out any co i
183 cut <− c o i [ ! c o i %in% unique ( s i g . t$variable ) ]
184 cut <− t . r e s u l t [ t . r e s u l t $variable %in% cut , ]
185
186 other0s <− t . r e s u l t [ t . r e s u l t $variable %in% c ( ’ Glucose ’ ) , ]
187 ##bonfer ron i cut out compounds found only in one donor AND had l a r g e spread
188 ##these compounds s t i l l need to be d i s cus s ed
189
190 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−t bon f e r r on i . csv ’ , s i g . t )
191
192 #ge t t i n g compounds where one group i s s i g n i f i c a n t l y d i f f e r e n t from ever s i n g l e
group
193 marker custom <− function (data ) {
194 donor <− c (as . character (data$g1 ) , as . character (data$g2 ) )
195 t <− as . data . frame ( table ( donor ) )
196 t$variable <− unique (data$variable )
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197 print ( t )
198 marker <− t [ t$Freq == 3 , ]
199 out <− marker [ , c ( ’ v a r i ab l e ’ , ’ donor ’ ) ]
200 return ( out )
201 }
202
203 marker <− ddply ( s i g . t , ’ v a r i a b l e ’ , marker custom )
204
205 #Gett ing markers t ha t only have one donor t ha t i s d i f f e r e n t from every s i n g l e o ther
group
206 table . marker <− as . data . frame ( table (as . character (marker$variable ) ) )
207 uni . marker <− as . character ( table . marker$Var1 [ table . marker$Freq == 1 ] )
208
209 marker2 <− marker [ marker$variable %in% uni . marker , ]
210
211 #compare to those done by v i s u a l i n spec t i on
212 cut . s i g t <− c o i [ ! c o i %in% unique ( s i g . t$variable ) ] #cut by bon fer ron i
213 t . c u t s i g <− t . r e s u l t [ t . r e s u l t $variable %in% cut . s i g t , ]
214 cut .m1 <− c o i [ ! c o i %in% unique (marker$variable ) ] #cut by marker d e f i n i t i o n
215 t . cut1 <− s i g . t [ s i g . t$variable %in% cut .m1 , ]
216 cut .m2 <− c o i [ ! c o i %in% unique (marker2$variable ) ] #cut by marker f o r one donor
217 t . cut2 <− s i g . t [ s i g . t$variable %in% cut .m2 , ]
218
219 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−marker . csv ’ , marker )
220 write . csv ( f i l e=’ . /Resu l t s/ p r o f i l e d i v e r s i t y−marker2 . csv ’ , marker2 )
221 #Gett ing p l o t data and order−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
222
223 p2 . data <− stat [ stat$variable %in% coi , ]
224 p2 . data$variable <− factor ( p2 . data$variable , levels=levels ( c o i ) )
225
226 pattern <− ’ ( . ∗Hydroxy | henyl ) (? ! a l an ine ) ( . ∗ ) ’
227 match <− ’\\1−\n\\2 ’
228
229 new . va lue s <− as . character (gsub ( pattern , match , p2 . data$variable , p e r l=TRUE) )
230 new . levels <− as . character (gsub ( pattern , match , levels ( p2 . data$variable ) , p e r l=TRUE
) )
231
232 p2 . data$wrap <− factor (new . va lues , levels=new . levels )
233
234 #Plo t t i n g out data va lues−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
235 p2 <− ggp lot ( p2 . data , aes ( x=donor , y=value ) ) +
236 geom er ro rba r ( aes (ymax=ymax , ymin=ymin ) ) +
237 geom point ( s i z e =1.5) +
238 f a c e t wrap (˜wrap , s c a l e s=’ f r e e ’ , ncol=5) +
239 theme bw(10) +
240 scale x d i s c r e t e ( labels=c ( ’A ’ , ’B ’ , ’C ’ , ’ MET−2 ’ ) ) +
241 ylab ( ’ Concentrat ion (mM) ’ ) +
242 xlab ( ’Donor ’ )
243 ggsave ( ’ ./Plot s/P r o f i l e d i v e r s i t y /markers3 . png ’ , p2 ,
244 he ight=24, width=7∗2 . 54 , un i t s=’cm ’ )
245
246 t i f f ( f i l e=’C: /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/Manuscript/Manuscript A/
Journal o f Proteome Research/Figure 4 . t i f ’ ,
247 he ight=24/2 . 54 , width=7, un i t s=’ in ’ , r e s =300 ,)
248 print ( p2 )
249 dev . of f ( )
C.5 Analysis of Perturbations of Human Fecal Microbiota
Propagated In Vitro
PCA analysis.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #Modif ied f o r Manuscript B
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3
4 #Analys i s to compare samples across p r o j e c t s
5
6 #load ing requr i ed packages
7 require (RSQLite )
8 require ( ggp lot2 )
9
10 #sourc ing requ i red func t i ons
11 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/ ’ )
12 source ( ’ funct ion−pca .R ’ )
13 source ( ’ funct ion−p l o t t i n g 2D sco r e .R ’ )
14 source ( ’ funct ion−p l o t t i n g 2D load ing .R ’ )
15 source ( ’ funct ion−pca d i a gno s t i c s .R ’ )
16 source ( ’ funct ion−data cleanup .R ’ )
17 source ( ’ funct ion−s c a l i n g .R ’ )
18
19 #s e t t i n g working d i r e c t o r y
20 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript B ’
)
21
22 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
23 #Input data
24 # Choose d r i v e r
25 drv <− dbDriver ( ’ SQLite ’ )
26
27 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
28 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
29
30 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
31 q . hour , q . phase , q . dose , q . treatment , q . gen t reat , q . expt ,
32 d . va r i ab l e , d . va lue
33 FROM Data d INNER JOIN Qua l i f i e r q
34 ON d . f i l e = q . f i l e
35 INNER JOIN Rank r
36 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
37 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
38 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
39 AND q . s t a t e = ’ ss ’
40 AND q . donor NOT IN ( ’C’ , ’RP1 ’ )
41 AND q . expt != ’RP2’
42 ORDER BY q . sampleID ; ” )
43
44 input2 <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
45 q . hour , q . phase , q . dose , q . treatment , q . gen t reat , q . expt ,
46 d . va r i ab l e , d . va lue
47 FROM Data d INNER JOIN Qua l i f i e r q
48 ON d . f i l e = q . f i l e
49 INNER JOIN Rank r
50 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
51 WHERE r . Conf idence = 1
52 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
53 AND q . s t a t e = ’ ss ’
54 AND q . donor NOT IN ( ’C’ , ’RP1 ’ )
55 AND q . expt != ’RP2’
56 ORDER BY q . sampleID ; ” )
57 dbDisconnect ( con )
58
59 #s e t t i n g working d i r e c t o r y
60 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript B/
Analys i s ’ )
61
62 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
63 #Performing c learnup func t ion to remove DSS, contaminants and compounds o f
64 #zero concentra t ion
65
66 c l ean . data <− data cleanup ( input2 , ’ sampleID ’ , ’ v a r i a b l e ’ , ’ va lue ’ ,
67 form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ , ’DPI ’ ,
68 ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ , ’ gen t r e a t ’ ,
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69 ’ expt ’ ) ,
70 form . x=’ va r i ab l e ’ , contaminants=NULL, export=FALSE)
71
72 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
73 #conver t ing f a c t o r s to appropr ia te c l a s s e s
74 c l ean . data$run <− as . character ( c l ean . data$run )
75 c l ean . data$gen t r e a t <− factor ( c l ean . data$gen t reat ,
76 levels=c ( ’None ’ , ’ Norepinephr ine ’ , ’RePOOPulate ’ ,
77 ’ Clindamycin+RePOOPulate ’ , ’ Clindamycin ’ ,
78 ’Vancomycin ’ ) )
79 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
80 #performing the PCA
81 pca . data = perform pca ( c l ean . data , sampleID=’ sampleID ’ ,
82 variable=’ va r i ab l e ’ , va lue=’ va lue ’ ,
83 form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ , ’DPI ’ ,
84 ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ , ’ gen t r e a t ’ ,
85 ’ expt ’ ) ,
86 form . x=’ va r i ab l e ’ ,
87 scale=’UV’ , c en t e r=TRUE, convert .NA=TRUE)
88 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
89 #performing d i a gno s t i c s on PCA
90 d i a gno s t i c . r e s u l t s = s c r e e plot ( pca . data )
91
92 #unpacking the d i a gno s t i c r e s u l t s
93 d i a gno s t i c . number = d i a gno s t i c . r e s u l t s [ [ ’ number ’ ] ]
94 d i a gno s t i c . exp la ined = d i a gno s t i c . r e s u l t s [ [ ’ exp la ined ’ ] ]
95 d i a gno s t i c . plot = d i agno s t i c . r e s u l t s [ [ ’ p l o t ’ ] ]
96 d i a gno s t i c . plot = d i agno s t i c . plot + g g t i t l e ( ’ Scree Plot (UVN) ’ )
97
98 #pr in t i n g out d i a gno s t i c r e s u l t s
99 print ( d i a gno s t i c . number )
100 print ( d i a gno s t i c . exp la ined )
101 print ( d i a gno s t i c . plot )
102 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
103 #p l o t t i n g PCA−processed data
104 #Score p l o t 2D
105 # Note : Arguments f o r score p l o t func t i on are
106 # (pca data , q u a l i f i e r data , PCs=1:4 , co lour=NULL, shape=NULL, s i z e=NULL,
107 # l a b e l=NULL, t i t l e=NULL, legend . o r i=’ hor i zon ta l ’ , b l a c k whi te=FALSE)
108
109 s co r e plot = sco r e plot 2d( pca . data , PCs=1:4 ,
110 co l our=’ gen t r e a t ’ , shape=’ donor ’ ,
111 legend . o r i= ’ ho r i z on t a l ’ , o u t l i n e=FALSE,
112 black white=FALSE)
113
114 p . s c o r e <− s c o r e plot [ [ ’ p ’ ] ]
115 c o l l e c t e d . data <− s c o r e plot [ [ ’ c o l l e c t e d . data ’ ] ]
116
117 e l l i p s e custom <− function (d) {
118
119 #Ca lcu l a t ing e l l i p s e f o r 95% conf idence
120 e l l i p s eSD = cor (d$x . value , d$y . va lue )
121 e l l i p s eD f = as . data . frame ( e l l i p s e ( e l l i p seSD , scale=c ( sd (d$x . va lue ) ,
122 sd (d$y . va lue ) ) ,
123 cent r e=colMeans (d [ , c ( ’ x . va lue ’ , ’ y . va lue ’ ) ] ) ,
124 t=2) )
125 return ( e l l i p s eD f )
126 }
127
128 e .path <− ddply ( c o l l e c t e d . data , ’ view ’ , e l l i p s e custom )
129
130
131 #Drawing an e l l i p s e f o r 95% conf idence
132 p . s c o r e = p . s co r e +
133 # geom path ( data=e . path , aes ( x=x , y=y ) , l i n e t y p e =2, a lpha =0.5) +
134 # sca l e co lour manual ( va lue s=c ( ’ b lack ’ , ’ darkorange1 ’ , ’ corn f l owerb lue ’ ,
135 # ’ b lack ’ , ’ char treuse ’ , ’ b lue ’ , ’ grey30 ’ ) ,
136 # guide legend ( t i t l e =’Run ’ ) ,
284
137 # l a b e l s=c ( ’NA’ , ’ 1 ’ , ’ 2 ’ , ’ 3 ’ , ’ 4 ’ , ’ 5 ’ , ’ 6 ’ ) ) +
138 scale shape manual (name=’Donor ’ , labels=c ( ’A ’ , ’B ’ , ’MET−2 ’ ) , va lue s=c ( 16 , 7 , 5 ) ) +
139 scale co l ou r manual ( va lue s=c ( ’ cyan4 ’ , ’ darkorch id4 ’ , ’ cha r t r eu s e ’ ,
140 ’ darkorange1 ’ , ’ deeppink1 ’ , ’ b lue ’ , ’ grey30 ’ ) ,
141 labels=c ( ’None ’ , ’ Norepinephr ine ’ , ’MET−1 ’ ,
142 ’ Clindamycin+MET−1 ’ , ’ Clindamycin ’ ,
143 ’Vancomycin ’ ) ,
144 guide legend ( t i t l e=’Treatment ’ ,
145 ) ) +
146 gu ides ( col=guide legend ( byrow=TRUE,nrow=2) )
147
148 ggsave ( ’ . . /Plot s/PCA p l o t s/treatment−s c o r e . png ’ , p . score , he ight =15, width=25,
un i t s=’cm ’ )
149
150 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
151 #Loading p l o t 2D
152 # Note : Arguments f o r l oad ing p l o t func t i on are ( pca data , PCs=1:4 , l a b e l=NULL,
t i t l e=NULL,
153 # view mode=’compressed ’ )
154
155 #I f you want a l l compound l a b e l s shown , enter a l l paths in l a b e l argument
156 a l l paths = rownames( pca . data$ r o t a t i on )
157
158 #I f you want a l l and only compound wi th in the sub s e t o f o b s e r va t i ons processed in
the PCA funct ion , can crea t e a temperary group c a l l e d ’a ’ to enter in f o r the
l a b e l argument
159 #a = pathway l i s t $Carb [ pathway l i s t $Organic %in% rownames ( pca processed data$
r o t a t i on ) ]
160
161 load ing plot = load ing plot 2d( pca . data , PCs=1:4 , l a b e l=a l l paths , o u t l i n e=TRUE,
162 t i t l e=NULL, view mode = ’ compressed ’ )
163
164 p . load <− l oad ing plot [ [ ’ p ’ ] ]
165 load . data <− l oad ing plot [ [ ’ c o l l e c t e d . data ’ ] ]
166
167 ggsave ( ’ . . /Plot s/PCA p l o t s/treatment−l oad ing . png ’ , p . load ,
168 he ight =14.5∗ 1 . 5 , width=25∗2 , un i t s=’cm ’ )
Treatment analysis.R
1 #//////////////////////////////////////////////////////////////////////////////////
/////
2 #Modif ied f o r Manuscript B
3 #Ant i b i o t i c treatment ana l y s i s
4 #Heat map
5
6 #load ing requ i red packages
7 require ( ggp lot2 )
8 require (RODBC)
9 require (RSQLite )
10 require ( gr idExtra )
11 require ( s c a l e s )
12
13 #sourc ing requ i red func t i ons
14 setwd ( ’ c : /Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/ ’ )
15 source ( ’ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
16 source ( ’ funct ion−data cleanup .R ’ )
17 source ( ’ funct ion−ex t r a c t legend .R ’ )
18 source ( ’ funct ion−bin func t i on .R ’ )
19
20
21 #s e t t i n g working d i r e c t o r y
22 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript B/
Analys i s ’ )
23 source ( ’ . . /Functions/ funct ion−de f ined binning .R ’ )
24 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
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25 #Input data
26 con <− odbcConnect ( ’MySQLDSN’ )
27
28 input <− sqlQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
29 q . hour , q . phase , q . dose , q . treatment , q . gentreat , q . expt ,
30 d . va r i ab l e , d . va lue
31 FROM l i q u i d g o l d . data d INNER JOIN l i q u i d g o l d . q u a l i f i e r q
32 ON d . f i l e = q . f i l e
33 INNER JOIN l i q u i d g o l d . rank r
34 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
35 WHERE r . Conf idence = 1
36 AND (q . run != 8 OR q . run IS NULL)
37 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
38 AND q . s t a t e = ’ ss ’
39 AND q . donor NOT IN ( ’C’ , ’RP1 ’ )
40 AND q . expt != ’RP2’
41 ORDER BY q . sampleID ; ” )
42
43 odbcClose ( con )
44
45 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
46 #Performing data cleanup to remove zero va lue compounds
47 #al so ca s t s data in to wide format
48 c l ean <− data cleanup ( input , form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
49 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
50 ’ g ent r ea t ’ , ’ expt ’ ) ,
51 form . x=’ va r i ab l e ’ , convert .NA=TRUE)
52
53 #make sure a l l compounds have a va lue f o r each donor
54 data . c a s t <− dcast ( c lean , formula=sampleID+donor+run+v e s s e l+DPI+hour+phase+dose+
55 treatment+gent r ea t+expt˜variable , va lue . var=’ value ’ )
56
57 #Assigning 0 to where compound was not p r o f i l e d
58 data . c a s t [ , 1 2 : ncol (data . c a s t ) ] [ i s .na(data . c a s t [ , 1 2 : ncol (data . c a s t ) ] ) ] <− 0
59
60 #mel t ing back to long format
61 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
62 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
63 ’ g ent r ea t ’ , ’ expt ’ ) )
64 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
65 #Gett ing d e s c r i p t i v e s t a t s f o r compounds wi th in gen t r ea t f o r each donor
66 stat <− ddply (data . melt , c ( ’ donor ’ , ’ g en t r ea t ’ ) , d e s c r i p t i v e . stat , data . type=’ long ’ ,
67 variable=’ va r i ab l e ’ )
68
69 #t t e s t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
70 #t e s t i n g i f the change from non−t r e a t ed to t r ea t e d i s s i g n i f i c a n t u s in t t−t e s t
71
72 t custom <− function (data , g en t r ea t ) {
73
74 none <− data [ data$gent r ea t == ’None ’ , ]
75 out <− none
76 out$p . va l <− NA
77
78 for ( i in gent r ea t ) {
79
80 t r e a t <− data [ data$gent r ea t == i , ]
81
82 #when t r ea t e d samples have more than 1 value , can use comparison o f 2 means
83 i f ( length (unique ( t r e a t$sampleID ) ) > 1) {
84 p . va lue=t . t e s t ( none$value , t r e a t$value )$p . va lue
85 output <− t r e a t
86 output$p . va l <− p . va lue
87
88 out <− rbind ( out , output )
89 }
90
91 #when t r ea t e d samples have only 1 value , do 1−sample t t e s t , where t r ea t e d
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va lue
92 #i s the t rue mean
93 else i f ( length (unique ( t r e a t$sampleID ) ) == 1) {
94 x . bar <− mean( none$value )
95 y . va lue <− t r e a t$value
96 x . sd <− sd ( none$value )
97 n <− length (unique ( none$sampleID ) )
98
99 t . stat <− ( x . bar − y . va lue )/ ( x . sd/sqrt (n) )
100 p . va lue <− 2∗pt(−abs ( t . stat ) , n−1)
101
102 output <− t r e a t
103 output$p . va l <− p . va lue
104
105 out <− rbind ( out , output )
106 }
107
108 #when the gen t r ea t i s not in t ha t donor
109 else i f ( length (unique ( t r e a t$sampleID ) ) < 1) {
110 out <− out
111 }
112 }
113 return ( out )
114 }
115
116 t . r e s u l t <− ddply ( stat , c ( ’ donor ’ , ’ v a r i a b l e ’ ) ,
117 t custom , c ( ’ Clindamycin ’ , ’RePOOPulate ’ ,
118 ’ Clindamycin+RePOOPulate ’ , ’ Norepinephr ine ’ , ’
Vancomycin ’ ) )
119 #wri t e . csv ( f i l e =’check t r e s u l t . csv ’ , t . r e s u l t )
120
121 #Mann Whitney t e s t
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
122 #t e s t i n g i f the change from non−t r e a t ed to t r ea t e d i s s i g n i f i c a n t us ing mann
whitney t e s t
123
124 mw custom <− function (data , g en t r ea t ) {
125
126 none <− data [ data$gent r ea t == ’None ’ , ]
127 out <− none
128 out$p . va l <− NA
129
130 for ( i in gent r ea t ) {
131
132 t r e a t <− data [ data$gent r ea t == i , ]
133
134 #when t r ea t e d samples have more than 1 value , can use comparison o f 2 means
135 i f ( length (unique ( t r e a t$sampleID ) ) > 1) {
136 p . va lue=wi lcox . t e s t ( none$value , t r e a t$value )$p . va lue
137 output <− t r e a t
138 output$p . va l <− p . va lue
139
140 out <− rbind ( out , output )
141 }
142
143 #when t r ea t e d samples have only 1 value , do 1−sample t t e s t , where t r ea t e d
va lue
144 #i s the t rue mean
145 else i f ( length (unique ( t r e a t$sampleID ) ) == 1) {
146 x . bar <− mean( none$value )
147 y . va lue <− t r e a t$value
148 x . sd <− sd ( none$value )
149 n <− length (unique ( none$sampleID ) )
150
151 t . stat <− ( x . bar − y . va lue )/ ( x . sd/sqrt (n) )
152 p . va lue <− 2∗pt(−abs ( t . stat ) , n−1)
153
154 output <− t r e a t
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155 output$p . va l <− p . va lue
156
157 out <− rbind ( out , output )
158 }
159
160 #when the gen t r ea t i s not in t ha t donor
161 else i f ( length (unique ( t r e a t$sampleID ) ) < 1) {
162 out <− out
163 }
164 }
165 return ( out )
166 }
167
168 mw. r e s u l t <− ddply ( stat , c ( ’ donor ’ , ’ v a r i a b l e ’ ) ,
169 mw custom , c ( ’ Clindamycin ’ , ’RePOOPulate ’ ,
170 ’ Clindamycin+RePOOPulate ’ , ’ Norepinephr ine ’ , ’
Vancomycin ’ ) )
171
172 #ge t t i n g d i f f e r e n c e between none and treatment means
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
173
174 d i f f custom <− function (data , g en t r ea t ) {
175 none <− data [ data$gent r ea t == ’None ’ , ]
176 out <− none
177 out$uni . t r e a t <− NA
178 out$d i f f <− NA
179 out$norm . d i f f <− NA
180 out$per . d i f f <− NA
181
182 for ( i in gent r ea t ) {
183 t r e a t <− data [ data$gent r ea t == i , ]
184 i f (nrow( t r e a t ) != 0) {
185 d i f f <− t r e a t
186 d i f f $uni . t r e a t <− paste (unique ( t r e a t$gent r ea t ) ,unique ( t r e a t$donor ) , sep=’ ’ )
187 d i f f $d i f f <− unique ( t r e a t$avg )−unique ( none$avg )
188 d i f f $norm . d i f f <− (unique ( t r e a t$avg )−unique ( none$avg ) )/ (unique ( none$avg )+
unique ( t r e a t$avg ) )/2∗100
189 d i f f $per . d i f f <− (unique ( t r e a t$avg )−unique ( none$avg ) )/unique ( none$avg )∗100
190
191 out <− rbind ( out , d i f f )
192 }
193 else i f (nrow( t r e a t ) == 0) out <− out
194 }
195 return ( out )
196 }
197
198 d i f f <− ddply (mw. r e su l t , c ( ’ donor ’ , ’ v a r i a b l e ’ ) ,
199 d i f f custom , c ( ’ Clindamycin ’ , ’RePOOPulate ’ ,
200 ’ Clindamycin+RePOOPulate ’ , ’ Norepinephr ine ’ , ’ Vancomycin
’ ) )
201
202 #removing none rows−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
203
204 d i f f <− d i f f [ d i f f $gent r ea t != ’None ’ , ]
205
206 #g i v i n g a r t i f i c i a l d i f f va lue s where non s i g n i f i c a n t d i f f e r e n c e s
207 #are ass i gned percent d i f f e r e n c e o f zero
208 d i f f $ s i g . p e r d i f f <− d i f f $per . d i f f
209 d i f f $ s i g . p e r d i f f [ d i f f $p . va l > 0 . 0 5 ] <− 0
210
211 #a r t i f i c i a l l y turn ing compounds with h i s i g . p e r d i f f i n to NA to make
212 #i t a d i f f e r e n t co lour when p l o t t i n g
213 d i f f $ s i g . p e r d i f f [ d i f f $ s i g . p e r d i f f > 100 & ! i s .na( d i f f $ s i g . p e r d i f f ) ] <− NA
214
215 #zero compounds
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
216
217 #Gett ing compounds with zero concentra t ion in none or t rea ted , but not both
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218 zero . cmpd <− unique (as . character ( d i f f $variable [ ! i s .na( d i f f $per . d i f f ) &
219 ( d i f f $per . d i f f == −100 | d i f f $per .
d i f f == ’ In f ’ ) ] ) )
220
221
222 zero . data <− d i f f [ d i f f $variable %in% zero . cmpd , ]
223
224 bin . l i s t <− de f ined binning ( )
225
226 #s e t t i n g working d i r e c t o r y back
227 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript B/
Analys i s ’ )
228
229 zero . order <− l i s t ( )
230 for ( i in 1 : length ( bin . l i s t ) ) {
231 temp <− zero . data [ z e ro . data$variable %in% bin . l i s t [ [ i ] ] , ]
232 temp <− unique ( temp [ , c ( ’ uni . t r e a t ’ , ’ v a r i a b l e ’ , ’ d i f f ’ ) ] )
233 temp$variable <− factor ( temp$variable , levels=rev ( levels ( bin . l i s t [ [ i ] ] ) ) , ordered
=TRUE)
234 temp$uni . t r e a t <− factor ( temp$uni . t r ea t ,
235 levels=c ( ’ Norepinephr ine A ’ , ’RePOOPulate A ’ ,
236 ’ Clindamycin+RePOOPulate A ’ ,
237 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’ Vancomycin RP2
’ ) ,
238 ordered=TRUE)
239 temp <− temp [ order ( temp$variable ) , ]
240 temp <− temp [ order ( temp$uni . t r e a t ) , ]
241
242 zero . order [ [ i ] ] <− temp
243 }
244
245 zero . export <− do . ca l l ( rbind . data . frame , z e ro . order )
246 write . csv ( f i l e=’ . . /Resu l t s/ zero . data . csv ’ , ze ro . export )
247
248 #hi compounds
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
249 #ge t t i n g compounds t ha t have s i g . p e r d i f f > 100
250 h i . cmpd <− unique (as . character ( d i f f $variable [ d i f f $per . d i f f > 100 &
251 ! i s .na( d i f f $per . d i f f ) ] ) )
252
253 h i . data <− d i f f [ d i f f $variable %in% hi . cmpd , ]
254 h i . data <− hi . data [ ! hi . data$variable %in% zero . cmpd , ]
255
256 h i . order <− l i s t ( )
257 for ( i in 1 : length ( bin . l i s t ) ) {
258 temp <− hi . data [ h i . data$variable %in% bin . l i s t [ [ i ] ] , ]
259 temp <− unique ( temp [ , c ( ’ uni . t r e a t ’ , ’ v a r i a b l e ’ , ’ per . d i f f ’ ) ] )
260 temp$variable <− factor ( temp$variable , levels=rev ( levels ( bin . l i s t [ [ i ] ] ) ) , ordered
=TRUE)
261 temp$uni . t r e a t <− factor ( temp$uni . t r ea t ,
262 levels=c ( ’ Norepinephr ine A ’ , ’RePOOPulate A ’ ,
263 ’ Clindamycin+RePOOPulate A ’ ,
264 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’ Vancomycin RP2
’ ) ,
265 ordered=TRUE)
266 temp <− temp [ order ( temp$variable ) , ]
267 temp <− temp [ order ( temp$uni . t r e a t ) , ]
268
269 h i . order [ [ i ] ] <− temp
270 }
271
272 for ( i in 1 : length ( h i . order ) ) {
273 h i .write <− hi . order [ [ i ] ]
274 write . csv ( f i l e=paste ( ’ . . /Resu l t s/hi . data ’ , i , ’ . csv ’ , sep=’ ’ ) , h i .write )
275 }
276 #dens i t y p l o t s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
277 #look ing at dens i t y p l o t o f mean concent ra t ions
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278 plot (density ( stat . d i f f $avg ) )
279 plot (density ( stat . z e ro$avg ) )
280 plot (density ( stat . h i$avg ) )
281 plot (density ( d i f f . data$ s i g . p e r d i f f [ ! i s .na( d i f f . data$ s i g . p e r d i f f ) ] ) )
282
283 #Assigning d i f f data to b ins as de f ined by none−t r e a t ed samples
−−−−−−−−−−−−−−−−−−−−−−−−−−
284
285 bin . none <− bin . l i s t
286 bin . t r e a t <− bin function ( dif f , bin=c ( 20 , 1 0 , 1 , 0 . 1 , 0 ) )
287 bin . t r e a t <− do . ca l l (c , bin . t r e a t )
288
289 none . cmpd <− c ( )
290 t r e a t . cmpd <− c ( )
291 for ( i in 1 : length ( bin . none ) ) {
292 temp <− as . character ( bin . none [ [ i ] ] )
293 temp2 <− as . character ( bin . t r e a t [ [ i ] ] )
294 none . cmpd <− c ( none . cmpd , temp)
295 t r e a t . cmpd <− c ( t r e a t . cmpd , temp2 )
296 }
297
298 #check i f any compouds in t r ea t ed samples not in non−t r e a t e d samles
299 # i f no can j u s t use none sample b inning
300 i f (any( ! t r e a t . cmpd %in% none . cmpd)==FALSE) bin . l i s t <− bin . none
301
302 #i f yes , then need to augment none sample b inning to inc lude those compounds
303 #in the r i g h t orer
304 ####wri t e when needed####
305
306 #Se t t i n g treatment order−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
307
308 d i f f $gent r ea t <− factor ( d i f f $gentreat ,
309 levels=c ( ’ Norepinephr ine ’ , ’RePOOPulate ’ ,
310 ’ Clindamycin+RePOOPulate ’ ,
311 ’ Clindamycin ’ , ’ Vancomycin ’ ) )
312
313 d i f f $uni . t r e a t <− factor ( d i f f $uni . t r ea t ,
314 levels=c ( ’ Norepinephr ine A ’ , ’RePOOPulate A ’ ,
315 ’ Clindamycin+RePOOPulate A ’ ,
316 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’ Vancomycin RP2 ’ )
)
317
318 d i f f $pad <− s p r i n t f ( ’%022s ’ , d i f f $variable )
319 #d i f f $ v a r i a b l e <− f a c t o r ( d i f f $ va r i a b l e , l e v e l s=none . cmpd , ordered=TRUE)
320
321 pad . l i s t <− l i s t ( )
322 for ( i in 1 : length ( bin . none ) ) {
323 pad . temp <− s p r i n t f ( ’%022s ’ , as . character ( bin . l i s t [ [ i ] ] ) )
324 pad . l i s t [ [ i ] ] <− pad . temp
325 }
326
327 pad . order <− c ( )
328 for ( i in 1 : length ( pad . l i s t ) ) {
329 temp <− as . character ( pad . l i s t [ [ i ] ] )
330 pad . order <− c ( pad . order , temp)
331 }
332
333 #hi compounds f o r t a b l e
2−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
334 #Compounds with percent change > 100%
335 h i . cmpd <− unique ( d i f f $variable [ d i f f $per . d i f f > 100 & ! i s .na( d i f f $per . d i f f ) ] )
336
337 #d i f f data f o r those compounds
338 out <− unique ( d i f f [ d i f f $variable %in% hi . cmpd , c ( ’ v a r i ab l e ’ , ’ uni . t r e a t ’ , ’ per . d i f f ’ ,
’ p . va l ’ ) ] )
339
340 #conver t ing per . d i f f to zero i f i n s i g n i f i c a n t
341 out$per . d i f f [ out$p . va l > 0 . 0 5 ] <− 0
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342 #transforming in to cas ted form
343 out2 <− dcast ( out , variable˜uni . t r ea t , va lue . var=’ per . d i f f ’ )
344
345 #re−order ing columns to p a r t i c u l a r order
346 out3 <− out2 [ , c ( ’ v a r i ab l e ’ , ’ Norepinephr ine A ’ , ’RePOOPulate A ’ , ’ Clindamycin+
RePOOPulate A ’ ,
347 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’ Vancomycin RP2 ’ ) ]
348
349 #rearranging compounds to bin order
350 out3$variable <− factor ( out3$variable , levels=none . cmpd , ordered=TRUE)
351 out3 <− out3 [ order ( out3$variable ) , ]
352
353 #Adding compound c l a s s e s
354 type . i n f o <− unique (cmpd . i n f o [ cmpd . i n f o$Compound %in% hi . cmpd , 1 : 2 ] )
355 type . i n f o$Compound <− factor ( type . i n f o$Compound , levels=none . cmpd , ordered=TRUE)
356 type . i n f o <− type . i n f o [ order ( type . i n f o$Compound) , ]
357
358 out3$class <− type . i n f o$Type
359
360 path . i n f o <− cmpd . i n f o [ cmpd . i n f o$Compound %in% hi . cmpd , ]
361
362 #expor t as csv
363 #wri t e . csv ( f i l e = ’ . ./Resu l t s/h i percent d i f f e r e n c e . csv ’ , out3 )
364 write . csv ( f i l e=’ . . /Resu l t s/path i n f o . csv ’ , path . i n f o )
365
366 #expor t ing h i and zero data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
367 #expor t ing h i data and zero data to csv f i l e
368 zero . data2 <− unique ( ze ro . data [ , c ( ’ v a r i ab l e ’ , ’ uni . t r e a t ’ , ’med ’ , ’ d i f f ’ ) ] )
369
370
371 #order ing zero . data2 so v a r i a b l e s are in order o f median va lue s
372 order . ze ro2 <− zero . data2 [ order ( ze ro . data2$med , dec r ea s ing=TRUE) , ]
373 order . ze ro2$variable <− factor (order . ze ro2$variable ,
374 levels=rev (unique (order . ze ro2$variable ) ) ,
375 ordered=TRUE)
376 zero . ordered2 <− zero . data2
377 zero . ordered2$variable <− factor ( ze ro . ordered2$variable ,
378 levels=levels (order . ze ro2$variable ) )
379 zero . ordered2$uni . t r e a t <− factor ( ze ro . ordered2$uni . t r ea t ,
380 levels=c ( ’ Norepinephr ine A ’ , ’RePOOPulate A ’ ,
381 ’ Clindamycin+RePOOPulate A ’ ,
382 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’
Vancomycin RP2 ’ ) )
383
384 zero . out <− dcast ( ze ro . data2 , formula=variable˜uni . t r ea t , va lue . var=’ d i f f ’ )
385
386 #wri t e . csv ( f i l e = ’ . ./Plo t s/ zero data . csv ’ , zero . out )
387
388
389 h i . data2 <− unique ( h i . data [ , c ( ’ v a r i ab l e ’ , ’ uni . t r e a t ’ , ’med ’ , ’ s i g . p e r d i f f ’ ) ] )
390
391 #order ing h i . data2 so v a r i a b l e s are in order o f median va lue s
392 order . h i2 <− hi . data2 [ order ( h i . data2$med , dec r ea s ing=TRUE) , ]
393 order . h i2$variable <− factor (order . h i2$variable , levels=rev (unique (order . h i2$
variable ) ) ,
394 ordered=TRUE)
395 h i . ordered2 <− hi . data2
396 h i . ordered2$variable <− factor ( h i . ordered2$variable , levels=levels (order . h i2$
variable ) )
397 h i . ordered2$uni . t r e a t <− factor ( h i . ordered2$uni . t r ea t ,
398 levels=c ( ’ Norepinephr ine A ’ , ’RePOOPulate A ’ ,
399 ’ Clindamycin+RePOOPulate A ’ ,
400 ’ Clindamycin A ’ , ’ Clindamycin B ’ , ’
Vancomycin RP2 ’ ) )
401
402 h i . out <− dcast ( h i . ordered2 , formula=variable˜uni . t r ea t , va lue . var=’ s i g . p e r d i f f ’ )
403
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404 #wri t e . csv ( f i l e =’check h i data . csv ’ , h i . data )
405 #wri t e . csv ( f i l e =’check zero data . csv ’ , zero . data )
406 #wri t e . csv ( f i l e = ’ . ./Plo t s/h i data . csv ’ , h i . out )
407
408 #binning h i data by s i g . p e r d i f f
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
409 #binning h i . data by s i g . p e r d i f f
410 h i . data$bin <− NA
411 hi . data [ h i . data$ s i g . p e r d i f f >= 1000 & ! i s .na( h i . data$ s i g . p e r d i f f ) , ’ bin ’ ] <− ’ bin1
’
412 h i . data [ h i . data$ s i g . p e r d i f f >= 500 & hi . data$ s i g . p e r d i f f < 1000 &
413 ! i s .na( h i . data$ s i g . p e r d i f f ) , ’ bin ’ ] <− ’ bin2 ’
414 h i . data [ h i . data$ s i g . p e r d i f f >= 100 & hi . data$ s i g . p e r d i f f < 500 &
415 ! i s .na( h i . data$ s i g . p e r d i f f ) , ’ bin ’ ] <− ’ bin3 ’
416
417 #conver t ing compounds to charac ter c l a s s and a l s o g e t t i nng compounds in each bin
418 bin . cmpd <− l i s t ( )
419 for ( i in c ( ’ bin1 ’ , ’ bin2 ’ , ’ bin3 ’ ) ) {
420 temp <− hi . data [ h i . data$bin == i & ! i s .na( h i . data$bin ) , ]
421 bin . cmpd [ [ i ] ] <− as . character (unique ( temp$variable ) )
422 }
423
424 #Gett ing only compounds found in one bin and not any other b ins be f o r e i t
425 common . cmpd <− c ( bin . cmpd [ [ 1 ] ] )
426 h i . l i s t <− l i s t ( bin . cmpd [ [ 1 ] ] )
427
428 for ( i in 2 : length ( bin . cmpd) ) {
429 h i . l i s t [ [ i ] ] <− bin . cmpd [ [ i ] ] [ ! bin . cmpd [ [ i ] ] %in% common . cmpd ]
430 common . cmpd <− c (common . cmpd , h i . l i s t [ [ i ] ] )
431 }
432 #order ing h i . data so v a r i a b l e s are in order o f median va lue s
433 order . h i <− hi . data [ order ( h i . data$med , dec r ea s ing=TRUE) , ]
434 order . h i$variable <− factor (order . h i$variable , levels=rev (unique (order . h i$variable )
) ,
435 ordered=TRUE)
436 h i . ordered <− hi . data
437 h i . ordered$variable <− factor ( h i . ordered$variable , levels=levels (order . h i$variable )
)
438
439 h i . ordered$gent r ea t <− factor ( h i . ordered$gentreat ,
440 levels=levels (ordered . data$gent r ea t ) )
441 h i . ordered$uni . t r e a t <− factor ( h i . ordered$uni . t r ea t ,
442 levels=levels (ordered . data$uni . t r e a t ) )
443
444 #p l o t t i n g−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
445
446 plot . l i s t <− l i s t ( )
447 legend . l i s t <− l i s t ( )
448 f i g . l i s t <− l i s t ( )
449 f i g . l e g <− l i s t ( )
450 l e g . l im <− l i s t ( )
451
452 l e g . width <− c (10 ,10 ,10 ,10 ,10 )
453 l e g . pos <− l i s t (c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 6 , 0 . 45 ) )
454 f i g . width <− c ( 8 . 6 , 8 . 5 , 8 . 6 , 9 . 2 , 9 . 4 )
455 f i g . he ight <− c ( 2 . 4 , 2 . 8 , 4 . 2 , 1 3 . 5 , 1 1 . 2 )
456
457 margin <− l i s t (c ( 0 . 1 , 0 . 8 , 0 . 9 , 0 . 8 ) ,
458 c ( 0 . 1 , 0 . 8 , 1 , 1 ) ,
459 c ( 0 . 1 , 0 . 8 , 0 . 9 , 0 . 5 ) ,
460 c ( 0 , 0 . 2 , 0 , 0 ) ,
461 c ( 0 , 0 . 2 , 0 , 0 ) )
462
463 #Panels 1:3−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
464 for ( i in 1 : 3 ) {
465 plot . data <− unique ( d i f f [ d i f f $variable %in% bin . l i s t [ [ i ] ] ,
466 c ( ’ v a r i ab l e ’ , ’ pad ’ , ’ g en t r ea t ’ , ’ uni . t r e a t ’ , ’ p . va l ’ ,
467 ’ avg ’ , ’med ’ , ’ d i f f ’ , ’ per . d i f f ’ , ’ s i g . p e r d i f f ’ ) ] )
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468
469 #Se t t i n g compound order
470 plot . data$variable <− factor (as . character (plot . data$variable ) ,
471 levels=rev ( none . cmpd [ none . cmpd %in% bin . l i s t [ [ i ] ] ] ) ,
472 ordered=TRUE)
473 plot . data$pad <− factor (as . character (plot . data$pad ) ,
474 levels=rev ( pad . order [ pad . order %in% pad . l i s t [ [ i ] ] ] ) ,
ordered=TRUE)
475
476
477 plot . data$ l a b e l <− ’∗ ’
478
479 #wri t e . csv ( f i l e=pas te ( ’ . . /Resu l t s/check p l o t data ’ , i , ’ . csv ’ , sep= ’ ’) , temp)
480 #ge t t i n g legend l im i t s
481 max. l im <− max(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
482 min . l im <− min(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
483 l a r g e r . l im <− max(abs (max. l im ) , abs (min . l im ) )
484 l e g . l im [ [ i ] ] <− c(− l a r g e r . lim , l a r g e r . l im )
485 print (max. l im )
486 print (min . l im )
487
488 plot . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=uni . t r ea t , y=pad , l a b e l=l a b e l ) )
489
490 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] + geom t i l e ( f i l l =NA, co l ou r=’ white ’ )
491
492 i f (any( i s .na(plot . data$ s i g . p e r d i f f ) )==FALSE) {
493 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
494 geom t i l e ( aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ )
495 print ( ’ here1 ’ )
496 }
497
498 else i f (any( i s .na(plot . data$ s i g . p e r d i f f ) )==TRUE) {
499 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
500
501 #f i l l t i l e by s i g . p e r d i f f
502 geom t i l e (data=plot . data [ ! i s .na(plot . data$ s i g . p e r d i f f ) , ] ,
503 aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ )
504
505 i f (nrow(plot . data [ plot . data$p . va l <=0.05 &
506 plot . data$per . d i f f == −100 &
507 ! i s .na(plot . data$per . d i f f ) , ] ) > 0) {
508
509 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
510
511 #compounds with percent d i f f o f −100% co loured with red with ∗
512 geom t i l e (data=plot . data [ plot . data$p . va l <=0.05 &
513 plot . data$per . d i f f == −100 &
514 ! i s .na(plot . data$per . d i f f ) , ] ,
515 co l our=’ white ’ , f i l l = ’ red ’ ) +
516 geom text (data=plot . data [ plot . data$p . va l <=0.05 &
517 plot . data$per . d i f f == −100 &
518 ! i s .na(plot . data$per . d i f f ) , ] ,
519 co l our=’ white ’ , s i z e =6, h ju s t =0.5 , v ju s t =0.8)
520 }
521
522 i f (nrow(plot . data [ ( plot . data$p . va l <= 0.05 &
523 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$ s i g . p e r d i f f ) )
|
524 plot . data$per . d i f f == ’ In f ’ , ] ) > 0) {
525
526 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
527
528 #compounds percent d i f f > 100% or In f (0 in none , 1 in t r ea t ed ) co loured
b lue with ∗
529 geom t i l e (data=plot . data [ ( plot . data$p . va l <= 0.05 &
530 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$
s i g . p e r d i f f ) ) |
531 plot . data$per . d i f f == ’ In f ’ , ] ,
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532 co l our=’ white ’ , f i l l = ’ blue ’ ) +
533 geom text (data=plot . data [ ( plot . data$p . va l <= 0.05 &
534 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$
s i g . p e r d i f f ) ) |
535 plot . data$per . d i f f == ’ In f ’ , ] ,
536 co l our=’ white ’ , s i z e =6, h ju s t =0.5 , v ju s t =0.8)
537 }
538
539 print ( ’ here2 ’ )
540
541 }
542 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
543 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
544 scale x d i s c r e t e ( labels=c ( ’ Norepinephr ine ’ , ’MET−1 ’ , ’ Clindamycin+\nMET−1 ’ ,
545 ’ Clindamycin (A) ’ , ’ Clindamycin (B) ’ , ’ Vancomycin ’ ) ) +
546 scale f i l l g rad ientn ( colours=c ( ’ red ’ , ’ white ’ , ’ b lue ’ ) ,
547 va lue s=r e s c a l e (c(− l a r g e r . lim , 0 , l a r g e r . l im ) ) ,
548 name=’ Percent D i f f e r e n c e \nin Concentrat ion \ t ’ ,
549 l im i t s=l e g . l im [ [ i ] ] ) +
550 theme bw(12) +
551 theme (panel . background=element rect ( ’ grey60 ’ ) ,
552 panel . grid . major=element l i n e ( co l ou r = ’ grey40 ’ ) ,
553 axis . text . x=element blank ( ) ,
554 axis . t i c k s . x=element blank ( ) ,
555 axis . t i t l e . x=element blank ( ) ,
556 axis . t i t l e . y=element blank ( ) ,
557 legend . key . width=uni t ( 1 . 1 , ’cm ’ ) ,
558 legend . key . he ight=uni t ( 0 . 3 5 , ’cm ’ ) ,
559 legend . p o s i t i o n=c ( 0 . 5 5 , 0 . 4 ) , legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
560 legend . text=element text ( s i z e =7.5) ,
561 legend . t i t l e=element text ( s i z e =7.5) ,
562 plot .margin=uni t (margin [ [ i ] ] , ’cm ’ ) )
563
564 legend . l i s t [ [ i ] ] <− g legend (plot . l i s t [ [ i ] ] )
565
566 #Export as panels−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
567 i f (FALSE) {
568 #expor t as EPS; pane l s wi th l egend
569 setEPS ( )
570 postscript ( f i l e=paste ( ’ . . /Resu l t s/ t e s t p l o t ’ , i , ’ . eps ’ , sep=’ ’ ) ,
571 o n e f i l e=TRUE, paper=’ s p e c i a l ’ , h o r i z on t a l=FALSE,
572 he ight=f i g . he ight [ i ]+1 , width=f i g . width [ i ] , p o i n t s i z e =10)
573 grid . arrange ( legend . l i s t [ [ i ] ] , plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
574 he i gh t s=c ( 0 . 1 , 0 . 9 ) )
575 dev . of f ( )
576
577 #expor t as EPS; pane l s separa te from legend
578 setEPS ( )
579 postscript ( f i l e=paste ( ’ . . /Resu l t s/ t e s t p l o t ’ , i , ’ . eps ’ , sep=’ ’ ) ,
580 o n e f i l e=FALSE, paper=’ s p e c i a l ’ , h o r i z on t a l=FALSE,
581 he ight=f i g . he ight [ i ] , width=f i g . width [ i ] , p o i n t s i z e =10)
582 f i g . l i s t [ [ i ] ] <− grid . arrange (plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
583 dev . of f ( )
584
585 #expor t as PNG − pane l s
586 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f bin ’ , i , ’ . png ’ , sep=’ ’ ) ,
587 type=’ c a i r o ’ , he ight=f i g . he ight [ i ] , width=f i g . width [ i ] , un i t s=’cm ’ , r e s
=240 , p o i n t s i z e =10)
588 f i g . l i s t [ [ i ] ] <− grid . arrange (plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
589 dev . of f ( )
590
591 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f l e g ’ , i , ’ . png ’ , sep=’ ’ ) ,
592 he ight=1, width=l e g . width [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e =10)
593 f i g . l e g [ [ i ] ] <− grid . arrange ( legend . l i s t [ [ i ] ] )
594 dev . of f ( )
595 }
596 }
597
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598 #pane l s 4 and 5−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
599 for ( i in 4 : length ( bin . l i s t ) ) {
600 plot . data <− unique ( d i f f [ d i f f $variable %in% bin . l i s t [ [ i ] ] ,
601 c ( ’ v a r i ab l e ’ , ’ pad ’ , ’ g en t r ea t ’ , ’ uni . t r e a t ’ , ’ p . va l ’ ,
602 ’ avg ’ , ’med ’ , ’ d i f f ’ , ’ per . d i f f ’ , ’ s i g . p e r d i f f ’ ) ] )
603
604 #Se t t i n g compound order
605 plot . data$variable <− factor (as . character (plot . data$variable ) ,
606 levels=rev ( none . cmpd [ none . cmpd %in% bin . l i s t [ [ i
] ] ] ) ,
607 ordered=TRUE)
608 plot . data$pad <− factor (as . character (plot . data$pad ) ,
609 levels=rev ( pad . order [ pad . order %in% pad . l i s t [ [ i ] ] ] ) ,
ordered=TRUE)
610
611
612 plot . data$ l a b e l <− ’∗ ’
613
614 #wri t e . csv ( f i l e=pas te ( ’ . . /Resu l t s/check p l o t data ’ , i , ’ . csv ’ , sep= ’ ’) , temp)
615 #ge t t i n g legend l im i t s
616 max. l im <− max(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
617 min . l im <− min(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
618 l a r g e r . l im <− max(abs (max. l im ) , abs (min . l im ) )
619 l e g . l im [ [ i ] ] <− c(− l a r g e r . lim , l a r g e r . l im )
620 print (max. l im )
621 print (min . l im )
622
623 plot . l i s t [ [ i ] ] <− ggp lot (plot . data , aes ( x=uni . t r ea t , y=pad , l a b e l=l a b e l ) )
624
625 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] + geom t i l e ( f i l l =NA, co l ou r=’ white ’ )
626
627 i f (any( i s .na(plot . data$ s i g . p e r d i f f ) )==FALSE) {
628 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
629 geom t i l e ( aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ )
630 print ( ’ here1 ’ )
631 }
632
633 else i f (any( i s .na(plot . data$ s i g . p e r d i f f ) )==TRUE) {
634 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
635
636 #f i l l t i l e by s i g . p e r d i f f
637 geom t i l e (data=plot . data [ ! i s .na(plot . data$ s i g . p e r d i f f ) , ] ,
638 aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ )
639
640 i f (nrow(plot . data [ plot . data$p . va l <=0.05 &
641 plot . data$per . d i f f == −100 &
642 ! i s .na(plot . data$per . d i f f ) , ] ) > 0) {
643
644 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
645
646 #compounds with percent d i f f o f −100% co loured with red with ∗
647 geom t i l e (data=plot . data [ plot . data$p . va l <=0.05 &
648 plot . data$per . d i f f == −100 &
649 ! i s .na(plot . data$per . d i f f ) , ] ,
650 co l our=’ white ’ , f i l l = ’ red ’ ) +
651 geom text (data=plot . data [ plot . data$p . va l <=0.05 &
652 plot . data$per . d i f f == −100 &
653 ! i s .na(plot . data$per . d i f f ) , ] ,
654 co l our=’ white ’ , s i z e =6, h ju s t =0.5 , v ju s t =0.8)
655 }
656
657 i f (nrow(plot . data [ ( plot . data$p . va l <= 0.05 &
658 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$ s i g . p e r d i f f
) ) |
659 plot . data$per . d i f f == ’ In f ’ , ] ) > 0) {
660
661 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
662
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663 #compounds percent d i f f > 100% or In f (0 in none , 1 in t r ea t ed ) co loured
b lue with ∗
664 geom t i l e (data=plot . data [ ( plot . data$p . va l <= 0.05 &
665 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$
s i g . p e r d i f f ) ) |
666 plot . data$per . d i f f == ’ In f ’ , ] ,
667 co l our=’ white ’ , f i l l = ’ blue ’ ) +
668 geom text (data=plot . data [ ( plot . data$p . va l <= 0.05 &
669 plot . data$per . d i f f > 100 & ! i s .nan(plot . data$
s i g . p e r d i f f ) ) |
670 plot . data$per . d i f f == ’ In f ’ , ] ,
671 co l our=’ white ’ , s i z e =6, h ju s t =0.5 , v ju s t =0.8)
672 }
673
674 print ( ’ here2 ’ )
675
676 }
677 #
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
678 plot . l i s t [ [ i ] ] <− plot . l i s t [ [ i ] ] +
679 scale x d i s c r e t e ( labels=c ( ’ Norepinephr ine ’ , ’MET−1 ’ , ’ Clindamycin+\nMET−1 ’ ,
680 ’ Clindamycin (A) ’ , ’ Clindamycin (B) ’ , ’ Vancomycin ’ ) )
+
681 scale f i l l g rad ientn ( colours=c ( ’ red ’ , ’ white ’ , ’ b lue ’ ) ,
682 va lue s=r e s c a l e (c(− l a r g e r . lim , 0 , l a r g e r . l im ) ) ,
683 name=’ Percent D i f f e r e n c e \nin Concentrat ion \ t ’ ,
684 l im i t s=l e g . l im [ [ i ] ] ) +
685 theme bw(12) +
686 xlab ( ’ Treatment ’ ) +
687 theme (panel . background=element rect ( ’ grey60 ’ ) ,
688 panel . grid . major=element l i n e ( co l ou r = ’ grey40 ’ ) ,
689 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
690 axis . t i t l e . y=element blank ( ) ,
691 plot .margin=unit (c ( 0 . 5 , 0 . 8 , 0 , 0 ) , ’cm ’ ) ,
692 legend . key . width=uni t ( 1 . 1 , ’cm ’ ) ,
693 legend . key . he ight=uni t ( 0 . 3 5 , ’cm ’ ) ,
694 legend . p o s i t i o n=c ( 0 . 5 5 , 0 . 4 ) , legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
695 legend . text=element text ( s i z e =7.5) ,
696 legend . t i t l e=element text ( s i z e =7.5) ,
697 plot .margin=unit (margin [ [ i ] ] , ’cm ’ ) )
698
699 legend . l i s t [ [ i ] ] <− g legend (plot . l i s t [ [ i ] ] )
700
701 #Export as panels−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
702 i f (FALSE) {
703 #expor t as EPS; pane l s wi th l egend
704 setEPS ( )
705 postscript ( f i l e=paste ( ’ . . /Resu l t s/ t e s t p l o t ’ , i , ’ . eps ’ , sep=’ ’ ) ,
706 o n e f i l e=TRUE, paper=’ s p e c i a l ’ , h o r i z on t a l=FALSE,
707 he ight=f i g . he ight [ i ]+1 , width=f i g . width [ i ] , p o i n t s i z e =10)
708 grid . arrange ( legend . l i s t [ [ i ] ] , plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ )
,
709 he i gh t s=c ( 0 . 1 , 0 . 9 ) )
710 dev . of f ( )
711
712 #expor t as EPS; pane l s separa te from legend
713 setEPS ( )
714 postscript ( f i l e=paste ( ’ . . /Resu l t s/ t e s t p l o t ’ , i , ’ . eps ’ , sep=’ ’ ) ,
715 o n e f i l e=FALSE, paper=’ s p e c i a l ’ , h o r i z on t a l=FALSE,
716 he ight=f i g . he ight [ i ] , width=f i g . width [ i ] , p o i n t s i z e =10)
717 f i g . l i s t [ [ i ] ] <− grid . arrange (plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
718 dev . of f ( )
719
720 #expor t as PNG − pane l s
721 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f bin ’ , i , ’ . png ’ , sep=’ ’
) ,
722 type=’ c a i r o ’ , he ight=f i g . he ight [ i ] , width=f i g . width [ i ] , un i t s=’cm ’ , r e s
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=240 , p o i n t s i z e =10)
723 f i g . l i s t [ [ i ] ] <− grid . arrange (plot . l i s t [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
724 dev . of f ( )
725
726 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f l e g ’ , i , ’ . png ’ , sep=’ ’
) ,
727 he ight=1, width=l e g . width [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e =10)
728 f i g . l e g [ [ i ] ] <− grid . arrange ( legend . l i s t [ [ i ] ] )
729 dev . of f ( )
730 }
731 }
732
733
734 #Se t t i n g p l o t dimensions
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
735 widths <− l i s t (c (10 ,6 )/2.54+1 , #1
736 c (10 ,6 )/2.54+1 , #2
737 c (10 ,6 )/2.54+1 , #3
738 c (10 ,6 )/2.54+1 , #4
739 c ( 1 0 , 1 0 . 4 )/2.54+1) #5
740
741 he i gh t s <− l i s t (c ( 1 , 2 . 4 )/2 . 54 , #1
742 c ( 1 , 3 )/2 . 54 , #2
743 c ( 1 , 4 . 8 )/2 . 54 , #3
744 c (1 , 15 )/2 . 54 , #4
745 c ( 1 , 1 1 . 3 )/ 2 . 54 ) #5
746
747
748
749 #PNG−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
750 png ( f i l ename=’ . . /Plot s/ treatment e f f e c t s /Percent D i f f e r en c e 4 . png ’ ,
751 width=10.5/2 .54∗2 , he ight=sum(c ( he i gh t s [ [ 4 ] ] , h e i gh t s [ [ 3 ] ] ) ) ,
752 un i t s=’ in ’ , r e s =240 , p o i n t s i z e =10)
753 grid . arrange ( arrangeGrob ( legend . l i s t [ [ 1 ] ] ,
754 plot . l i s t [ [ 1 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
755 legend . l i s t [ [ 2 ] ] ,
756 plot . l i s t [ [ 2 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
757 legend . l i s t [ [ 5 ] ] ,
758 plot . l i s t [ [ 5 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
759 ncol=1, he i gh t s=c ( he i gh t s [ [ 1 ] ] , h e i gh t s [ [ 2 ] ] , h e i gh t s [ [ 5 ] ] ) ,
760 widths=c ( widths [ [ 1 ] ] , widths [ [ 2 ] ] , widths [ [ 5 ] ] ) ) ,
761 arrangeGrob ( legend . l i s t [ [ 3 ] ] ,
762 plot . l i s t [ [ 3 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
763 legend . l i s t [ [ 4 ] ] ,
764 plot . l i s t [ [ 4 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
765 ncol=1, he i gh t s=c ( he i gh t s [ [ 3 ] ] , h e i gh t s [ [ 4 ] ] ) ,
766 widths=c ( widths [ [ 3 ] ] , widths [ [ 4 ] ] ) ) ,
767 ncol=2)
768 grid . text ( ’A ’ , x=uni t ( 0 . 5 , ’cm ’ ) , y=uni t ( 2 1 . 1 , ’cm ’ ) , gp=gpar ( cex=1.5) )
769 grid . text ( ’C ’ , x=uni t ( 0 . 5 , ’cm ’ ) , y=uni t ( 1 7 . 4 , ’cm ’ ) , gp=gpar ( cex=1.5) )
770 grid . text ( ’E ’ , x=uni t ( 0 . 5 , ’cm ’ ) , y=uni t ( 12 . 95 , ’cm ’ ) , gp=gpar ( cex=1.5) )
771 grid . text ( ’B ’ , x=uni t (11 , ’cm ’ ) , y=uni t ( 2 1 . 2 , ’cm ’ ) , gp=gpar ( cex=1.5) )
772 grid . text ( ’D ’ , x=uni t (11 , ’cm ’ ) , y=uni t ( 1 5 . 4 , ’cm ’ ) , gp=gpar ( cex=1.5) )
773
774 dev . of f ( )
775
776 #EPS−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
777
778 setEPS ( )
779 postscript ( f i l e=’ . . /Resu l t s/ t e s t p l o t . eps ’ ,
780 o n e f i l e=FALSE, paper=’ s p e c i a l ’ , h o r i z on t a l=FALSE,
781 width=10.5/2 .54∗2 , he ight=sum(c ( he i gh t s [ [ 4 ] ] , h e i gh t s [ [ 3 ] ] ) ) ,
782 p o i n t s i z e =10)
783 grid . arrange ( arrangeGrob ( legend . l i s t [ [ 1 ] ] ,
784 plot . l i s t [ [ 1 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
785 legend . l i s t [ [ 2 ] ] ,
786 plot . l i s t [ [ 2 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
787 legend . l i s t [ [ 5 ] ] ,
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788 plot . l i s t [ [ 5 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
789 ncol=1, he i gh t s=c ( he i gh t s [ [ 1 ] ] , h e i gh t s [ [ 2 ] ] , h e i gh t s [ [ 5 ] ] ) ,
790 widths=c ( widths [ [ 1 ] ] , widths [ [ 2 ] ] , widths [ [ 5 ] ] ) ) ,
791 arrangeGrob ( legend . l i s t [ [ 3 ] ] ,
792 plot . l i s t [ [ 3 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
793 legend . l i s t [ [ 4 ] ] ,
794 plot . l i s t [ [ 4 ] ] + theme ( legend . p o s i t i o n=’ none ’ ) ,
795 ncol=1, he i gh t s=c ( he i gh t s [ [ 3 ] ] , h e i gh t s [ [ 4 ] ] ) ,
796 widths=c ( widths [ [ 3 ] ] , widths [ [ 4 ] ] ) ) ,
797 ncol=2)
798 dev . of f ( )
799
800
801
802 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
803 #p l o t t i n g percent d i f f where per . d i f f i s > 100%
804
805 plot . l i s t 3 <− l i s t ( )
806 l e g . l i s t 3 <− l i s t ( )
807 l e g . l im3 <− l i s t ( )
808
809 l e g . pos3 <− l i s t (c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 6 , 0 . 45 ) )
810 l e g . width3 <− c ( 8 , 8 , 8 , 9 , 10 )
811
812 f i g . width3 <− c ( 8 . 7 , 8 . 5 , 9 . 3 , 9 . 8 , 11)
813 f i g . he ight3 <− c ( 4 . 3 , 3 . 9 , 8 . 2 , 1 7 . 5 , 1 3 . 5 )
814 f i g . prop3 <− l i s t (c ( 0 . 3 , 0 . 7 ) , c ( 0 . 4 , 0 . 96 ) , c ( 0 . 0 5 , 0 . 95 ) , c ( 0 . 0 5 , 0 . 95 ) , c
( 0 . 0 5 , 0 . 9 5 ) )
815
816 for ( i in 1 : length ( h i . l i s t ) ) {
817 plot . data <− hi . ordered [ h i . ordered$variable %in% hi . l i s t [ [ i ] ] ,
818 c ( ’ v a r i ab l e ’ , ’ g en t r ea t ’ , ’ uni . t r e a t ’ , ’ p . va l ’ ,
819 ’ avg ’ , ’med ’ , ’ d i f f ’ , ’ per . d i f f ’ , ’ s i g . p e r d i f f ’ ) ]
820
821 #wri t e . csv ( f i l e=pas te ( ’ check h i data p l o t t ed ’ , i , ’ . csv ’ , sep= ’ ’) , p l o t . data )
822
823 #ge t t i n g legend l im i t s
824 h i .max <− max(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
825 h i .min <− min(plot . data$ s i g . p e r d i f f [ ! i s .na(plot . data$ s i g . p e r d i f f ) ] )
826 h i . l a r g e r <− max( h i .max, h i .min)
827 l e g . l im3 [ [ i ] ] <− c(−hi . l a r g e r , h i . l a r g e r )
828
829 plot . l i s t 3 [ [ i ] ] <− ggp lot (plot . data , aes ( x=uni . t r ea t , y=variable ) )
830
831 i f (any( i s .nan(plot . data$ s i g . p e r d i f f ) )==FALSE) {
832 plot . l i s t 3 [ [ i ] ] <− plot . l i s t 3 [ [ i ] ] +
833 geom t i l e ( aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ )
834 print ( ’ here1 ’ )
835 }
836
837 else i f (any( i s .nan(plot . data$ s i g . p e r d i f f ) )==TRUE) {
838 plot . l i s t 3 [ [ i ] ] <− plot . l i s t 3 [ [ i ] ] +
839 geom t i l e (data=plot . data [ ! i s .na(plot . data$ s i g . p e r d i f f ) , ] ,
840 aes ( f i l l =s i g . p e r d i f f ) , c o l ou r=’ white ’ ) +
841 geom t i l e (data=plot . data [ i s .nan(plot . data$ s i g . p e r d i f f ) , ] , c o l ou r=’ white ’ ,
842 f i l l = ’ grey30 ’ , alpha =0.5)
843 print ( ’ here2 ’ )
844 }
845
846 plot . l i s t 3 [ [ i ] ] <− plot . l i s t 3 [ [ i ] ] +
847 scale x d i s c r e t e ( labels=c ( ’ Norepinephr ine ’ , ’ Repoopulate ’ , ’ Clindamycin+\n\
tRepoopulate ’ ,
848 ’ Clindamycin (A) ’ , ’ Clindamycin (B) ’ , ’ Vancomycin ’ ) ) +
849 scale f i l l g rad ientn ( colours=c ( ’ red ’ , ’ white ’ , ’ b lue ’ ) ,
850 va lue s=r e s c a l e (c(−hi . l a r g e r , 0 , h i . l a r g e r ) ) ,
851 name=’ Percent D i f f e r e n c e \nin Concentrat ion \ t ’ ,
852 l im i t s=l e g . l im3 [ [ i ] ] ) +
853 theme bw(10) +
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854 xlab ( ’ Treatment ’ ) +
855 ylab ( ’Compound ’ ) +
856 theme (panel . grid . major=element l i n e ( co l ou r = ’ grey40 ’ ) ,
857 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
858 legend . p o s i t i o n=l e g . pos3 [ [ i ] ] , legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
859 legend . key . width=uni t (1 , ’cm ’ ) ,
860 legend . key . he ight=uni t ( 0 . 3 , ’cm ’ ) ,
861 legend . text=element text ( s i z e =7.5) ,
862 legend . t i t l e=element text ( s i z e =7.5) )
863
864 l e g . l i s t 3 [ [ i ] ] <− g legend (plot . l i s t 3 [ [ i ] ] )
865
866 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f−hi range ’ , i , ’ . png ’ , sep=’ ’
) ,
867 he ight=f i g . he ight3 [ i ] , width=f i g . width3 [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e
=10)
868 f i g <− grid . arrange (plot . l i s t 3 [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
869 dev . of f ( )
870
871 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s /per d i f f−hi l e g ’ , i , ’ . png ’ , sep=’ ’ ) ,
872 he ight=1, width=l e g . width3 [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e =10)
873 l e g <− grid . arrange ( l e g . l i s t 3 [ [ i ] ] )
874 dev . of f ( )
875 }
876
877 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
878 plot . l i s t 2 <− l i s t ( )
879 legend . l i s t 2 <− l i s t ( )
880 f i g . l i s t 2 <− l i s t ( )
881 f i g . l e g2 <− l i s t ( )
882 l e g . l im2 <− l i s t ( )
883 plot . data . l i s t <− l i s t ( )
884
885 #customiz ing p l o t s p e c i f i c a t i o n s
886 l e g . pos2 <− l i s t (c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 5 , 0 . 5 ) , c ( 0 . 6 , 0 . 45 ) )
887 l e g . width2 <− c ( 8 , 8 , 8 , 9 , 10 )
888
889 f i g . width2 <− c ( 8 . 7 , 8 . 5 , 9 . 3 , 8 , 11)
890 f i g . he ight2 <− c ( 4 . 3 , 3 . 9 , 8 . 2 , 8 , 1 3 . 5 )
891 f i g . prop2 <− l i s t (c ( 0 . 3 , 0 . 7 ) , c ( 0 . 4 , 0 . 96 ) , c ( 0 . 0 5 , 0 . 95 ) , c ( 0 . 0 5 , 0 . 95 ) , c
( 0 . 0 5 , 0 . 9 5 ) )
892
893 for ( i in 1 : ( length ( uni . l i s t 2 )−1) ) {
894 plot . data <− unique (ordered . data2 [ ordered . data2$variable %in% uni . l i s t 2 [ [ i ] ] , ] )
895
896 plot . data . l i s t [ [ i ] ] <− plot . data
897
898 #ge t t i n g legend l im i t s
899 max. l im <− max(plot . data$d i f f [ ! i s .nan(plot . data$d i f f ) ] )
900 min . l im <− min(plot . data$d i f f [ ! i s .nan(plot . data$d i f f ) ] )
901 l a r g e r . l im <− max(abs (max. l im ) , abs (min . l im ) )
902 l e g . l im2 [ [ i ] ] <− c(− l a r g e r . lim , l a r g e r . l im )
903 print (max. l im )
904 print (min . l im )
905 plot . l i s t 2 [ [ i ] ] <− ggp lot (plot . data , aes ( x=uni . t r ea t , y=variable ) )
906
907 i f (any( i s .na(plot . data$d i f f ) )==FALSE) {
908 plot . l i s t 2 [ [ i ] ] <− plot . l i s t 2 [ [ i ] ] +
909 geom t i l e ( aes ( f i l l =d i f f ) , co l ou r=’ white ’ )
910 }
911
912 else i f (any( i s .na(plot . data$d i f f ) )==TRUE) {
913 plot . l i s t 2 [ [ i ] ] <− plot . l i s t 2 [ [ i ] ] +
914 geom t i l e (data=plot . data [ ! i s .nan(plot . data$d i f f ) , ] ,
915 aes ( f i l l =d i f f ) , c o l ou r=’ white ’ ) +
916 geom t i l e (data=plot . data [ i s .nan(plot . data$d i f f ) , ] , c o l ou r=’ white ’ ,
917 f i l l = ’ grey30 ’ , alpha =0.5)
918
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919 }
920 plot . l i s t 2 [ [ i ] ] <− plot . l i s t 2 [ [ i ] ] +
921 scale x d i s c r e t e ( labels=c ( ’ Norepinephr ine ’ , ’ Repoopulate ’ , ’ Clindamycin+\n\
tRepoopulate ’ ,
922 ’ Clindamycin (A) ’ , ’ Clindamycin (B) ’ , ’ Vancomycin ’ ) ) +
923 scale f i l l g rad ientn ( colours=c ( ’ red ’ , ’ white ’ , ’ b lue ’ ) ,
924 va lue s=r e s c a l e (c(− l a r g e r . lim , 0 , l a r g e r . l im ) ) ,
925 name=’ D i f f e r e n c e \nin Concentrat ion \ t ’ ,
926 l im i t s=l e g . l im2 [ [ i ] ] ) +
927 theme bw(10) +
928 xlab ( ’ Treatment ’ ) +
929 ylab ( ’Compound ’ ) +
930 theme (panel . grid . major=element l i n e ( co l ou r = ’ grey40 ’ ) ,
931 axis . text . x=element text ( h ju s t =0, v ju s t =1, ang le=−45) ,
932 legend . p o s i t i o n=l e g . pos2 [ [ i ] ] , legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
933 legend . key . width=uni t (1 , ’cm ’ ) ,
934 legend . key . he ight=uni t ( 0 . 3 , ’cm ’ ) ,
935 legend . text=element text ( s i z e =7.5) ,
936 legend . t i t l e=element text ( s i z e =7.5) )
937
938 legend . l i s t 2 [ [ i ] ] <− g legend (plot . l i s t 2 [ [ i ] ] )
939
940 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s / d i f f bin ’ , i , ’ . png ’ , sep=’ ’ ) ,
941 he ight=f i g . he ight2 [ i ] , width=f i g . width2 [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e
=10)
942 f i g . l i s t 2 [ [ i ] ] <− grid . arrange (plot . l i s t 2 [ [ i ] ] + theme ( legend . p o s i t i o n=’ none ’ ) )
943 dev . of f ( )
944
945 png ( f i l ename=paste ( ’ . . /Plot s/ treatment e f f e c t s / d i f f l e g ’ , i , ’ . png ’ , sep=’ ’ ) ,
946 he ight=1, width=l e g . width2 [ i ] , un i t s=’cm ’ , r e s =240 , p o i n t s i z e =10)
947 f i g . l e g2 [ [ i ] ] <− grid . arrange ( legend . l i s t 2 [ [ i ] ] , h e i gh t s=f i g . prop2 [ [ i ] ] )
948 dev . of f ( )
949
950 }
C.6 Functions
function-summary preprocessing.R
1 #//////////////////////////////////////////////////////////////////////////////////
2 #Function fo r preproces s ing expor ted f i l e s t ha t contain
3 #molecular weight o f compounds and pH of samples
4
5 #input : f i l e − i s the csv f i l e name , a long with i t s path
6 # ob j e c t − i s the o b j e c t name you want to s t o r e the processed raw data in
7 #output : data − data frame of the concentra t ion summaries with appropr ia te column
names
8 # and row names
9 # mol . wt − molecular we igh t s o f compounds
10
11 summary . p r ep roce s s <− function ( f i l e . name) {
12
13 #reading csv f i l e
14 data <− read . csv ( f i l e=f i l e . name , header=FALSE, check .names=FALSE,
15 encoding=’UTF−8 ’ )
16
17 #removing compound molecular we igh t s and sample pH va lue s
18 mol . data <− data [ c ( 3 , 4 ) , c ( 1 , 3 : ncol (data ) ) ]
19
20 col . name <− as . character (as .matrix ( ( mol . data [ 1 , 2 : ncol (mol . data ) ] ) ) )
21 row . name <− as . character (as .matrix (mol . data [ 2 , 1 ] ) )
22
23 mol . weight <− mol . data [ 2 , 2 : ncol (mol . data ) ]
24 colnames (mol . weight ) <− col . name
25 rownames(mol . weight ) <− row . name
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26
27 data <− data [ c ( 3 , 5 :nrow(data ) ) ,c ( 1 , 3 : ncol (data ) ) ]
28
29 #crea t ing vec to r o f column names
30 col . name <− as .matrix (cbind ( ’ f i l e ’ , data [ 1 , 2 : ncol (data ) ] ) )
31 colnames (data ) <− col . name
32
33 #removing redundant row of compounds , compounds are now column names
34 data <− data [ 2 :nrow(data ) , ]
35
36 #turning a l l concen t ra t ions in to numeric c l a s s
37 for ( i in 2 : ncol (data ) ) data [ , i ] <− as .numeric (as . character (data [ , i ] ) )
38
39 #turning a l l f i l e names in to charac t e r s
40 data$ f i l e <− as . character (data$ f i l e )
41
42 return ( l i s t ( ’ data ’=data , ’mol . wt ’=mol . weight ) )
43
44 }
function-data cleanup.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #This funct ion−Removing contaminants and zero−columns
3 data cleanup = function ( dataset , sampleID=’ sampleID ’ , variable=’ va r i ab l e ’ ,
4 va lue=’ va lue ’ , form . y , form . x , contaminants=NULL,
5 export=FALSE, convert .NA=FALSE) {
6
7 #load ing requ i red packages
8 require ( reshape2 )
9 require ( p ly r )
10 #Gett ing l i s t o f compounds be fo r e anything i s removed
11 pre = unique ( datase t [ , variable ] )
12
13 #Removing DSS
14 datase t = datase t [ ! datase t [ , variable ] %in% c ( ’DSS−d6 ( Chemical Shape Ind i c a t o r ) ’ ,
15 ’DSS ( Chemical Shape Ind i c a t o r ) ’ ) , ]
16
17 check . dss = any( datase t [ , variable ] %in% c ( ’DSS−d6 ( Chemical Shape Ind i c a t o r ) ’ ,
18 ’DSS ( Chemical Shape Ind i c a t o r ) ’ ) )
19
20 #Removing contaminants
21 datase t = datase t [ ! datase t [ , variable ] %in% contaminants , ]
22
23 #Gett ing l i s t o f compounds a f t e r DSS and contaminants removed
24 post = unique ( datase t [ , variable ] )
25
26 #Checking i f contaminants were removed
27 check . contaminants = pre [ ! pre %in% post ]
28 check . contaminants = check . contaminants [ ! check . contaminants %in% c ( ’DSS−d6 (
Chemical Shape Ind i c a t o r ) ’ ,
29 ’DSS ( Chemical
Shape
Ind i c a t o r )
’ ) ]
30
31 #Removing compounds with zero concent ra t ions in every sample
32 subset = ddply ( dataset , variable , summarise , sample=sampleID ,
33 value=value )
34
35 zero . va lue s <− ddply ( subset , variable , summarise ,
36 unique . va lue s=length (unique ( va lue ) ) )
37
38 constant <− zero . va lue s [ ze ro . va lue s$unique . va lue s == 1 , ]
39
40 #Removing those rows
41 datase t = datase t [ ! datase t [ , variable ] %in% constant [ , variable ] , ]
42
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43 i f ( export==TRUE) {
44 #Bui ld ing the formula needed to cas t data to wide format
45 form . y <− paste ( form . y , c o l l a p s e=’ + ’ )
46 form = as . formula (paste ( form . y , form . x , sep=’ ˜ ’ ) )
47
48 wide <− dcast (data=dataset , formula=form , value . var=value )
49 check2 <− dcast (data=dataset , formula=form , value . var=value )
50
51 write . csv ( wide , f i l e=’ datacheck wide . csv ’ )
52 write . csv ( dataset , f i l e=’ datacheck long . csv ’ )
53
54 }
55
56 i f ( convert .NA==TRUE) {
57 #conver t ing NAs in to 0
58 datase t$value [ i s .na( datase t$value ) ] <− 0
59 write . csv ( dataset , f i l e=’ c l ean data check . csv ’ )
60 }
61
62 #Print ing out conf i rmat ions
63 cat ( ’Compounds with zero or constant concent ra t i on in a l l samples :\n ’ )
64 cat (paste ( ’ \ t ’ , constant [ , variable ] , c o l l a p s e=’ \n ’ ) , ’ \n ’ )
65 cat ( ’Are the re Compounds with na concent ra t i on ?\n ’ )
66 cat (any( i s .na( datase t [ , va lue ] ) ) , ’ \n ’ )
67
68
69 cat ( ’DSS inc luded ?\n ’ )
70 cat (check . dss , ’ \n ’ )
71 cat ( ’ Contaminants removed :\n ’ )
72 cat (paste ( ’ \ t ’ , check . contaminants , c o l l p a s e=’ \n ’ ) , ’ \n ’ )
73 return ( datase t )
74 }
function-descriptive statistics.R
1 #/////////////////////////////////////////////////////////////////////////////////
2 #Function to ob ta in d e s c r i p t i v e data o f data
3 # ca l c u l a t e s mean , standard dev ia t ion , standard error , ymax , ymin
4 # has opt ion to s c a l e data , and correspod ing d e s c r i p t i v e s t a t s
5
6 #input : f u l l . data − q u a l i f i e r and concentra t ion data
7 # data . type − ’ long ’ or ’ wide ’ ; s p e c i f i e s format o f f u l l . data
8 # va r a i b l e − charac ter s t r i n g o f how you want long data to be broken up ;
9 # not requ i red f o r wide data
10 # q u a l i f i e r − q u a l i f i e r data ; used so can separa te out from f u l l . data
11 # sca l e . data − l o g i c a l ; r e t r i e v e s t a t s on the s ca l ed ver s ion o f the data ;
12 # mean cen t re s and un i t var iance s c a l e s the data
13
14 #output : s t a t − data frame of d e s c r i p t i v e s t a t i s t i c s
15 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
16 d e s c r i p t i v e . stat <− function ( f u l l . data , data . type=’ wide ’ , variable=NULL,
17 q u a l i f i e r=NULL, scale . data=FALSE) {
18
19 require ( p ly r )
20 i f (data . type==’ wide ’ ) {
21 #separa t ing concentra t ion data from q u a l i f i e r data in f u l l . data
22 data <− f u l l . data [ , ( ncol ( q u a l i f i e r )+1) : ncol ( f u l l . data ) ]
23
24 i f ( scale . data==FALSE) {
25 stat <− data . frame ( avg = apply (data , 2 , mean) ,
26 med = apply (data , 2 , median) ,
27 stdev = apply (data , 2 , sd ) ,
28 compound = colnames (data ) )
29
30 stat$se <− stat$ stdev/sqrt (nrow(data ) )
31 stat$ymax <− stat$avg + stat$se
32 stat$ymin <− stat$avg − stat$se
33 }
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34
35 else i f ( scale . data==TRUE) {
36 stat <− data . frame ( scale . avg = apply (data , 2 , mean) ,
37 scale .med = apply (data , 2 , med) ,
38 scale . s tdev = apply (data , 2 , sd ) ,
39 compound = colnames (data ) )
40
41 stat$scale . se <− stat$scale . s tdev/sqrt (nrow(data ) )
42 stat$scale . ymax <− stat$scale . avg + stat$scale . se
43 stat$scale . ymin <− stat$scale . avg − stat$scale . se
44
45 }
46 }
47
48 else i f (data . type==’ long ’ ) {
49 i f ( scale . data==FALSE) {
50 stat <− ddply ( f u l l . data , variable , mutate ,
51 avg = mean( va lue ) ,
52 med = median( va lue [ va lue != 0 ] ) ,
53 stdev = sd ( va lue ) ,
54 n=length ( va lue ) )
55
56 stat$se <− stat$ stdev/sqrt ( stat$n)
57 stat$ymax <− stat$avg + stat$se
58 stat$ymin <− stat$avg − stat$se
59
60 #turning a l l NAs to zero in median
61 stat$med [ i s .na( stat$med) ] <− 0
62
63 }
64 else i f ( scale . data==TRUE) {
65 stat <− ddply ( f u l l . data , variable , mutate ,
66 scale . avg = mean( va lue ) ,
67 scale .med = median( va lue [ va lue != 0 ] ) ,
68 scale . s tdev = sd ( va lue ) )
69
70 stat$scale . se <− stat$scale . s tdev/sqrt (nrow( f u l l . data ) )
71 stat$scale . ymax <− stat$scale . avg + stat$scale . se
72 stat$scale . ymin <− stat$scale . avg − stat$scale . se
73 }
74 }
75 return ( stat )
76 }
function-extract legend.R
1 #//////////////////////////////////////////////////////////////////////////////////
//////
2 #func t ion to e x t r a c t l egend from a g gp l o t
3 #to be used the g r i d . arrrange from gr idExtra package
4
5 #Extract Legend
6 g legend<−function ( a . gp lo t ) {
7 tmp <− ggp lot g tab l e ( ggp lo t bu i ld ( a . gp lo t ) )
8 l e g <− which( sapply (tmp$grobs , function ( x ) x$name) == ”guide−box” )
9 legend <− tmp$grobs [ [ l e g ] ]
10 return ( legend ) }
function-pca.R
1 #/////////////////////////////////////////////////////////////////////////////
2
3 #Functions f o r making proces s ing and ana ly z ing data su b s e t s crea ted e a r l i e r
4
5 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
6 #Function fo r Performing PCA ana l y s i s
7 #when running the s c r i p t :
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8 #enter as : pca processed data −−> process to be app l i e d to the output numeric
data , PCA
9
10
11 #input : data − numeric data to be used f o r PCA, c a l l e d output numeric , unpackaged
from ’ funct ion−data input ’ f i l e
12 # form . y − y v a r i a b l e in formula ; u s ua l l y i s q u a l i f i e r column names to be
put in to formula t ha t ca s t s data
13 # form . x − x v a r i a b l e in formula ; u s ua l l y the v a r i a b l e s invo l v ed ( i . e .
compound)
14 # va r i a b l e − the column name in which v a r i a b l e s are s to red ( i . e . ’Compound
’ )
15 # va lue − the column name in which data va lue s are s to red ( i . e . ’
concentrat ion ’ )
16 # sca l e − ’UV’ f o r un i t variance , ’UVN’ fo r no un i t variance , ’ pareto ’
17 # center − mean cen te r ing ; d e f a u l t to TRUE
18 #output : PCA−processed data , c a l l e d pca data
19 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
20 #Loading requ i red packages
21 require ( reshape2 )
22
23 perform pca = function (data , sampleID=’ sample name ’ , variable , value ,
24 form . y , form . x , scale , c en t e r = TRUE, convert .NA=FALSE) {
25
26
27
28 #Gett ing column names fo r q u a l i f i e r s and fo r concent ra t ions
29 numeric . long = c ( variable , va lue )
30 qual . long = colnames (data ) [ ! colnames (data ) %in% numeric . long ]
31
32 #Bui ld ing the formula needed to cas t data to wide format
33 form . y <− paste ( form . y , c o l l a p s e=’ + ’ )
34 form = as . formula (paste ( form . y , form . x , sep=’ ˜ ’ ) )
35
36 #Casting data to wide format ; i n c l ude s q u a l i f i e r s
37 data . wide = dcast (data=data , formula=form ,
38 value . var=value )
39
40 i f ( convert .NA==TRUE) {
41 #conver t ing NAs in to 0
42 data . wide [ i s .na(data . wide ) ] <− 0
43 write . csv (data . wide , f i l e=’ data check2 . csv ’ )
44 }
45
46 #separa t ing out concentra t ion and q u a l i f i e r s in wide format
47 conc . wide = data . wide [ , unique (data [ , variable ] ) ]
48 qual . wide = data . wide [ , qual . long ]
49
50 #Converting concentra t ion data to numeric c l a s s
51 for ( i in conc . wide ) { i <− as .numeric ( i ) }
52
53 #Unit Variance Sca l ing , s c a l i n g weight o f 1/sk
54 i f ( scale == ’UV’ ) {
55 scale = TRUE
56 }
57 #No Unit Variance Sca l ing
58 else i f ( scale == ’UVN’ ) {
59 scale = FALSE
60 }
61 #Pareto sca l ing , s c a l i n g weight o f 1/( sk ) e−2
62 else i f ( scale == ’ pareto ’ ) {
63 scale = for ( column in 1 : ncol (data ) ) {
64 data [ , column ] = data [ , column ] /sqrt ( sd (data [ , column ] ) )
65 }
66 }
67
68 #Creating pca model
69 pca data = prcomp ( conc . wide , scale=scale , c en t e r=center ,
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70 na . action=na . omit )
71
72 print (summary( pca data ) )
73
74 #Adding q u a l i f i e r s to pca score data
75 pca data$x = cbind ( qual . wide , pca data$x )
76
77 #Melt ing pca score data back to long format ,
78 #where v a r i a b l e i s PC number and va lue i s score va lue on tha t PC
79 pca . melt = melt ( pca data$x , id . vars=qual . long )
80
81 #Removing ’PC’ in PC column names , so only l e f t wi th a number
82 pca . melt$variable = as .numeric (gsub ( ’PC ’ , ’ ’ , pca . melt$variable ) )
83
84 #Get r i d o f l a s t PC i f i t i s odd
85 i f (max( pca . melt$variable ) %% 2 == 1) {
86 pca . melt = pca . melt [ pca . melt$variable != max( pca . melt$variable ) , ]
87 }
88
89 #Creating a new ob j e c t where has columns o f o f odd number PCs and even number PCs
90 odd .PCs = pca . melt$variable %% 2 == 1
91 sp l i t = pca . melt [ odd .PCs , qual . long ]
92 sp l i t$x . va lue = pca . melt$value [ odd .PCs ]
93 sp l i t$y . va lue = pca . melt$value [ ! odd .PCs ]
94 #Creating a column c a l l e d PC, to g i v e the PC number
95 sp l i t$x .PC = pca . melt$variable [ odd . PCs ]
96 sp l i t$y .PC = pca . melt$variable [ ! odd .PCs ]
97 #Adding column ’ view ’ to de s c r i b e which PCs are be ing p l o t t e d
98 sp l i t$view = paste ( ’PC ’ , pca . melt$variable [ odd . PCs ] , ’ vs ’ ,
99 ’PC ’ , pca . melt$variable [ ! odd .PCs ] )
100
101 #Replacing the pca model score data with the melted and sor t ed ver s ion crea ted
here
102 pca data$x = sp l i t
103
104 return ( pca data )
105 }
function-pca diagnostics.R
1 #////////////////////////////////////////////////////////////////////////
2
3 #Functions f o r performing d i a gno s t i c t e s t s on the pca data , e va l ua t i n g which PCs to
cons ider
4
5 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
6
7 #Function fo r performing PCA d i a gno s t i c s
8 #when running the s c r i p t :
9 #enter as = d i a gno s t i c r e s u l t s
10 #unpackage as d i a gno s t i c r e s u l t s number = d i a gno s t i c s data [ [ ’ number ’ ] ]
11 # d ia gno s t i c s r e s u l t s exp la ined = d i a gno s t i c s data [ [ ’ exp la ined ’ ] ]
12 # d ia gno s t i c s r e s u l t s p l o t = d i a gno s t i c s data [ [ ’ p l o t ’ ] ]
13
14 #input : the PCA model output o f prcomp ()
15 #Output : var ies , de f ined by i n d i v i d u a l func t i on
16
17 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
18 #Scree p l o t d i a gno s t i c
19 #
20 #Output : ’number ’ − the number o f PCA components to use
21 # ’ exp la ined ’ − % variance exp la ined by ’number ’ PCs
22 # ’ p lo t ’ − g g p l o t o b j e c t wi th generated scree p l o t
23
24 s c r e e plot = function (model)
25 {
26 #Making sure the r i g h t packages are loaded
27 require ( ggp lot2 )
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28
29 #Test ing i f the model i s indeed the r e s u l t o f a prcomp func t ion
30 i f ( class (model) != ’ prcomp ’ )
31 {
32 stop ( ’ Input to s c r e e p l o t must be the output o f prcomp ( ) func t i on ’ )
33 }
34
35 #Converting standard de v i a t i on s to var iance
36 var iance = model$sdev∗∗2
37 var iance = var iance/sum( var i ance )∗100
38
39 #Looking at d i f f e r e n c e s between s e q u en t i a l var iance va lue s
40 d i f f e r e n c e = var iance [− length ( var i ance ) ] − var iance [ 2 : length ( var i ance ) ]
41
42 #Creating a permanent da ta s e t t ha t w i l l be used l a t e r f o r p l o t t i n g
43 #for now , every va lue i s ass i gned INCLUDE, and INCLUDE i s de f ined as TRUE
44 datase t = data . frame ( x=1: length ( d i f f e r e n c e ) ,
45 y=d i f f e r e n c e ,
46 INCLUDE=TRUE)
47
48 #Looping through data to exc lude PC variance d i f f e r en c e s , and c r ea t ing a s t r a i g h t
l i n e f i t
49 #with every i t e r a t i o n
50 for ( i in 1 :min(10 , nrow( datase t )−2) )
51
52 {
53 #Marking po in t f o r exc lus ion , making a l l INCLUDE va lue s equa l to FALSE
54 datase t [ i , ’INCLUDE ’ ] = FALSE
55
56 #Ca lcu l a t ing l eng t h o f x vec to r ( in sum , TRUE i s equa l to 1 , FALSE, 0)
57 x length = sum( datase t$INCLUDE)
58
59 #Generating we igh t s f o r l i n e a r r e g r e s s i on . We want the f i r s t po in t s to have a
l o t
60 #more weight than the l a s t po in t s . To do th i s , we crea t e a weight vec to r from 1
to
61 #0.1 in equa l segments , then cube i t to ampl i fy the e f f e c t .
62 weight = seq (1 , . 1 , length . out=x length )∗∗3
63
64 #Fi t t i n g l i n e a r model , lm = to f i t l i n e a r model , y ˜ x means y=f ( x ) , where y i s
the d i f f e r e n c e in var iance between two suc c e s s i v e va lue s
65 #f i t t i n g the l i n e a r model wi th the da ta s e t ass i gned prev ious l y , and us ing a l l
rows with INCLUDE in i t s column
66 model = lm( y ˜ x , data=datase t [ datase t$INCLUDE, ] )
67
68 #Extrac t ing p r o b a b i l i t y t ha t the s l ope i s a c t u a l l y 0
69 prob = summary(model)$coef f ic ients [ 2 , 4 ]
70
71 #see o b j e c t s o f the model by >pr in t (summary(model ) ) .
72 #Column 2 of o b j e c t Co e f f i c i e n t s i s the Std . Error
73 #Column 4 of o b j e c t Co e f f i c i e n t s i s Pr(>| t | ) , which in context , g i v e s the
p r o b a b i l i t y t ha t the s l ope i s zero
74
75 #I f the p r o b a b i l i t y i s s u f f i c i e n t l y high , the s l ope
76 #i s deemed to be zero and there i s l im i t e d improvement
77 #from subsequent PC components ; e x i t s c r i p t
78 i f ( prob > 0 . 05 ) break
79 }
80
81 #Stor ing the l a s t PC index ( i ) b e f o r e the loop terminated
82 n = i
83
84 #Ca lcu l a t ing how much var iance t h i s number
85 #of components w i l l e xp l a in
86 exp la ined = sum( var i ance [ 1 : n ] )
87
88 #Creating a new var iance da ta s e t from d ia gno s t i c r e s u l t s
89 d i a gno s t i c r e s u l t s = data . frame ( x=1: length ( var i ance ) ,
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90 y=var iance ,
91 Type=i f e l s e (c ( datase t$INCLUDE, TRUE) , #t e s t i f INCLUDE in
the da ta s e t i s TRUE
92 ’Not s i g n i f i c a n t ’ , #i f yes , type out ’Not
s i g n i f i c a n t ’
93 ’ S i g n i f i c a n t ’ ) ) #i f no , type out ” S i gn i f i c an t
’
94
95 #Creating a ba s i c g g p l o t o b j e c t as v a l i d a t i o n
96 p = ggp lot ( d i a gno s t i c r e s u l t s )
97 p = p + geom point ( aes ( x=x , y=y , co l our=Type ) )
98 p = p + stat smooth (data=d i agno s t i c r e s u l t s [ d i a gno s t i c r e s u l t s $Type == ’Not
s i g n i f i c a n t ’ , ] ,
99 aes ( x=x , y=y) , se=FALSE, method=’ lm ’ , co l ou r=’ black ’ )
100
101 p = p + xlab ( ’ P r i n c i pa l Component ’ )
102 p = p + ylab ( ’ Variance exp la ined (%) ’ )
103 p = p + scale co l ou r manual ( va lue s=c ( ’ S i g n i f i c a n t ’=’ red ’ , ’Not s i g n i f i c a n t ’=’
b lack ’ ) )
104
105 return ( l i s t ( ’ number ’=n , ’ exp la ined ’=expla ined , ’ p l o t ’=p) )
106 }
function-plotting D score.R
1 #///////////////////////////////////////////////////////////////////////////
2
3 #Functions f o r p l o t t i n g pca r e s u l t s
4
5 #Li s t o f de f ined func t i ons :
6 # score p l o t 2d
7
8 #Making sure the r i g h t packages are loaded
9 require ( ggp lot2 )
10 require ( grid )
11 require ( p ly r )
12 require ( reshape2 )
13 require ( e l l i p s e )
14
15 #sourc ing requ i red func t i ons
16 source ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Functions/
funct ion−p l o t t i n g 1D sco r e .R ’ )
17
18 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
19
20 #Function fo r p l o t t i n g 2D score p l o t s
21 #when running the s c r i p t :
22 #enter as : score p l o t
23
24 #Input : the PCA model output o f prcomp ()
25 #Output : A s i n g l e g gp l o t 2 p l o t o b j e c t
26
27 #Note : Here , the use o f ”2D” imp l i e s t ha t 2 p r i n c i p a l components
28 #are cons idered at a time . As the p l o t t i n g i s a c t u a l l y
29 #qu i t e simple , t h i s i s no more than a shor t cu t func t i on fo r
30 #repeated use . Two d i f f e r e n t modes are used . In ’ f u l l ’ mode ,
31 #each p r i n c i p a l component i s compared aga ins t each other i . e .
32 #PC 1 vs PC 2 , PC 1 vs PC 3 , e t c . . . In ’ compressed ’ mode , only
33 #succ e s s i v e p r i n c i p a l components are compared i . e . PC 1 vs PC 2 ,
34 #PC 3 vs PC 4 , e t c . . .
35 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
36
37 #Input : ’ pca data ’ − the PCA model output o f prcomp ()
38 # ’PCs ’ − vec to r o f Pr inc ipa l Components to cons ider
39 # ’ colour ’ − name of q u a l i f e r data column to be used as the co lour a e s t h e t i c
40 # ’ shape ’ − name of q u a l i f e r data column to be used as the shape a e s t h e t i c
41 # ’ s i z e ’ − name of q u a l i f e r data column to be used as the s i z e a e s t h e t i c
42 # ’ l a b e l ’ − name of q u a l i f e r data column to be used as the po in t l a b e l s
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43 # ’ view mode ’ − the view at which the p r i c i p a l components are compared ;
e i t h e r compressed or f u l l ,
44 # where compressed i s PC1 v PC2, PC3 v PC4 etc , and f u l l i s PC1 v
PC2, PC1 v PC3, PC1 v PC4 e tc .
45 # ’ b l a ck white ’ − p l o t w i l l be in b l a c k and whi te
46 #Output : ’ p l o t ’ − g g p l o t o b j e c t wi th generated p l o t
47
48 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
49
50 s co r e plot 2d = function ( pca data , PCs=1:4 ,
51 co l our=NULL, shape=NULL, s i z e=NULL, l a b e l=NULL, t i t l e=NULL
,
52 legend . o r i=NULL, ou t l i n e=FALSE, black white=FALSE)
53 {
54 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
55 #Input t e s t i n g
56
57 #Test ing i f the pca data i s indeed the r e s u l t o f a prcomp func t ion
58 i f ( class ( pca data ) != ’ prcomp ’ )
59 {
60 stop ( ’ Input ”pca data” to s co r e p l o t 2d must be the output o f prcomp ( ) func t i on
’ )
61 }
62
63 #Test ing q u a l i f i e r rownames to make sure they are the same as the rownames o f the
score matrix
64 #i f ( l eng t h ( i n t e r s e c t ( rownames ( pca data$x ) , rownames ( q u a l i f i e r data ) ) ) != l e n g t h (
rownames ( q u a l i f i e r data ) ) )
65 #{
66 # stop ( ’ Input ” q u a l i f i e r data” to score p l o t 2d must have the same rownames as
the score matrix in ”pca data ” ’)
67 #}
68
69 #Test ing i f PCs are numeric
70 i f ( ! i s .numeric (PCs) )
71 {
72 stop ( ’ Input ”PCs” to s co r e p l o t 2d must be a vec to r o f numeric va lue s
cor re spond ing to t a r g e t p r i n c i p a l components ’ )
73 }
74
75 #Test ing to make sure t ha t PCs are in the input data
76 i f (any(PCs > ncol ( pca data$x ) ) )
77 {
78 stop ( ’ Input ”PCs” to s co r e p l o t 2d must not be out s id e o f the pca data
p r i n c i p a l component range ’ )
79 }
80
81 #Checking i f co lour , shape , or s i z e cond i t i ons are column names in q u a l i f e r data
82 a e s t h e t i c s = c ( ’ c o l ou r ’=colour , ’ shape ’=shape , ’ s i z e ’=s i z e )
83 a e s t h e t i c s = a e s t h e t i c s [ ! i s . null ( a e s t h e t i c s ) ] #Excluding d e f a u l t NULL en t r i e s
84 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
85
86 #Extract scores
87 s co r e . data = as . data . frame ( pca data$x )
88
89 #Copying out the standard dev i a t i on in f o from pca data as a dataframe
90 var iance = as . data . frame ( pca data$sdev )
91 #Converting standard de v i a t i on s to var iance
92 var iance = var iance∗∗2
93 var iance = var iance/sum( var i ance )∗100
94 var iance = round( var iance , d i g i t s =1)
95
96 #I n i t i a l i z i n g a new vec tor to s t o r e c o l l e c t e d . data
97 c o l l e c t e d . data = c ( )
98
99 #The way in which the c o l l e c t e d data i s b u i l t up and
100 #I f only 1 PC was s p e c i f i e d , c a l l i n g
101 #score p l o t 1d in s t ead
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102 i f ( length (PCs) == 1)
103 {
104 p = sco r e plot 1d( pca data , PCs ,
105 co lour , shape , s i z e , l abe l , pt lab , t i t le ,
106 perform checks=FALSE, group labels )
107 return (p)
108 }
109
110 #I t e r a t i n g through the PCs , two at a time .
111 for ( i in seq (1 , length (PCs) , by=2) )
112 {
113 view . data = sco r e . data [ s c o r e . data$x .PC==i , ]
114 view . data$view . var = paste ( ’PC ’ , i , ’ ( ’ , va r i ance [ i ] , ’%) ’ , ’ vs . ’ ,
115 ’PC ’ , i +1, ’ ( ’ , va r i ance [ i +1] , ’%) ’ )
116
117 #Adding to c o l l e c t e d . data
118 c o l l e c t e d . data = rbind ( c o l l e c t e d . data , view . data )
119
120 }
121
122 #Converting View to fac tor , p re s e rv ing order ing
123 c o l l e c t e d . data$view . var = factor ( c o l l e c t e d . data$view . var ,
124 levels=unique ( c o l l e c t e d . data$view . var ) )
125
126 #Ca lcu l a t ing p l o t l im i t s
127 x l im i t = max(abs ( c o l l e c t e d . data$x . va lue ) )∗1 .15
128 y l im i t = max(abs ( c o l l e c t e d . data$y . va lue ) )∗1 .1
129
130 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
131 #Generating p l o t
132
133 p = ggp lot ( c o l l e c t e d . data )
134
135 #I f s i z e d e s c r i p t o r has been s p e c i f i e d , use i t as an ae s t h e t i c ,
136 i f ( ! i s . null ( s i z e ) ) {
137 p = p + geom point ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ ,
138 co l our=colour , shape=shape , s i z e=s i z e ) , alpha =0.8)
139 }
140 else
141 { #otherwise , d e f a u l t to 3 and make po in t s with b l a c k ou t l i n e
142 i f ( ou t l i n e==TRUE) {
143 p = p + geom point ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ , shape=shape ) ,
144 co l ou r=’ black ’ , s i z e =4, alpha =0.8)
145 }
146
147 p = p + geom point ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ , c o l ou r=colour , shape=
shape ) ,
148 s i z e =3, alpha =0.8)
149 #Al t e rna t i v e s c r i p t f o r making po in t s with b l a c k ou t l i n e
150 #though there i s i n t e r na l bug with l egend
151 #p = p + geom point ( aes s t r i n g ( x=’xPC’ , y=’yPC’ , f i l l =colour , shape=shape ) ,
152 # colour=’ b lack ’ , s i z e =4, a lpha =0.8)
153 #p = p + sca l e shape manual ( va lue s =21:25)
154 }
155
156 #Cusomizing co lour s o f po in t s
157 #i f co lour i s d i s c r e t e g i v e customized co lour s
158 i f ( ! i s .numeric ( c o l l e c t e d . data [ , c o l ou r ] ) & length (unique ( c o l l e c t e d . data [ , c o l ou r ] ) )
< 8) {
159 p = p + scale co l ou r manual ( va lue s=c ( ’ deeppink1 ’ , ’ darkorange1 ’ , ’ c o rn f l owe rb lue ’
,
160 ’ darkorch id4 ’ , ’ cha r t r eu s e ’ , ’ b lue ’ , ’ grey30
’ ) )
161
162 }
163 else i f ( ! i s .numeric ( c o l l e c t e d . data [ , c o l ou r ] ) & length (unique ( c o l l e c t e d . data [ ,
c o l ou r ] ) ) >= 8 ) {
164 p = p + scale co l ou r brewer ( palette=’Dark2 ’ )
309
165
166 }
167 #i f co lour i s cont inuous g i v e co lour grad iaen t
168 else i f ( i s .numeric ( c o l l e c t e d . data [ , c o l ou r ] ) ) {
169
170 p = p + scale co l ou r g rad i en t ( low=’ red ’ )
171 }
172
173
174 #Adding t e x t only i f the ” l a b e l ” d e s c r i p t o r has been prov ided
175 i f ( ! i s . null ( l a b e l ) )
176 {
177 i f ( l a b e l == ’ Plot Treat ’ ) {
178 p = p + geom text ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ , l a b e l=labe l , alpha=’
Plot Treat ’ ) ,
179 h ju s t =−0.05 , v ju s t =0.75 ,
180 s i z e =5, f o n t f a c e=’ p l a i n ’ , l i n e h e i g h t =0.8)
181 p = p + scale alpha manual ( va lue s=l i s t ( ’None ’=0, ’ Norepinephr ine ’=1,
182 ’ Clindamycin ’=1, ’ Repoopulate ’=1,
183 ’ Clindamycin+RePOOPulation ’=1) , guide=
FALSE)
184 }
185 else {
186 p = p + geom text ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ , l a b e l=l a b e l ) ,
187 h ju s t =−0.5 , v ju s t =0.3 ,
188 s i z e =5, f o n t f a c e=’ p l a i n ’ , l i n e h e i g h t =0.8)
189
190 }
191 }
192
193 #Creating scheme fo r b l a c k and whi te p l o t s
194 i f ( b lack white == TRUE) {
195 p = p + geom point ( aes s t r i n g (x=’x . va lue ’ , y=’y . va lue ’ , shape=shape , f i l l =
co l ou r ) ,
196 s i z e =3, alpha =0.8) +
197 scale shape manual ( va lue s =21:25) +
198 scale f i l l manual ( va lue s=c ( ’ grey30 ’ , ’ white ’ ) )
199 }
200
201 #Adding t i t l e only i f ” t i t l e ” d e s c r i p t o r has been prov ided
202 i f ( ! i s . null ( t i t l e ) ) p = p + g g t i t l e ( l a b e l=t i t l e )
203
204 #Drawing o r i g i n
205 p = p + geom v l i n e ( x i n t e r c ep t =0, alpha =0.3)
206 p = p + geom h l i n e ( y i n t e r c ep t =0, alpha =0.3)
207
208 p = p + xlab ( ’PC sco r e ’ ) +
209 ylab ( ’PC sco r e ’ ) +
210 theme bw(16) +
211 theme ( axis . t i t l e . x = element text ( s i z e =14, f a c e=’ bold ’ ) ,
212 axis . t i t l e . y = element text ( s i z e =14, f a c e=’ bold ’ ) ,
213 axis . text = element text ( s i z e =12, co l our=’ black ’ ) ,
214 legend . t i t l e = element text ( s i z e =14) ,
215 legend . text = element text ( s i z e =14) ,
216 legend . key = element rect ( co l ou r=’ white ’ ) ,
217 legend .margin = unit (0 , ”cm” ) ,
218 legend . p o s i t i o n = ’ bottom ’ ,
219 panel . border=element rect ( s i z e =2, co l our=’ black ’ ) ,
220 panel .margin=unit ( . 0 5 , ’ npc ’ ) )
221
222 #Legend o r i en t a t i on
223 i f ( legend . o r i == ’ ho r i z on t a l ’ ) {
224 p = p + theme ( legend . d i r e c t i o n=’ ho r i z on t a l ’ ,
225 legend . p o s i t i o n=’ bottom ’ )
226 }
227 else i f ( legend . o r i == ’ v e r t i c a l ’ ) {
228 p = p + theme ( legend . d i r e c t i o n=’ v e r t i c a l ’ ,
229 legend . p o s i t i o n=’ r i g h t ’ )
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230 }
231
232 #Se t t i n g l im i t s
233 p = p + xlim(−x l imi t , x l im i t )
234 p = p + ylim(−y l imi t , y l im i t )
235
236 #While the r e s t o f the p l o t t i n g code i s generic ,
237 #the f a c e t t i n g w i l l change based on view
238 #i f ( view mode == ’ compressed ’ )
239 p = p + f a c e t wrap (˜ view . var , ncol=min( f loor ( length (PCs)/2) , 3) ) +
240 theme ( s t r i p . text . x = element text ( s i z e =12, f a c e=’ bold ’ ) )
241 #e l s e i f ( view mode == ’ f u l l ’ ) p = p + f a c e t g r i d ( yLabel ˜ xLabe l )
242
243 return ( l i s t ( ’ c o l l e c t e d . data ’=c o l l e c t e d . data , ’ p ’=p) )
244 }
function-plotting D loading.R
1 #///////////////////////////////////////////////////////////////////////////
2 #Function fo r p lo t t ing2D Loading p l o t
3 #
4 #Here , the use o f ”2D” imp l i e s t ha t 2 p r i n c i p a l components
5 #are cons idered at a time . Unl ike the score p lo t , l oad ing p l o t groupings
6 #( pathways ) are not e x c l u s i v e i . e . a compound may be long to more than one
7 #grouping . This makes i t d i f f i c u l t to use colour , shape , and other a e s t h e t i c s
8 #in the same manner as f o r the score p l o t . For now , the se op t ions w i l l be
9 #removed
10 #
11 #when running the s c r i p t :
12 #enter as : l oad ing p l o t
13 #
14 #Input : ’ pca data ’ − the PCA model output o f prcomp ()
15 # ’PCs ’ − vec to r o f Pr inc ipa l Components to cons ider
16 # ’ l a b e l ’ − vec to r o f compounds t ha t shou ld be l a b e l l e d on the score p l o t
17 # ’ view mode ’ − one o f e i t h e r ’ f u l l ’ or ’ compressed ’ ( see score p l o t )
18 #
19 #Output : ’ p l o t ’ − g g p l o t o b j e c t wi th generated p l o t
20
21 load ing plot 2d = function ( pca data , PCs=1:4 , l a b e l=NULL, ou t l i n e=FALSE,
22 t i t l e=NULL, view mode=’ compressed ’ )
23 {
24 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
25 #Input t e s t i n g
26
27 #Test ing i f the pca data i s indeed the r e s u l t o f
28 #a prcomp func t ion
29 i f ( class ( pca data ) != ’ prcomp ’ )
30 {
31 stop ( ’ Input ”pca data” to s co r e p l o t 2d must be the output o f prcomp ( ) func t i on
’ )
32 }
33
34 #Test ing i f PCs are numeric
35 i f ( ! i s .numeric (PCs) )
36 {
37 stop ( ’ Input ”PCs” to s co r e p l o t 2d must be a vec to r o f numeric va lue s
cor re spond ing to t a r g e t p r i n c i p a l components ’ )
38 }
39
40 #Test ing to make sure t ha t PCs are in the input data
41 i f (any(PCs > ncol ( pca data$ r o t a t i on ) ) )
42 {
43 stop ( ’ Input ”PCs” to s co r e p l o t 2d must not be out s id e o f the pca data
p r i n c i p a l component range ’ )
44 }
45
46 #Checking i f g iven l a b e l s are in the l oad ing data
47 i f (any( ! l a b e l %in% rownames( pca data$ r o t a t i on ) ) )
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48 {
49 stop (paste ( ’The f o l l ow i ng l a b e l s do not correspond to v a r i a b l e s in ”pca data ” :\
n\ t ’ ,
50 paste ( l a b e l [ ! l a b e l %in% rownames( pca data$ r o t a t i on ) ] , c o l l a p s e=’ , ’ )
) )
51 }
52 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−>
53
54 #Extract l oad ing s
55 load ing data = as . data . frame ( pca data$ r o t a t i on )
56
57 var iance = as . data . frame ( pca data$sdev )
58 #Converting standard de v i a t i on s to var iance
59 var iance = var iance∗∗2
60 var iance = var iance/sum( var i ance )∗100
61 var iance = round( var iance , d i g i t s =1)
62
63 #I n i t i a l i z i n g a new vec tor to s t o r e c o l l e c t e d data
64 c o l l e c t e d data = c ( )
65
66 #The way in which the c o l l e c t e d data i s b u i l t up and
67 #presented depends on the view model
68 i f ( view mode == ’ compressed ’ )
69 {
70
71 #I f only 1 PC was s p e c i f i e d , c a l l i n g
72 #lod ing p l o t 1d in s t ead
73 i f ( length (PCs) == 1)
74 {
75 p = load ing plot 1d( pca data , PCs , l abe l , t i t le ,
76 perform checks=FALSE)
77 return (p)
78 }
79 #I t e r a t i n g through the PCs , two at a time .
80 #I f there i s an odd number o f PCs , the l a s t one i s dropped
81 for ( i in seq (1 , length (PCs)−1, by=2) )
82 {
83 view data = load ing data [ , c ( i , i +1) ]
84 view data$View = paste ( ’PC ’ , i , ’ ( ’ , va r i ance [ i ] , ’%) ’ , ’ vs . ’ ,
85 ’PC ’ , i +1, ’ ( ’ , va r i ance [ i +1] , ’%) ’ )
86
87 #Changing score column names
88 colnames ( view data ) [ 1 : 2 ] = c ( ’xPC ’ , ’yPC ’ )
89
90 #I n i t i a l i z i n g t e x t column with b lanks
91 view data$Text = ’ ’
92
93 #Adding l a b e l s
94 view data [ l abe l , ’ Text ’ ] = l a b e l
95
96 #Adding to c o l l e c t e d data
97 c o l l e c t e d data = rbind ( c o l l e c t e d data , view data )
98 }
99 }
100 else i f ( view mode == ’ f u l l ’ )
101 {
102 #I t e r a t i n g through the PCs one at a time . As the comparison
103 #i s f a c t o r i a l , two loops are used , 1v2 , 1v3 , . . . , 2v1 , 2v2 , e t c
104 for ( i in PCs)
105 {
106 for ( j in PCs)
107 {
108 view data = load ing data [ , c ( i , j ) ]
109 view data$xLabel = paste ( ’PC ’ , i , ’ ( ’ , va r i ance [ i ] , ’%) ’ )
110 view data$yLabel = paste ( ’PC ’ , j , ’ ( ’ , va r i ance [ j ] , ’%) ’ )
111
112 #Changing score column names
113 colnames ( view data ) [ 1 : 2 ] = c ( ’xPC ’ , ’yPC ’ )
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114
115 #I n i t i a l i z i n g t e x t column with b lanks
116 view data$Text = ’ ’
117
118 #Adding l a b e l s
119 view data [ l abe l , ’ Text ’ ] = l a b e l
120
121 #Adding to c o l l e c t e d data
122 c o l l e c t e d data = rbind ( c o l l e c t e d data , view data )
123 }
124 }
125 }
126 else
127 {
128 stop ( ’ Input ”view mode” must be one o f ” f u l l ” or ” compressed” ’ )
129 }
130
131 #Ca lcu l a t ing p l o t l im i t s
132 x l im i t = max(abs ( c o l l e c t e d data$xPC) )∗1 .1
133 y l im i t = max(abs ( c o l l e c t e d data$yPC) )∗1 .1
134
135 #Generating p l o t
136 p = ggp lot ( c o l l e c t e d data )
137
138 #I f h i g h l i g h t i n g w i l l be performed , use a l e s s s tark , grey tone ,
139 #otherwise , use b l a c k with transparency to l im i t o v e r p l o t t i n g
140 i f ( i s . null ( l a b e l ) ) p = p + geom point ( aes ( x=xPC, y=yPC) , co l ou r=’ black ’ , s i z e =5,
alpha =.7)
141 else i f ( i s . null ( l a b e l ) & ou t l i n e == TRUE) {
142 p = p + geom point ( aes ( x=xPC, y=yPC) , co l ou r=’ grey ’ , s i z e =5)
143 }
144 #Adding t e x t only i f the ” l a b e l ” d e s c r i p t o r has been provided ,
145 #the po in t s with t e x t are a l s o h i g h l i g h t e d
146 i f ( ! i s . null ( l a b e l ) )
147 {
148 p = p + geom text ( aes ( x=xPC, y=yPC, l a b e l=Text ) ,
149 h ju s t =−0.1 , v ju s t =0, s i z e =5, f o n t f a c e =2)
150
151 }
152 i f ( ! i s . null ( l a b e l ) & ou t l i n e==TRUE) {
153 p = p + geom point (data=co l l e c t e d data [ c o l l e c t e d data$Text != ’ ’ , ] ,
154 aes ( x=xPC, y=yPC) , s i z e =5, shape=1)
155 }
156
157 #Adding t i t l e only i f ” t i t l e ” d e s c r i p t o r has been prov ided
158 i f ( ! i s . null ( t i t l e ) ) p = p + g g t i t l e ( l a b e l=t i t l e )
159
160 #Drawing o r i g i n
161 p = p + geom v l i n e ( x i n t e r c ep t =0, alpha =0.3)
162 p = p + geom h l i n e ( y i n t e r c ep t =0, alpha =0.3)
163
164 p = p + xlab ( ’PC load ing ’ ) + ylab ( ’PC load ing ’ )
165
166 #Se t t i n g l im i t s
167 p = p + xlim(−x l imi t , x l im i t )
168 p = p + ylim(−y l imi t , y l im i t )
169
170 #While the r e s t o f the p l o t t i n g code i s generic ,
171 #the f a c e t t i n g w i l l change based on view
172 i f ( view mode == ’ compressed ’ ) p = p + f a c e t wrap (˜ View , ncol=min( f loor ( length (
PCs)/2) , 3) ) +
173 theme bw(16) +
174 theme ( axis . t i t l e . x = element text ( s i z e =14, f a c e=’ bold ’ ) ,
175 axis . t i t l e . y = element text ( s i z e =14, f a c e=’ bold ’ ) ,
176 axis . text = element text ( s i z e =12, co l our=’ black ’ ) ,
177 legend . t i t l e = element text ( s i z e =14) ,
178 legend . text = element text ( s i z e =12) ,
179 legend . key = element rect ( co l ou r=’ white ’ ) ,
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180 legend .margin = unit (0 , ”cm” ) ,
181 panel . border=element rect ( s i z e =2, co l our=’ black ’ ) ,
182 s t r i p . text . x = element text ( s i z e =14, f a c e=’ bold ’ ) )
183 else i f ( view mode == ’ f u l l ’ ) p = p + f a c e t grid ( yLabel ˜ xLabel ) +
184 theme bw(16) +
185 theme ( axis . t i t l e . x = element text ( s i z e =14, f a c e=’ bold ’ ) ,
186 axis . t i t l e . y = element text ( s i z e =14, f a c e=’ bold ’ ) ,
187 axis . text = element text ( s i z e =12, co l our=’ black ’ ) ,
188 legend . t i t l e = element text ( s i z e =14) ,
189 legend . text = element text ( s i z e =12) ,
190 legend . key = element rect ( co l ou r=’ white ’ ) ,
191 legend .margin = unit (0 , ”cm” ) ,
192 s t r i p . text . x = element text ( s i z e =14, f a c e=’ bold ’ ) )
193
194 return ( l i s t ( ’p ’=p , ’ c o l l e c t e d . data ’=c o l l e c t e d data ) )
195 }
function-scaling.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #This func t i on i s to s c a l e me tabo l i t e data be f o r e i t goes to PCA process ing ,
3 #or wi thout PCA proces se ing :
4 # Sca l ing to Acetate
5 # Mean cen te r ing
6 # Unit var iance s c a l i n g
7 # Note : mean cen te r ing and uni t var iance i s done through the perform pca funct ion ,
8 # so i f pass ing data from
9
10 #input : data − unprocessed concentra t ion data
11 # normalize − s c a l e a l l compounds wi th in one obse rva t i on to a s i n g l e compound
,
12 # d i v i d e s every compound by the concentra t ion o f normal i z ing
compound
13 #
14 #output : sca ledData − concentra t ion data t ha t has undergone the s p e c i f i e d s c a l i n g
15 #
16 #//////////////////////////////////////////////////////////////////////////////////
/
17
18 require ( reshape2 )
19
20
21
22 s c a l i n g = function (data , sampleID=’ sampleID ’ , variable=’ va r i ab l e ’ , va lue=’ va lue ’ ,
23 normal ize=NULL, cent r e=TRUE, UV=FALSE) {
24
25 i f ( ! i s . null ( normal ize ) ) {
26 setwd ( ’C:/Users/Sandi/Dropbox/Liquid Gold/R Sc r i p t s/V 3.0/ ’ )
27 source ( ’ ./Functions/ funct ion−normal ize .R ’ )
28 normal ized = ddply (data , sampleID , f normal ize , variable=variable , s c a l=value ,
29 normal ize=normal ize )
30
31 #remove the compound by which the concent ra t ions are sca led , o therwi se PCA w i l l
f a i l
32 proce s sed . data = normal ized [ normal ized [ , variable ] != normal ize , ]
33 print ( ’ data i s normal ized by Acetate ’ )
34 print ( ’ Acetate removed from ana l y s i s as i t s va lue i s one ’ )
35 }
36 i f ( i s . null ( normal ize ) ) {
37 proce s sed . data = data
38 }
39
40 i f ( c en t r e==TRUE) {
41 proce s sed . data = ddply ( proce s s ed . data , variable , mutate ,
42 s c a l=value−mean( va lue ) )
43 print ( ’ data i s mean centred ’ )
44 }
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45 i f ( c en t r e==FALSE) {
46 proce s sed . data = proces sed . data
47 }
48
49 i f (UV==TRUE) {
50 proce s sed . data = ddply ( proce s s ed . data , variable , mutate ,
51 s c a l=s c a l/sd ( s c a l ) )
52 print ( ’ data i s s c a l ed by un i t var i ance ’ )
53 }
54 i f (UV==FALSE) {
55 proce s sed . data = proces sed . data
56 }
57
58 return ( proce s s ed . data )
59 }
function-t test.R
1 #//////////////////////////////////////////////////////////////////////////////////
////////////////
2 #func t ion to perform the t t e s t
3
4 #Fi r s t g e t t i n g the t s t a t i s t i c f o r each compound
5 t S t a t i s t i c = function (data , value , variable , group1 , group2 , n) {
6
7 #Separat ing out popu la t ion and t e s t groups
8 pop = data [ data [ , variable ] == group1 , ]
9 pop = pop [ , colnames ( pop ) == value ]
10
11 sample = data [ data [ , variable ] == group2 , ]
12 sample = sample [ , colnames (sample ) == value ]
13
14 #Ca lcu l a t ing t s t a t i s t i c
15 pop = ddply (pop , ’ compound ’ , transform , average = mean( concent ra t i on ) )
16 pop = ddply (pop , ’ compound ’ , mutate , stdev = sd ( concent ra t i on ) )
17 pop = pop [ , colnames ( pop )%in% c ( ’ compound ’ , ’ average ’ , ’ s tdev ’ ) ]
18 pop = unique ( pop )
19 print ( head ( pop ) )
20
21 i f (FALSE) {
22 sample = ddply (sample , ’ compound ’ , transform , average = mean( concent ra t i on ) )
23 sample = sample [ , colnames (sample ) %in% c ( ’ compound ’ , ’ average ’ ) ]
24
25 ca l c 1 = data . frame ( compound = pop1 . c a l c$compound ,
26 sub = abs ( pop1 . c a l c$average−pop2 . c a l c$average ) )
27 ca l c 2 = data . frame ( compound = control . c a l c$compound ,
28 s s = control . c a l c$ stdev∗sqrt (2/n) )
29 s s = data . frame ( compound = pop1 . c a l c$compound , s s = ca l c 1$sub/ ca l c 2$ s s )
30 }
31
32 return ( l i s t ( ’ pop ’=pop , ’ sample ’=sample ,
33 ’ c a l c 1 ’=ca lc1 , ’ c a l c 2 ’=ca lc2 , ’ s s ’=s s ) )
34 #abs ( app ly ( contro l , 2 ,mean)−app ly ( treatment ,2 ,mean)/( app ly ( contro l , 2 , sd )∗ s q r t (2/
n) ) )
35 }
36
37 i f (FALSE) {
38 t e s t = t S t a t i s t i c (comp . input , va lue=’ compos i t ion ’ , variable=’Gen Treat ’ ,
39 group1=’None ’ , group2=’ Clindamycin ’ , 2)
40
41 control . c a l c = t e s t [ [ ’ pop1 . c a l c ’ ] ]
42 t r e a t . c a l c = t e s t [ [ ’ pop2 . c a l c ’ ] ]
43 ca l c 1 = t e s t [ [ ’ c a l c 1 ’ ] ]
44 ca l c 2 = t e s t [ [ ’ c a l c 2 ’ ] ]
45 s s = t e s t [ [ ’ s s ’ ] ]
46 }
47 i f (FALSE) {
48 t t e s t func = function (data , value , variable , group1 , group2 ) {
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49 x = data [ data [ , variable ] == group1 , ]
50 x = x [ , colnames ( x ) == value ]
51
52 y = data [ data [ , variable ] == group2 , ]
53 y = y [ , colnames ( y ) == value ]
54
55 t e s t = t . t e s t (x , y )
56 out = t e s t$p . va lue
57 return ( out )
58 }
59 }
function-siegel tukey test.R
1 s i e g e l . tukey <− function (x , y , id . col = FALSE, ad jus t .median = F,
2 rnd = −1, a l t e r n a t i v e = ”two . s ided ” , mu = 0 , pa i r ed =
FALSE,
3 exact = FALSE, c o r r e c t = TRUE, conf . i n t = FALSE, conf .
l e v e l = 0 . 95 ) {
4 ###### pub l i s h ed on :
5 # ht tp ://www. r−s t a t i s t i c s . com/2010/02/ s i e g e l−tukey−a−non−parametric−t e s t−for−
e qua l i t y−in−v a r i a b i l i t y −r−code/
6 ## Main author o f the func t i on : Daniel Malter
7
8 # x : a vec tor o f data
9
10 # y : Group ind i c a t o r ( i f id . c o l=TRUE) ; data o f the second
11 # group ( i f
12 # id . co l=FALSE) . I f y i s the group ind i c a t o r i t MUST take 0
13 # or 1 to i nd i c a t e
14 # the groups , and x must contain the data f o r both groups .
15
16 # id . co l : I f TRUE ( d e f a u l t ) , then x i s the data column and y
17 # i s the ID column ,
18 # ind i c a t i n g the groups . I f FALSE, x and y are both data
19 # columns . id . co l must
20 # be FALSE only i f both data columns are o f the same l eng t h .
21
22 # ad ju s t . median : Should between−group d i f f e r e n c e s in medians
23 # be l e v e l e d be f o r e
24 # performing the t e s t ? In ce r t a in cases , the S i ege l−Tukey
25 # t e s t i s s u s c e p t i b l e
26 # to median d i f f e r e n c e s and may ind i c a t e s i g n i f i c a n t
27 # d i f f e r e n c e s in
28 # v a r i a b i l i t y that , in r e a l i t y , stem from d i f f e r e n c e s in
29 # medians .
30
31 # rnd : Should the data be rounded and , i f so , to which
32 # decimal ? The d e f a u l t
33 # (−1) uses the data as i s . Otherwise , rnd must be a
34 # non−nega t i v e i n t e g e r .
35 # Typica l l y , t h i s opt ion i s not needed . However ,
36 # occas i ona l l y , d i f f e r e n c e s in
37 # the p r e c i s i on with which ce r t a in func t i ons re turn va lue s
38 # cause the merging
39 # of two data frames to f a i l w i th in the s i e g e l . tukey
40 # func t ion . Only then
41 # rounding i s necessary . This opera t ion shou ld not be
42 # performed i f i t a f f e c t s
43 # the ranks o f o b s e r va t i on s .
44
45 # . . . arguments passed on to the Wilcoxon t e s t . See
46 # ?wi l cox . t e s t
47
48 # Value : Among other output , the func t i on re turns the data ,
49 # the S i ege l−Tukey
50 # ranks , the a s soc i a t ed Wilcoxon ’ s W and the p−va lue f o r a
51 # Wilcoxon t e s t on
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52 # t i e−ad jus t ed S i ege l−Tukey ranks ( i . e . , i t performs and
53 # returns a
54 # Siege l−Tukey t e s t ) . I f s i g n i f i c a n t , the group with the
55 # smal l e r rank sum has
56 # grea t e r v a r i a b i l i t y .
57
58 # References : Sidney S i e g e l and John Wilder Tukey (1960) ”A
59 # nonparametric sum
60 # of ranks procedure f o r r e l a t i v e spread in unpaired
61 # samples .” Journal o f the
62 # American S t a t i s t i c a l Assoc ia t ion . See a lso , David J .
63 # Sheskin (2004)
64 # ”Handbook o f parametric and nonparametric s t a t i s t i c a l
65 # procedures .” 3rd
66 # ed i t i on . Chapman and Hal l/CRC. Boca Raton , FL.
67
68 # Notes : The S i ege l−Tukey t e s t has r e l a t i v e l y low power and
69 # may, under c e r t a in
70 # condi t ions , i nd i c a t e s i g n i f i c a n c e due to d i f f e r e n c e s in
71 # medians ra ther than
72 # d i f f e r e n c e s in v a r i a b i l i t i e s ( cons ider us ing the argument
73 # ad ju s t . median ) .
74
75 # Output ( in t h i s order )
76
77 # 1. Group medians ( a f t e r median adjustment i f s p e c i f i e d )
78 # 2. Wilcoxon−t e s t f o r between−group d i f f e r e n c e s in medians
79 # ( a f t e r the median
80 # adjustment i f s p e c i f i e d )
81 # 3. Data , group membership , and the S i ege l−Tukey ranks
82 # 4. Mean S iege l−Tukey rank by group ( sma l l e r va lue s i nd i c a t e
83 # grea t e r
84 # v a r i a b i l i t y )
85 # 5. S i ege l−Tukey t e s t (Wilcoxon t e s t on t i e−ad jus t ed
86 # Siege l−Tukey ranks )
87
88 i s . formula <− function ( x ) class ( x ) == ” formula ”
89
90 i f ( i s . formula ( x ) ) {
91 y <− do . ca l l (c , l i s t (as . name( a l l . vars ( x ) [ 2 ] ) ) , env i r = parent . frame (2 ) )
92 x <− do . ca l l (c , l i s t (as . name( a l l . vars ( x ) [ 1 ] ) ) , env i r = parent . frame (2 ) ) # I am
using parent . frame (2) s ince i f the name of the v a r i a b l e in the equat ion i s
’ x ’ , then we w i l l mis taken ly ge t the func t i on in here in s t ead o f the
vec to r .
93 id . col <− TRUE
94 # pr in t ( x )
95 # pr in t ( l s . s t r ( ) )
96 # data=data . frame ( c ( x , y ) , rep ( c (0 ,1) , c ( l eng t h ( x ) , l en g t h ( y ) ) ) )
97 # pr in t ( data )
98 }
99
100 i f ( id . col == FALSE) {
101 data = data . frame (c (x , y ) , rep (c (0 , 1) , c ( length ( x ) , length ( y ) ) ) )
102 } else {
103 data = data . frame (x , y )
104 }
105 names(data ) = c ( ”x” , ”y” )
106 data = data [ order (data$x ) , ]
107 i f ( rnd > −1) {
108 data$x = round(data$x , rnd )
109 }
110
111 i f ( ad jus t .median == T) {
112 ##cat (”\n” , ”Adjus t ing medians . . . ” , ”\n” , sep = ””)
113 data$x [ data$y == 0 ] = data$x [ data$y == 0 ] − (median(data$x [ data$y ==
114 0 ] ) )
115 data$x [ data$y == 1 ] = data$x [ data$y == 1 ] − (median(data$x [ data$y ==
116 1 ] ) )
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117 }
118 ##cat (”\n” , ”Median o f group 1 = ” , median ( data$x [ data$y == 0 ] ) ,
119 ## ”\n” , sep = ””)
120 ##cat (”Median o f group 2 = ” , median ( data$x [ data$y == 1 ] ) , ”\n” ,
121 ## ”\n” , sep = ””)
122 ##cat (” Test ing median d i f f e r e n c e s . . . ” , ”\n”)
123 ##pr in t ( w i l cox . t e s t ( data$x [ data$y == 0] , data$x [ data$y == 1 ] ) )
124
125 # The f o l l ow i n g must be done fo r the case when id . co l==F
126 x <− data$x
127 y <− data$y
128
129 ##cat (” Performing S i ege l−Tukey rank trans format ion . . . ” , ”\n” ,
130 ## ”\n”)
131
132
133
134 sort . x <− sort (data$x )
135 sort . id <− data$y [ order (data$x ) ]
136
137 data .matrix <− data . frame ( sort . x , sort . id )
138
139 base1 <− c (1 , 4)
140 i t e r a t o r 1 <− matrix ( seq ( from = 1 , to = length ( x ) , by = 4) ) −
141 1
142 rank1 <− apply ( i t e r a t o r 1 , 1 , function ( x ) x + base1 )
143
144 i t e r a t o r 2 <− matrix ( seq ( from = 2 , to = length ( x ) , by = 4) )
145 base2 <− c (0 , 1)
146 rank2 <− apply ( i t e r a t o r 2 , 1 , function ( x ) x + base2 )
147
148 #pr in t ( rank1 )
149 #pr in t ( rank2 )
150
151 i f ( length ( rank1 ) == length ( rank2 ) ) {
152 rank <− c ( rank1 [ 1 : f loor ( length ( x )/2) ] , rev ( rank2 [ 1 : cei l ing ( length ( x )/2) ] ) )
153 } else {
154 rank <− c ( rank1 [ 1 : cei l ing ( length ( x )/2) ] , rev ( rank2 [ 1 : f loor ( length ( x )/2) ] ) )
155 }
156
157
158 unique . ranks <− tapply (rank , sort . x , mean)
159 unique . x <− as .numeric (as . character (names(unique . ranks ) ) )
160
161 rank .matrix <− data . frame (unique . x , unique . ranks )
162
163 ST.matrix <− merge(data .matrix , rank .matrix , by . x = ” so r t . x” ,
164 by . y = ”unique . x” )
165
166 ##pr in t (ST. matrix )
167
168 ##cat (”\n” , ”Performing S i ege l−Tukey t e s t . . . ” , ”\n” , sep = ””)
169
170 ranks0 <− ST.matrix$unique . ranks [ST .matrix$sort . id == 0 ]
171 ranks1 <− ST.matrix$unique . ranks [ST .matrix$sort . id == 1 ]
172
173 ##cat (”\n” , ”Mean rank o f group 0 : ” , mean( ranks0 ) , ”\n” , sep = ””)
174 ##cat (”Mean rank o f group 1 : ” , mean( ranks1 ) , ”\n” , sep = ””)
175
176 ##pr in t ( w i l cox . t e s t ( ranks0 , ranks1 , a l t e r n a t i v e = a l t e r na t i v e ,
177 ## mu = mu, paired = paired , exac t = exact , co r r e c t = correc t ,
178 ## conf . i n t = conf . int , conf . l e v e l = conf . l e v e l ) )
179
180 #put t i n g func t i on outputs as o b j e c t s so can be e x t r a c t ed
181 mean . rank0 <− mean( ranks0 )
182 mean . rank1 <− mean( ranks1 )
183 s t . t e s t <− wi lcox . t e s t ( ranks0 , ranks1 , a l t e r n a t i v e = a l t e r na t i v e ,
184 mu = mu, pa i red = paired , exact = exact , c o r r e c t = cor r e c t
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,
185 conf . i n t = conf . int , conf . l e v e l = conf . l e v e l )
186
187 return ( l i s t ( ’ s t . ranks ’=ST.matrix , ’mean . rank0 ’=mean . rank0 ,
188 ’mean . rank1 ’=mean . rank1 , ’ s t . t e s t ’=s t . t e s t ) )
189 }
190
191
192
193
194
195
196
197 i f (F) {
198
199 #Example :
200
201 ### 1
202 x=c ( 4 , 4 , 5 , 5 , 6 , 6 )
203 y=c ( 0 , 0 , 1 , 9 , 10 , 10 )
204 s i e g e l . tukey (x , y , F)
205 s i e g e l . tukey (x , y ) #same as above
206
207 ### 2
208 # example f o r a non equa l number o f cases :
209 x=c ( 4 , 4 , 5 , 5 , 6 , 6 )
210 y=c ( 0 , 0 , 1 , 9 , 10 )
211 s i e g e l . tukey (x , y ,F)
212
213 ### 3
214 x <− c (33 , 62 , 84 , 85 , 88 , 93 , 97 , 4 , 16 , 48 , 51 , 66 , 98)
215 id <− c ( 0 , 0 , 0 , 0 , 0 , 0 , 0 , 1 , 1 , 1 , 1 , 1 , 1 )
216 s i e g e l . tukey (x , id ,T)
217 s i e g e l . tukey (x˜ id ) # from now on , t h i s a l s o works as a func t i on . . .
218 s i e g e l . tukey (x , id ,T, ad jus t .median=F, exact=T)
219
220 ### 4
221 x<−c
(177 ,200 ,227 ,230 ,232 ,268 ,272 ,297 ,47 ,105 ,126 ,142 ,158 ,172 ,197 ,220 ,225 ,230 ,262 ,270)
222 id<−c ( rep ( 0 , 8 ) , rep (1 , 12 ) )
223 s i e g e l . tukey (x , id ,T, ad jus t .median=T)
224
225
226 ### 5
227 x=c (33 ,62 ,84 ,85 ,88 ,93 ,97 )
228 y=c (4 , 16 , 48 ,51 ,66 ,98 )
229 s i e g e l . tukey (x , y )
230
231 ### 6
232 x<−c ( 0 , 0 , 1 , 4 , 4 , 5 , 5 , 6 , 6 , 9 , 10 , 10 )
233 id<−c ( 0 , 0 , 0 , 1 , 1 , 1 , 1 , 1 , 1 , 0 , 0 , 0 )
234 s i e g e l . tukey (x , id ,T)
235
236 ### 7
237 x <− c (85 ,106 ,96 , 105 , 104 , 108 , 86)
238 id<−c ( 0 , 0 , 1 , 1 , 1 , 1 , 1 )
239 s i e g e l . tukey (x , id ,T)
240
241 }
stat custom.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Function to ge t d e s c r i p t i v e s t a t i s t i c e s
3 #meant to be used in s i d e a ddp ly
4
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5 #ge t t i n g mean normalized va lue s f o r each compound
6 stat custom <− function (d , va lue ) {
7 stat <− data . frame ( avg = mean(d [ , va lue ] ) ,
8 med = median(d [ , va lue ] [ d [ , va lue ] != 0 ] ) ,
9 stdev = sd (d [ , va lue ] ) ,
10 n=length (d [ , va lue ] ) )
11
12 stat$se <− stat$ stdev/sqrt ( stat$n)
13 stat$ymax <− stat$avg + stat$se
14 stat$ymin <− stat$avg − stat$se
15
16 stat$ r max <− range (d [ , va lue ] ) [ 2 ]
17 stat$ r min <− range (d [ , va lue ] ) [ 1 ]
18 stat$per r max <− abs ( stat$ r max−stat$avg )/stat$avg∗100
19 stat$per r min <− abs ( stat$ r min−stat$avg )/stat$avg∗100
20
21 out <− cbind (d , stat )
22 return ( out )
23 }
linear model.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #Test f o r l i n e a r model
3
4 #Extrac t s est imate , stanadard error , t e s t s t a t i s t i c , p−va lue f o r s l ope and
i n t e r c e p t
5
6 lm custom <− function (data , group , va lue=’ va lue ’ ) {
7 d <− data
8 f <− paste ( value , group , sep=’˜ ’ )
9
10 r e s u l t <− lm(as . formula ( f ) , data=d)
11 r e s u l t .sum <− summary( r e s u l t )
12
13 out <− data . frame ( s l ope=r e s u l t .sum$coef f ic ients [ 2 , 1 ] ,
14 s l ope . se=r e s u l t .sum$coef f ic ients [ 2 , 2 ] ,
15 s l ope . t=r e s u l t .sum$coef f ic ients [ 2 , 3 ] ,
16 s l ope . p=r e s u l t .sum$coef f ic ients [ 2 , 4 ] ,
17 i n t=r e s u l t .sum$coef f ic ients [ 1 , 1 ] ,
18 i n t . se=r e s u l t .sum$coef f ic ients [ 1 , 2 ] ,
19 i n t . t=r e s u l t .sum$coef f ic ients [ 1 , 3 ] ,
20 i n t . p=r e s u l t .sum$coef f ic ients [ 1 , 4 ] )
21
22 return ( out )
23 }
normalize.R
1 #///////////////////////////////////////////////////////////////////////////////
2 #Function to normal ize concen t ra t ions by one compound
3 #wr i t t en fo r Fecal water samples
4
5 norm custom <− function (d . stat , variable=’ va r i ab l e ’ , va lue=’ va lue ’ ,
6 norm=’ Acetate ’ , norm . va l=’ avg ’ ,norm . name=’norm ’ ) {
7 norm . value <− unique (d . stat [ , norm . va l ] [ d . stat [ , variable]==norm ] )
8 d . stat [ , norm . name ] <− d . stat [ , va lue ]/norm . value
9 out <− unique (d . stat [ , ! colnames (d . stat ) %in%
10 c ( ’med ’ , ’ s tdev ’ , ’n ’ , ’ s e ’ , ’ymax ’ , ’ ymin ’ ) ] )
11 return ( out )
12 }
multiple linear regression.R
1 #////////////////////////////////////////////////////////////////////////////////
2 #mu l t i p l e l i n e a r r e g r e s s i on
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3 #for comparison o f b i a s and i n t e r a c t i on between more than one independent v a r i a b l e s
4
5 mlr custom <− function (d , f ) {
6 l .model <− lm( formula=f , data=d)
7 l . r e s u l t <− summary( l .model)
8 l . coef <− as . data . frame ( l . r e s u l t $ c o e f f i c i e n t )
9 rname <− data . frame ( rname=rownames( l . coef ) )
10 out <− cbind ( rname , l . coef )
11 out$variable <− as . character (unique (d$variable ) )
12 return ( out )
13 }
mlr prediction.R
1 #//////////////////////////////////////////////////////////////////////////////////
2 #Pred ic t ing data po in t s a long the p lane o f a mu l t i p l e l i n e a r r e g r e s s i on
3 #obta in s mlr model f i r s t , then app l i e s data po in t s based on tha t model
4 mlr predict <− function (d , f ) {
5 l .model <− lm( formula=f , data=d)
6 d$p r ed i c t i o n <− predict ( l .model)
7 return (d)
8 }
linear model.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #Test f o r l i n e a r model
3
4 #Extrac t s est imate , stanadard error , t e s t s t a t i s t i c , p−va lue f o r s l ope and
i n t e r c e p t
5
6 lm custom <− function (data , group ) {
7 d <− data
8 f <− paste ( ’ va lue ’ , group , sep=’˜ ’ )
9
10 r e s u l t <− lm(as . formula ( f ) , data=d)
11 r e s u l t .sum <− summary( r e s u l t )
12
13 out <− data . frame ( s l ope=r e s u l t .sum$coef f ic ients [ 2 , 1 ] ,
14 s l ope . se=r e s u l t .sum$coef f ic ients [ 2 , 2 ] ,
15 s l ope . t=r e s u l t .sum$coef f ic ients [ 2 , 3 ] ,
16 s l ope . p=r e s u l t .sum$coef f ic ients [ 2 , 4 ] ,
17 i n t=r e s u l t .sum$coef f ic ients [ 1 , 1 ] ,
18 i n t . se=r e s u l t .sum$coef f ic ients [ 1 , 2 ] ,
19 i n t . t=r e s u l t .sum$coef f ic ients [ 1 , 3 ] ,
20 i n t . p=r e s u l t .sum$coef f ic ients [ 1 , 4 ] ,
21 r e s .sum=sum( r e s u l t .sum$residuals ) )
22
23 return ( out )
24 }
ANOVA-mean.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2
3 #ANOVA
4 #Test ing va r i a t i on about the mean wi th in and between groups
5 aov custom <− function (data , group ) {
6 d <− data
7
8 grand <− mean(d$value ) #grand mean
9
10 s s . grp <− ddply (d , group , mutate , avg=mean( va lue ) ) #within−group mean
11 s s . grp$grand <− grand #adding grand mean
12
321
13 s s r <− sum( ( s s . grp$value − s s . grp$avg )∗∗2) #sum of sqr o f w i th in groups
14 s sa <− sum( ( s s . grp$avg − s s . grp$grand )∗∗2) #sum of sqr o f between groups
15
16 d f r <− nrow(d)−length (unique (d [ , group ] ) ) #n−q
17 dfa <− length (unique (d [ , group ] ) )−1 #q−1
18
19 msa <− s sa/dfa #mean square between group
20 msr <− s s r/d f r #mean square wi th in group
21
22 f <− msa/msr #f s t a t i s t i c
23 p . va l <− 1−pf ( f , dfa , d f r )
24 out <− data . frame ( variable=unique (d$variable ) , f . va l=f , p . va l=p . va l )
25 return ( out )
26 }
kruskal wallis.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #kruska l−Wal l i s f o r UC expt 2
3
4 #kruska l w a l l i s t e s t
5 kruska l custom <− function (data , group ) {
6 d <− data
7 r e s u l t <− kruska l . t e s t (data$value , as . factor (data [ , group ] ) )$p . va l
8 d$p . va l <− r e s u l t
9 return (d)
10 }
tukey.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Tukey ’ s HSD func t ion fo r UC Expt 2
3
4 tukey custom <− function (data , group ) {
5 grps <− unique (data [ , group ] )
6 pa i r <− combn( grps , 2 )
7 out <− c ( )
8 for ( i in 1 : ncol ( pa i r ) ) {
9 grp1 <− data [ data [ , group ] == pa i r [ 1 , i ] , ]
10 grp2 <− data [ data [ , group ] == pa i r [ 2 , i ] , ]
11
12 grand <− mean(data$value ) #grand mean
13 s s . grp <− ddply (data , group , mutate , avg=mean( va lue ) ) #within−group mean
14 s s . grp$grand <− grand #adding grand mean
15 s s r <− sum( ( s s . grp$value − s s . grp$avg )∗∗2) #sum of sqr o f w i th in groups
16 d f r <− nrow(data )−length (unique (data [ , group ] ) ) #n−q
17
18 avg1 <− mean( grp1$value )
19 avg2 <− mean( grp2$value )
20 n <− nrow( grp1 )
21 se <− sqrt ( s s r/n)
22
23 q . stat <− (max(c ( avg1 , avg2 ) )−min(c ( avg1 , avg2 ) ) )/se
24 p . va l <− ptukey (q . stat , n , df=df r )
25
26 output <− data . frame ( g1=pa i r [ 1 , i ] , g2=pa i r [ 2 , i ] , p . va l=p . va l )
27 out <− rbind ( out , output )
28 }
29 return ( out )
30 }
correlation.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
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2 #Corre la t ion r e l a t i o n s h i p
3
4 #Returns c o r r e l a t i on c o e f f i c i e n t , p−va lue and t e s t s t a t i s t i c
5
6
7 co r r custom <− function (data , x , y , methods=’ pearson ’ ) {
8 d <− data
9 x <− as .numeric (data [ , x ] )
10 y <− as .numeric (data [ , y ] )
11 co r r . r e s u l t <− cor . t e s t (x , y , method=methods , a l t e r n a t i v e=’ two . s ided ’ )
12 p . va l <− co r r . r e s u l t $p . va lue
13 stat <− co r r . r e s u l t $ s t a t i s t i c
14 es t imate <− co r r . r e s u l t $ es t imate
15 out <− data . frame ( stat=stat , e s t imate=est imate , p . va l=p . va l )
16 return ( out )
17 }
Student t test.R
1 #//////////////////////////////////////////////////////////////////////////////////
//
2 #Function to perform Student ’ s t t e s t
3
4 t custom <− function (data , group ) {
5
6 grps <− unique (data [ , group ] )
7 grp1 <− data [ data [ , group ] == grps [ 1 ] , ]
8 grp2 <− data [ data [ , group ] == grps [ 2 ] , ]
9
10 r e s u l t <− t . t e s t ( grp1$value , grp2$value )
11 t . stat <− r e s u l t $ s t a t i s t i c
12 p . va l <− r e s u l t $p . va lue
13
14 out <− c ( variable=unique (data$variable ) , t . stat=t . stat , p . va l=p . va l )
15
16 return ( out )
17 }
function-heat map bin.R
1 #//////////////////////////////////////////////////////////////////////////////////
/////////////
2 #Function to d i v i d e data in to bins , and have them returned in a pa r t i c u l a r order
3 # bes t to be used fo r p l o t t i n g heat maps
4 # only makes 5 b ins
5
6 #input : data = dataframe tha t conta ins the va lue to be represen ted in p l o t ; long
form
7 # bin = vec tor o f 5 va lue s are the bin l im i t s , in decreas ing order
8 # va r i a b l e = name of column tha t ho ld s the v a r i a b l e s to be represen ted in the
p l o t
9 # order . data = dataframe tha t ho ld s the va lue s by which the compounds shou ld
be ordered ;
10 # usua l l y i s the same as data
11 # order . va lue = name of column tha t ho ld s va lue s by which order . var shou ld be
ordered
12 # order . var = name of column the v a r i a b l e s to be ordered ;
13 # order . var and v a r i a b l e shou ld ho ld the same in f o
14
15 #output : uni . l i s t = c l a s s l i s t ; l i s t o f compounds in each bin
16 # ordered . data = dataframe of data to be p l o t t ed , and compounds are ordered
17 # by a decreas ing value , u s ua l l y mean concentra t ion
18 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
19
20 bin . heatmap <− function (data , bin , variable , order . data , order . var , order . va lue ) {
21
22
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23 #Assigning data to b ins
24 order . data$bin <− NA
25 order . data [ order . data [ , order . va lue ] >= bin [ 1 ] , ’ bin ’ ] <− ’ bin1 ’
26 order . data [ order . data [ , order . va lue ] >= bin [ 2 ] & order . data [ , order . va lue ] < bin
[ 1 ] , ’ bin ’ ] <− ’ bin2 ’
27 order . data [ order . data [ , order . va lue ] >= bin [ 3 ] & order . data [ , order . va lue ] < bin
[ 2 ] , ’ bin ’ ] <− ’ bin3 ’
28 order . data [ order . data [ , order . va lue ] >= bin [ 4 ] & order . data [ , order . va lue ] < bin
[ 3 ] , ’ bin ’ ] <− ’ bin4 ’
29 order . data [ order . data [ , order . va lue ] >= bin [ 5 ] & order . data [ , order . va lue ] < bin
[ 4 ] , ’ bin ’ ] <− ’ bin5 ’
30
31 #conver t ing compounds to charac ter c l a s s and a l s o g e t t i nng compounds in each bin
32 bin . cmpd <− l i s t ( )
33 for ( i in c ( ’ bin1 ’ , ’ bin2 ’ , ’ bin3 ’ , ’ bin4 ’ , ’ bin5 ’ ) ) {
34 temp <− order . data [ order . data$bin == i , ]
35 bin . cmpd [ [ i ] ] <− as . character (unique ( temp [ , variable ] ) )
36 }
37
38 #Gett ing only compounds found in one bin and not any other b ins be f o r e i t
39 common . cmpd <− c ( bin . cmpd [ [ 1 ] ] )
40 uni . l i s t <− l i s t ( bin . cmpd [ [ 1 ] ] )
41
42 for ( i in 2 : length ( bin . cmpd) ) {
43 uni . l i s t [ [ i ] ] <− bin . cmpd [ [ i ] ] [ ! bin . cmpd [ [ i ] ] %in% common . cmpd ]
44 common . cmpd <− c (common . cmpd , uni . l i s t [ [ i ] ] )
45 }
46
47 #with in bins , order ing compounds by order . va lue and s e t t i n g v a r i a b l e order
48 ordered . data <− c ( )
49 ordered . l i s t <− l i s t ( )
50 for ( i in 1 : length ( uni . l i s t ) ) {
51 cmpd <− uni . l i s t [ [ i ] ]
52 temp . data <− order . data [ order . data [ , order . var ] %in% cmpd , ]
53 colnames ( temp . data ) [ colnames ( temp . data )==order . va lue ] <− ’ o rder . va l ’
54 max. data <− ddply ( temp . data , order . var , summarize ,
55 max. va lue=max(order . va l ) )
56 temp . order <− max. data [ order (max. data$max. value , d e c r ea s i ng=TRUE) , ]
57 temp . order [ , order . var ] <− factor ( temp . order [ , order . var ] ,
58 levels=rev ( temp . order [ , order . var ] ) ,
59 ordered=TRUE)
60
61 temp <− data [ data [ , variable ] %in% cmpd , ]
62 temp [ , variable ] <− factor ( temp [ , variable ] , levels=levels ( temp . order [ , order . var
] ) )
63 ordered . data <− rbind (ordered . data , temp)
64
65 temp . l i s t <− unique ( temp [ , variable ] )
66 temp . l i s t <− temp . l i s t [ order ( temp . l i s t , d e c r ea s ing=TRUE) ]
67 ordered . l i s t [ [ i ] ] <− as . character ( temp . l i s t )
68 }
69
70 return ( l i s t ( ’ uni . l i s t ’=ordered . l i s t , ’ ordered . data ’=ordered . data ) )
71
72 }
function-bin function.R
1 #//////////////////////////////////////////////////////////////////////////////////
///////
2 #Function to bin data
3
4 #input : data = dataframe tha t conta ins the va lue to be represen ted in p l o t ; long
form
5 # bin = vec tor o f 5 va lue s are the bin l im i t s , in decreas ing order
6 # va r i a b l e = name of column tha t ho ld s the v a r i a b l e s to be binned
7 # va lue = name of column tha t ho ld s va lue s t ha t determines the b ins
8
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9 #output : uni . l i s t = c l a s s l i s t ; l i s t o f compounds in each bin
10 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
11 bin function <− function (data , bin , variable=’ va r i ab l e ’ , va lue=’ value ’ ) {
12
13 #Assigning data to b ins
14 data$bin <− NA
15 data [ data [ , va lue ] >= bin [ 1 ] , ’ bin ’ ] <− ’ bin1 ’
16 data [ data [ , va lue ] >= bin [ 2 ] & data [ , va lue ] < bin [ 1 ] , ’ bin ’ ] <− ’ bin2 ’
17 data [ data [ , va lue ] >= bin [ 3 ] & data [ , va lue ] < bin [ 2 ] , ’ bin ’ ] <− ’ bin3 ’
18 data [ data [ , va lue ] >= bin [ 4 ] & data [ , va lue ] < bin [ 3 ] , ’ bin ’ ] <− ’ bin4 ’
19 data [ data [ , va lue ] >= bin [ 5 ] & data [ , va lue ] < bin [ 4 ] , ’ bin ’ ] <− ’ bin5 ’
20
21 #conver t ing compounds to charac ter c l a s s and a l s o g e t t i nng compounds in each bin
22 bin . cmpd <− l i s t ( )
23 for ( i in c ( ’ bin1 ’ , ’ bin2 ’ , ’ bin3 ’ , ’ bin4 ’ , ’ bin5 ’ ) ) {
24 temp <− data [ data$bin == i , ]
25 bin . cmpd [ [ i ] ] <− as . character (unique ( temp [ , variable ] ) )
26 }
27
28 #Gett ing only compounds found in one bin and not any other b ins be f o r e i t
29 common . cmpd <− c ( bin . cmpd [ [ 1 ] ] )
30 uni . l i s t <− l i s t ( bin . cmpd [ [ 1 ] ] )
31
32 for ( i in 2 : length ( bin . cmpd) ) {
33 uni . l i s t [ [ i ] ] <− bin . cmpd [ [ i ] ] [ ! bin . cmpd [ [ i ] ] %in% common . cmpd ]
34 common . cmpd <− c (common . cmpd , uni . l i s t [ [ i ] ] )
35 }
36
37 return ( uni . l i s t )
38 }
defined binning.R
1 #///////////////////////////////////////////////////////////////////////////////
2 #Modif ied f o r Liquid Gold Manuscript A
3 #wr i t t en fo r Manuscript A −− f unc t i on to de f ine bins , and return which bin
4 #each compound i s in .
5
6 de f ined binning <− function ( ) {
7
8 #Se t t i n g working d i r e c t o r y
9 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Analys i s ’ )
10
11 #load ing requ i red packages
12 require (RSQLite )
13 require ( ggp lot2 )
14 require ( p ly r )
15 require ( reshape2 )
16 require ( gr idExtra )
17
18 #sourc ing requ i red func t i ons
19 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
20 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
21
22 source ( ’ . . /Functions/ funct ion−heat map bin .R ’ )
23
24
25 #Input data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
26 # Choose d r i v e r
27 drv <− dbDriver ( ’ SQLite ’ )
28
29 # Create connect ion ( f o r SQLite , t h i s i s a f i l e )
30 con <− dbConnect ( drv , ’ . . /Data source f i l e s /data . db ’ )
31
32 input <− dbGetQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
33 q . hour , q . phase , q . dose , q . treatment , q . gen t reat ,
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34 q . expt , d . va r i ab l e , d . va lue
35 FROM Data d INNER JOIN Qua l i f i e r q
36 ON d . f i l e = q . f i l e
37 INNER JOIN Rank r
38 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
39 WHERE r . Conf idence = 1 AND q . gen t r e a t = ’None ’
40 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
41 AND q . s t a t e = ’ ss ’
42 AND (q . run != 8 OR q . run IS NULL)
43 AND q . donor != ’RP1’
44 AND q . expt != ’RP2’
45 ORDER BY q . sampleID ; ” )
46
47 cmpd . i n f o <− dbGetQuery ( con , ”SELECT c .Compound , c . Type , p . Pathway , m. main
48 FROM Cmpd type c INNER JOIN Pathway p
49 ON c .Compound = p .Compound
50 INNER JOIN Main pathway m
51 ON p . Pathway = m. path
52 ORDER BY c .Compound” )
53
54 dbDisconnect ( con )
55
56 #Se t t i n g working d i r e c t o r y
57 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/LG Manuscript
A/Analys i s ’ )
58
59 #data cleanup
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
60
61 #Performing data cleanup to remove zero va lue compounds
62 #al so ca s t s data in to wide format
63 c l ean <− data cleanup ( input , form . y=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
64 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
65 ’ gen t r e a t ’ , ’ expt ’ ) ,
66 form . x=’ va r i ab l e ’ , convert .NA=TRUE)
67
68 #make sure a l l compounds have a va lue f o r each donor
69 data . c a s t <− dcast ( c lean , formula=sampleID+donor+run+v e s s e l+DPI+hour+phase+dose+
70 treatment+gen t r e a t+expt˜variable , va lue . var=’ value ’ )
71
72 data . c a s t [ i s .na(data . c a s t ) ] <− 0
73
74 #mel t ing back to long format
75 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
76 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
77 ’ gen t r e a t ’ , ’ expt ’ ) )
78
79
80 #de s c r i p t i v e s t a t s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
81 #Gett ing d e s c r i p t i v e s t a t s f o r each donor
82 stat <− ddply (data . melt , ’ donor ’ , d e s c r i p t i v e . stat , data . type=’ long ’ , variable=’
va r i ab l e ’ ,
83 q u a l i f i e r=q u a l i f i e r , scale . data=FALSE)
84
85 #Assigning data to b ins
86 bin . data <− bin . heatmap ( stat , bin=c ( 20 , 1 0 , 1 , 0 . 1 , 0 ) , ’ v a r i a b l e ’ ,
87 order . data=stat , order . var=’ va r i ab l e ’ , order . va lue=’ avg ’ )
88
89 uni . l i s t <− bin . data [ [ ’ uni . l i s t ’ ] ]
90
91 #ge t t i n g dataframe of v a r i a b l e s and t h e i r b ins
92 b ins <− c ( )
93 for ( i in 1 : length ( uni . l i s t ) ) {
94 d <− data . frame ( bin=i , variable=uni . l i s t [ [ i ] ] )
95 b ins <− rbind ( bins , d )
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96 }
97
98 return ( b ins )
99 }
function-weighted compound class.R
1 #//////////////////////////////////////////////////////////////////////////////////
/
2 #Function to i l l u s t r a t e p r o f i l e d i v e r s i t y
3 #Gett ing propor t ion o f compound types weighted to t h e i r concen t ra t ions
4 #to be used in ddply , grouped by donor
5
6 custom perc <− function (d , cmpd . class=’Type ’ ) {
7
8 #Firs t , g e t t i n g sum of a l l compound concent ra t ions f o r each sample
9 output <− ddply (d , ’ sampleID ’ , mutate , sample . t o t a l=sum( value , na .rm=TRUE) )
10
11 #Gett ing mean p r o f i l e t o t a l s
12 output$sample . avg <− mean( output$sample . t o t a l )
13
14 #Sum of compound c l a s s e s wi th in samples
15 output <− ddply ( output , c ( ’ sampleID ’ ,cmpd . class ) , mutate ,
16 sample . class=sum( value , na .rm=TRUE) )
17
18 #Mean compound c l a s s
19 output <− ddply ( output , cmpd . class , mutate , class . avg=mean(sample . class ) )
20
21 #Mean compound c l a s s as percent o f p r o f i l e t o t a l
22 output$perc <− output$class . avg/output$sample . avg∗100
23
24 out <− unique ( output [ , c ( ’ donor ’ , ’ sample . avg ’ ,cmpd . class , ’ c l a s s . avg ’ , ’ perc ’ ) ] )
25 return ( out )
26 }
function-defined binning.R
1 #//////////////////////////////////////////////////////////////////////////////////
//////
2 #Function to ge t order o f con t ro l data − modi f ied f o r t h e s i s
3
4
5 #input : data = dataframe of non−t r e a t ed samples ;
6 # ho lds the va lue s by which the compounds shou ld be ordered
7
8 #output : order . l i s t = dataframe of data to be p l o t t ed , and compounds are ordered
9 # by a decreas ing va lue
10 #−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
11
12 de f ined binning <− function ( ) {
13
14 wd <− getwd ( )
15
16 #Se t t i n g working d i r e c t o r y
17 setwd ( ’C:/Users/Sandi/Dropbox/Pro j e c t s/Liquid Gold/R Sc r i p t s/V 3.0/Analys i s ’ )
18
19 #load ing requ i red packages
20 require (RSQLite )
21 require ( ggp lot2 )
22 require ( p ly r )
23 require ( reshape2 )
24 require ( gr idExtra )
25
26 #sourc ing requ i red func t i ons
27 source ( ’ . . /Functions/ funct ion−data cleanup .R ’ )
28 source ( ’ . . /Functions/ funct ion−d e s c r i p t i v e s t a t i s t i c s .R ’ )
29 source ( ’ . . /Functions/ funct ion−heat map bin .R ’ )
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30
31
32 #Input data
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
33 # Create connect ion and s e l e c t i n g database
34 con <− odbcConnect ( ’MySQLDSN’ )
35
36 input <− sqlQuery ( con , ”SELECT q . sampleID , q . donor , q . run , q . v e s s e l , q .DPI ,
37 q . hour , q . phase , q . dose , q . treatment , q . gentreat , q . expt ,
38 d . va r i ab l e , d . value , t . tax c l a s s
39 FROM l i q u i d g o l d . data d INNER JOIN l i q u i d g o l d . q u a l i f i e r q
40 ON d . f i l e = q . f i l e
41 INNER JOIN l i q u i d g o l d . rank r
42 ON d . va r i ab l e = r .Compound AND q . expt = r . expt
43 INNER JOIN gene ra l . tax t
44 ON d . va r i ab l e=t . syn
45 WHERE r . Conf idence = 1 AND q . gent r ea t = ’None ’
46 AND (q . run != 8 OR q . run IS NULL)
47 AND d . va r i ab l e NOT IN ( ’ Xanthine ’ , ’ Glycero l ’ )
48 AND q . s t a t e = ’ ss ’
49 AND q . donor != ’RP1’
50 AND q . expt != ’RP2’
51 ORDER BY q . sampleID ; ” )
52
53 odbcClose ( con )
54
55 #data cleanup
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
56
57 #Performing data cleanup to remove zero va lue compounds
58 #al so ca s t s data in to wide format
59 c l ean <− data cleanup ( input , convert .NA=TRUE)
60
61 #make sure a l l compounds have a va lue f o r each donor
62 data . c a s t <− dcast ( c lean , formula=sampleID+donor+run+v e s s e l+DPI+hour+phase+dose+
63 treatment+gent r ea t+expt˜variable , va lue . var=’ value ’ )
64
65 data . c a s t [ , 1 2 : ncol (data . c a s t ) ] [ i s .na(data . c a s t [ , 1 2 : ncol (data . c a s t ) ] ) ] <− 0
66
67 #mel t ing back to long format
68 data . melt <− melt (data . cast , id . vars=c ( ’ sampleID ’ , ’ donor ’ , ’ run ’ , ’ v e s s e l ’ ,
69 ’DPI ’ , ’ hour ’ , ’ phase ’ , ’ dose ’ , ’ treatment ’ ,
70 ’ g ent r ea t ’ , ’ expt ’ ) )
71
72 data . melt <− unique (merge(data . melt , c l ean [ , c ( ’ tax c l a s s ’ , ’ v a r i a b l e ’ ) ] ,
73 by=’ va r i ab l e ’ ) )
74 #separa t ing out q u a l i f i e r and data
75 q u a l i f i e r <− data . melt [ , 1 : 1 1 ]
76 x . data <− data . melt [ , 1 2 : 1 3 ]
77
78 #de s c r i p t i v e s t a t s
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
79 #Gett ing d e s c r i p t i v e s t a t s f o r each donor
80 stat <− ddply (data . melt , ’ donor ’ , d e s c r i p t i v e . stat , data . type=’ long ’ ,
81 variable=’ va r i ab l e ’ )
82
83 #Binning
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
84 #Assigning data to b ins
85 bin . data <− bin . heatmap ( stat , bin=c ( 20 , 1 0 , 1 , 0 . 1 , 0 ) , ’ v a r i a b l e ’ ,
86 order . data=stat , order . var=’ va r i ab l e ’ , order . va lue=’ avg ’ )
87
88 uni . l i s t <− bin . data [ [ ’ uni . l i s t ’ ] ]
89 ordered . data <− bin . data [ [ ’ ordered . data ’ ] ]
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90
91 var <− levels (ordered . data$variable )
92 var <− factor (var , levels=var , ordered=TRUE)
93
94 for ( i in 1 : length ( uni . l i s t ) ) {
95 uni . l i s t [ [ i ] ] <− factor ( uni . l i s t [ [ i ] ] , levels=var )
96 }
97
98 #s e t t i n g working d i r e c t o r y back
99 setwd <− wd
100 return ( uni . l i s t )
101 }
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